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Foreword
The search for the molecular basis of drug addiction led, in the
mid-seventies, to the exciting discovery of opioid receptors and a
variety of endogenous and exogenous ligands. The fact that
thousands of publications have appeared already is astounding and
attests to the attention attracted by this area. The discovery of
multiple opioid receptors brings an additional dimension to research
in this area, and medicinal chemists have already succeeded in
synthesizing many highly specific ligands to these receptor subtypes.
The interest in this area is not only to develop nonaddictive
peptide analgetic substitutes for morphine, but also to understand
the role of these endogenous peptides in health and in disease.
Although several thousand analogs of enkephalins and other opioid
peptides have been synthesized, including some that are stable and
can be taken orally, a nonaddicting opioid has yet to be synthesized.
Hence, the National Institute on Drug Abuse felt that it was timely
to call together experts in the area to evaluate current research on
the development of new opioid peptides with potential value for
basic research and therapeutics.
In this monograph, emphasis is placed on structure-activity
relationships, conformational analysis using various spectroscopies,
computer assisted drug design, and molecular mechanics. It is hoped
that the discussions of current research by various experts
presented here will helpful in establishing future goals for
development of new molecular entities with desired biological
activity or receptor specificity. An effort has been made to cover
all aspects of medicinal chemistry pertaining to opioid peptides, so
that the volume can serve as a broadly useful reference text.
Marvin Snyder, Ph.D., Director
Division of Preclinical Research
National Institute on Drug Abuse
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Introduction
Rao S. Rapaka, Ph.D.
The discovery of opioid peptides has opened up new scientific area
and posed questions which are still at an early stage of
exploration. This area is of major interest to the immediate and
long-range goals of the National Institute on Drug Abuse, and in
order better to focus the rapidly expanding research areas
associated with peptide chemistry and its potential application to
drug abuse research and therapeutic treatment, the Institute
sponsored a technical review in September 1984.
This monograph presents contributions both from the symposium
speakers and from other invited authors in the various aspects of
the medicinal chemistry of the opioid peptides and the opiates.
Highlights of these reviews are presented here. Biosynthetic,
analytical, and molecular pharmacology aspects are presented in NIDA
Research Monograph 70.
A number of presentations are on structure-activity relationships
(SAR) of the opioid peptides--Drs. Morley and Dutta on the SAR of
enkephalins, Dr. Chang on morphiceptins, and Dr. Feuerstein on
dermorphins. Conformational restriction has produced, to date,
highly active µ- and -selective enkephalin analogs. This feature
is described extensively by Drs. Schiller and Hruby. In addition,
conformational restriction by stereochemically constrained analogs
is described by Drs. Kishore and Balaram. Very recent work on the
synthesis of dehydro and cyclopropyl amino acids is presented by Dr.
Stammer; and a general review on enkephalin SAR, including the
design of peptides with predictable specificity and the
synthesis of enzymatically stable peptides, is presented by Dr.
Shimohigashi. An excellent and elaborate account of peptide
conformation and biological activity, with general examples from
such peptides as gramicidin analogs and elastin analogs, is given by
Dr. Urry.
A number of presentations are related to conformational analysis of
the opioid peptides, advanced methodologies, and design of
peptides. Nuclear magnetic resonance as a tool in determination of
conformations, along with a preliminary background on peptide
conformations (such as -turns and -sheets), 2-D NMR, and NOE, is
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presented by Dr. Khaled. An update on X-ray crystallographic
research on enkephalins and enkephalin analogs, such as [p-bromo
Phe4]-leucine enkephalin and Tyr-D-Nle-Gly-Phe-NleS, is presented
bv Drs. Camerman and Camerman. Applications of the comolementarv
techniques FT-IR and laser Rama spectros copies to the determination
of conformational states of Leu5- and Met5- enkephalins are
described by Dr. Renugopalakrishnan and colleagues. An account on
computer-aided drug design is given by Dr. Marshall and colleagues,
and an investigation on SAR of opioids by an interdisciplinary
approach is discussed by Dr. Loew and her associates. An excellent
account of conformational analysis and conformational restriction in
the design of receptor-selective analogs is given by Dr. Schiller.
Great progress in research on opioid peptides has been made possible
by simultaneous advances in the techniques of synthesis,
purification, and analysis of peptides. In this volume, synthetic
techniques are discussed by Dr. Stewart.
In this monograph, one approach to understanding receptor types, by
affinity labels, is discussed by Drs. Portoghese and Takemori.
Receptor types and analysis of binding data are dicussed at greater
length in NIDA Research Monograph 70.
A review of the historical search for a nonaddicting
analgesic--starting from days of opium use to the development of
agonists, antagonists, and the advent of opioid peptides--and of
future hopes is presented by Dr. Archer.
Through the interdisciplinary exchanges that took place at this
conference and the resulting volumes, an effort has been made to
summarize the existing information in the area of opioid peptides
and to discuss the implications of that information for future
research objectives.
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Frontiers of Research in the Medicinal
Chemistry and Molecular Pharmacology of
Opioid Peptides
Rao S. Rapaka, Ph.D.
The conquest of pain has been long sought by monks, medical
practitioners, quacks, and laymen, alike, and each of them has
attempted to achieve their goal in their own way. Opium was
used for centuries by the ancient cultures for its analgetic
effects. In 1806, Serturner discovered the analgetic effects
of morphine. However, the side effects of the opiates, such as
addiction liability and respiratory depression, were soon
realized. This further motivated research for other compounds,
either from naturally occurring plant drugs or synthetic
sources. A number of useful compounds--such as meperidine,
methadone, d-propoxyphene, nalorphine, phenazocine, etc.--were
synthesized. However, the goal to discover an ideal analgetic
without the undesirable side effects has not been achieved. In
the meantime, advances in the neurosciences, endocrinology,
protein synthesis, molecular biology, and other sciences have
resulted in a better understanding of brain function and its
modulation. The characterization of opiate receptors (Pert and
Snyder 1973; Simon et al. 1973; Terenius 1973) and later the
isolation and structure determination of the enkephalins (Hughes
et al. 1975) have ignited an explosive interest in the under-
standing of the role of the endogenous ligands in general, and
their role in brain function in particular. Subsequent
developments in recombinant DNA technology added an important
tool to research on precursors of the endogenous ligands.
The opiate receptor--the site where the opiates interact to
produce the biologic effect--was soon to be called the opioid
receptor, as the endogenous ligands are peptides. A number of
other opioid peptides were soon discovered. Following their
discovery, several hundred synthetic analogs were made and
tested. Extensive pharmacological testing and studies on
binding at the receptor site showed that the opioid receptors
are heterogeneous (Martin et al. 1976) and that at least four
types of receptors exist (Martin et al. 1976; Lord et al.
1977). As information accumulated on opioid peptide families
and their functions, it seemed that it would be useful to
discuss the pertinent questions on the medicinal chemistry and
molecular pharmacology of opioid peptides.
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Research on opioids is progressing in several directions. Some
of the important topics that have attracted a great deal of
attention by researchers are: biosynthesis, processing of
precursors, endogenous antagonists, specificity in drug design,
conformational restriction in analog design, inhibitors of
enkephalin-degrading enzymes as analgetic drugs, conformational
features of peptides, conformation-receptor selectivity,
retro-inverse analogs, amphiphilic helices, receptor types and
their structure and organization, drug-receptor interaction, the
role of lipids in the interaction, and analytical methodology.
Some of these aspects are reviewed in a preliminary fashion
below. (For additional information, see reviews by Udenfriend
and Kilpatrick 1983; Coplov and Helme 1983; Hughes 1983; Rapaka
et al. 1985.)
Biosynthesis of opioid peptides is being actively investigated.
A number of translational and posttranslational events are
involved in the generation of active peptides, and these
processes occur in a well-defined order. Processing of the
opioid peptides appears to be tissue-specific, and different
sets of processing enzymes seem to be responsible for the
tissue-specific processing of the neuroendocrine peptides.
Pairs of basic amino acids serve as signals for the processing
enzymes. The enzymes appear to be trypsinlike and, quite often,
carboxypeptidase like activity is also involved (Fricker 1985;
Rapaka et al., in press). Other posttranslational modifications
include phosphorylation, acetylation, sulfation, methylation,
glycosylation, amidation, etc.
Processing of precursor peptides to bioactive peptides is
largely explored using synthetic peptides (Marks et al., this
volume; Rapaka et al., in press). In addition to the "dibasic
residues," X-Arg-Pro- appears to be another processing signal as
postulated by Matsuo (NIDA Research Monograph 70), or referred
to as the single arginine cleavage (Weber et al. 1983). This is
exemplified by the generation of metorphamide (Weber et al.
1983) or adrenorphin (Matsuo et al., NIDA Research Monograph
70) from proenkephalin (corresponding to 210-217). Another
example of single arginine cleavage is the generation of
dynorphin(1-8) from prodynorphin corresponding to 209-216
residues). Single arginine cleavage was also postulated for the
processing of dynorphin B-29 to dynorphin B(1-13) at the Thr-Arg
bond (Devi and Goldstein 1984). Here it is to be noted that Arg
is followed by Ser (not Pro).
Another interesting processing event is amidation. The
mechanism of C-terminal amidation was investigated by Bradbury
et al. (1982). C-terminal amidation involves the action of a
specific enzyme, and glycine is a mandatory amino acid in the
C-terminal position. The amide does not arise from amnonia or
by direct amidation or transamidation. The mechanism involves
removal of hydrogen from the C-terminal glycine and spontaneous
hydrolysis of the imino linkage. Amidation is well known for
neurohypophyseal peptides, oxytocin, and vasopressin; and
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more and more amidated opioid peptides are being isolated.
Metorphamide or adrenorphin Tyr-Gly-Gly-Phe-Met-Arg-Arg-
Val-NH2 is an amidated peptide. Dermorphin, Tyr-D-Ala-Gly-
Phe-Tyr-Pro-Ser-NH2, is another amidated peptide and is
isolated from the skin of the South American frog of the
phyllomedusa species (Montecucchi et al. 1981). Recently,
another amidated peptide, amidorphin, was isolated from bovine
adrenal medulla (Seizinger et al. 1983). A very significant
aspect in the isolation of this peptide is that it was logically
deduced to be a processed product of the known bovine pro-
enkephalin A sequence, as it has the necessary processing
signals, including a terminal glycine essential for amidation.
The other significant aspect of the paper is that the expected
product was first synthesized to establish the presence of the
proposed endogenous product.
An important aspect of amidation is its effect on receptor
selectivity. This is reflected in the decreased -receptor
affinity of Met5-enkephalinamide as compared to Met5-
enkephalin. However, amidation of Val-8, as in metorphamide,
causes an increased affinity at the k-receptor site with an
insignificant change at the µ and sites.
Li (NIDA Research Monograph 70) and colleagues have determined
the primary sequence for -endorphins from various species.
They all consist of 31 amino acids with Tyr-Gly-Gly-Phe-Met at
the N-terminal sequence. Although minor differences are noted
in the primary sequence for -endorphins isolated from various
species as compared to the human, it appears that the amino acid
sequence in general is highly conserved. These various
-endorphins isolated from several species, due to minor changes
in the primary sequence, may be considered as the naturally
occurring analogs of the -endorphin. Biological activity of
some of these endorphins was evaluated and it was found that the
ratio of binding activity to analgetic potency varied for these
endorphins. This might be due to the fact that once the peptide
was bound to the receptor, the analgetic potency might depend on
the efficacy of the agonists.
In addition, smaller fragments of -endorphin appear to be
present in the pituitary glands of several animals. In fact,
-endorphin (1-27) was isolated from porcine tissue (Smyth et
al. 1978) and was later synthesized (Zaoral et al. 1981) . This
naturally occurring -endorphin (1-27) inhibits the analgetic
properties of -endorphin. Other synthetic fragments of
-endorphin (1-28) and (1-26) also inhibit analgesia induced
by -endorphin (Nicolas and Li 1985). These observations
have led Li and colleagues to formulate the following hypo-
thesis: "Inhibition of a peptide hormone by a naturally
occurring segment of the same hormone may be a general
phenomenon in biologically active peptides."
After the realization that the opioid receptor is heterogeneous
and that there are at least three types of receptors (µ, and
k) and possibly a fourth type several groups have attempted
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to understand the features essential for receptor selectivity.
Several thousand analogs of enkephalins were synthesized and
receptor specificity was investigated (see Shimohigashi, this
volume; Fournie-Zaluski et al. 1981; Roques et al. 1982).
Following rational design, -receptor specific enkephalin
analogs, such as H-Tyr-D-Ser-Gly-Phe-Leu-Thr-OH (DSLET) and
H-Tyr-D-Thr-Gly-Phe-Leu-Thr-OH (DTLET), were developed. To
summarize briefly, the principal characteristics for -receptor
binding affinity for noncyclic (excluding the conformationally
restricted analogs) enkephalin analogs are:
a) hydrophilic side chain in position 2,
b) aromatic residue (4th position),
c) C-terminal carboxyl group in the fifth position, and
d) the lengthening of the peptide chain by Thr6 residue.
Here, it is to be noted that (D-Pen2, D-Pen5)
enkephalin, a conformationally restricted analog, is
the most selective -ligand available (See Hruby, this
volume and references therein).
Characteristics of high specificity for µ-binding sites are,
a) D-residue in the second position,
b) shortening of the enkephalin sequence,
c) removal of the terminal carboxyl group,
d) replacement of Phe4 residue with lipophilic alkyl
chain and stereo-orientation of the Phe4 residue, and
e) N-methylation of Phe4 residue.
Although these modifications produced significantly improved
receptor-specific ligands, alternate approaches were also
attempted.
One of the synthetic approaches that has resulted in the
development of highly receptor-selective ligands is confor-
mational restriction or constriction. For an excellent
minireview on conformational restriction in peptides via amino
acid side chains, see Hruby (1982). Linear peptides are highly
flexible and exist in a conformational equilibrium. Moreover,
the conformational states may be influenced by the solvent and
the surrounding environment. Hence, if one of the various
conformers is the most active form, then dilution of the active
forms can be avoided by reducing the number of inactive forms.
Formation of cyclic peptides is one of the main modes. Some
other structural modifications include N-methylation of the
amide NH, replacement of the -H (to -CH3), formation
of disulphide bonds, and similar side-chain cyclizations. These
conformationally restrained analogs might have increased agonist
or antagonist properties due to enhanced conformational in-
tegrity, thus possessing increased specificity and biological
activity. These analogs may have increased enzymatic stability,
as well. This technique has already been utilized for de-
veloping analoqs with desired properties in the oxytocin and
bradykinin series. In the opioid peptides, a number of
conformationally restricted analogs were synthesized for the
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enkephalin peptides. As the integrity of the Tyr residue has to
be maintained at position 1, and as manipulations are
permissible at positions 2 and 5, mast of these analogs were
modified at positions 2 and 5. One of the earliest syntheses
was by Schiller and colleagues using w-diaminobutyric acid
as the second residue and affecting the cyclization of w-amino
group to the C-terminal carboxyl group (DiMaio and Schiller
1980; DiMaio et al. 1982). Similarly, other cyclic peptides
were synthesized utilizing cyclizations between the side chains
of Lys and Orn, with those of Asp and Glu (Schiller et al.
1985). Generally, the cyclic peptides exhibited preference for
µ-receptors over -receptors and were biologically more active,
whereas the corresponding open chain analogs did not show
similar preference or enhanced activity. Another type of
side-chain to side-chain cyclization was attempted using Cys
residues in the 2 and 5 positions.
Using this technique, Hruby and colleagues (this volume)
syntesized a series of analogs. Among these analogs,
[D-Pen2, Cys5]-enkephalin, [D-Pen2, Pen5]-enkephalin and   
[D-Pen2, D-Pen5]-enkephalin are some of the very highly
selective -receptor selective compounds. (D-Pen2,D-Pen5)-
Enkephalin demonstrates beneficial effects of further confor-
mational restriction of gem-dimethyl groups of the Pen moiety.
It also appears that the cyclic analogs and the linear compounds
have similar modes of binding to receptor sites.
Other types of sterically constrained enkephalins are those that
contain -amino isobutyric acid and cyclopentane-1-carboxylic
acid residues (see Kishore and Balaram, this volume).
Another mode of conformational restriction is the synthesis of
peptides incorporating -dehydroamino acids (referred to as
the dehydro- or -amino acids) or the cyclopropyl amino acids
-amino acids). These amino acid substitutions confer unique
chemical and stereochemical properties, as they effect both
chemical reactivity and conformation. For reviews, see Noda et
al. (1983) and Stammer (this volume, 1982). A substitution at
the second position, i.e., -Ala2-enkephalin, facilitated,
interaction at the µ-receptor site (due to enhanced lipo-
philicity), whereas substitution at 3-position in enkephalin may
have facilitated the interaction at the -receptor site.
Studies on -Phe4-enkephalins indicated that the Z-compound
(phenyl ring and C=O are trans) sterically favors interaction
with the -receptor site (Shimohigashi and Stammer 1983). An
additional advantage of substitution with amino acids is that
peptide linkages with -dehydroamino acid residues are highly
resistant to enzymatic degradation at the C-terminal side and
completely resistant at the N-terminal side (Shimohiqashi et al.
1982). Enkephalin analogs with cyclopropyl amino acid residues
seem to be resistant to enzymatic degradation as well (Stammer,
this volume).
To date, conformational restriction appears to provide the most
successful approach in the design of synthetic analogs with high
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receptor selectivities.
Another original approach for improving the selectivity of
receptor binding, although less explored, is formation of
dimeric peptides (Shimohigashi, this volume; Shimohigashi et al.
1982; Rodbard et al. 1983). Dimeric penta- and tetra peptide
analogs of enkephalins were shown to exhibit enhanced affinity
and selectivity for the -receptor.
The biological activities of peptides generally depend on both
primary and secondary structure. For some cyclic peptides it
was shown that retro-isomers--in which the direction of the
amide bonds linking the residues is reversed--retain biological
activity. In these cyclic peptides, it may be assumed that
biological activity results from the three dimensional topology
and not from the peptide backbone. The concept of retro-
peptides has also been extended to linear peptides (Goodnan and
Chorev 1979). To obtain closeness in three-dimensional
structure, a further modification of chirality at each chiral
center was also investigated. These modified analogs are named
"retro-inverso-peptides." Several partially modified retro-
inverso-peptides were synthesized for a number of biologically
active peptides. These modifications helped in assessing the
relative importance of side-chain versus backbone structure in
conferring biological activity. An additional reason for syn-
thesis of these analogs is the expected resistance to bio-
degradation. This concept was applied in developing analogs of
enkephalins (Berman et al. 1983), enkephalinase inhibitors such
as retrothiorphan (Roques and Fournie-Zaluski, NIDA Research
Monograph 70), and dermorphin (Salvadori et al. 1985).
Prediction of the formation of certain types of secondary
structures from the amino acid sequences is very helpful in the
rational design of biologically active peptides. The amphi-
philic environment of the aqueous solution and lipid bilayar of
the membrane could impose a secondary structure on the peptide.
If the secondary structure formation is initiated by the mem-
brane, it is likely to be characterized by the amphiphilic
distribution of the individual amino acid side chains; amphi-
philic helical structures have been hypothesized to be important
in determining the biological activity of a number of peptides.
This approach was successfully utilized in the design of
-endorphin analogs (Blanc et al. 1983). For a review on
amphiphilic secondary structures, see Kaiser and Kezdy (1984).
One of the main problems in the bioassay of the peptides and in
their use as analgetics has been their ease of biodegradation
(NIDA Research Monograph 70: Marks et al.; Shimohigashi; Roques
and Fournie-Zaluski). Enzymes involved in the metabolism of
opioid peptides, as well as in their isolation, assay, and
specificity are described by Marks et al. Enkephalins are
easily metabolized; Tyr1-Gly2 bond is cleaved by
amniopepidases, Gly3-Gly4 bond by enkephalinase, and
Phe4-Leu5 (Met5) by carboxypeptidases. Although extensive
research has been carried out on these enzymes, the specificity
8
of enzymess and the precise mechanisms of action are still not
established. In addition to the specific cleavage at a
particular amide bond, sequential processing has also been
proposed as an alternate mechanism of action (Fricker 1985;
Mains et al. 1983; Rapaka et al. in press).
In order to prevent the degradation of the enkephalins, a
variety of approaches were utilized, such as replacement of
D-amino acid for L-amino acid, N-methylation of the amide
linkages, replacement of amide linkages, or substitution with
unusual amino acids (dehydroamino acids, etc.). A closely
related but more innovative approach is the rational design of
inhibitors for the enkephalin-degrading enzymes (Roques and
Fournie-Zaluski, this volume). These compounds will prolong the
duration of action of the endogenously released enkephalins and,
hence, may be devoid of the major side effects of narcotic
analgetics. A number of enkephalinase inhibitors are derived
from Phe-Leu bearing carboxyl groups (to chelate Zn required for
this metalloenzyme) and are of the general formula: R-CH-
-CONH-CH[CH2CH(CH3)2]COOH with R=-COOH,-CH2COOH,
-NH-CH2-COOH and -NH-CH2-CH2-COOH. Highly potent
enkephalinase inhibitors were also obtained from L-Phe- -Ala
derivatives. Another series of enkephalinase inhibitors was
obtained from compounds that contained a thiol group, R-CH-
)CONH-CH[CH2CH-(CH3)2]-COOH, where R=-CH2SH and
-SH-CH2-CO. Although these are excellent enkephalinase
inhibitors, they are also angiotensin converting enzyme (ACE)
inhibitors. To enhance the specificity, the "retro" compound
HS-CH2CH(CH2 ) NH-CO-CH2-COOH, retrothiorphan, was
developed which, while retaining enkephalinase inhibitors
property, exhibited significantly less ACE inhibitor property.
In summary, this type of rational design has provided re-
searchers with a number of inhibitors, such as thiorphan,
retrothiorphan, and kelatorphan. The clinical use of these
compounds, however, is not promising, due to the limited
bioavailability of some. Development of synthetic analogs that
are orally active or have good bioavailability may be of thera-
peutic use; and this is expected to be achieved in the near
future.
Conformational aspects of opioid peptides have been examined
extensively. Most of the work has been focused on enkephalins,
on morphiceptins, and to some extent on endorphins. The
presence of a -turn in enkephalins was proposed, from x-ray
crystallographic data and solution studies (Camerman and
Camerman, this volume; Schiller, this volume; Schiller 1984).
The number of hydrogen bonds (2 or 3), and the type of -turn
(type I or II or I' or II') are not yet agreed upon universally
and much more work is warranted in this area. Recently,
Yamashiro and Li (1984) reviewed the conformational features of
endorphins.
Some of the other opioid peptides of interest are dermorphin and
dynorphin. Few conformational studies are reported on dynorphin
in the literature (Schiller 1983; Maroun and Mattice 1981).
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From circular dichroism studies on dynorphin(1-13), Maroun and
Mattice concluded that dynorphin does not have an ordered
structure in water. However, addition of a detergent, such as
dodecyl sulfate, enhances helical content to some extent. From
fluorescence studies on the biologically active Trp4-analogs
of dynorphin(1-13), Schiller observed that Tyr1-Trp4 are at
least 15 Ao apart (unlike the enkephalin Tyr1-Trp4
residues, which appears to have a folded conformation) and the
predominant conformation is where the N-terminal tetrapeptide is
almost completely extended. In addition, Schiller proposed that
the these conformational differences between dynorphin and
Leu5-enkephalin may play a role in preferences for various
opioid receptor subclasses.
To date, few conformational studies have been done on dermorphin
(Salvadori et al. 1983; Arlandini et al. 1985; Bhatnagar et al.,
in press). Salvadori et al. suggested the presence of a linear
extended structure from NMR studies and, due to lack of
significant dependence on PMR parameters over a concentration
range, the results indicated a monomeric peptide. Arlandini et
al. (1985), using various spectroscopic techniques, suggested
that dermorphin may preferentially exist in an extended,
flexible conformation and that an intermolecularly stabilized
form exists in DMSO. Recently, from FT-IR, laser Raman, CD,
conformational energy calculations, and molecular modeling
studies, it was proposed that dermorphin contains two -turns--a
type III -turn between residues one and four and a type II
-turn between residue five and the terminal amide group. This
conformation with two -turns is highly folded and mimics the
"morphine-type" conformation; and due to this conformation, it
may act as a potent µ-receptor aqonist. This highly folded
conformation and the hydrophobic environment may explain its
stability as well (Bhatnagar et al., in press).
Although earlier conformational studies mainly addressed the
correlation of structure between opioid peptides and rigid
opiates, the discovery of multiple opioid receptors and the
realization that different opioid receptor types may have
differing conformational requirements (Schiller and DiMaio 1982)
changed the direction of research in this area considerably.
Conformational analysis using theoretical methods has been
extensively reviewed by Gorin et al. (1978) and Schiller
(1984). In addition, computer-assisted drug design (Marshall,
this volume) and multidisciplinary approaches have also played a
significant role in the understanding of conformational
features. Recently, a computational procedure for determining
the energetically favorable binding sites on macromolecules has
been reported (Goodford 1985) and this may be of help in druq
design.
The role of conformation and its relation to biological activity
is not fully established. The peptide may exist in a number of
conformations and may continuously interconvert, especially in
the case of small peptides such as the enkephalins. It is a
question of whether a bioactive conformation preexists, such as
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in the hydroxylation of protocollagen by proline hydroxylase
(Rapaka et al. 1978) or is adopted (such as the "zipper"-type
model, Burgen et al. 1975; See also Schiller, this volume).
Similar to the concept of Burgen et al. is the concept of
"orbital steering," where large rate accelerations are observed
in enzymatic reactions. In orbital steering, the reactive atoms
are constrained to react along selected pathways (Dafforn and
Koshland 1971). It is conceivable that the opioid receptors
have conformational requirements for interaction which differ
depending on the receptor type (Schiller and DiMaio 1982). A
folded -turn conformation, similar to morphine, was proposed to
be the bioactive conformation for morphine-like or µ-receptor
activity (Smith and Griffin 1978). On the contrary, Camerman et
al. (1983) proposed for µ-receptor binding that an extended
conformation is the preferred conformation. Doi et al. (1984)
found that Boc-Tyr-Gly-Gly-(4-bromo)Phe-Met-OH is composed of
antiparallel -sheets, that this structure is stabilized by
intermolecular hydrogen bonds, and that the Boc-peptide has
considerable analgetic activity (although less than the
zwitterionic peptide). From these observations, they proposed
that the dimeric extended conformation may be involved in
binding to the -receptor. This proposal is supported by the
finding that dimeric enkephalins exhibit enhanced binding to
-sites (Shimohigashi et al. 1982). Later, the same group
(Ishida et al. 1984) determined the crystal structures of
Leu5- and Met5-enkephalins and their (4-bromo)-Phe4-
analogs. From these studies they found that Leu5-enkephalins
have type I' -turn conformation and Met5-analogs possess an
extended dimeric conformation. They proposed that dimeric
extended forms interact with the -receptor, while the -turn
conformer interacts with the µ-receptor sites. Recently,
Renugopalakrishnan et al. (1985), from their conformational
studies using FT-IR and laser Raman spectroscopies, proposed
that -turn containing enkephalins interact with -receptor
sites and -sheet containing peptides interact with µ-receptor
sites. Future studies might help in determining the confor-
mation-receptor selectivity in the opioid peptides.
So far, I have discussed the ligand-receptor interaction as if
these were the only components involved. The situation is much
more complex. Interaction between the opioid peptides and lipid
bilayers might be a very important event in the molecular
mechanisms of biological activity of these peptides (Loh and Law
1980; Schwyzer et al. 1982). "The lipid phase of the membrane
acts as a matrix for the receptors and is essential for the
functionality and biological arrangement of the receptor
proteins" (Gysin and Schwyzer 1983). This does not mean that
lipids are the peptide receptors, but rather that they are a
means to capture peptides (either by hydrophobic or electro-
static interactions or both) and facilitate interaction with the
receptor (Berg and Purcell 1977). Gysin and Schwyzer inves-
tigated the head group and structure specific interaction of
dynorphin and enkephalin liposomes. -Agonists interacted more
with phosphatidylserine (PS) and a mixture of lecithin and
phosphotidic acid (PC/PA), than with cerebroside sulfate (CS).
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µ-Agonists interacted more strongly with CS liposomes than with
PS and PC/PA, and k-agonist dynorphin (1-13) interacted more
strongly and more equally with all the systems. This makes it
possible to distinguish ligand types by lipid head group
specificity. Several other groups studied the interaction of
lipids and detergents with hormonal peptides (Gremlich et al.
1984), methionine enkephalin (Spirtes et al. 1978), and
dynorphin(1-13) (Maroun and Mattice 1981). The significance of
these investigations has yet to be explored by further research.
An area of growing interest and need is the quantitative
analysis of opioid peptides. Although RIA methods are largely
being used at present, instrumental methods such as HPLC and
LC/MS that are accurate, specific, sensitive, and reproducible
are required. These methods are essential to provide specific
analysis of low levels of endogenous peptides (active com-
ponents, precursors, and metabolites) and to understand
pathological states mediated through either lower or higher
levels of these peptides. These methods should be available in
conjuction with immunoassay methods to determine the levels of
synthetic peptides if they are used as druqs. These methods
should also be available for the pharmacokinetic evaluation of
the various bioactive moieties in biofluids.
Current research on opioid receptors has been reviewed
extensively (Simon, NIDA Research Monograph 70; Robson et al.
1983). In earlier studies, Pert and colleagues (Bowen et al.
1981; Olgiati 1982;) characterized type I and II receptors. The
receptor types are now understood better. For reviews see
Simon, this volume; Goldstein and James 1984; Herz 1984;
Paterson et al. 1984; and Kosterlitz 1985. Now sub-types are
already identified for some receptors. In the near future, the
receptor types will be mapped and the subtle differences
involved in their structure and organization will be
understood. At present, it may be speculated that endogenous
ligands might exist for µ-, and k-receptors. A recent report
indicated the existence of morphine as an endogenous compound in
the bovine CNS and in the skin of the toad and other animals
(Oka et al. 1985). This raises the question of whether there
exists an endogenous peptide ligand for the µ-receptor and
whether it is peptidic in nature. A PCP receptor has been
identified (Quirion et al. 1981) and evidence sugqests that the
endogenous ligand is present and is peptidic in nature (Quirion
et al. 1984). One might speculate that this will be an area of
research in drug abuse in the near future.
Other developments include synthesis of peptide antaqonists such
as ICI 174,864 (Cotton et al. 1984) and photoaffinity agents
such as azido DTLET (Garbay-Jaureguiberry et al. 1983; Morley
1983) and [D-Ala2,Leu5]-enkephalin N-[(2-nitro-4-azidopheny)-
amino]ethylamide [Fujoka et al. 1984).
Attempts are also under way to develop clinically useful druqs
and evaluate tnem. One example, FK 33-824, was shown to be
useful for detoxifying hard-core heroin abusers (Wen 1982).
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Extensive research has been carried out on naturally occurring
and synthetic opiates in order to obtain more useful analqetic
agents. Opioid peptides offer more promise than the opiates in
drug development because:
1. These compounds are endogenous and, on metabolic
degradation (unlike the opiates), break down to amino
acids. Hence, the metabolites are nontoxic and do not cause
kidney and liver damage (unlike the opiates).
2. Since the peptides are made up of several subunits, the
amino acid residues, a large number of analogs can be
synthesized from a few basic building blocks. Moreover,
simple modifications, such as substitution of unnatural
amino acids, sterically constrained amino acids, or other
modifications, may be attempted to develop analogs with a
desired biological activity.
3. The peptide analogs (unlike the opiates) are flexible
conformationally and are ideal molecules to investigate
relationships between 3-D structure and biological
activity. They may be cyclized or subjected to other
synthetic modifications, so that analogs of varying and
controlled flexibility can be synthesized and studied
(unlike the opiates).
4. As these molecules are substantially polar, solution
studies can be performed with different solvents and ions
(calcium, sodium, etc.) to understand their influences on
peptide conformations.
5. Technology for the synthesis of peptides is readily
available and solid-phase peptide synthesis is already
automated to a considerable extent, so that even complex
molecules can be synthesized in large quantities. Even the
ultimate goal of synthesizing pro-enkephalin (about 250
residues) and pro-dynorphin to provide scientists with
adequate material for studies on processing mechanisms seems
possible (see Bodanszky 1985).
6. To date, the compounds that are highly selective for
-receptors have been opioid peptides.
7. Due to the unique character of some of the peptide drugs,
i.e., their inability to cross placental barrier (due to
placental enzymatic deactivation of the peptides), these
drugs have a distinct advantage for being used as analgetics
in pregnant females. They are definitely superior to
meperidine in this respect.
At present, research in opioid peptides is progressing at a
rapid rate. Some of the important aspects follow:
Analgetic peptides are to be designed that will show minimal
drug dependence potential; the peptides of potential interest
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are enkephalins, endorphins, dynorphins, dermorphins,
morphiceptins, and related opioid peptides. Some of the goals
are: a) the development of peptide analogs that can be
administered orally, that have long duration of action, and that
are without the potential for abuse; and b) synthesis of
inhibitors of enkephalin-degrading enzymes as potential
analgetics. Extensive SAR studies on the opioid peptides may be
of great value in the rational design of these analogs. It is
further anticipated that SAR studies on opioid peptides might
result in the development of antagonists and mixed agonist-
antagonists that are clinically useful in the treatment of
opiate addiction.
Several hundred analogs of the opioid peptides have been
evaluated to aid in delineating the essential features of the
µ-and -receptors. The synthesis of even more specific analogs
for all types of receptors can be anticipated.
The receptor types are well differentiated on the basis of
binding studies and/or pharmacological studies. However,
considerable information on sites and functions is still
lacking. Particularly, the component peptides of the different
receptors must be isolated and characterized, and receptors or
receptor models must be synthesized or reaggregated to
understand mechanism(s) of action. It may be possible to study
the conformation of the receptor in response to environment-
mediated conformational changes (i.e., lipids, ions, solvents,
ionic strength, polarity, etc.) and the conformation of the
drug-receptor complex itself.
A number of conformational studies have been conducted on opioid
peptides; however, most of them are performed on enkephalin
peptides as they are relatively small pentapeptides and are
easily accessible. Conformational studies using theoretical
solid-state and solution methods have to be extended to all the
pertinent opioid peptides and their analogs. The effects of the
surrounding environment (solvent, pH, ionic effects, etc.) must
be examined; and, finally, the receptor-bound conformation of
the drug must be determined. Advanced methods such as X-ray
crystallography, FT-IR, laser Raman, nuclear magnetic resonance,
C.D., and computer-assisted drug design will play an increasing
role in these studies.
Research in the opioid peptides is progressing at a rapid rate.
In the near future, we may look forward to still more exciting
discoveries, and there is room for optimism to believe that
therapeutically useful peptide analgetics may soon be
developed.
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AUTHOR'S NOTE
This review is not comprehensive. Only a few selected
references and topics are included, as it is impossible fully to
review an extremely active area such as this, and other authors
have presented pertinent topics and references. For further
information on the topics or references, the reader is referred
to the following chapters in this monograph, NIDA Research
Monograph 70, and The peptides: Analysis, Synthesis, Biology.
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Synthesis of Opioid Peptide Analogs
John M. Stewart, Ph.D.
INDTRODUCTION
Elucidation of the structures of the first opioid peptides, the
enkephalins, in 1975, stimulatad an unprecedented wave of syn-
thetic activity. Fortunately, peptide synthetic methods had been
develoqed to the point where synthesis of opioid peptides was
easily accomplished, particularly the small ones. In this chap-
ter, contemporary methods of peptide synthesis will be discussed,
especially as they apply to the cpioid peptides.
Peptides may be synthesized either in solution, using classical
organic synthetic procedures, or by the newer method of solid
phase peptide synthesis introduced by Merrifield. Solution syn-
thesis may be practical for small peptides, particularly if large
quantities are to be synthesized. Successful application of solu-
tion methods generally requires that the person performing the
synthesis be skilled and experienced in peptide synthetic proce-
dures. On the other hard, solid phase peptide synthesis (SPPS),
introduced twenty years ago, allows rapid synthesis of a wide
variety of peptides and doss not require a high degree of chem-
ical shill on the part of the person doing the synthesis. It has
been applied sucessfully to the synthesis of many longer pep-
tides, such as ß-endorphin and its analogs. The availability of
commercial automatic peptide synthesizers sakes SPPS a rapid and
convenient procedure. It is particularly useful for synthesism of
a wide variety of analogs, such as has been done in the case of
the cpioid peptides.
PRINCIPLES OF PEPTIDE SYNTHESIS
Successful peptide synthesis rests upon two maajor factors: 1)
application of a suitable set of selectively removable blocking
groups for the reactive functions of the amino acids to be in-
corporated into the peptide, and 2) use of suitable activating
reagents to perform the coupling reactions involved. Synthesis of
a tripeptide is depicted schematically in figure 1. During every
coupling step, only those reactive groups which are intended to
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FIGURE 1
Schematic Synthesis of a Tripeptide
S=stable blocking groups; L=labile blocking group
react are left unprotected. Other reactive groups are blocked
either by stable blocking groups (indicated with S),which remain
intact throuh out the process of assembly of the desired peptide,
or by means of a labile blocking group (indiated above as L),
which will be removed at each step of the synthesis. Synthesis
usually begins at the carboxyl end of the peptide. The most com-
monly used procedure for synthesis of peptides of the size range
of the opioid peptides is that of stepwise synthesis, in which a
single amino acid is added at each coupling reaction. It is ex-
tremely important that optical purity of all the amino acid resi-
dues be maintained throughout the synthesis. For all the natur-
ally occuring amino acids, the L isomer is used. However, in
synthesis of enzyme-resistant opioid analogs, D-amino acids are
frequently used. Coupling reactions must be chosen with care to
avoid racemization of the amino acid residue which is activated
during the coupling reaction. The most reliable method for avoid-
ing such racemization is coupling of single amino acids, each
having its -amino group protected with a urethane-type pro-
tecting group.The most commonly used such urethane group at the
present time is the t-butylaxycarbonyl (Boc) group: its structure
is indicated in figure 3. The Boc protecting group is commonly
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FIGURE 2
Mechanism of coupling Reactions Mediated by DCC
removed at each step of the synthesis by treatment of the pro-
tected peptide with anhydrous acid, much as trifluoracetic acid
(TFA) in an inert solvent such as dichloramethane (DCM).
When the Boc group is used for the labile -protecting group, the
stable blocking groups are usually derived fran benzyl-related
blocking groups. Thus, the stable blocking group for the C-
terminal carboxyl of the peptide may be a benyl ester, which can
also be used for blocking side chain carboxyls of aspartic and
glutamic acid residues. The aliphatic hydroxyl groups of serine
and threonine may be blocked as benzyl ethers. The hydroxyl group
of tyrosine and the amino group of lysine are usually blocked
with a group related to the benyloxycarbonyl blocking group,
which has been in use for many years in peptide chemistry.
Arginine and histidine side chains are most commonly blocked with
the p-toluene sulfonyl (Tos) group. All these stable blocking
groups can be removed from the peptide at the end of the synthe-
sis by treatment with a strong anhydrous acid, such as liquid
anhydrous hydrogen fluoride.
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More labile systems of blocking groups have been developed for
peptide synthesis. For example, the labile blocking group can be
the biphenylylpropoxycarbonyl (Bpoc) or the phenylisopropyl-
oxycarbonyl (Poc) group. When these very labile groups are used
for -protection, side chains can be blocked with functions
related t-butyl groups, such as t-butyl esters and Boc groups.
Very dilute TFA is used to remove the labile protecting group at
each stage of the synthesis, while more concetrated TFA can be
used to remove the stable blocking groups at the end of the
synthesis.
These two synthetic schemes outlined above depend for their
success on the differential lability to anhydrons acid of the
labile and stable blocking groups. Some reaserch has been done on
developement of orthogonal systems of blocking groups where the
labile and stable blocking groups are removed by completely dif-
ferent types of reagents. Such a systen can use the fluorenyl-
methoxycarbonyl (Fmoc) -blocking group; it is removed by treat-
ment with an amine such as piperidine. The stable blocking groups
can be t-butyl derived functions, which are stable to the mine
used to remove the labile blocking group. This systen has re-
ceived only limited application to synthesis of opioid peptides,
principally due to the greeter cost of Fmoc amino acid deriva-
tives. Furthermore, yields have usually been quite satisfactory
using selective acidolysis procedures.
Given a set of blocking groups suitable for the synthesis at
hand, ate needs then to choose appropriate coupling reactions. By
far the most commenly used coupling reagent is dicyclohexylcarbo-
diimide (DOC). Use of DOC is particularly convenient, since it
can usually simply be added to the solution containing the amine
and carboxyl component to be coupled. It reacts rapidly with the
free carboxylic acid present to form an "active ester" interned-
iate (the isaurea),which may react with the amine component dir-
ectly or may proceed through an intermediate symetrical anhy-
dride (see figure 2). Rearrangement of the isourea to the N-acyl
urea is an undesired side reaction. Coupling reactions mediated
by DOC can also be modified by addiction of other reagents, such as
as 1-hydroxybensotriazole (HOBt). This leads to intermediate for-
mation the HOBt active ester, which may minimize racemization
and may also facilitate some coupling reactions. If glutamine is
being incorporated into the peptide, it can also minimize dehy-
dration of the omega amide group to a nitrile. Mixed anhydrides
have also been frequently used to promote coupling reactions,
particularly in solution synthesis methods. However, a dis-
cussion of such reagents is beyond the scope of this article. A
good introduction to peptide synthesis in general is given by the
book of Bodanszky et al. (1976).
SYNTHESIS OF PEPTIDES IN SOLUTION
Peptide chmists working during the last fifty years have de-
veloped methods suitable for effective synthesis of peptides in
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solution, applying the principles outlined in the previous
section. Solution methods have been used mainly for synthesis of
shorter opioid peptides, such as analogs of the enkephalins.
Solution synthesis is usually used for production of large
quantities of peptides, particularly if the peptide chain is
short. Solution synthesis also offers the opportunity for use of
segment coupling methods, in which a small block peptide is
synthesized and then coupled to the reminder of the chain in me
step. A major problem with segment synthesis methods is that of
racemization of the carboxy-terminal residue in the segment when
it is activated for coupling. However, this is not a problem with
enkephalin synthesis if the fragment is properly chosen, since
glycine residues cannot racemize and the presence of two glycine
residues in the enkephalin sequence allows for convenient
breaking of the chain into segments. This approach can offer
practical advantages for synthesis of a series od analogs
modified at the carboxy end. For example, variations in the
structure of enkephalins at the 4 and 5 positions (phenylalanine
amd leucine or methionine) could utilize a blocked fragment
consisting of tyrosyl-glycyl-glycine or tyrosyl-D-alanyl-glycine
for coupling to various C-teminal dipeptides. In solid phase
synthesis (SPPS), the entire sequence must usually be repeated in
a stepwise fashion for each of such analogs.
Various combinations of the blocking groups and coupling reagents
described in the previous section have been used in the synthesis
of opioid peptides. Syntheses of these peptides described in the
literature may appear very simple, and in principle they are.
However, successful results in solution synthesis of peptides
generally requires considerable experience. The novice will fre-
quently waste a great deal of time and money attempting to syn-
thesize even small peptides by these methods, and is advised to
use solid phase techniques instead.
Amides ob enkephalin peptides have been found to have high
potency, particularly for mu receptors. In solution synthesis,
peptide amides are synthesized by beginning the synthesis with
the mide of the C-terminal residue to be incorporated into the
peptide, e.g., methionine amide. They can also be synthesized
fran peptide esters by ammonolysis, provided there are no
aspartic or glutamic residues in the peptide (these would be
concomitantly changed to asparagine and glutamine residues).
Certain enkephalin analogs in which the C-terminal methionine
carboxyl group has been reduced to an alcohol have been found to
be very potent. Such peptide alcohols can be synthesized by
beginning the synthesis with a benzyl ether of the C-terminal
alcohol and using HF for final deblocking of the finished
peptide. If there are no aspartic or glutamic acid residues in
the peptide, the synthesis my be carried out with the methyl
ester of the C-terminal residue. Treatment of the finished
blocked peptide with lithiumborohydride will then yield the C-
terminal alcohol.
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SOLID PHASE PEPTIDE SYNTHESIS
Solid phase peptide synthesis was introduced by Bruce Merrifield
in 1963 in the hope of overcoming many of the problems inherent
in solution methods of peptide synthesis. The experience of the
past twenty years has shawn that hope to be amply justified.
Autmatic instruments have been develcped and are available
ambercially which will carry out SPPS rapidly and efffectively.
Many thousands of peptides have been synthesized with SPPS. In
contrast to the relatively high degree of technical sophisti-
cation required for successful peptide synthesis in solution,
successful SPPS of many peptides can be carried out by persons
with no prior experience in peptide synthesis and only limited
competence as organic chemists. As one imnunolcgist said, "solid
phase synthesis is so simple than even an inmunologist can do
it!" The comprehensive review of Barany and Merrifield (1980)
provides an encyclopedic coverage of the solid phase literature,
and the laboratory manual of Stewart and Young (1984) provides
specific laboratory directions for synthesis of peptides by SPPS.
FIGURE 3
The Merrifield Scheme of Solid PHase Peptide Synthesis.
The polymer is 1%-crosslinked polystyrene; TFA=trifluoroacetic
acid; TEA=triethyl amine; DCC=dicyclohexylcarbodiimide.
26
Solid phase peptide synthesis is a special case of the general
scheme of stepwise synthesis of peptides fran the carboxy end,
in which the stable blocking group for the C-terminal carboxyl
of the peptide being synthesized is an insoluble polymer (figure
3). In the Merrifield system of SPPS, the C-terminal amino acid
residue is esterified to a functionalized cross-linked poly-
styrene resin, which serves as the carrier. Mast SPPS has been
done with Boc amino acids. Follwing attachment of the first Boc
amino acid to the resin, the resin is analyzed for the degree of
substitution of the amino acid cm the polymer. A batch of Boc-
amino acid resin is then placed in the reaction vessel of a
manual or automatic synthesis apparatus; the resin need never
be rmoved from the vessel until the assembly of the peptide is
finished. By avoiding any transfer of material from one vessel to
another during the synthesis, much loss of material is elimi-
nated. The Boc group is removed from the amino acid on the resin
by treatment with an acidic reagent, usually TFA in DCM. HCL in
dioxane has also been used successfully for my syntheses, but
is less covenient to use. The amino acid-resin is then treated
with a tertiary amine base to neutralize the acid salt and
liberate the free amino group for coupling with the next Boc-
amino acid. The next Boc-amino acid can be coupled to the amino
acid-resin by use of DCC or any other oonvenient method for
coupling. Use of DOC: is rapid and convenient, and usually gives
satisfactory results. In those cases where complete coupling
cannot be achieved in one or two cycles, use of an active ester
(either formed in situ by addition of HOBt or used pre-formed
HOBt active ester) or use of a Boc-amino acid symetrical
anhydride can be tried. Symmetrical anhydrides are very effective
for promoting complete coupling reactions, but their use involves
additional work and is frequently not necessary. Repetition of
the deprotection, neutralization and coupling steps with each Boc-
amino acid to be introduced into the peptide sequence will then
yield the blocked peptide an the resin. If the peptide being syn-
thesized is to have a free carboxyl group, treatment of the pep-
tide-resinwith liquid anhydrous HF will cleave and deprotective
peptide in me operation.
If all deprotection and coupling reactions go fully to com-
pletion, a homogeneous peptide will be assembled on the resin.
If the cleavage reagent does no harm to the peptide, then the
crudepeptidewill be essentially pure. Using the best of modern
techniques, this level of success can frequently be achieved
in practice. In such cases purification of the final peptide is
very simple. After the initial Boc-aminoacylresin is synthesized
and analyzed, autamatic synthesizers can carry out assembly of
the peptide at the rate of one residue every two to fair hours.
Cleavage of the peptide fran the resin with HF will require an
additional half day of time. If the synthesis procdures were
carried out effectively, purification can then frequently. be a
simple short operation like chromatography or countercurrent
distritution. The speed of SPPS carried out in this way makes
it particularly practical for synthesis of analogs of opioid
peptides, especially those analogs in which variation in the
sequence will be toward the anino end of the peptide. In that
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case, a large batch of aminoacyl-resin can be carried through the
synthesis up to the point where the different substitutions will
be made. Individual syntheses can then be carried out with the
desired amino acids on a smaller scale, using portions of the
peptide-resin previously prepared.
Synthesis of peptide amides is also convenient by SPPS. If the
peptide chain does not contain aspartic or glutamic acid resi-
dues, the sequence can be assembled on Merrifield resin and
cleaved by amonolysis. However, if the sequence contains these
residues (ß-endorphin contains glutamic acid residues), this
approach is not satisfactory, because the glutamic residue will
be banged to glutamine if the ammnolysis is conducted on a
peptide resin in which the glutamic side-chain carboxyl is
blocked with a benzyl ester. A hydroxymethyl resin support can
be used for a synthesis, however, in which the labile system of
blocking groups or the orthogonal systen (as described above) is
used. In those cases, the glutamic carboxyls can be protected as
t-butyl esters, which should not be converted to glutamine
residues during ammonolysis. A simpler approach uses for the
insoluble support a resin which will yield a peptide amide
directly upon cleavage of the peptide with anhydrous HF. Such
resins are the benzhydrylamine (BHA) and methylbenzbydrylamine
(MBHA) resins (see figure 4). If an aminanethyl resin analogous
to the hydroxymethyl Merrifield resin is used for synthesis of
peptides, HF will not cleave the peptide fran the resin, as that
group is not sufficiently labile. If the aminomethyl resin is
FIGURE 4
Synthesis of peptide Amides via Amine Resins
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labilized by addition of another phenyl or p-methylphenyl residue
as in the case of the BHA and MBHA resins, the nitrogen-carbon
linkage is now sufficiently labile that treatment of peptide-BHA
(or MBHA) resins with HF will yield peptide amides directly. The
linkage of peptides to the MBHA resin is somewhat more labile
than in the case of the BHA resin, and the MBHA is more
satisfactory for the synthesis of peptides whose C-terminal
residue is me which makes the peptide relatively resistant to
acicdolysis, such as phenylalanine or leucine. Miny analogs of [D-
Ala1]-methionine-enkephalin amide have been synthesized on these
resins. Directions for synthesis and use of these resins are
given in the laboratory manual of Stewart and Young (1984).
Peptide alcohols,whichhavebeen found useful in the enkephalin
series, can also be synthesized satisfactorily by solid phase
methods if the amino acid sequence does not contain glutamic or
aspartic residues. The peptide sequence is assembled on the hy-
droxymethyl Merrifield resin, and the blodced peptide-resin is
treated with lithium borohydride to effect reductive cleavage to
an alcohol of the ester linking the peptide to the resin.This
procedure is also described in the Stewart and Young manual.
SIDE REACTIONS DURING PEPTIDE SYNTHESIS
If an appropriate set of blocking groups and reaction conditions
is chosen for synthesis of peptides, undesirable side reactions
during assembly and deblocking of the peptide can be minimized.
If the conditions for solid phase synthesis recommended in the
Stewart and Young manual are followed, little difficulty can be
expected However, if less than ideal condtions and derivatives
are used, some problems can be expected. Methionine-enkephalin
contains two residues which can cause problems: methionine and
tyrosine. The sulfur in methionine residues can be readily al-
kylated under appropriate conditions (see figure 5). Such condi-
tions can cccur during deblocking of the peptide. When benzyl
blocking groups are removed from side-chain functions during HF
cleavage, the benzyl oation, if allowed to persist for any sig-
nificant length of time,will alkylate methionine to the sulfon-
ium derivative. The sulfonium derivative of methionine-enkephalin
has very low biological activity. This undesirable alkylation can
FIGURE 5
Formation of Methionine Sulfonium Peptides
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be prevented by inclusion of a large excess of scavenger reagent
in the clevage reaction mixture. Such reagents as anisole and
methylethylsulfide are commonly used for this purpose.Methionine
can also be oxidized easily to the sulfoxide derivative. Indeed,
the sulfoxcide has been found highly potent the case of certain
methionine-enkephalin derivatives. However, in this case, the
synthesis can be done with Boc-methionine sulfoxide, which should
be stable throughout the synthesis and HF cleavage. If sulfoxide
is not desired, syntheses can usually be carried out with Boc-
methionine without significant oxidation to the sulfoxide. How-
ever, if it is found that in a particular sequence or under par-
ticular reaction conditions being used this undesirable oxidation
takes place, any sulfoxide in the peptide-resin can be reduced
conveniently to methionine by inclusion of 2-mecaptopyridine in
the HF cleavage reaction mixture (see Stewart and Young 1984).
If the hydroxyl group of tyrosine is blocked during synthesis as
the benzyl ether, HF treatment can yield some of the unde-
sired 3-benzyl tyrosine (see figure 6). This Friedel-Crafts type
reaction is promoted by anhydrous HF. The alkylation can be
prevented if large quantities of scavenger are included in the
cleavage reaction mixture. Most peptide chemists currently prac-
ticing solid phase synthesis do not use O-benzyl tyrosine for
this reason. The 2,6-dichlorobenyl and the 2-bromocarbobenzoxy
derivatives have been found to yield very little of the undesired
alkylated derivate. Bath the 3-benzyl tyrosine and the S-benzyl
methionine analogs of enkephalin have been found to have very
little biological potency. One should normally take pains, there
fore, to suppres these side reactions. Other possible side
reactions which may be encountered during solid phase synthesis
are disscused in the Stewart and Young laboratory manual.
If the directions given in the Stewart and Young manual are
followed even novices could be able to synthesize opioid
peptides without serious problems. Only general procedures are
given in that manual. If the chemist wishes to follow a set of
directions specific fox methionine-ankephalin, such directions
FIGURE 6
Alkylation of the Tyrosine Ring by Benzyl Groups
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can be found in the volume of "Methods of Enzymology" dealing
with synthesis of neuropeptides (Stewart 1983).
PURIFICATION AND ANALYSIS OF PEPTIDES
Following assembly and deblocking of a desired synthetic psptide,
the product must be purified essentially to homogeneity and
analyzed for identity before being used. While some ideas of
biological potency my be obtained in rapid screening programs by
use of new analogs not fully purified, accurate quantitative data
can only be obtained with fully purified peptides. Physical
studies on peptides also require synthetic wterials of the
highest purity.
When peptides are synthesized in solution, the intermediate
products are usually pirified frequently during the various steps
of the synthesis. In that case, final purification of the peptide
is frequently quite simple. However , even if the final protected
peptide is fully purified, same by products may be introduced
during deblocking, and these must be removed. Some small peptides
can be satisfactorily synthesized in solution by repetitive
procedures without full purification at each stage. In those
casses, final purification of the product can be quite difficult.
In solid phase synthesis there is normally no opportunity for
purification ob the peptide at intermediate stages, and the only
purification possible cones after removal of the peptide fran the
resin support. In order to achieve a homogeneous product, every
deprotection and coupling reaction must go fully to completion.
If the best available techniques are used for synthesis, this
god can be practically achieved, or at least very nearly so.
Every assembly of opioid peptides on solid phase resins should
finish with a deprotection step, in order to remove the
protecting group fran the chain to minimize alkylation side
reactions during cleavage. This is equally true if the final
cleavage will be done by HP or on labile resin systems by use of
trifluorcacetic acid. As noted above, adequate scavengers must
always be used during the cleavage to minimize side reactions.
Procedures using partition methods, such as countercurrent
distribution, partition chromotography or reversed-phase high
performance liquid chromotography (HPLC) are particularly
appropriate for purification of opioid peptides synthesized by
solid phase methods. The crude synthetic peptide usually contains
some of the scavengers used in the cleavage reaction, and these
materials are frequently very different in polarity fran the
desired peptide. Moreover, if alkylation of methionine or
tyrosine residues has occurred, these by products will also differ
significantly in polarity and partition coefficiant. The benzyl
tyrosine derivative will be found to be sore hydrcphobic while
the methionine sulfonium derivative will be more hydrophilic, and
thus readily separated fran the desired product by partition.
Quantities greater than 100 mg of peptide can usually be
purified by an overnight automatic run in a Craig countercurrent
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distribution apparatus. Preparative HPLC is even more rapid, but
the apparatus is quite expensive and the resins used will also
represent a significant expenditure, especially since the packing
material can reasonably be used only for one peptide. Peptides
frequently adsorb quite tightly to the reversti-phase material
and the final traces are gradually eluted in subsequent runs. In
commercial Or very large-scale operations, where large amounts
of peptide or repeated syntheses will be made, this may be very
practical. For the investigator synthesizing large numbers of
analogs, the economics may be a problem. Partition chromotography
has long been used for purification of synthetic peptides, and
while very large columns will be needed for purification of
significant quantities of peptide, this an be done rapidly.
All these procedures are discussed in the laboratory manual of
Stewart and Young.
All purifications mist be accompanied by suitable analytical
techniques which will reveal the presence of any impurities in
the synthetic product and indicate their nature. Paper electro-
phoresis is uniquely appropriate for this purpose. Thin-layer
electrcphoresis can also be used but is not quite as convenient.
Gel electrophoresis is not appropriate for small peptides of the
size of the opioids because of excessive diffusion of the
peptide in the gel matrix. If suitable amino acid markers are
included as standards in an adjacent channel, in paper or thin-
layer electrophoresis, quite accurate information on the size and
charge of the peptide product can be obtained. Inpurities
differing in charge and differing significantly in size are
readily resolved. Electrophoresis can be done in buffers of
different pH in order to enable appropriate jud regarding
inpurities to be made. Thin layer chranatcgraphy (TLC) is also a
valuable analytical technique. It is particularly useful for
indicating the presence of impurities which differ in hydro-
phobicity from the desired product.
If meaningful infomation on purity of synthetic peptides is to
be obtained, it is critical that the procedures used for analysis
be based upon different phenomena than the procedures used for
purification. For example, if the peptide WaS purified by a per-
tition method such as countercurrent distribution or reversed-
phase partition HPLC, then similar HPLC or TLC should not be used
to assess purity. Rather, a method utilizing charge and/or size
of the peptide should be used, such as electrcphoresis or ion-
exchange TLC. In any event, once homogeneity has been acheived by
a suitable purification procedure or procedures, and has been
demonstrated by appropriate analytical methods, an aliquot of the
peptide should be hydrolyzed with acid and the ratio of consti-
tutent amino acids determined by amino acid analysis. Since all
opioid peptides contain tyrosine, the acid hydrolysis mixture
should contain phenol to prevent loss of tyrosine by chlorination
due to contamination of the HCL by chlorine. If tryptophan-con-
taining analogs are synthesized, reasonable values for this acid-
labile amino acid can often be obtained by including marcepto-
ethanol in the hydrolysis mixture. Since many opioid peptides
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contain methionine residues, anaslysis of the oxidation state of
this residue is quite important. The biological potency of a
peptide can frequently change drastically depending upon whether
the methionine residue is present per se or is oxidized to
the sulfaxide. Rydrolysis with 6 N HCL converts methionine
sulfoxide largely to methionine, so the original state of that
residue cannot be determined in this way. Rather the peptide must
be hydrolyzed with methanesulfonic acid, which does not disturb
the oxidation state of methionine residues. Precise details of
these procedures are given in the Stewart and Young (1984)
handbook.
Accurate amino acid analysis also provides a reasonable estimte
of the "working molecular weight" of the peptide. Samples of
carefully purified and lyophilized peptides contain varying
amounts of non-peptide material. Peptides which have a net acidic
or basic charge will also contain a counter-ion to neutralize
these excess charges. These salts must be taken into account in
deriving the theoretical molecular weight. One must also remember
that the final salt form will depend upon the acidic or basic
strength of the final purificaticn system. Far example, a peptide
containing a free amino and carboxyl group in addition to a
single arginine residue will be found to contain one mole of
acetic acid if it is purified fran an acetic acid-containing
system. On the other hand, if the peptide is purified finally
from a system conaining trifluorcetic acid, two moles of TFA
will be bound to the peptide since TFA is a stronger acid than
the carboxyl group of the peptide chain. This same consideration
alsoapplies to the side-chain carboxyl groups of aspartic and
glutamic acids. The theoretical molecular weight calculated in
this way (containing bound salt) is useful for determining the
purity of the synthetic peptide. The most practically useful
value, however, is the "working molecular weight," which is the
reciprocal of the average micromoles per milligram of peptide
analyzed. In calculating this ratio, one should not include
values found for residues known to be destroyd during hy-
drolysis, such as marine, theronine, and tryptophan. This
"working molecular weight" should be applied by the person
synthesizing the peptide to whomever will use the peptide, 80
that accrate molar potencies can be calculated.
STORAGE AND HANDLING OF PEPTIDES
Most synthetic opioid peptides will be found to be quite stable
if stored absolutely dry and in the freezer. When the peptide
container is removed from the cold, the contianer should be
allowed to warm to room temperature in a desiccator before the
container is opened; other wise atmspheric moisture will condense
on the cold peptide particles. When the peptide is again stored,
this moisture will accelerate degradation of the peptide. Pep-
tides should be stored in relatively small aliguots in separate
containers, so that a large batch of peptide is not repeatedly
warmed and chilled.
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Amino acid analysis frequently reveals that lyophilized peptides
contain considerable quantities of solvent. If these peptides
were lyophilized from acetic acid, as is often the case, cold
storage is particularly important to avoid degradation of the
peptide by the acetic acid in the sample. Peptide bonds adjacent
to aspartic acid residues are particularly labile to this type of
degradation.
Amide bonds, of the C-terminal amide if it is present, and of
glutamine and asparagine side chains, are also a problem. Glu-
tamine and asparagine amides have been found to be particularly
labile when they occur in the peptide sequence adjacent to the
basic residues, such as arginine or lysine; asparagine amides are
the more labile. This typed hydrolysis can occur during storage
of the "dry" peptide as well as after the peptide is dissolved in
aqueous solution. This hydrolysis is also more rapid if the "dry"
peptide contains excess acid or base, or if it is dissolved in a
solution that is significantly removed fran neutrality. The sur-
face of glass is alkaline, particularly if the glass is aged. All
glass containers to be used for storage of peptides or peptide
solutions should be rinsed with molar acetic acid and dried care
fully. For most careful work, they should then be silanized.
Many peptides, particularly those that are basic and/or hydro-
phobic, adsorb avidly to surfaces of glass and some plastics.
The extremely high potency of some opioid peptides causes them to
be used in very dilute solutions in biological experiments. In
some cases, these experiments may be totally invalid due to
adsorption of peptide from solution onto the surfaces of test
tubes, pipettes, and syringes. Among the plastics, polystyrehe is
particularly bad for peptide adsorption and should not be used.
Polyethylene and polypropylene are probably the best plastics for
use with peptides,although some peptides will stick to these
surfaces. If low concentrations of peptides must be used, adsorp-
tion can be prevented by such measures as making all the dilu-
tions in 0.01 M acetic acid, or by including a low concentra-
tion of protein in the solution, in addition to silanizing the
glass surface. The method chosen will depend upon the require-
ments of the experiments. In certain cases, a difference of 1,000-
fold in potency of a peptide solution has been ovserved when
dilute acetic acid was included in the solution.
Oxidation of methionine residues in dilute solutions of peptide
is a serious problem. All solvents to be used for dissolving such
peptides should be thoroughly bubbled with nitrogen before use.
some very potent enkephalin analogs have contained disulfide
rings formed from two residues of cysteine or penicillamine in
the peptide chain. Such disulfides are extremely labile in solu-
tion if the pH is above neutrality. At higher pH, disulfide in-
terchange occurs, and the monomeric peptide may be rapidly con-
vertd to dimers and polymers, which are usually biologically
inactive. Experience with oxytocin and vasopressin solutions has
shown that they retain their potency best when slightly acidified
(pH 5) and stored just above the freezing point. These conditions
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may also be most appropriate for storage of solutions of disul-
fide-containing opioid peptides.
When dissolving peptides for use, only fairly concentrated solu-
tions (such as 0.1 mg/ml) should be frozen for storage. These
solutions should be divided into small aliquots containing the
amount to be used for one day's experiments. The tubes should
be flushed with nitrogen, closed tightly to prevent spillage or
lyophilization in the freezer, and frozen. The ease of dissolu-
tion of peptides depends strongly upon the physical state of
the material. If the peptide was lyophilized from fairly dilute
solution, it will be finely divided and will usually dissolve
readily, except in the case of some hydrophobic peptides, which
are difficult in any case. If the peptide was dried by evap-
oration or lyophilized fron a very concentrated solution, the
material may be in the form of hard particles which dissolve
only very slowly. Such particles may have an index of refraction
similar to that of the aqueous medium, and their failure to
dissolve may not be noticed unless the solution is examined with
a magnifier. Very hydrophobic peptides may need to be dissolved
first in a mall amount of a powerful solvent such as dimethyl
sulfoxide and then diluted with hater or saline. In this case,
appropriate controls must be run. Bubbling air through the
pipette or vortexing should not be used for mixing if there is
any possibility of oxidation of the peptide.
DESIGN OF OPIOID PEPTIDE ANALOGS
NEW analogs of opioid peptides are synthesized for a variety of
reasons. A major goal has beeu to find analogs which will have
absolute selectivity for the various classes of opioid receptors.
When such selectivity is achieved, further modifications may well
be undertaken to improve the resistance of the peptide to enzy-
matic degradation in order to increase potency and prolong
activity in vivo and in vitro. Such selective, potent and long-
acting analogs will find many practical applications. Addi-
tional analogs may need to be designed in order to delineate more
precisely the nature of peptide receptor interactions, as well as
for certain physical chemical studies. Analogs containing easily
detectable "reporter" functions are particularly useful in such
studies. Potent selective antagonists are much needed for a
variety of reasons, both practical and theoretical. Since there
are no universally applicable rules for design of peptide antag-
onists, this letter search has been particularly frustrating.
Conformational restriction has been a very valuable tool in
design of selective opioid analogs. The ancestral opiate
compound, morphine, and many of its analogs synthesized by
medicinal chemists were the years have led the way for more
recent peptide work. Use of N-methyl amino acids in peptide
analogs not only restricts the conformtions available to
the peptide, but frequently confers enzyme resistance as well.
Some -methyl amino acids have been incorporated into opioids
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with startling results. Aditional work needs to be done with
other -alkyl amino acid residues. Conformtional restriction by
cyclization of all or part of the peptide chain has also been
very useful in opioids.
Examination of the lists of opioid analogs in this volume and
in other publications will show the degrees of selectivity,
enzyme resistance and antagonist that peptide chemists have been
able to incorporate into analogs at the present time. These
developments will not be discussed again here. Details of two
groups of peptides not covered elsewhere will be discussed in
somewhat more detail. Several aspects of the wisdan gaind from
three decades of peptide analog work are sumnarized in a recent
article (Stewart, 1982).
MINIMUM STRUCTURE ENKEPHALINS
One of the earliest types of structure modification applied to
the enkephalin field was shortening of the peptide chain, either
by elimination of residues fran the ends or by removal of
residues within the sequence. From those experiments it was found
that while significant potency remained if the C-terminal
methionine or leucine residue was remved, the phenylalanine
residue in position 4 was critical for activity. It was also
found that activity was reduced to less than 1% of that of the
pentapeptide if one of the glycine residues was removed fran
within the chain. Fran this last work it was propsed that the
spacing between the essential phenolic side chain of the tyrosine
in position me and the phenylalanine side chain was critical for
biological activity. This last proposal was somewhat difficult to
understand in light of the fact that morphine combines well with
the opiate mu receptors and that considerable folding of the
enkephalin chain was required to make it conform roughly to the
morphine structure.
After it had been learned that enkephalin potency could be
greatly enhanced by replacing the glycine in position two with a
Dalanine residue and converting the C-terminals to an amide
(Marley, this volume), we foumd (Chipkin et al. 1981) that the
tetrapeptide Tyr-DAla-Phe-Met-amide was more potent than Met-
enkephalin and nearly as potent as Tyr-DAla-Gly-Phe-Met-amide.
Evidently the problem with the earlier experiments was not that
the Tyr-Phe spacing is so critical but rather that the shortened
peptide Was being degraded very rapidly, even in the in vitro
assay system. This result led to a systematic investigation
enkephalin analogs having even shorter chains (vavrek et al.
1981) (see table 1). The most surprising result of this
investigation was that Tyr-DAla-phenylpropyl amide had nearly the
full potency of Met-enkephalin on stimulated guinea pig ileum and
produced analgesia in vivo. It is interesting that in this com-
pound the spacing along the peptide chain from the tyrosine to
the aromatic ring is not identical to the spacing in Tyr-DAla-
Phe-Met-amide, which we had previously found to be quite potent.
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TABLE 1.
Relative Potencies on Guinea Pig Ileum of Minimum
Structure Enkephalins
Tyr-Gly-Gly-Phe-Met 100
Tyr-Gly-Gly-Phe-Met-amide 160
Tyr-DAla-Gly-Phe-Met-amide 140
Tyr-DAla-Phet-Met-amide 120
Tyr-Pro-Phe-amide 19
Tyr-DAla-Phe-amide 25
Tyr-DAla-phenylethylamide 6
Tyr-DAla-phenylpropylamide 77
Tyr-DAla-phenylbutyl amide 13
The same spacing as in the tetrapeptide is found in Tyr-DAla-
phenylethyl amide, which has very low potency (table 1). In our
potent dipeptide the separation is me carbon atom further. The
reason for this difference is not understood at this time.
Perhaps when the mu receptor structure is known will will have
answers to these questions. Resistance to enzymatic degradation
is doubtless an important factor in the high potency of Tyr-DAla-
phenylpropyl amide. The only amide bonds in this compound involve
the amino or carboxyl group of D-alanine, and they should be
quite stable to most enzymes.
Sane work done with Stammer (see Stamner, this volume) on
enkephalins containing -unsaturated amino acids is also of
interest in this regard. When a double bond is introduced between
the alpha and beta carbons, the resulting amino acid is quite
rigid, and the phenyl ring is held in a position toward the
carboxyl in the case of the isomer away from the carboxyl
in the case of the Z isomer.When these two isomers were
incorporated into the potent pentapeptide enkephdlin Tyr-DAla-Gly-
Phe-Met-amide in place of the phenylalanine residue, the
potencies were dramatically different (see table 2). The analog
containing Z-Phe, in which the aromatic ring is held toward the
tyrosine, was super-potent, while the analog containing E-Phe,
in which the phenyl ring is held away from the tyrosine, had
TABLE 2
Relative Potency on Ileum of Some Altered Enkephalins
The  symbol indicates the direction of the phenyl ring in the
analog .
Tyr-Gly-Gly-Phe-Met
Tyr-DALa-Gly-Phe-Met-amide
Tyr-DALa-Gly- ZPhe-Met-amide
Tyr-DALa-Gly- Phe-Met-amide
Tyr-DALa-Phe-Met-amide
Tyr-DAla- ZPhe-Met-amide
100 
150
500
low
130
low
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FIGURE 7
Solution Synthesis of the Dipeptide Enkephalin
negligible activity on ileum. This result suggests that the
spacing between the binding sites for the aromtic rings on the
receptors is rather closely specified, and that the flexibility
of the normal pentapeptide allows sufficient bending of the
molecule to bring the two aromatic rings into the correct
spacing. Since we had found Tyr-DAla-Phe-Met-amide to be very
potent, we then examined this analog in which the phenylalanine
had been replaced by Z-Phe; this analog was essentially
inactive on ileum. unfortunately, the corresponding E-Phe
analog was not made, but it probably would have had more potency.
Evidently in these compressed analogs the phenyl ring must bend
somewhat away fran the tyrosine ring - or at least not be held
rigidly toward it.
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The dipeptide amide enkephalins are mainly mu receptor agonists;
they have quite low potency on the stimulated mouse vas differences
and for binding to delta receptors (Vavrek et al. 1983). The
receptor selectivity (and relative potency for guinea pig ileum
versus muse MS deferens) could be enhanced by addition of a
lysine residue to the amino terminus of these short-chain
enkephalins. Surprisingly, addition of the lysine residue caused
only a alight decrease of ileum potency; the increased
selectivity was due to a great loss of vas deferens potency.
The potent dipeptide derivative Tyr-DAla-phehylpropyl amide can
be synthesized readily by either solid phase or classical
solution methods of peptide synthesis. For solid phase synthesis
(Vavrek et al. 1981), the dipeptide Boc-Tyr(BrZ)-DAla was
assembled on Merrifield resin. Brz designates the 2-
bramobenzyloxycarbonyl protecting group used for the hydroxyl
group of tyrosine. The dipsptide-resin was treated for ah
extended time with methanol and Methyl amine to remove the
peptide as the methyl ester. This ester was then treated with
phenyl-n-propyl amine to convert it to the amide. For synthesis
of large quantities of the peptide, the solution synthesis scheme
shown in figure 7 was used. Boc-D-alanine was converted to the
amide with 3-phenyl-n-propyl amine, using DOC as coupling agent.
Following renewal of the Boc group with TFA and neutraliation of
the salt, Boc-Tyr(BrZ) was coupled, again using DOC. Treatment
with TFA for removal of the Boc group and then removal of the BrZ
group with HF in the presence of scavengers yielded the desired
dipsptide amide.
DYNORPHIN-REALTED PEPTIDES
Of the three major classes of opioid peptides, the dyhorphin
group were the last to be characterized (see the chapters in this
volume by Chavkin and Kasterlitz). These appear to be the
endogenous ligands for the kappa class of opioid receptors. Among
the peptides available at this time, dynorphin(1-9) appears to be
a very elective ligand for kappa receptors. It has the amino
acid sequence Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg. Unfortunately,
this peptide is rapidly degraded by enymes, and is thus not
practical for in vivo work. Even for receptor binding studies on
isolated membranes, a "cocktail" of enzyms inhibitors must be
used. One rapid cleavage is at the bond following the leucine
residue; this cleavage yields Leu-enkephalin, which is
principally a delta receptor agonist. This cleavage thus destroys
the kappa selectivity. It would be extremely useful if enzyme
resistance could be built into this peptide to yield a stable,
selective kappa agonist.
The aualog containing D-alanine in position 2 was synthesized
quite soon after the dynorphin sequence was known; that peptide
was found to be mainly a delta agonist. It was suggested that the
peptide  was probably being cleaved to yield [DAla2]-Leu-
enkephalin, a potent delta agonist. In order to investigate this
question, we synthesized several analogs of dynorphin(1-9) which
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TABLE 3
Potencies of Dynorphin(1-9) Analogs for Binding to
MU, Delta and Kappa Receptors in Guinea Pig Brain
Peptide Structure Relative Potency
Mu Delta Kappa
Tyr-Gly-Gly-Phe-LeU-Arg-Arg-Ile-Arg 1 1 1
Tyr-Gly-Gly-Phe-Leu-DArg-Ile-Darg 42 1.6 0.2
Tyr-Gly-Gly-Phe-Leu-DArg-DArg-Ile-DArg-NH2 77 1.3 0.6
Tyr-DAla-Gly-Phe-Leu-Arg-Arg-Ile-Arg 29 1.9 0.1
Tyr-DAla-Gly-Phe-Leu-DArg-DArg-Ile-DArg 43 7.7 0.04
Tyr-DAla-Gly-Phe-Leu-DArg-Ile-DArg-NH2 81 5.6 0.1
incorporated D-amino acids at various places and in addition
examined the effects of making the C-terminal amide of these
peptides. All of these changes should impart added enzyme
resistance to the peptides. Table 3 gives the structures of the
peptides synthesized and compares their binding to guinea pig
brain receptors. Fran these experiments (Paterson et al. 1984),
done in the cold to minimize enzymatic degradation, it is clear
that all the modifications caused loss of potency at the kappa
receptor while enhancing binding potency at both mu and delta
receptors. Other experiments done at roan temperature or in the
presence of enzyme inhibitors showed that the D-alanine
substitution conferred enzyme stability on the peptides, while
the D-arginine substitutions were not effective. The effect of
the D-alanine substitution in dynorphin peptides then is clearly
to change receptor specificity. Additional work is needed for
develqment of stable, selective kappa agonists.
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Structure-Activity Relationships of
Opioid Peptides
J. S. Morley, D.Sc., and A. S. Dutta, Ph.D.
INTRODUCTION
Since our last review (Morley 1980). several new aspects of the structure-activity
relationships (SAR) of enkephalinlike peptides have been explored. Most are
covered in separate chapters of this volume: SAR of conformationally restricted
opioid peptides Schiller; Hruby); SAR of active di-, tri-, and tetrapeptide
analogs (Stewart); SAR of dehydro-, cyclopropyl-, and multichain analogs
(Stammer); SAR of dermorphin analogs (Feuerstein/Faden), SAR of morphiceptin
analogs (Chang, and SAR enkephalin analogs in relation to specificity (Hruby;
Roques). We have therefore decided to restrict our own coverage to an update of
subject matters contained in our last review--general principles of SAR, the
effect of single substitution in [Met/Leu] enkephalin on activity in isolated tissue
preparations, and selected in vivo effects--and the outstanding additional topics
not covered by other authors.
We discard use of the popular names Met-enkephalin and Leu-enkephalin, since
these contravene nomenclature rules (Morley 1981). Instead, the forms
[Met]enkephalin and [Leu] enkephalin. now recommended by the International
Union of Pure and Applied Chemistry (IUPAC) and the International Union of
Biochemistry (IUB), are employed. Nomenclature proposals for describing
backbone-modified enkephalins (see Morley 1981) are also recommended.
GENERAL PRINCIPLES
“Activity,” as measured in in vitro, “receptor” binding, and even in vivo studies,
continues too frequently to be interpreted as “activity at opiate receptor(s).” This
has often led to speculation as to the nature of opiate receptors based on the
results of SAR studies. In our last review (Morley 1980), which analyzed the
molecular processes involved before activity is expressed, we stressed that such
speculation is unjustified. The interplay of two of these processes--the events at
the receptor, and proteolysis--has now been convincingly demonstrated by
McKnight et al. (1983). By adding inhibitors of peptidases, the observed potency
of [Met]enkephalin, for example, in the guinea pig myenteric plexus-longitudinal
muscle (GPI), mouse vas deferens (MVD), and rat vas deferens (RVD) tests was
increased 18-, 13-, and 200-fold, respectively. The potencies of
[Leu]enkephalin, and hexa-, hepta-, and octapeptide C-terminal extensions of
[Met] and [Leu]enkephalin, were likewise increased in the presence of peptidase
inhibitors, with the greatest effects being seen in the RVD test; whereas the
4 2
potencies of more metabolically stable opioid peptides (e.g., beta-endorphin) were
little affected.
If we can assume that the combination of peptidase inhibitors used by McKnight
et al. (1983) specifically eliminates the capacity of the tissues to inactivate
enkephalins, interpretation of results in isolated tissues becomes more secure.
For example, the 25-fold greater potency of [D-Ala2, MePhe4, Gly-ol5]
enkephalin, as compared with [Met]enkephalin in the GPI test without inhibitors
(which some had previously interpreted as reflecting greater activity of the
analog at the opiate receptor), reduces to near equipotency when inhibitors are
present. If the assumption is correct, we may now conclude that the receptor
interaction of the two peptides is very similar. More instructively, two patterns
of activity remain on after comparing the activities of metabolically unstable
analogs in the ‘inhibited’ GPI and MVD tests, and more stable analogs in the two
normal tests. An enkephalinlike pattern, observed with [Met] and
[Leu]enkephalin,[D-Ala2, L and D-Leu5] enkephalin, and most endogenous opioid
peptides, is characterized by greater potency in the MVD as compared with the
GPI test. In contrast, a morphine like pattern, characterized by greater potency in
the GPI as compared with the MVD test, is seen with some synthetic peptides,
e.g., [D-Ala2, MePhe4, Gly-ol5]enkephalin. This finding is compatible with the
evidence for two distinct receptors--predominantly mu in the GPI and delta in
the MVD--in the tissues, but the dangers of drawing conclusions as to the nature
of receptors based on work with agonists should be recognized.
Use of cocktails of peptidase inhibitors in receptor binding assays has not yet
been described, but we can assume that similar shifts of potencies will be
observed.
RESULTS USING ISOLATED TISSUE PREPARATIONS
The tables given in our last review (Morley 1980) showing the effect of single
substitution (any one amino acid position varied, but not two) on the potency of
[Met] or [Leu]enkephalin, or their methyl esters or amides, are now updated
(tables 1 to 7). We also include data on peptide backbone modifications (table 8);
in these cases, the [D-Ala2]enkephalin series is included since [D-Ala2]enkephalin
has often served as reference compound.
All potencies have again been related to [Met]enkephalin = 1. When
[Leu]enkephalin has been used as standard in the original paper, the conversion
factor [Leu]enkephalin = 0.37 x [Met]enkephalin in the GPI test (Morgan et al.
1976) has been applied. When values for neither [Met] nor [Leu]enkephalin have
been quoted, the IC50 values for analogs have been compared with the following
IC50 values for [Met]enkephalin (McKnight et al. 1983): 125 nM (GPI)
50. 17.7
nM (MVD).
Limitation of space permits only cursory discussion of the new results. At the
Tyr1 position, restriction in the degree of conformational freedom of the residue
as in the tetralin analog (table 2, third compound listed) leads to a sevenfold to
eightfold increase in potency in the GPI test, and a thirtyfold decrease in the
MVD test, as compared with the reference compound, [Leu]enkephalin (Deeks et
al. 1983). The inactivity of the indanyl analog (table 2, fourth compound listed)
illustrates the differential effect of restricting conformational flexibilit on
potency in the two tests. Requirement of the p-hydroxy group of Tyr1 for
activity is questioned from the finding that a melphalan analog (in which the p-
hydroxyl group is replaced by bis-2-chloroethylamino) of [D-Ala2, Leu5]
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T A B L E  1
N-Terminlly Substituted Derivatives. In Vitro Activitya of Analogs of
Type X-Tyr-Gly-Gly-Phe-
apotencies in the eletrically stimulated guinea pig and mouse vas deferences and receptor binding relative to
[Met]enkephal = 1.
bAbbreviations  for amino acids and their use in the formulation of derivatives follow the various recommendations of the
IUPAC-IUB Commision Biochemical Nomenclature.
ccomparism of data obtained by different investigators seldom justified.
TABLE 2
Variation of Tyrosine1 Residue. In Vitro Activitya of Analogs of X-Gly-Gly-Phe-
X =
Analogb G u i n e a  M o u s e  R e c e p t o r  R e f e r e n c e
p i g d e f e r e n s  b i n d i n g
Y = i l e u n c
( - )  i somer
(+)  isomer
( - )  i somer
(+)  isomer
a- c See footnotes to table 1.
Met-Ome 0.005 0.001
Leu-OH
Friedmann et  a l .  1982
Amar et al. 1983
Leu-OMe 1.3 0 .052 Deeks  e t  a l .  1983
Leu-OMe 0.028 0.00036
M e t - N H 2  i nac t ive  inac t ive
M e t - N H 2  i nac t ive  inac t ive
Met-NH2 i n a c t i v e  i n a c t i v e
M e t - N H 2  i nac t ive  inac t ive
Deeks  e t  a l .  1983
Ramakrishman & Portoghese
1982
Ramkrishman & Portoghese
1982
TABLE 3
Variation of Glycine2 Residue. In Vitro Activitya of Analogs of Type Tyr-X-Gly-Phe-
a - c  S e e  f o o t n o t e s  t o  T a b l e  1
T A B L E  4
Varaiation of Glycine5 Residue. In Vitro Acivitya of Analogs of Type
Tyr-Gly-X-Phe-
TABLE 5
variation of Glycine2,5 residue. In Vitro Activitya of Analogs of Type Tyr-X-Phe-
a-c See footnotes to Table 1.
TABLE 6
Variation of Phelylalanine4 Residue. In Vitro Activitya of Type Tyr-Gly-Gly-X-
a - c  S e e  F o o t n o t e s  t o  T a b l e  1
a-c  See Footnotes to table 1
Variation of Met/Leu5 Residue In Vitro Activity of Analogs of Type Tyr-Gly-Gly-Phe-X
TABLE 7
(Table 7 continued next page)
Table 7 (continued)a
a - c  S e e  f o o t n o t e s  t o  t a b l e  1 .
enkephalin methyl ester has high affinity for mu and delta binding sites (IC60 50
and 10 nM respectively) (Szucs et al. 1984), and activity in the GPI test
(Medzihradszky 1984). Judgment on this issue must be suspended since cleavage
of the bis-2-chloroethyl-amino group to a hydroxy group (via ethyleneimmonium
intermediate), under the conditions of the tests, seems possible, offering an
alternative explanation of the results. However, in support of the conclusion of
Szucs et al., it will be recalled that the (tyrosine) O-methyl ether of
[Met]enkephalin, presumably metabolically stable at the p-position, is claimed to
have significant activity in the GPI test (see Morley 1980). The Azgly3 (-NH-
NH-CO-) analog still remains the only 3-substituted enkephalin with appreciable
activity in any test, suggesting exploration of planar 2, 3-substituted analogs.
Such analogs have not yet been described (see table 5). At the Met/Leu5
position, substitution of the carboxyl group of [Nle]enkephalin by a phosphonic
or sulphonic acid group causes, respectively, a 5- or 12-fold increase in potency
in the GPI test, and a 26- or 14-fold increase in the MVD test (table 7, 16th and
17th compounds listed) (Bajusz et al. 1980). The increased acidity and bulkiness
of the phosphonic acid group apparently favors interaction at the delta binding
site. In contrast, similar replacements in [D-Nle6]enkephalin result in substantial
loss of activity.
Turning to the backbone modifications (table 8). significant activity in one or
more of the tests results from replacement of the Tyr1-Gly2 peptide bond by
CH2-NH or CH2 -CH2 (Szelke et al. 1979; Hudson et al. 1980), by CH=CH (Hann
and Sammes 1980; Hann et al. 1982; Cox et al. 1980), but not by CS-NH (Clausen
et al. 1983. 1984); replacement of the bond by an aminoxy linkage (CO-NH-O)
provides a weakly active analog (Salvadori et al. 1981). Replacement of the
Gly2-Gly3 peptide bond by CS-NH leads to a 1.48-fold increase in potency in
the GPI test and a 15- to 22-fold increase in the MVD test (Clausen et al. 1983,
1984); other modifications of the bond (CH=CH, CH2S, CH2-NH, CH2-CH2, CO-
NH-O) lead to inactive analogs (see table 8 for references). Replacement of the
Gly3-Phe4 peptide bond by CH2-NH leads to slightly increased potency in the
GPI test, and to decreased potency in the MVD test (Szelke et al. 1979); other
modifications lead to almost inactive analogs (CH2-S. CH2-SO, CO-NH-O).
Finally, all replacements of the Phe4-Met/Leu5 peptide bond (CS-NH, CH2-NH,
CO-NH-O. CH2-S, NH-CO, CO-O) lead to analogs having potencies similar to,
or slightly greater than. those of the reference compound (analogs in the D-Ala2
series should be compared with [D-Ala2]enkephalin).
ENKEPHALIN ANTAGONISTS
A significant development in the past 2 years has been the emergence of
antagonists which are structurally related to the enkephalins. They are of two
main types--one based on N,N-diallyenkephalin with delta binding site
specificity, and the other based on enkephalin (1-4) tetrapeptide dialkyl amides
with mu binding site specificity. The former type has probably been explored
more extensively, but little of the work has yet been published. All published
work on both types is summarized in table 9.
Dealing first with the N,N-diallyl type, it has been known for some years that
substitution of the (N) methyl group of morphine and other opiates by certain
lipophilic groups (e.g., allyl, cyclopropylmethyl) leads to loss of agonist activity,
and may provide analogs with potent antagonist activity (e.g., naloxone,
naltrexone). Monosubstitution of such groups at the amino terminus of
enkephalins provides only weak agonists or partial agonists, but Shaw et al.
(1982) found that substitution of diallyl at the amino terminus provided an
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TABLE 8
In Vitro Activitiesa of backbone Modified Analogs of Tyr-Gly-GLy-Phe-Met and Tyr-Gly-Gly-Phe-Leu
(Table 8 continued next page)
Table  8  (cont inued)
Table 8 (continued)
(Table 8 continued next page)
Table 8 (continued)
a- c see footnotes to table 1.
TABLE 9
Enkephal in Antagonist and Their Potency
analog, N,N-diallyl-[Leu]enkephalin methyl ester (ICI 139462) (table 9, , 2nd
compound listed), devoid of agonist activity, which effectively antagonized the
action of [Leu]enkephalin in the MVD, but was much less effective in
antagonizing the action of normorphine. Based on this lead, the metabolically
more stable N,N-diallyl-Tyr-Gly-Gly-psi(CH2S)-Phe-Leu-OH (ICI 154129)
(table 9, 8th compound listed) evolved, which is approximately 30 times more
potent against [Leu]enkephalin than against normorphine in the MVD, and which
is effective in vivo in antagonizing a response mediated by delta-type opiate
agonist (Gormley et al. 1982). No simple relationship was found to exist between
the agonist activity of a given enkephalin analog and antagonist potency of its
diallyl congener (Belton et al. 1983). Thus, N,N-diallylation of the potent and
relatively mu selective agonists [D-Ala2Leu5]enkephalin. [D-Met2,
Leu5]enkephalin methyl ester. and (D-Met2, Pro-NH2
5]enkephalin gave rise to
weak nonspecific antagonists (table 9; 4th, 6th, and 7th compounds listed). In
these analogs, the delta antagonist potencies are severely reduced relative to N,N-
diallyl-[Leu]enkephalin. More surprisingly, the N,N-diallyl analog of the potent
and relatively delta selective agonist [D-Ala2, D-Leu5]enkephalin was found to be
a weak delta partial agonist, with little or no mu antagonist activity (table 9, 5th
compound listed). Replacement of the Gly3-Phe4 peptide bond by a
methylenethio (CH2-S) linkage in [Leu]enkephalin or [D-Phe
4, Leu5]enkephalin
gave analogs (table 9; 8th and 9th compounds listed) which were both moderately
potent and highly selective delta antagonists as diallyl congeners. The effect of
replacing the Gly3 residue by D- and L-Ala was also explored by Belton et al.
(results not shown in table 9). Replacement of Gly3 by L-Ala led to sevenfold
reduction in potency, but the D-Ala3 derivative was equipotent with N,N-
diallyl-[Leu]enkephalin. This result contrasts markedly the results of 3-
substitution in enkephalin agonists.
The tetrapeptide N,N-diallylamide type of antagonists arose from an investigation
of structural substituents which may interact with complementary structural
features adjacent to the opiate receptor (Bower et al. 1981). In this series,
antagonist activity was found to be restricted to a relatively limited range of
structures; the nitrogens of Phe4 and C-terminal amide must be fully substituted,
and the latter must bear a 2-phenylethyl group. Greater structural flexibility is
tolerated with respect to the other obligatory C-terminal amide substituent;
isoamyl, phenethyl, and 3-methylthiopropyl (table 9; 10th, 12th, and 13th
compounds listed) substituents provided essentially pure antagonists of
approximately equal activity, which reversed the effect of morphine in the MVD
at least 10 times more easily than they reversed the effects of [Met]enkephalin.
When the second substituent on the terminal amide was methyl (table 9; 11th
compound listed), antagonism in the MVD test was weak, and the analog was a
weak agonist in the GPI test.
IN VIVO TESTING
Attention continues to be mostly directed to assessment of the antinociceptive
activity of analogs, using the mouse tail flick, hot plate, or writhing tests.
Results with the most potent analogs, administered by various routes, have
recently been summarized (Morley 1983). Results with a more comprehensive
range of analogs are given in table 10.
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TABLE 10
Molar Potencies of Enkaphalin Analogs Relative to MetE (In Vitro Tests) or Morphine (In Vivo Tests)
(Table 10 continued next page)
TABLE 10  (cont inued)
Mouse writhing test (algesic agant phanylquinone or unspecified).
aResults obtained using electrically-stimulatad guinea pig myenteric plxus-longitudinal muscle test (GPI), or mouse vas deferens (MVD) teat.
bAnalog administered intracerabroventricularly (icv). subcutaneously (sc), intravenously (iv), intraperitoneally (ip), or orally (po);
usually in mice (SC, iv, ip, po), or rata (icv).
cAbbreviation for amino acids and, their use in the formation of deravatives follow the various recommendations of the IUPAC-IUB Commission
on Biochemical Nomenclature. Pip = L-pipecolic acid; HCys = L-homocysteinethiolators; Nfe = (R) 2-amino-4-phenylbutanoic  acid; Ia = 3-
methylbutyl.
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Design Principles: Enkephalins With
Predictable Mu/Delta Receptor Specificity
Yasuyuki Shimohigashi, Ph.D.
INTRODUCTION
Since the discovery of enkephalins in 1975 (Hughes et al.), numerous
studies have been done during the last 10 years to elucidate the
structure-activity relationships (SAR) of enkephalins and related
peptides by scientists belonging to various disciplines. A number
of questions have been raised, such as, What determines the receptor
affinity? What determines the biological activity? What determines
mu/delta receptor selectivity? etc. Considerable activity has been
directed toward answering these questions, and by now a reasonable
amount of infomation is available to answer the above questions.
Table 1 shows the number of publications in enkephalin and related
areas, as listed in Biological Abstracts and chemical Abstracts.
It is interesting to note that publications in this area of research
have shown a steady growth both in biological and chemical abstracts;
however, there appears to be a major growth in chemical abstract
publications, particularly in the medicinal chemistry area. This
indicates the interest of chemists in important research topics such
as structure elucidation. conformational similarity of enkephalin to
morphine, the finding of multiple types of opiate receptors, and the
recent finding of various enkephalin-containing peptides in precursor
proteins and mechanisms for processing. Among them, the most impor-
tant turning point on the SAR studies of enkephalins is the postu-
lation Martin et al. 1976; Lord et al. 1977) and confirmation
(Robson and Kosterlitz 1979; Chang and Cuatrecasas 1979) of a multi-
plicity of opiate receptors: mu receptors to which morphine binds
preferentially, and delta receptors which prefer natural enkephalina.
Although before that point most of the synthetic efforts were centered
on obtaining highly bioactive peptides (Coy and Kastin 1980; Morley
1980), it is obvious that the accumulated information by such SAR
studies has greatly helped us to better understand the receptor
specificity to design more specific and more selective ligands for
each receptor.
Recent research highlights in the genetic structure elucidation of
protein precursors have suggested the presence of a number of
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TABLE  1
Numbers of Enkephalin Publications Listed in
Biological and Chemical Abstracts
Year Biological ChemicalAbstracts Abstracts
1975 1 3
1976 14 35
1977 143 174
1978 224 291
1979 412 201
1980 580 535
1981 692 326
1982 752 494
1983 522 587
(Searched by NIH Library Medline)
enkephalin like pept ides having the enkephalin sequences in their N-
terminal portion. These include elongated-enkephalins (Noda et al.
1982; Gubler et al. 1982; Comb et al. 1982), neo-endorphins and
dynorphins (Kakidani et al. 1982), and endorphins (Nakanishi et al.
1979). It is not clear yet whether these peptides have different
functions and receptors. On the other hand, sane studies have sug-
gested that the opiate receptors designated as “delta” may not be
so closely related in the central and peripheral nervous systems
(Brantl et al. 1982; Shimhigashi et al., unpublished). The eluci-
dation of such a further heterogeneity of the receptors and their
functions must be one of the research directions of future SAR stud-
ies on enkephalins, and thus it becomes more important to have an
insight into the interaction between the enkephalins and their
receptors.
A new generation of the SAR studies has also been developed recently
by the bioevaluation of various conformationally restricted analogs
such as dehydro- (Shimohigashi et al. 1981a. 1982b). cyclopropyl-
(Kimura et al. 1983). cyclic- (Schiller and DiMaio 1982; Mosberg et
al. 1983). and thioamide- (Clausen et al. 1984) enkephalins, and of
dimeric enkephalins (Shimohigashi et al. 1982b, 1982c). Such more
dynamic structure-activity studies are certainly useful as probes of
specific receptor interactions.
In this article, the classical structure-activity studies of enkeph-
alins will be reviewed briefly and reevaluated in order to better
interpret the new SAR data specific for delta and mu opiate receptor
Structural elements in the enkephalin molecule essential to the spe-
cific interaction with these receptors will be analyzed as character
istics for the predictable receptor specificity.
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ENZYMOLYSIS OF ENKEPHALINS
Enzymatic Degradation of Enkephalins
The in vivo inactivation of opioid peptides is due to their suscep-
tibility to enzymatic degradation during passage to their receptors
(Schwartz et al. 1981). Studies of 3H-enkephalins in mice and rats
have shown that their half-life is extremely short (Meek et al. 1977;
Stine et al. 1980). Enzymatic hydrolysis is possible at all the
peptide linkages in the eknkaphalin sequence. A shown in the figure 1.    
i.e., Tyr1-Gly2 by amniopeptidases  (Hambrook et al. 1976; Marks et
al. 1977): Gly2-Gly3 by dipeptidylaminopeptidase (enkephalinase B)
(Gorenstem and Snyder; 1979), Gly3-Phe4 by enkephalinase (Malfroy
et al. 1978), and Phe4-Leu5 (or Met5) by carboxypeptidases (Marks
et al. 1977; Meek et al. 1977). The most important cleavage is the
removal of the Tyr1 residue by aminopeptidases, which have been found,
besides in blood (Coletti-Previero et al. 1981; Turkall et al. 1982),
as a membrane-bound form in brain (Schnebli et al. 1979; Hui et al.
1983). neuroblastoma x glioma hybrid cells (NG-105-18) (Deslauriers
et al. 1980), and guinea pig ileum (GPI) (Geary et al. 1982). En-
kephalinase, a membrane-bound carboxydipeptidase; seems responsible
for the metabolism of enkephalins, and its distribution in brain has
been demonstrated to be in good agreement with that of enkephalin
and opiate receptors (Schwartz et al. 1981).
For the prevention of these enzymatic degradations, potent and spe-
cific inhibitors of enkephalin-degrading enzyms have been developed
especially to protect the peptide in the bioassay systems. Puro-
mycin (Barclay and Phillipps 1978; Vogel and Altstein 1979) and
bestatin (Wagner and Dixon 1981) have been shown to be potent inhibi-
tors of aminopeptidases. Thiorphan (Roques et al. 1980), some hy-
droxmic acid derivatives of peptides (Hudgin et al. 1981) and amino
enkephalinase B carboxypeptidases
H—Tyr1—Gly2—Gly3—Phe4—Met5 (or Leu5)—OH
aminopeptidases enkephalinase
FIGURE 1
Enzymatic Degradations of Enkephalin
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acids (Coletti-Previero et al. 1982), and phosphoryl-Leu-Phe
(Altstein et al. 1982) strongly protect the enkephalins fran the
action of enkephal inase. Bacitracin, a nonspecific inhibitor of
a variety of peptidases, inhibits the aminopeptidases and enkepha-
linase equally well (Schwartz et al. 1981; Hudgin et al. 1981) and
it is utilized most frequently for protection of enkephalin assay
systems.
Blood-Brain Barrier
Another important key to in vivo biological activities after systemic
administration of the enkephalin is their passage through the blood-
brain barrier. After administration of enkephalin analogs by both
the intracranial and intraperitoneal routes and then monitoring the
general activity in goldfish, Olson et al. (1978) suggested that
enkephalin analogs might cross the blood-brain barrier. Rapoport et
al. (1980) have also shown, by using radioactive opioid peptides,
that they have a moderate and significant cerebrovascular permeabil-
ity in rats. However, Pardridge and Mietus (1981) have suggested
that a high-affinity receptor or transport mechanism for Leu-enkeph-
alin does not exist in the blood-brain barrier, and the barrier
contains active aminopeptidase and enkephalinase components. Thus,
the interaction of enkephalins with the barrier have been character-
ized by both a very low permeability and a high enzymic degradative
activity. Such a low permeability (2% to 3%) was also demonstrated
by Conford et al. (1978). The reported results regarding the en-
kephalin transport through the blood-brain barrier are somewhat
confl ict ing.
HIGHLY BIOACTIVE ENKEPHALIN ANALOGS RESISTANT TO ENZYMOLYSIS
Effect of General Modifications on Enkephalin Enzymolysis
Since enkephalins are immediately degraded by a variety of peptidases
before they reach their receptors, one of the synthetic approaches to
more active analogs of enkephalins has been directed toward the pre-
vention of these enzymatic degradations to prolong their circulatory
l i f e . This has been done by various chemical modifications of the
peptide molecule. In general, the replacement of L-amino acids by
D-amino acids and N-methylation of amide linkages are ordinary pro-
cedures to prevent the enzymatic hydrolysis of the peptides. The
results of these modifications of enkephalins are clear, as shawn in
table 2. Enkephalin has three optically active amino acid residues:
Tyr, Phe, and Leu (or Met). The Tyr and Phe residues cannot toler-
ate the L- and D-amino acid substitution, destroying almost all of
its activity (Coy et al. 1976; Beddell et al. 1977a). Even the
combination of D-Tyr and D-Phe completely destroys the receptor
affinity (Shimohigashi et al., unpublished data). These results
may be related to the importance of the stereo-orientation of aro-
matic groups in enkephalins to opiate receptor recognition (Shimo-
higashi et al. 1984b). However, the Leu5 residue is quite insensi-
tive to the replacement by D-Leu, which retains almost complete
activity.
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The N-methylation of the Gly2 and Gly3 residues interferes with the
interaction of the peptide with the receptors
while the N-methylation of the Tyr1 and Phe4 residues preserves con-
(Beddell et al. 1977b).
siderable activity (Beddell et al 1977b; Dutta et al. 1977). The
substitution of MeLeu for the Leu5 residue has been shown to enhance
the activity (Dutta et al. 1977). It should be noted that such
small structural modifications alter dramatically the activity of
enkephal ins .
Classical Structure-Activity Studies of Enkephalins
Numerous chemical modifications for each amino acid residue in the
enkephalin sequence have been done as a structural variation for the
elucidation of dynamic structure-activity relationships. A number
of SAR studies have clarified the mine acid residues that are es-
sential
Phe4 residues, as shown in figure 2. In general, chemical modifi-
to biological activities. These include the Tyr1, Gly3 and
cation of these residues resulted in loss of activity. In order to
obtain a highly bioactive analog, other residues like Gly2 and Leu5
or Met5 have therefore been the main target of modifications for
prevention of enzyrmolysis and for increased affinity with the
receptors.
Tyrosine-l. For the Tyr1 residue, all of its structural elements
are required for the biological activity (table 3). The p-hydroxy
group (Morgan et al. 1976; Beddell et al. 1977a), aromatic ring,
with only one methylene spacer between the ring and -carbon (Bed-
dell et al. 1977b; Dutta et al. 1977). asymetry of the -carbon
(Coy et al. 1976). and amino group (Morgan et al 1976; Gacel et al.
1979) are all structural requirements of the Tyrl residue for the
TABLE 2
Relative Activitieis of Leu-enkephalin Analogs
Raving D-Amino Acid or N-Methylamino Acid Substitutionsa
Substitutions Relative Potency
( M V D )
D-amino acid
D-Tyrl
D-Phe4
D-Leu5
N-methylamino acid
MeTyr1
Metyr1
Sar3
MePhe4
MeLeu5
0 . 4
0.03
118
63
0.3
0.3
0.3
150b
a) Calculated relative to Leu-enkephalin (=100) using data
of Beddell et al. (1977a) and Dutta et al. (1977).
b) Relative activity in GPI.
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FIGURE 2
Chemical Structure of Enkephalin and Its Structural Elements
Essential for Biological Activities (With Shadowing)
Leu-enkephalin: R = CH(CH3)2, Met-enkephalin: R = CB2SCH3
TABLE 3
Relative Activities of Met-enkephalins
Having Chemical Modifications on Tyrosine-1 Residue
Modifications Relative Potency”)
G P I  M V D
References
Amino Group
des-amino
NH2CH2CO- 
NH2(CH2)2-5CO-
CH3CO-
CH3-
CH3(CH2)1-7-
p-Hydroxy Group
des-hydroxy
CH3O-
Tyr-substitution
des-Tyr
D-Tyr
homo-Tyrb)
p-OH-pheGlyc)
Inactive inactive Morgan et al. 1976
19 30 Gacel et al. 1979
1.3 0.3 Gactl et al. 1979
0.1 Dutte et al. 1977
145 23 Somers & Hayes 1981
4-67 0.8-2.7 Summers & Hayes 1981
0.2
inactive
0.2
0.03 Morgan et al. 1976
2.3 Beddell et al. 1977b
0.1 Dutta et al. 1977
0.1 Coy et al. 1976
3.7 Beddell et al. 1977b
Dutta et al. 1977
a) Relative to Met-enktphalin (-100)
b) Substituted by Leu5
c) Substituted by Leu-OCH3
5
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fundamental activity of the enkephalin. The removal of the residue,
per se, eliminates canpletely the activity (Hambrook et al. 1976).
Thus, tyrosine is an essential constituent of the enkephalin, and
there appears to be no way at present to modify it chemically for
an increased receptor affinity. The only exception, however, is
N-alkylation by methyl or pentyl of the amino group, which gives a
fairly good activity in an isolated and electrically stimulated
smooth muscle preparation of the GPI (Sumners and Hayes 1981).
Glycine-2. Since any chemical modifictaion of the Tyr1 residue
destroys the activity, the prevention of degradation by aminopep-
tidases should be achieved by modification of the Gly2 residue.
Fortunately, the replacement of this residue with various D-amino
acids leads to a preservation or even enhancement of potency. For
example, D-Ala (Coy et al. 1976; Beddell et al. 1977b; Walker et al.
1977), D-Met (Dutta et al. 1977; Shaw et al. 1978), D-Ser (Shaw et
al. 1978), and D-Thr (Dutta et al. 1977) in position 2 give a fairly
active enkephalin analog.
isolated a novel opioid
Surprisingly, Montecucchi et al. (1981)
which contains the D-Ala2
peptide “dermorphin” fran the skin of frogs,
Gly-Tyr-Pro-Ser-NH2.
residue in its sequence: H-TYr-D-Ala-Phe-
Glycine-3. The Gly3 residue is essential for the enkephalin activ- 
ity. Almost all the modifications of this residue eliminate the
activity. The exceptions are substitutions with azaglycine (Dutta
et al. 1977) and dehydroalanine (Shimohigashi and Strammer 1982b)
which exhibit a considerable potency in the GPI and in receptor
binding, respectively.
Phenylalanine-4. In order to overcome the enzyme barrier by en-
kephalinase at the Gly3-Phe4 linkage, N-Methylation of the Phe4
residue results in retention of some activity (table 2) and seems
synergistic with further modifications in other positions for a
higher activity. Whilst, placement of D-Phe or any other D-amino
acid in position 4 results in a total loss of activity. The bulki-
ness or hydrophobicity of the side-chain may be one of structural
requirements at this position, since a considerable retention of
potency has been observed when the aromatic ring is saturated
(Dutta et al. 1977) or when it is substituted by carboranylalanine
containing boron atoms (Eberle et al. 1977) or by tryptophan
(Schiller et al. 1978). The stereo-orientation of the phenyl group
is apparently important in receptor recognition, as evidenced by
synthesis of dehydrophenylalanine4-enkephalins (Shimohigashi et al.
1982d, 1984b) and cyclopropylphenylalanine4-enkephalins (Kimura et
al. 1983). in which the phenyl ring is conformationally restricted
to each particular arrangement.
Leucine or Methionine-5. The native enkephalins, Leu- and Met-
enkephalins. possess a difference only at this position in their
amino acid sequence. Leu-enkephalin is slightly more active in iso-
lated smooth muscle of the mouse vas deferens (MVD) and less active
(20% to 40%) in the GPI (Beddell et al. 1977b; Dutta et al. 1977)
(table 6). Although it is generally accepted that the MVD contains
predaninantly delta receptors, and that the GPI contains
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predaninantly mu receptors, it is not clear yet that even these two
natural enkephalins have different receptors and functions.
For prevention of degradation by carboxypeptidases, modifications
of the C-terminal COOH group by esterification, amnidation, or reduc-
tion to alcohol increase the activity considerably in the GPI, but
not in the MVD. This fact is one of the important lines of evidence
for postulation of a multiplicity of opiate receptors and is also
important information regarding the structural requirements of this
residue for synthesis of the receptor selective analogs (Ronai et
al. 1979, 1981). Replacement of leucine by an amino acid having a
relatively smaller side chain, like alanine, leads to a drastic drop
in potency, while use of a similar sized mine a id,
or norleucine, results in fair activity. Met(O)5-enkephalin exhib-
like isoleucine
its 40% to 70% activity of Met-enkephalin (Beddell et al. 1977b;
Schiller et al. 1977). Even the removal of the terminal COOH group
or the Leu5 (or Met5) residue itself results in the retention of
considerable activity when compared with the removal of the Tyr1
residue (Beddell et al. 1977b; Dutta et al. 1977). The elongation
of mine acid residues fran the carboxyl end of the enkephalin se-
quence does not alter potency and sometimes even elicits a higher
potency (Beddell et al. 1977b; Terenius et al. 1976). This obser-
vation seems rather reasonable after the discovery of various potent
elongated-enkephalins in nature.
Highly Bioactive Enkephalin Analogs
Ineffectiveness due to short duration of action of Leu- and Met-en-
kephalins in most physiological and pharmacological systems is main-
ly a function of their susceptibility to enzymatic degradation.
The bioevaluation Of the enkephalins has thus required same special
steps to be taken in assay systems: the direct injection into a tar-
get tissue, temperature adjusmmt (0°C). or addition of proteolytic
enzyme inhibitors. It was evident that further elucidation of their
biological roles and functions would be greatly facilitated by the
availability of opioid peptides resistant to enzymatic hydrolyses
and having greater activity. This line of study has, of course,
aimed at the development of more effective analgesics than at the
usual alkaloid opiates. The term "highly bioactive" must be satis-
fied by the following requirements: (1) an increased receptor affin-
ity, (2) an increased enzyme stability, (3) an increased transporta-
bility, and (4) an increased permeability of the blood-brain barrier.
It is important for the SAR study to evaluate the extent to which
the above requirements play a role in the molecular mechanism of
action of enkephalin analogs. Classical structure-activity studies
have clarified some such components essential to enkephalin activity
(figure 2). The design for the synthesis of highly potent analogs
has been carried out by a canbination of chemical modifications of
portions not included in the essential structural elements.
Pentapeptide enkephalin analogs. Table 4 lists sane representative
examples of highly bioactive enkephalin analoga and their act ivit ies
in vivo and in vitro. The first reported analog was [D-Ala2,Met-
NH2
5]-enkephalin,having modifications at positions 2 and 5
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T A B L E  4
Relative Potencies of Highly Bioactive Pentapeptide Enkephalin Analogs
Enkephalins
Inhibitory Activitiesa) Analgesic Activitiesb)
G P I MVD Reference c ) I . C . V .  I . V . References c )
D-Ala 2 ,Met-NH2
5
D-Ala2,MePhe
4,Met(0)-ol5
D-Ala 2 ,D-Leu 5
D-Ala2rMeMet-NH2
5
D-Ala2,F5Phe
4,Met-NH2
5
D-Met2,Pro-NH2
5
D-Met2,Thz-NH2
5
Leu-enkephalin
Met-enkephalin
morphine
7 8 0
2 , 1 2 0
3 3 0
2 , 9 2 0
3 8 0
9 4
2,720
5 0 0
5 0 0
9 7
2 0
1 0 0
2 2 0
1 1 9
100
3
Shav 1978
Kosterlitz 1980
Rosterlitz 1980
Frederickson 1981
Coy 1978
Shav 1978
Kosterlitz 1980
Kosterlitz 1980
1 0 0 3 Pert 1978
1,000 6 4 0 Roemer 1977
1 5 8 Belluzzi 1978
23,800 Rederickzon 1981
1,000 Coy 1978
7 . 8 0 0 5 9 0 Bajusz 1977
2 , 7 0 0 4 8 0 Yamashiro 1977
weak Inact ive  Beddel l  1977a
0 . 0 1 Inactive Beddel l  19778
1 0 0 1 0 0
a) Relative to Met-enkephalin (-100)
b) Relative to morphine (-100)
c) Only shows top authors listed  in references.
simultaneously (Pert et al. 1976b; Coy et al. 1976; Shaw et al.
1978). This analog binds to opiate receptors with almost the same
aff inity as Met-enkephalin and causes profound and long-lasting
analgesia when injected into rat brain (Pert et al. 1976b). After
a systematic SAR study, Roemar and coworkers (Roemer et al. 1977;
Roemer and Pless 1979) achieved the synthesis of [D-Ala2, MePhe4
Met(O)-ol5]enkephalin (FK 33-824), utilizing a series of modifica-
tions with D-amino acid at position 2, N-ethylation or p-nitration
of Phe and with amino acid alcohol at position 5. This compound
is extremely bioactive and produces analgesia even when administered
oral ly . Many other analogs, some of which are listed in table 4,
have been reported as highly bioactive enkephalins (see previous
reviews by Coy and Rastin 1980; Morley 1980). However, their re-
ceptor affinity is not necessarily improved drmatically and most
of the analogs invariably lose the receptor specificity for the
delta and mu receptors to result in nonselective or mu-preferential
1 igands . Thus, their high potency has been suggested to be due to
the combined effects of enzyme stability in the circulation and
tissues and due to favorable transport properties.
Enkephalin analogs with shortened sequence. McGregor et al. (1978)
have shown that the tetrapeptide amide resulting from the removal
of the amino acid in position 5 is as potent as morphine in vivo
and suggested that the tetrapeptide sequence would be a minimal
structural requirement essential for the enkephalin activity. Such
reported highly active analogs with shortened sequences are shown
in table 5. Some of tetrapeptide acyl-hydrazide analogs were re-
ported to be several times more active than morphine in the in vivo
assay (Fujino et al. 1979). One of the most successful synteses
of an analog with potent and long-lasting peripheral and central
opioid activity is that of H-Tyr-D-Met(O)-Gly-MePhe-ol by Kiso et
al. (1981), which is 23,300 times and 9 times as active as morphine
in the GPI and tail-flick analgesic assays, respectival
be noted that the removal of the C-terminal Leu5 or Met5 followed
y.  It  should
by chemical modifications enhances the opioid agonist activity in
the GPI and in vivo, but leads to a considerable drop in activity
in the MVD. This fact indicates at least that the high potency of
shortened enkephalins is due to their retention or increase in af-
finity for mu receptors, accompanied by a decrease in affinity for
delta receptors.
Enkephalin Analogs Containing Unusual Amino Acids
Modifications of peptide bond with regard to the direction or elec-
trical properties have also been attempted for prevention of bio-
degradation by proteolytic enzymes. These include the retroinverso
isomers (Chorev et al. 1979), isosteric analogs (Cox et al. 1980;
Hudson et al. 1980; Kawasaki and Maeda 1982), and depsi-analogs
(Gesellchen et al. 1981). Analogs containing so-called fatty amino
acids, such as carboranylalanine and t-butylglycine, in position 4
lor 5 were reported to be almost as active as Met-enkepha in in the
isolated muscle assays (Schwyzer et al. 1981; Do and Sohwyzer 1981;
Fauchere 1982).
74
TABLE 5
Relative Potencies of Enkephalin Analogs Having Shortened Sequences
Inhibitory
Enkephalins Activit ies
a)
GPI MVD
H-Tyr-D-Ala-Gly-Phe-NH2
800 7
H-Tyr-D-Ala-Gly-EtPhe(pF)-NH2 550
H-Tyr-D-Ala-Gly-NHCH2CH2C6H5 440 2
H-Tyr-D-Met(O)-Gly-MePhe-ol 5.1x106
H-Tyr-D-Met(O)-Gly-MePhe-NHNHCOEt
H-Tyr-D-Met-Gly-Phe-NH2 3,760 12
H-Tyr-Ala-Phe-Met-NH2 120
Met-enkephalin 100 100
morphine 220 3
a) Relative to Met-enkephalin (=100)
b) Relative to morphine (=100)
c) Only shows top authors listed in references.
Analgesic
Activityb) Referencesc)
i . c . v .  o r  i . v .
2 5 0 McGregor 1978
Fournie-Zalueki 1981
1.2x10 6 Shuman 1981
100 Morgan 1917
900 Kiso 1981
400 Fujino 1981
1,810 Ronai 1979
5 0 Chipkin 1981
0.01 Beddell 1977a
100 Kosterlitz 1980
Shimohigashi et al. (1981a) have synthesized a series of dehydro-
enkephalins containing -dehydrogenated amino acid residues
(-NHC(=CHR)CO-) in each position of [D-Ala2, Leu5]enkephalin and
have shown that dehydrogenation of the enkephalin molecule can
afford a peptide with full receptor and biological activity having
unchanged delta-selectivity. Thus, simple dehydrogenation of an
amino acid residue in a peptide sequence may elicit at least one
or all of three changes in the properties: (1) physicochemical and
conformational, i.e., rigidity, increased hydrophobicity restricted
orientation of ß-substituents, and possible ß-turn type folding;
(2) chemical, i.e., a new site of electrophilicity at the -double
bond; and (3) biological, i.e., an increased resistance to enzymatic
degradation providing a longer in vivo lifetime. Some of these
properties have been demonstrated for dehydro-enkephalins (Shimo-
higashi et al. 1981b. 1982d. 1983, 1984b).
Enzyme Stability of Synthetic Enkephalin Analogs
Stability of enkephalin analogs synthesized for prevention of pro-
teolytic breakdown has been examined by means of brain hanogenates
and various purified ezymes. and it was demonstrated that the
enhanced in vivo activity of some analogs can be explained by their
greater resistance to enzvmatic hvdrolysis. Met-enkephalin is
completely degraded after 30 minutes by incubation with mouse brain
homogenates, while [D-Ala2, Met-NH2
5]enkephalin analog is stable
for at least 3 hours (Marks et al. 1978) The Tyr1-D-Ala2 linkage
in FK 33-824 is also quite stable, since 50%. of the compound can
survive similar conditions even after 6 hours (Huguenin and Maurer
1980). Fauchere and coworkers (Fauchere and Petermann 1980; Eberle
et al. 1977) observed a considerable resistance of carboranylala-
nine-containing enkephalin analog to various purified enzymes such
as aminopeptidase M, -chymotrypsin, and pepsin. When mined with
carboxypeptidase Y, the saturated Leu-enkephalin is rapidly hydro-
lyzed from the COOH-terminus. However, it was demonstrated that
peptide linkages with -dehydromino acid residues placed in the
enkephalin molecule are strongly resistant to the enzyme at the
carboxyl side and completely resistant at the amino side of the
dehydro residue (Shimohigashi et al. 1982a).
RECEPTOR-SPECIFIC ENKEPHALIN ANALOGS
Multiple Opiate Receptors
Following the postulation of three distinct types of opiate recep-
tors (mu, kappa, and sigma) (Martin et al. 1976), the possible
existence of another type of opiate receptors was proposed for the
endogenous peptides of enkephalins and endorphins (Lord et al. 1977).
Since then, several lines of pharmacological and biochemical evi-
dence have confirmed the heterogeneity of opiate receptors. In
the assay to evaluate the inhibitory activity for the electrically
stimulated contraction of isolated smooth muscle preparations, it
was demonstrated that morphine is more potent than enkephalins in
the GPI by interacting with the mu receptors. However, enkephalins
are more potent than morphine in the MVD, and the receptor
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responsible for the opiate action in this tissue was designated as
“delta.” Although these tissues contain predominantly mu and delta
receptors, it was found that the GPI contains additional kappa and
sigma receptors (Su et al. 1981), and the MVD contains additional
mu and kappa receptors (Lord et al. 1977).
The presence of multiple opiate receptors was also demonstrated in
brain by examining the independent receptor binding affinity using
low concentrations of radiolabeled mu and delta ligands (Chang and
Cuatrecasas 1979; Robson and Kosterlitz 1979). The ratio of recep-
tors in the guinea pig brain was calculated as 25% (mu), 45% (delta),
and 30% (kappa) (Kosterlitz et al. 1981). Radioautographical stud-
ies have also elucidated regional differences in the distribution
of the three receptor subtypes in the brain (Pert et al. 1976a;
Goodman et al. 1980; Goodman and Snyder 1982).
The fact that the specific receptor for enkephalins is different
fran that for morphine dramatically altered the research direction
of the structure-activity studies of enkephalins. The classical
SAR studies based on somewhat opportunistic bioevaluations must thus
be reevaluated to find the structural characteristics for discrimi-
native recognition of delta and mu receptors by enkephalin analogs.
Also, a new direction in the synthesis of analogs has been under-
taken to obtain more specific and more selective ligands for each
receptor (Ronai et al. 1981; Wüster et al. 1980).
Delta-Receptor Specificity: Enkephalinlike Characteristics
The substantiation of opiate receptor multiplicity has inevitably
required the reevaluation of the specificity and selectivity of
enkephalins for at least two distinct receptors: mu and delta.
Eventually, it became clear that most of the enkephalin peptides,
which bear various chemical modifications for enzyme stability and
favorable transport in the circulation, are nonspecific or mu-pref-
erential and that their pattern of activity resembles that of mor-
phine rather than that of the naturally occurring peptides. There
was an indication that Met-enkephalin is mu-preferential, while Leu-
enkephalin is delta-preferential , as evidenced by both uncle and
binding assays (Lord et al. 1977; Kosterlitz et al. 1980). Espe-
cially for the elucidation of functional roles of the delta recep-
tors, it becomes urgent to unravel the important determinants of
delta specificity and selectivity and then to synthesize more en-
kephal inlike peptides.
The Tyr1 residue, per se, is essential to the display of enkephalin-
like activity via delta receptors.
Replacement of the Gly2 residue with D-alanine increases the potency
5 to 10 times in the muscle assays of both GPI and MVD. When the
delta selectivity is calculated, however, Met- and Leu-enkephalins
show a different profile due to their different extent of potency
increments in each tissue. [D-Ala2]-Met-enkephalin shows almost
unchanged selectivity of Met-enkephalin because of simultaneous gain
in mu and delta activities, whereas delta-preferential Leu-enkephalin
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drastically loses its delta selectivity by D-Ala2-substitution due
to a marked increase in mu activity (table 6). These results indi-
cate that a hydrophobic subsite for the specific interaction with
the D-Ala2 residue may exist in the mu receptors (Fournie-Zaluski
et al. 1981). -Dehydrogenation of D-Ala2 in Leu-enkephalin pro-
vides further evidence that a hydrophobic character in position 2
facilitates the interaction with the mu receptors (Shimohigashi and
Stammer 1982a). On the other hand, a nonhydrophobic character in
position 2 appears favorable for interaction with the delta recep-
tors.
As for the Gly3 residue, it seems that the presence of this amino
acid itself in enkephalin is important for delta, but not mu, recep-
tor interaction. The evidence supporting this postulate are as
follows: (1) Chipkin et al. (1981) reported that the tetrapeptide
analogs of des-Gly3-enkephalin are potent agonists in the GPI; (2)
dermorphins , having an N-terminal amino acid sequence very similar
to enkephalin but missing the Gly3 residue, also display high mu
activity (Broxardo et al. 1981); and. similarly, (3) morphiceptin or
beta-casomorphin-4-amide (H-Tyr-Pro-Phe-Pro-NH2). which lacks Gly
3,
is highly selective for the mu site in rat brain membranes (Chang
et al. 1981; Brantl et al. 1982). These results suggest that the
presence or absence of glycine at position 3 in these enkephalin like
peptides influences the interrelationship of the Tyr1 and Phe resi-
dues, and such a relationship between the two aromatic groups appears
to be of great importance in discriminative receptor recognition
(Chang and Cuatrecasas 1981). Thus, the delta receptors may require
the Gly5 residue for enkephalins as an adequate spacing element
between the Tyr1 and Phe residues, as one of the conformational
determinants of the enkephalin molecule, or as a structural factor
to interact directly with a particular subsite located in the delta
receptors.
The phenyl ring of the side chain in Phe4 plays a crucial role in
delta-receptor recognition. The importance of its existence in po-
sition 4 was demonstrated by Rogues et al. (1979) by replacement of
the phenyl ring by an aliphatic hydrophobic moiety, which causes a
total loss of activity in the MVD but retention of some activity in
the GPI. Whilst, the importance of the stereo-orientation of aro-
matic groups (Tyr and Phe) in enkephalins to opiate receptor recog-
nition has been emphasized by the synthesis of dehydrophenylalanine4-
enkephalins having the Z- (phenyl and C=O, trans) and E- (phenyl
and C=O, cis) configurations (figure 3) (Shimohigashi et al. 1982d,
1984b). The Z-isomer exhibits an enhanced or unchanged receptor
affinity over the saturated analogs, showing a greater delta selec-
t i v i ty . However. the E-isomer is dramatically decreased in its
affinity for both receptors, which is almost equal to that of inac-
tive [D-Ala2, D-Phe4]-Leu-enkephalin. Due to the difference in the
orientations of the phenyl groups in the Z- and E-isomers of Phe,
the phenyl ring in the zPhe4-enkephalin is held rigidly toward the
amino end of the enkephalin sequence, to which the other aromatic
amino acid (Tyr1) residue appears. In contrast, the phenyl group
in the E-isomer is restricted to the opposite arrangement. These
results clearly show that the molecular shape, restricted and
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FIGURE 3
Chemical Structures of Dehydrophenylalanine4-enkephaline
Having the Z- (1) and E- (2) Configurations
stabilized by the Z-configuration of Phe4, enhances discriminative
recognition between the opiate receptors. Recent work leading to
the incorporation of cyclopropylphenylalanines into enkephalin has
shown similar results (Kimra et al. 1983; unpublished data). Col-
lectively, a subtle discriminative recognition between delta and mu
receptors by these conformationally restricted analogs may be due
to the different stereochemical requirements of each receptor at the
binding regions corresponding to the two aromatic groups in the en-
kephalin ligand.
Leu-enkephalin is delta-preferential (table 6), indicating that an
isobutyl side-chain of Leu5 is an appreciable receptor-discriminating
component. Placement of D-Leu in position 5 results in a marked
gain in delta selectivity in muscle assays, as shown in table 6. The
COOH-terminal modifications, such as amidation and esterification,
invariably cause a change in delta versus mu selectivity, arid at
least partially eliminate interaction with the delta receptors.
Therefore, the COOH group can be recognized as one of the most im-
portant enkephalinlike characteristics. It should be noted, however,
that the mechanism of a selectivity shift by COOH modifications may
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TABLE 6
Receptor Selectivity of Enkephalin Analogs with Substitutions at Position 2 and 5a)
Amino Acids I n h i b i t o r y  A c t i v i t i e s b )
position 2 position 5 GPI MVD
Delta
c )Selectivity
Gly
D-Ala
D-Ala
D-Ala
D-Ala
Gly
D-Ala
D-Ala
D-Ala
morphine
Met-OH
Met-OR
D-Met-OH
D-Met-OCH3
D-Met-NH2
Leu-OH
Leu-OH
D-Leu-OH
D-Leu-OCH3
100 100 10.7
560 500 9.5
180 590 35.5
300 300 10.7
130 60 4.9
35 170 51.6
550 900 17.6
330 2,720 88.5
990 160 1.8
220 3 0.14
a) Calculated using data of Beddell et al. (1977a) and Kosterlitz et al. (1980).
b) Relative to Met-enkephalin (=100).
c) Selectivity ratio defined as IC50(GPI)/IC50(MVD).
be different between the binding assays in rat brain and the isolat-
ed muscle assays (Shimohigashi et al. 1982d). For the muscle assays,
the existence of the COOH group is distinctly effective for obtain-
ing a high delta potency, while it causes a decrease in the mu
affinity in the receptor binding assays. Sane possibilities may
account for this difference: (1) in the muscle assays a degradation
of the carboxyl-free peptides may occur; (2)  in the MVD both mu and
delta receptors are present; (3) the ligands may have same agonist-
antagonist properties; and (4) the delta receptors in rat brain and
in the MVD may have a structural subtlety in interacting with enkeph-
alin peptides. By characterizing the acidic function of the COOH
group, Bajusz et al. (1980) synthesized a series of analogs contain-
ing amino sulfonic acid and amino phosphonic acid residues at posi-
tion 5. Those analogs had little effect on their receptor selec-
tivity.
In summy, structural elements for each residue that result in
greater specificity and selectivity for the delta receptors in the
enkephalin sequence, or the so-called “enkephalin like characteristics,”
are as follows (figure 4):
( i ) the Tyr1 residue,
(ii) non hydrophobicity in position 2,
(iii) the Gly3 residue,
(iv) existence of the phenyl group and its stereo-orientation in
position 4,
(v) the isobutyl side-chain of Leu5, and
(vi) the C-terminal COOH group.
FIGURE 4
Enkephalin like Characteristics
Essential for Specific Interactions with Delta Opiate Receptors
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Leu-enkephalin, per se, which possesses all of these characteris-
tics, can be an ideal ligand for the delta receptor under physio-
logical conditions. Among these characteristics, (i), (iii), (iv),
and (vi) appear to
ence of Tyr1, Gly3,
be particularly important. However, the exist-
and COOH group is inevitable in Leu-enkephalin,
and thus factor (iv), which is related to the phenyl ring in posi-
tion 4, seems a very important determinant for eliciting and
enhancing delta specificity and selectivity.
The most utilized delta ligand to date is [D-Ala2, D-Leu5]enkephalin
(DADLE), which exhibits a selectivity ratio, defined as the ratio
of  (IC 5 0 s  in  mu/IC 5 0  in  delta) ,  o f  50 to  100 in muscle  assays
(GPI/MVD), and of about 10 in binding assays in using rat brain
(3H-naloxone/3H-DALE). Taking a nonhydrophobic character at position
tion 2 into consideration, Roques’ group has synthesized Leu-enkeph-
alin analogs containing ß-hydroxyamino acid, D-Ser, or D-Thr at posi-
tion 2, with a Thr extension at position 6 (Gacel et al. 1980; Zajac
et al. 19831. Their selectivity ratio was reported to be 1,000 to
3,000 in muscle assays, but only 7 to 20 in rat brain binding as-
says. A selectivity ratio of 170 to 330 in similar muscle assays,
however, has been reported by another group (Mosberg et al. 1983),
and thus the design and synthesis of a highly delta-specific ligand
still appear to be of great importance and urgency. It is note-
worthy that these reported delta ligands possess little restriction
or rigidity around the Phe4 residue.
Mu-Receptor Specificity
One way to increase mu-receptor specificity is to eliminate sane of
the enkephalinlike or delta characteristics from the peptide mole-
cule without introducing any chemical modifications at the Tyr1
residue. It should be noted that such a synthetic sequence seems
to coincide with the design for highly bioactive enkephalins as
described above. In fact, the peptides having these types of modi-
fications have been proved to be nonselective or mu-preferential
due to their decrease in delta specificity. Highly potent FK 33-824
is mu-selective with a selectivity ratio of about 7 in both muscle
and binding assays, mainly due to a pronounqced gain in mu potency
(Kosterlitz et al. 1980). Similarly, a shortened peptide analog
synthesized by Kiso et al. (1981) was reported to be several thou-
sandfold more selective for mu than for delta receptors in binding
assays (Quirion et al. 1982). This extreme mu selectivity is appar-
ently caused by a drastic loss of delta affinity, but not by a great
gain in mu affinity. This may be related to the removal of the
amino acid residue at position 5 followed by a possible conforma-
tional alteration. The most utilized mu-specific ligand to date is
[D-Ala2, MePhe4, Gly-ol5]enkephalin (DAGO), an analog of FK 33-824.
This peptide lacks only the side chain of Met(O)-ol5 residue in FK
33-824, and its mu selectivity ratio is almost 100 in rat brain
binding assays Wanda et al. 1981).
Ligand characteristics for mu-receptor specificity can be summarized
as follows: (1) the Tyr1 residue, (2) hydrophobicity in position 2,
and (3) the phenyl ring arranged in a specific array in position 3
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or 4. It seems that N-methylation of Phe4, for example, in FK 33-
824 and DAGO, may elicit a favorable interaction with mu receptors
which is presumably due to restriction of sane conformational pa-
rameters for suitable spacial arrangement of the phenyl group,
together with an increased resistance to enkephalinase.
Conformationally Restricted Enkephalin Analogs
For the elucidation of more dynamic and definitive structure-activ-
ity relationships, the incorporation of conformational constraints
into enkephalin peptides has been recognized as a useful structural
variation to permit an assessment of the stereochemical consequences
on the resulting biological profiles, especially on receptor spec-
ificity and selectivity. Since a different conformational feature
required for interaction with different subtypes of opiate receptors
can be obtained fran conformational flexibility, the restriction of
this flexibility may lead to an analog having the conformation to
interact preferentially with only one class of receptors. One
approach toward such a restriction involves cyclization of enkeph-
alin peptides, and it has proven to be adequate to increase mu-or
delta-receptor selectivity (Schiller and DiMaio 1982; Mosberg et al.
1983).
A potent cyclic enkephalin was first reported by DiMaio and Schiller
(1980); cyclfzation was performed between the COOH-terminal carboxyl
group of Leu and the -amino group of D- -diamino butyric acid
placed in position 2. The resulting cyclic peptide was found to be
mu-preferential in both muscle and binding assays, while its open-
chain analog was almost nonselective (Schiller and DiMaio 1982).
By canparison of the potency and selectivity of cyclic and open-chain
peptides, it is suggested that different receptors have different
structural preferences for each complementary ligand. Schiller et
al. (1981) also synthesized cyclic analogs containing a cystine
bridge between positions 2 and 5, which exhibit moderate selectivi-
ties for the mu receptors (figure 5a). Quite interestingly, extrem-
ely high delta selectivity has been obtained for analogs of cystine
enkephalin only by virtue of substitutions of cysteine by penicil-
lamine (ß,ß-dimethyl cysteine) at both positions 2 and 5, as shown
in figure 5b (Mosberg et al. 1983). Its delta
3,200 in GPI/MVD assays and 175 in 3H-naloxone/3H-DADLE rat brain
selectivity is almost
binding assays. The structural difference between these two S-S
bridged cyclic enkephalins lies in the existence or absence of a
dimethyl group on the ß-carbon at positions 2 and 5 and amide modi-
fication at the COOH terminus. The effect of dimethyl substitutions
seems to cause a dramatic selectivity shift in receptor recognition.
This indicates that the mu and delta receptors have a more subtle
conformational variation for discrimination and optimal interaction
with each specific ligand. It is interesting to note that the Phe4
residue, which impacts an important enkephalin like character, exists
within the constraint of cyclic structure. Another interesting
cyclic analog, synthesized by Siemion et al. (1981). is a semi-rigid
Leu-enkephalin peptide having an azo-bridge between Tyr1 and Phe4
residues (figure 5c). By observing a long-lasting morphine like
analgesic effect in vivo, they suggested that the biologically
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FIGURE 5
Chemical Structures of Conformationally Restricted Cyclic Enkephalins
(a) Mu-preferential [D-Cys2-D-Cys5]enkephalin Amide,
(b) Delta-Selective [D-Pen2-D-Pen5]enkephalin (Pen: Penicillamine),
and (c) Azo-bridged Enkephalin
active conformation of enkephalin interacting with the opiate recep-
tor must be such that both aromatic rings of Tyr and Phe would
appear close to each other.
Local conformational restriction by incorporation of such unusual
amino acids as dehydro or cyclopropylamino acids, can also affect
strongly the overall molecular conformation of enkephalins and their
receptor interactions. This has been well demonstrated by synthesis
of the Z- and E-isomers of dehydrophenylalanine4-enkephalins, as
mentioned previously.
Camerman et al. (1983) and Karle et al. (1983) have recently eluci-
dated the crystal structure of Leu-enkephalin, in which four
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conformers with extended backbones form an infinite antiparallel ß-
sheet. An intriguing feature is the interrelationship between the
aromatic rings of Tyr1 and Phe4 residues located on opposite sides
of the backbone. Two of the four conformer are similar and some-
what puckered, having a distance of 8.2-8.9Å between the two aro-
matic rings, while the other two conformers are also similar in
having a flat backbone (13.3-13.9Å). Such a steric difference in
Leu-enkephalin might be related to the differential recognition of
mu and delta receptors (Shimohigashi et al. 1984b).
Receptor-Specific Enkephalin like Antagonists
For the agonist-antagonist profile, the structure-function relation-
ships of alkaloid opiates are well established. Substitution of the
methyl group by a typical antagonist-inducing pharmacophore, allyl
or cyclopropylmethyl, on the mine nitrogen of opiates usually in-
creases narcotic antagonist activity. However, application of these
modifications to the enkephalin peptides does not result in genera-
tion of analogs having an appreciably pure antagonist property (Hahn
et al. 1977; Morgan et al. 1977; Pert et al. 1977) Unfortunately,
the structure-activity studies of enkephalins have shed little light
on how to prepare peptidic antagonists. Specific enkephalin antago-
nists that have been reported possess very weak receptor affinity
in toto.
Shaw et al. (1982) reported a delta-selective pure enkephalin antag-
onist having modifications such as diallylation of the amino group
of Tyr1 and replacement of the peptide bond of Gly3-Phe4 by a CH2-S
linkage (figure 6a). Its antagonist activity in reversing the ef-
fects of normorphine or Leu-enkephalin on the MVD indicates that the
peptide acts predominantly on the delta receptors. However, its
potency seems considerably poor (Shaw et al. 1982), and its extremely
weak receptor affinity has also been found to be 340 times less than
that of agonist DADLE in rat brain binding assays (Zajac et al. 1983).
On the other hand, Bower et al. (1981) synthesized mu-selective en-
kephalin antagonists by furnishing additional groupings to the en-
kephalin molecule, based on the idea that antagonists would bind to
the receptor enviromnent adjacent to the agonist receptor (figure
6b). Their binding to opiate receptor labeled by 3H-naloxone was
almost unaffected by sodim ion addition, indicating a pure antago-
nist property, although their receptor affinity was 10 to 70 times
less than that of naloxone.
MIF-I, H-Pro-Leu-Gly-NH2, the alleviative of Parkinson’s disease,
has been described as a blocker of the analgesic effects of enkeph-
alins and morphine in the tail-flick test in vivo (Kastin et al.
1979). Furthermore, Dickinson and Slater (1980)demonstrated that
MIF-I weakly and selectively inhibits mu receptors and suggested its
possible role as an endogenous antagonist. Maurer et al. (1982)
showed that a somatostatin analog, H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-
Cys-NH-CH(CH2OH)CHOHCH3, is an opiate mu antagonist having a recep-
tor affinity of 10% that of naloxone.
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FIGURE 6
Chemical Structures of Enkephalin like Antagonists
(a) Delta-selective N,N-Bisallyl-[Gly3(CH2S)Phe
4]-Leu-enkephalin,
and (b) Mu-selective Des-Leu5- D-Ala2, MePhe4 enkephalin-
(3-methylthiopropyl)-(2-phenylethyl)amide
DIMERIC ENKEPHALINS AND THEIR RECEPTOR SPECIFICITY
Delta Receptor-Specific Dimeric Enkephalins
A comprehension of the molecular mechanism of interaction between
the receptor and its complementary ligand would facilitate the better
design of more specific and more selective ligands in receptor ac-
tion. Efforts in clarifying receptor organization and dynamics on
the membrane have somewhat affected the synthetic and biochemical
studies of enkephalins. Among them, the suggestion by Hazum et al.
(1979) that delta receptors might be extremely closely clustered in
the membrane has provided anideato synthesize a newtype of delta-
specific ligand. It is likely that the overall macroscopic affinity
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of a ligand for its receptor is due to multiple interactions be-
tween a nunber of chemical elements in the ligand and corresponding
subsites present in the receptor. Structural variations by incor-
poration of modified groupings or constraints may enhance such
interactions, thereby increasing the receptor affinity. Also,
increased affinity can be attained by an increase in the number of
interactions or in binding energy obtainable with the resulting
multiple attachements to the receptors. In this rationale, multi-
valent ligands would offer a fair possibility, provided each peptide
unit in a ligand sustains parent active interactions with receptors.
Even a bivalent ligand in which two active molecules are cross-linked
by a spacer is expected to produce at least a twofold enhancement
in affinity, because of the statistical advantage in association.
Furthermore, if the connecting spacer is long enough to permit simul-
taneous binding or bridging between two adjacent receptor molecules,
the magnitude of enhancement in affinity should be much larger. I t
is likely that such bridging of receptors might be selective for
only a single type of receptor.
A systemic study on dimerization of enkephalin molecules has been
performed by Shimohigashi et al. (1982b, 1982c) on the basis of such
a subsite-interaction hypothesis (Delean et al. 1979) and of the
suggestion of receptor topological organization on the membrane
(Hazum et al. 1979). Earlier studies on enkephalin dimers has in-
volved their synthesis by Coy et al. (1978), Hazum et al. (1982),
and Lipkowski et al. (1982). In our case, the general strategy for
the synthesis of a series of enkephalin dimers was based on tradi-
tional SAR studies as described (figure 7): (1) Tyr-D-Ala-Gly-Phe-
Leu sequence was chosen as parent backbone for stability; (2) dimer-
ization was carried out at the COOH-terminal, since the NH2-terminal
has been established as essential for activity; and (3) methylene
bridges of varying length, (CH2)n with n = 2-22, was utilized as
spacers to provide simplicity, flexibility, and chemical stability.
Dimerization was performed at the carboxyl side of each amino acid
residue successively from the COOH terminus, producing dimeric
pentapeptide- (DPEn), tetrapeptide- (DTEn), and tripeptide- (DIREn)
enkephalins (figure 7). The examenation of the optimal spacer length
among these series would help to characterize receptor organization.
In the first series of DP the monamer for dimerization was a
pentapeptide H-Tyr-D-Ala-Gly-Phe-Leu-NH2 (DALEA), which cannot dis-
criminate well between delta mu receptors. In the mu assays
(GPI and binding assay using 3H-naloxone) , the dimer with spacer of
n = 2. DPE2. showed no significant changes in relative potency com-
pared with the monaner DALEA (Shimohigashi et al. 1982c; Costa et
al. 1985). Increases in the chain length resulted in a progressive
loss of potency In contrast, in the delta assays (MVD and binding
assay using 3H-DADLE) the pentapeptide dimers were considerably
more potent than monomer DALEA. The most active compound was DPE2,
which was eightfold and twentyfold more potent than DALEA in the
binding and MVD assays, respectively. Spacers of 4, 6, and 8 methy-
lene units caused a consistent increase in potency. Further exten-
sion of the methylene bridge to n = 10 and 12 resulted in a progres-
sive loss of activity. These results reveal several distinct
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FIGURE 7
Chemical Structure of Dimeric Enkephalins
Strategy and Expected Variation Following Dimerisation
features about the receptor action of dimers: 1) Nonselective mono-
mer becomes "delta-selective" by dimerization, and the selectivity
ratio of the most specific DPE2 is compatible with that of most
utilized delta ligand,DADLE, in both binding and muscle assays. I t
should be noted that DPE dimers lack the importantenkephalinlike
characteristic of the COOH-terminal free carboxy group, yet they
exhibit delta selectivity. 2) Relative potencies are higher in the
MVD biological assay than expected on the basis of binding affinities
in rat brain or muroblastoma-glioma hybrid cells. 3) The GPI ac-
tivity and mu-receptor affinity, however, are highly correlated: as
the methylene chain length increases from 2 to 12, there is a pro-
gressive drop in potency in both muscle and binding assays. The
fact that the linkage of two molecules of a nonselective ligand
(DALEA) results in a very delta-selective compound with enhanced
biological activity has elicited an attractive hypothesis that the
dimeric enkephalins might cross-link the delta receptors, presumably
clustering to ether with appropriate intermolecular distances (Ha-
zum et al. 1979) or they might cross-link copies of several enkeph-
alin binding sites in the delta receptors (Costa et al. 1985).
Several lines of evidence supporting these postulations have also
been presented by various kinds of kinetic studies (Costa et al.
1982; Krumins et al. 1982).
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The second series involves dimeric tetrapeptides of DTEn. The mono-
mer, H-Tyr-D-Ala-Gly-Phe-NH2 (DAPHA), showed little difference in
potency in the GPI and MVD assays, but had a tenfold increase in
selectivity for the mu receptor in the binding assays. A compara-
tive study between muscle and binding assays has also been performed
for the DTE dimers (Costa et al. 1985). DTEn with spacers of n = 2,
4, 6, 8, and even 10 methylene units were nearly equipotent with
monaner DAPHA in both GPI and binding assays. In contrast, a spacer
of n = 12 produced a dramatic drop in GPI activity and mu-binding
affinity, having only 8% to 9% of monaner activity (table 7). This
is in contrast with the marked enhancement of potency by DTE 2 in
the MVD and delta-binding assays. Thus, DTE12 becomes a "delta-
selective” ligand with a significant selectivity ratio of 20 to 90
(Shimohigashi et al. 1982b; Zajac et al. 1983; Costa et al. 1985).
Again, it should be noted that dimerization causes a striking selec-
tivity shift, although DTE dimers “lack” two enkephalin like charac-
teristics: the carboxyl group and Leu5 side-chain. In the delta
assay, the DTE dimers are consistently more potent than the DAPHA
monamer . However, the increase in MVD activity is significantly
less than that expected on the basis of delta-binding affinity (Costa
et al. 1985). Such a discrepancy has been seriously discussed as a
function of the spacer length, which produces hydrophobicity (Costa
et al. 1985; Shimhigashi et al. 1984a).
Bifunctional interaction of the most potent dimers of DPE2 and DTEl2
with delta receptors has also been demonstrated by evaluation of
activities of alkylmidated monamers having corresponding spacer
molecules: DALEA-C2 and DAPHA-Cl2 (Shimhigashi et al. 1984a; Costa
et al. 1985). Ethylamide substitution of DALEA, the spacer addition
which creates DALEA-C2, produces a threefold increase in MVD activ-
ity, but an insignificant (1.3 times) increase in delta binding
(table 7). When another enkephalin molecule is attached to DALEA-C2,
TABLE 7
Relative Activities of Enkephalin Monmers and Dimers
for Delta and Mu Opiate Receptors
Delta-activity Mu-activity
Enkephalins MVD 3H-DADLE GPI 3H-NAL
Penta-series
DALEA 100 100 100 100
DALEA-C2 300 130 160 82
DPE2 2,300 800 75 75
Tetra-series
DAPHA 100 100 100 100
DAPHA-Cl2 6 32 8 8
DTEl2 320 1,300 9 8
DALEA-C2 : H-Tyr-D-Ala-Gly-Phe-Leu-NH-CH2CH3
DAPHA-Cl2: H-Tyr-D-Ala-Gly-Phe-NH-(CH2)11-CH3
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creating a dimer DPE2, the increment in potency is about sevenfold
in both the muscle and binding assays. This increment is clearly
the net increase due to the bivalency of DPE2. Such an effect of
bivalency, however, cannot be observed in the mu assay systems.
Similarly, the net relative effect attributable to bivalency of the
DTE12 dimer is calculated as a fortyfold to fiftyfold increase in
delta, but not in mu, assays (table 7). It is now evident that most
of the increase in delta activity and affinity obtained by dimers
is the result of the simultaneous presence of the two enkephalin
peptides in one molecule.
In the third series, dimerization was performed using a nearly in-
active tripeptide, H-Tyr-D-Ala-Cly-NH2, with the same synthetic
strategy. The resulting dimeric tripeptide enkephalins, DTREn (n =
2-22), exhibited up to a several hundredfold increase in binding to
delta and mu receptors (Lutz et al. 1985). Delta affinity increased
progressively fran n = 2 to a broad plateau at n = 16. It  is  inter-
esting to note that if one amino acid residue were approximately as
long as a methylene chain with n = 3, then chain lengths of n = 2-6
for DPEn dimers--the most delta-active dimers in the series--would
correspond to n = 8-12 for DTEn, and to n = 14-18 for DTREn, dimers.
Such optimal spacer lengths have been found and must be related to
a characteristic feature of membrane organization of the delta re-
ceptors. Although all the DTRE dimers are mu-preferential or non-
selective, the almost 200-fold increase of DTRE16 in delta affinity
is quite notable, since it “lacks” the additional enkephalin like
characteristic of the Phe4 residue.
Several possible mechanisms have been proposed to explain theoret-
ically the gain in delta activity and selectivity by enkephalin
dirmers (Costa et al. 1985). Also, much effort has recently been
centered around the isolation and structure elucidation of the opiate
receptors. In combining these research efforts, it will become fea-
sible to obtain a novel receptor-specific enkephalin ligand, and,
clearly, the study of the dimeric enkephalins appears to be a guide-
post.
Mu Receptor-Specific Dimeric Enkephalins
Unexpectadly, the dimeric tripeptide enkephalin with a spacer length
n = 2, DTRE2, showed a dramatic increase in mu-selectivity (Lutz
et al. 1985). Its selectivity ratio of, mu versus delta receptors
was almost 150-fold, with a fair mu affinity (IC50 = 29 nm). DTRE2
is 10 times as potent as its monomer in delta receptor binding, but
almost 400 times in mu binding. Its agonistic activity was also
demonstrated in the GPI assay (Shimohigashi et al., unpublished data).
Although the mechanism of interaction between DTRE2 and mu receptors
is not clear at this manent, a considerable synthetic study is in
progress in our laboratory to elucidate the receptor action of such
shortened enkephal in dimers.
CONCLUDING REMARKS
With numerous structure-activity studies, it is now becoming more
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evident what determines mu and delta receptor specificity and selec-
tivity. Conspicuous structural elements necessary for the delta
receptor interaction have been analyzed and defined as enkephalin-
like characteristics. The characteristics of peptides for the mu
receptor interaction are also praninent in part. Emphasizing or
reinforcing these characters by chemical modifications would offer
a kind of “fully” receptor-specific and selective enkephalin-ligand.
At this moment, two distinct synthetic sequences seem promising for
the design of such ligands: the synthesis of conformationally re-
stricted peptides and the synthesis of multivalent peptides.
Little has been done in the way of SAR studies on elongated-enkeph-
alins and even in kappa receptor-specific dynorphins (Corbett et al.
1982). The natural ligand(s) for the mu receptors is still in ques-
tion. It is a fact that newly elucidated biological or biochemical
aspects of opiate and opioid peptides have affected dramatically the
structure-activity studies of enkephalins. If the characteristic
membrane feature of each opiate receptor, and then the structural
picture of binding sites, were specified for each corresponding
ligand, even a graphical &sign of the receptor-fitted
be possible. With burgeoning interest in elucidating heterogeneous
ligands would
receptor functions of the enkephalin peptides, the design and synthe-
sis of fully receptor-specific ligands will unequivocally became an
increasingly important requisite.
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Structure-Activity Relationship and
Pharmacology of the Highly Selective
µ-Opioid Agonist, Morphiceptin
Kwen-Jen Chang, Ph.D.
Morphiceptin is an amidated tetrapeptide with the
sequence of Tyr-Pro-Phe-Pro-NH2 (Chang et al. 1981).
This sequence is contained in ß-casein, which is a
major milk protein. Morphiceptin is structurally
related to the opioid peptide ß-casomorphin, a
heptapeptide (Tyr-Pro-Phe-Pro-Gly-Pro-Ile) originally
isolated from bovine casein peptone (Brantl et al.
1979). The amino acid composition and receptor selec-
tivity of morphiceptin differ from those of
enkephalins. Morphiceptin is a highly selective
opioid peptide agonist for µ-receptors (Chang et al.
1981; Zhang et al. 1981). This property is contrasted
to that of enkephalins which are selective for
-receptors (Lord et al. 1977; Chang and Cuatrecasas
1979). Because of its unique high selectivity for
µ-receptors, a number of morphiceptin analogs have
been synthesized in order to gain insight into the
structural requirements for µ-receptor activity and to
obtain more potent and metabolically stable µ-opioid
peptide. Structure-activity relationship (SAR) of
morphiceptin analogs will be first discussed below in
detail. Several potent analogs have also been
obtained. Some pharmacology of morphiceptin will be
summarized here. One morphiceptin analog, [NMePhe3,-
D-Pro4]morphiceptin (PL017), shows better receptor
affinity than morphiceptin and is the most potent
µ-opioid morphiceptin analog in in vivo studies (Chang
et al. 1983). The pharmacology of this morphiceptin
analog will be discussed in detail and compared with
classical µ-agonist, morphine, as well as -agonist,
[D-Ala2,D-Leu5]enkephalin (DADLE).
Structure-Activity Relationship
The SAR is based on the µ-receptor binding affinity
determined by the IC50 value, the concentration of a
compound required to decrease 50% of the specific
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binding of 125I-labeled µ-agonist, FK33824 [Tyr-D-Ala-
Gly-NMePhe-Mel(O)ol], to rat brain membranes (Chang
et al. 1979). The bioactivity of µ-receptors was also
examined to determine their ability to inhibit the
electrically stimulated muscle contraction of isolated
tissues.
TABLE 1
Relative Receptor Binding Activity of Morphiceptin
Analog with Various Substitutions at Fourth Amino
Acid Residue
Tyr-Pro-Phe-X-NH2
X = Pro (Morphiceptin)
D-Pro
Thz
Thz(o)
Tyr-Pro-NMePhe-Y
Y = D-Pro-NH2 (PL017)
D-Pro
D-Pro-ol
-OH
D-Pro-NHNH2
D-Pro-Gly-NH2
µ-Receptor Relative
Affinity” Affinityb
(IC50, nM) (%)
63 100
4.3 1,470
12 530
40 160
5.5 1,150
186 30
5 1,260
1,500 4
2,000 3
8.7 720
aµ-Receptor binding affinity was determined by the
concentration which inhibited the binding of 125I-
FK33824 to the µ-binding sites of rat brain
membranes by 50% (IC50) (Chang et al. 1979).bThe relative affinity is expressed as percent of the
parent compound (100%). Thz = thiazolidine-4-
carboxylic acid; Thz(o) = thiazolidine-4-carboxylic
acid sulfoxide; Pip = pipecolinic acid; Pro =
3,4-dehydroproline; Hyp = 4-hydroxyproline.
Morphiceptin contains two prolines at the second and
fourth positions. Levorotary configuration of proline
at the second position, but not the fourth position,
is essential for µ-receptor activity (Chang et al.
1981) Replacement of L-proline at second position
with D-proline produced an analog with little
activity. In contrast, replacing fourth L-proline
with D-proline, or various cyclic analogs such as
thiazolidine-4-carboxylic acid and thiazolidine-4-
carboxylic acid sulfoxide, yielded peptides of greater
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activity (table 1). The D-proline substitution is
most effective. This analog, [D-Pro4]morphiceptin, is
about 15 times more active than morphiceptin (Chang
et al. 1983).
As shown in table 1, methylation of amino group of
[D-Pro4]morphicept in produced an analog, [NMePhe3,-
D-Pro4)morphiceptin (PLO17), of comparable µ-receptor
binding affinity but greater in vivo activity (Chang
et al. 1983). Removal of thea amide group of PLO17
attenuates activity. However, the activity is
retained when the amide is changed to the carbinol.
Deleting the fourth amino acid or replacing the amide
with the hydrazine markedly reduces activity.
Activity is almost fully retained when glycineamide is
added to the fifth residue on the carboxyl terminus.
TABLE 2
Relative Receptor Binding Activity of Morphiceptin
Analogs with Various Amino Acids at Third Position
µ-Receptora Relativeb
Affinity Affinity
(IC50, nM) (%)
Tyr-Pro-X-D-Pro-NH2
X = Phe 4.3 100
N-Me-Phe 5.5 78
D-Phe 200 2
Trp 100 4
Pheg 1,500 0.3
Tvr 4,000 0.1
0-Me-Tyr 5,000 0.08
His 25,000 0.017
aµ-Receptor binding affinity was determined by the
concentration which inhibited the binding of 125I-
FK33824 to µ-binding sites of rat brain membranes by
50% (IC50) (Chang et al. 1979).bThe relative affinity is expressed as percent of the
parent compound (100%).
Phenylalanine at the third position is essential for
activity (table 2). Substitution of phenylalanine by
histidine, phenylglycine, tyrosine, or 0-methyl-
tyrosine dramatically reduces the affinity. Replace-
ment of phenylalanine with D-phenylalanine or trypto-
phan yielded peptides of considerably lower affinity.
Schiller et al. (1983) have also shown that the
addition of a nitro-group to phenylalanine of
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morphiceptin produces a drastic potency drop which is
sharply contrasted to the enkephalin analogs. The
Phe(pN03) substitution of enkephalins always yields
more potent enkephalin analogs.
The second amino acid can be substituted with other
cyclic amino acid analogs, such as thiazolidine-4-
carboxylic acid, pipecolinic acid, or 3,4-dehydro-
proline, with only a slight reduction in activity
(table 3) (Chang et al. 1983). Substitution with
other hydrophilic cyclic amino acid analogs, such as
thiazolidine-4-carboxylic acid sulfoxide or 4-hydroxy-
proline, greatly abolishes the activity. Unlike
enkephalins, the insertion of a glycine between second
and third amino acid virturally abolishes activity.
TABLE 3
Relative Receptor Binding Activity of Morphiceptin
Analogs with Various Amino Acids at Second Position
µ-Receptor Relative
Affinity Affinity
(IC50, nM) (%)
Tyr-X-NMePhe-D-Pro-NH2
X = Pro
Thz
Pip
Pro
Thz(O)
Hyp
Pro-Gly
5.5 100
25 22
16 34
21 34
80 6.9
800 0.69
12,000 0.06
All peptide analogs of morphiceptin that have been
synthesized so far exhibit extremely low affinity
toward -binding sites. The IC50 values determined in
the binding assay against the binding of 125I-labeled
-ligand, DADLE, to -sites are greater than 10 µM
(Chang et al. 1981, 1983). All active morphiceptin
analogs mentioned above retain very high selectivity
for µ-sites. The µ-site selectivity of (NMePhe3,-
D-Pro4]morphiceptin is superior to that of other
µ-agonists, such as morphine, fentanyl, FK33824, and
[D-Ala2,NMePhe4,gly-ol5]enkephalin (DAGO) (Chang 1984).
However, Brantl et al. (1982) have shown that
substitution of D-Ala at the second position leads to
an increased binding affinity to -sites, whereas the
affinity to µ-sites is unchanged; thus, the
selectivity is greatly reduced. Neither -receptors
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nor -receptors exhibit significant affinity for
morphiceptin and its analogs.
IN VITRO PHARMACOLOGY
Morphiceptin and most analogs can inhibit the
electrically stimulated smooth muscle contraction of
the guinea pig ileum (GPI), a µ-receptor dominated
tissue, as well as the mouse vas deferens (MVD), a
-receptor dominated tissue. The potency in MVD is
about five- to tenfold lower than that in GPI (Chang
et al. 1983). The correlation studies show that the
bioactivities in both tissues are highly correlated
with their µ-site binding affinities. Further studies
measuring the antagonist potency of naloxone revealed
that morphiceptin and analogs interact with
µ-receptors in the MVD despite the predominance of
-receptors in this tissue (Chang et al. 1983).
Naloxone competitively antagonizes PL017 in the MVD.
Schild plots yield a pA2 value of 8.7 for naloxone
against PL017,
of naloxone
which is very similar to the pA2 value
against µ-agonist morphine in the
µ-receptor dominated tissue of the GPI and is of an
order of magnitude greater than that against DADLE in
MVD (Chang et al. 1983). This result raises the
question on the validity of using the relative potency
ratio in GPI and MVD as a means to assess the µ- and
-receptor selectivity.
It was also recently shown that morphiceptin and
PL017, like enkephalin, can induce excitatory effect
on CA1 neurons in superfused hippocampus slices,
suggesting that µ-receptors can participate in the
excitatory effect in the  hippocampal formation
1983(Dingledine et al. Bostock et al. 1984).
As a highly selective µ-opioid, morphiceptin was shown
to decrease the somatic calcium-dependent act ion
potential of cultured mouse dorsal root ganglion (Werz
and MacDonald 1982, 1983), suggesting that µ-receptors
are involved in the regulation of Cal2+-dependent action
potential in dorsal root ganglion.
It is interesting to note that although the affinity
of PL017 for µ-sites is lower than that of morphine,
PL017 is more potent than morphine in all in vitro
studies (table 4), suggesting a difference in the way
in which peptide and alkaloid activate µ-receptors.
Another difference between alkaloid morphine and
peptide agonist is that desensitization occurs to. the
excitatory effect of morphiceptin but not to morphine
in the hippocampus slices (Dingledine et al. 1983).
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TABLE 4
Summary of the In Vitro Studies of [NMePhe3,-D-Pro4]-
Morphiceptin and Comparison with Morphine
[NMePhe3,
D-Pro4]-
Morphi-
ceptin Morphine References
Receptor binding
Ki value, nM 5.5 0.4 Chang et al.
1983
GTP sensitivity + +
Na+ sensitivity + +
Isolated tissues,
ED50
 Guniea pig
ileum
Mouse vas
def erens
Hippocampus
slices, ED50
34
240
134 Chang et al.
1983
1,300 Chang et al.
1983
0.4
µM
3 Bostock
et al. 1984
IN VIVO PHARMACOLOGY
Morphiceptin produces transient bradycardia
intravenous (i.v.) administration (Wei et al. 1980)
and elicits analgesia after intracerebroventricular
(i.c.v) injection (Brantl et al. 1982; Chang et al.
1982; Zhang et al. 1981: Barrett and Vaught 1982).
The analgesic activities of morphiceptin and ß-caso-
morphins correlate well with the µ-site binding
activities (Chang et al. 1982). [D-Pro4]Morphiceptin
also produces analgesic action (Matthies et al. 1982).
Morphiceptin produces a pressor response following
third, but not fourth, ventricular injection in
unanesthetized rats (Holaday 1982). In pentobarbitone
anesthetized rats, morphiceptin caused hypotension and
bradypnea after injection into the periventricularis
hypothalamus (Feuerstein and Faden 1982); it also
caused tachycardia at the lower doses, as well as
hypotension and bradypnea at the higher doses, after
injection into hypothalamic nucleus preopticus
medialis (Faden and Feuerstein 1983). Morphiceptin
produces catalepsy by i.c.v. administration (Chang
et al. 1982; Holaday 1982). All of these effects are
reversible by naloxone.
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In vivo studies have also been carried out for PL017
and compared with the classical µ-agonist morphine as
well as -agonist DADLE. These are summarized in
tables 5 and 6.
TABLE 5
Summary of the In Vivo Pharmacology of [NMePhe3,-
D-Pro4]Morphiceptin and Comparison Comparison with Morphine
(NMePhfe3,
D-Pro4]-
Morphi-
ceptin Morphine References
Analgesia, ED50,
nmole/animal
i.c.v. route
i.t. route
Tolerance &
physical
dependence
Depressor &
bradycardia
i.t., nmole/
animal
Respiratory
depression
V t/ T t o t
nmole/kg/
dog
Abolition of
conditioned
responses
0.23 8.4 Chang et al.
1983
1 ~30 Han et al.
1984
+ + Chang et al.
1983
~5 >100 Li and Han
1984
~50 ~800 Haddad et al.
1984
+ + Mauk et al.
1982 ; Lavond
et al. 1983
PL017 injected centrally produces analgesia (Chang
et al. 1983), respiratory depression (Haddad et al.
1984), and abolition of conditioned responses (Mauk
et al. 1982; Lavond et al. 1983. By intrathecal
(i.t.) injection, PL017 potently produces analgesic
(Han et al. 1984), depressor, and bradycardia effects
(Li and Han 1984). After chronic administration,
PL017 produces tolerance and physical dependence
(Chang et al. 1983). Like the above in vitro studies,
PL017 is far more potent than morphine by the same
route of administration in inducing these effects
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(table 5). Since similar results are obtained from
the in vitro studies in which the metabolism is not a
likely explenation for the higher potency for PL017,
we propose that the efficacy of peptide morphiceptin
or its analogs for activating the µ-receptor system is
higher than that of alkaloid morphine.
TABLE 6
Comparison of the Respiratory Effects of [NMePhe3,-
D-Pro4]Morphiceptin and [D-Ala2,-D-Leu5]-Enkephalin
[D-Ala2,-
D-Leu5]-
Enkephalin
[NMePhe3,D-
Pro4]Morphi-
(8) ceptin (µ)
Instantaneous minute
ventilation
Vt/Ttot
Tidal volume, Vt  then normal
Respiratory cycle time,
T t o t
Expiratory duration, Te,
Inspiratory duration, No change
Ti
Respiratory duty cycle
Ti/Ttot Slight
Like morphine, PL017 can induce respiratory depression
after intracisternal injection (Haddad et al. 1984).
In conscious dogs, strikingly different effects on the
ventilation and ventilatory pattern were observed
between PL017 and DADLE (table 6). PL017 induced a
fast and shallow breathing pattern, while DADLE
produced deep breathings separated by a period of
aprea (Haddad et al. 1984). Detailed analysis reveals
that DADLE induces a prolongation in expiratory time
(Te) and a decrease in instantaneous minute ventila-
tion (Vt/Ttot), which is a result of a decrease of tidal
volume (Vt) and an increase
(Ttot) In contrast, PL017 induces a decrease in. the
of respiratory cycle time
inspiratory time (Ti), Te,
in Vi/Ttot. The respiratory effects of µ- and
and Vt, with a net increase
-agonists can be reversed by naloxone, but larger
doses are required after DADLE than after PL017.
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These results suggest that µ- and -receptors in
conscious dogs participate in different regulatory
functions in breathing, and involve different neuronal
pathways.
CONCLUSION
Morphiceptin analogs with various substitutions at
positions 2, 3, and 4 have been synthesized and
studied for their receptor activities. Substitutions
with D-proline at fourth position and N-Me-Phe at
third position yield a potent and highly selective
µ-peptide agonist, PLO17. PL017 and morphiceptins
interact with µ-receptors in GPI and MVD. They elicit
analgesia by i.c.v. and i.t. injection, and evoke
depressor and bradycardia by i.t. injection. PL017
produces tolerance and physical dependence after
chronic administration. PL017 is more potent than
morphine in all pharmacological tests in spite of its
lower µ-receptor binding affinity. In conscious dogs,
PL017 and DADLE produce a profound difference in
regulating ventilation.
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Dermorphin: Autonomic Pharmacology and
Structure-Activity Relationships
Giora Feuerstein, M.D.
INTRODUCTION
In recent years, several biologically active peptides, such as
neurotensin, thyrotropin-releasing hormone, bombesin, and other
tachykinins, have been identified in the gastrointestinal tract
as well as in central and peripheral elements of the nervous
system (Dockray and Gregory 1980). Many of these neuroendocrine
peptides (e.g., bradykinin, CCK-8, substance P, bombesin) were
originally isolated from the skin of various
(Erspamer 1981) .
amphibian
Dermorphin is a hepta
species
tide recently
isolated from the skin of the south American frog of the genus
Phyllomedusae (Brocardo et al: 1981; Montecucchi, et al 1981)
and has the following amino acid sequence: H-Tyr1-D-Ala2-Phe3-
Gly4-Tyr5-Pro8-Ser7-NH2. In addition to demorphin, Hyp
6-
demorphin was also isolated from the skin of same of these
frogs. Dermorphinlike inmmoreactivity was also demonstrated in
rat brain, but the final identification of dermorphin in
mammalian tissue (central or peripheral) has not yet been made
(Negri et al. 1981). The structure of these new tides is
unique since they contain a D-amino acid residue in molecule
which is critical for the biological activity (L-Ala2-demorphin
is only 1% as active as dermorphin). The structure proposed for
the extracted dermorphin from the natural source has been
confirmed by synthesis (de Castiglione et al. 1981a).
Dermorphin has already been tested extensively for a variety of
opiate like activities. Moreover, analog of dermorphin were
already synthetized in order to clarify structure-activity
relationships for the multiple biological activities of these
opioid peptides.
This chapter summarizes the biological effects of dermorphin,
its site of action, the opiate receptors mediating its effects,
and the structure-activity relationships of this unique opioid
peptide.
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DERMORPHIN--OPIOID PEPTIDE
In Vitro Tests
Dermorphin displays a potent depressive action on electrically
stimulated contractions of the guinea pig ileum (GPI) and mouse
vas deferens (MVD)--two classical reparations for opioid
activity assay. In these actions, dermorphin is much more
potent than the endogenous enkephalins, -endorphin, and the
opiate prototype, morphine. In the GPI preparation, the only
peptide which is more potent (three-to- five-fold) than
dermorphin  is dynorphin A-(1-13) (Erspamer et al. 1981). In
the MVD, dynorphin6 A-(1-13) enkephalins are eqiupotent to
dermorphin, Hydro -dermorphin is 80% to 90% as potent
as dermorphion in  these tests. These preferential actions of
dermorphin on GPI suggest preferential u-receptor mediated
action as also indicated from in vitro binding studies (Glaser
et al. 1981).
Analgesia
Dermorphin is an extremely potent anal analgesic agent in most
species tested so far (rat,  mice,  rabbit) .  Surprisingly,
dermorphin does not produce analgesia in the chick at low doses
(Erspamer et al. 1981). Analgesia can be produced by micramole
doses injected ripherally. No known opiate or opioid peptide
can compete with dermorphin in analgesia tests (hot-plate, tail-
flick and even ß-endorphin is only one-twentieth as potent as
dermorphin. Actually, replacement by dermorphin or the N-
terminal sequence 1-7 of ß-endorphin results in increased
analgetic potency of the [denrmorphin1-7]-ß-endorphin as
compared to ß-endor phin (Yamashiro et al. 1983). In the hot-
plate test (rat, intracerebroventricular injection), dermorphin
is 2000-fold more potent than morphine (Erspamer 1981; Erspamer
et al. 1981; Broccardo et al. 1981; Yamashiro et al. 1983).
GASTROINTESTINAL EFFECTS OF DERMORPHIN
Sensory input from the gastrointestinal (GI) tract is conveyed
to several brain regions by afferent vagal nerves. Many of
these regions, e.g., the solitarius nucleus in the brain stem,
limbic areas, contain high levels of opiate receptors as well as
opioid peptides (Mar 1978; Snyder 1977). In addition, opiates
and opioid peptides were shown to have potent effects on various
GI functions.
Dermorphin was also tested for its effects on the GI tract by
both peripheral and central routes of administration. Der-
morphin was shown to inhibit basal gastric secretion or to
stimulate gastric secretion induced by various stimuli-- e.g.,
water distension of the stomach and insulin-induced gastric acid
secretion; however, histamine-induced gastric acid secrction was
resistant to inhibition by dermorphin (Improta et al. 1982). In
addition, dermorphin was also shown to affect the motility of
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both the stomach and intestine.
transit time are substantially increased by dermorphin
Gastric emptying and intestinal
(Broccardo et al. 1982.; Rossi et al. 1983). Intestinal transit,
however, is only partially blocked by dermorphin (Broccardo et
al. 1982).
The  subcutaneous  (s . c . )  or   intracerebroventr icular
administration of dermorphin produces all of these GI effects;
however, the dose of dermorphin necessary to produce GI
inhibition by the central route of  administration was
one-hundredth of the dose necessary to produce comparable
effects by peripheral administration of dermorphin, indicating
that the opioid peptides act through a centrally mediated
mechanism
All of the GI effects of demorphin could be completely pre-
vented by naloxone, suggesting an opiate receptor mediated
effect. Furthermore, the inhibition of intestinal propultion
induced by central administration of dermorphin can be blocked
by a quaternary naloxone analog injected into the cerebro-
ventricular system in a dose which has no effect when admin-
istered peripherally (Parolaro et al. 1983); thus., it seems that
the GI effects of demorphin are primarily medicated through a
centrally located opiate receptor.
Since the studies cited above were conducted on rats, which
differ from guinea pigs and other species in the type and
distribution of opiate receptors in the central nervous system,
it also would be important to investigate the GI effects of der-
morphin in other species. Moreover, the type of opiate receptor
and the specific sites (nuclei) in the brain where GI regulation
by dermorphin commences remain to be explored.
CARDIOVASCULAR AND RESPIRATORY EFFECTS OF DERMORPHIN
Opiates and opioid peptides were long known to affect blood
pressure, cardiac functions, and the respiratory system. There-
fore, it has been postulated that dermorphin, a potent opioid
peptide, might also significantly affect the cardiovascular and
respiratory systems. Indeed, administration of dermorphin to
human subjects causes a brief increase in blood pressure and
heart rate without affecting urinary electrolyte excretion
(Degli-Uberti et al. 1983b, 1983c). In the anesthetized dog,
systemic administration of demorphin elicits pressor and
cardiac acceleration responses (gander and Giles 1982).
In the conscious rat, intracerebroventricular injection of
dermorphin causes complex cardiovascular responses; while low
doses (picomoles) cause elevation of blood pressure and heart
rate, higher doses will cause hypotension and bradycardia
(Feuerstein and Faden 1983a). The cardiodepression produced by
higher doses of demorphin injected into the cerebroventricular
system is accompanied a respiratory depression as evident by
hypoxemia, elevated carbon dioxide, and reduction of blood pH
(respiratory acidosis)  these cardiorespiratory changes are
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accompanied by a marked increase in plasma catecholamines
(Feuerstein and Faden 1983a). However, the cardiac responses to
central administration of dermorphin are more complex: vagal
activation seems to underly the bradycardia produced by high
doses of dermorphin since the peripheral acting muscarinic
blocker, N-methyl-atropine, can prevent or reverse the brady-
cardia produced by dermorphin (Feuerstein and Faden 1983a.
Thus, dermorphin activates both the sympathetic and para-
sympathetic components of the autonomic nervous system. Also,
naloxone reverses all of the central cardiovascular effects of
dermorphin.
The anterior hypothalamus is probably the site for the central
cardiovascular effects of dermorphin since the pressor/cardiac
acceleration effects can be produced by picomole doses of
dermorphin microinjected into discrete nuclei of the hypo-
thalamus (Diz and Jacobowitz 1984; and Diz, Vitale, and
Jacobowitz 1984; Feuerstein and Faden 1983a). The role of the
sympatho-adrewmmdullary system in mediation of the cardiac
acceleration and pressor responses elicited by hypothalamic
injections of dermorphin is also indicated by the blockade of
the cardiac responses with the -adrenergic blocking agent,
propranolol. Yet, it should also be pointed out that other
brain nuclei besides the hypothalamus are involved in dermorphin
effects since dermorphin induces bradycardia, probably by
activation of efferent vagal neurons in the nucleus ambiguus and
the dorsal motor nucleus of the vagus. This suggestion,
however, awaits further clarification.
The cardiovascular and respiratory effects of dermorphin re-
semble those of [D-Ala2-MePhe4-Gly-ol3] enkephalin (DAGO), an
enkephalin analog which is 200-fold more selective for µ-
versus -opiate receptors (Kosterlitz et al. 1980; Pfeiffer et
al. 1982). Since all of the dermorphin effects on the cardio-
vascular system are produced at a much lower concentration than
DADLE, [D-Ala2-D-Leu3] enkephalin, a relatively selective
-receptor agonist, it is pertinent to suggest that µ-opiate
receptors mediate the central cardiovascular responses to
dermorphin. These conclusions are summarized in table 1.
ENDOCRINE AND METABOLIC EFFECTS OF DERMORPHIN
Many opiates and opioid peptides have been shown to affect the
regulation of glucose metabolism and the release of pituitary
hormones (Dupont et al. 1977; Van-Vugt and Meites 1980;
Locatelli et al. 1978). Opioid peptides and opioid receptors
are found in both central (brain, pituitary) and peripheral
organs involved in endocrine and metabolic regulation (Grandison
et al. 1980; Rivier et al. 1977).
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TABLE 1
1.
2.
3.
4.
5.
Central Cardiorespiratory Effects of Dermorphin
Complex Cardiovascular Responses
low doses: presser/cardiac acceleration
high doses: depressor/cardiac deceleration
site and receptor specific
Respiratory Depression
respiratory acidosis (low pH, low p02, high pC02)
Activation of the Sympatho-Adrenomedulary System
increases circulating epinephrine and norepinephrine
Activation of the Vagus (High Doses)
atropine reverses the bradycardia
µ-Opioid Receptors Mediate Dermorphin’s Effects
similarities to DAGO (highly selective µ-agonist)
highly sensitive to naloxone
Prolactin
When dermorphin (0.1 to 5 mg/kg, s.c.) is administered to the
rat, it produces a dose-dependent increase in plasma prolactin
(Rossi et al. 1983). This effect can also be  produced by
subnanomole  doses  o f  dermorphin  in jec ted  into  the
cerebroventricular space, and can also be seen in castrated male
rats. However, in vitro experiments show no direct effect of
dermorphin on prolactin release from rat pituary cells,
suggesting a hypothalamic site for dermorphin-induced prolactin
release (Giudici et al. 1984).
dermorphin was also shown to increase plasma levels of prolactin
in human subjects when infused systemically (Degli-Uberti et al.
1983a). The increase in prolactin response was more pronounced
in females than males. In both the rat and human studies,
naloxone effectively blocked the dermorphin effects, suggestion
an opiate receptor mediated response. However, Güllner and
Kel ly  (1983)  fa i led  to  increase  p lasma pro lact in  by
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low doses of dermorphin in jected intravenously into the
anesthetized rat. This discrepancy might be related to the
different rat species, the type of anaesthesia (Ketamine),
and/or the relatively low doses of dermorphin which might have
failed to reach sufficient levels in the brain.
Growth Hormone
Opiates and opioid peptides have been shown to release growth
hormone (GH) in rat and man (Von Graffenried et al . 1978;
Stubbs et al. 1978; Van-Vugt and Meits 1980). Dermorphin was
also shown to produce an increase in GH levels within minutes
after intravenous administration to the anesthetized rat
(Gullner and  Kelly 1983) or to human subjects (Degli-Uberti et
al 1983a). The increase in plasma GH by dermorphin could be
blocked by naloxone (Degli-Uberti et al. 1983a).
Calcitonin
Dennorphin administration to normal human volunteers (5µg/
kg/min over 30 min) does not change the plasma levels of
calcitonin over a 3-hour period. In addition, the circulating
levels of this hormone are not changed by naloxone infusion
(Degli-Uberti et al. 1983b). These data suggest that opiates
may not play a significant role in regulation of calcitonin
release. However, the role of opiates and dermorphin was not
examined during state where endogenous calcitonin release is
stimulated (e.g., hypercalcemia).
Thyroid Stimulating Hormone (TSH)
Intravenous injection of dermorphin to rats caused a
dose-dependent increment in plasma TSH levels (Gullner and
Kelly 1983). The increase in plasma TSH produced by dermorphin
in opposite to the effect of endogenous opioid peptides on this
anterior pituitary hormone (Bruni et al. 1977).
Luteinizing Hormone (LH)
Opioid peptides were previously shown to reduce plasma levels
of LH (Bruni et al. 1977). Dermorphin administration to adult
male rats causes a marked decrease in plasma LH at extremely
low doses (Gullner and Kelly 1983). The mechanism of this
effect has not been studied as yet.
ENDOCRINE AND METABOLIC EFFECTS OF DERMORPHIN
Several neuropeptides, (e.g., somatostatin, ß-endorphin) and
peptides isolated from frog skin (bombesin, substance P) have
been shown to affect glucose metabolism (Gullner et al - 1983;
Brown and Vale 1976). Injection of dermorphin to the rat at
doses up to 10 g did not effect plasma insulin or
somatostatin; however, plasma glucose was slightly reduced
while plasma glucagon was significantly increased (Gullner et
a l . 1983).
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dermorphin's effect of reducing blood glucose is opposite to the
increase in plasma glucose induced by ß-endorphin. Also, it is
still unclear whether dermorphinexists in the endocrine cells
of the pancreas or in any of the peripheral tissues involved in
these endocrine functions.
dermorphin Effects on the Renal-Adrenocortical Endocrine System
Opiates and opioid peptides have been shown to affect the
pituitary-adrenocortical functions in several species (Smythe et
al. 1980; Gaillard et al. 1981; Volavka et al. 1979). Der-
morphin infusions to normal volunteers caused elevation of
plasma renin activity (PRA) and a small decrease in plasma
cortisol which was accompanied by a similar decrease in plasma
adrenocorticotropic hormone (ACTH). Plasma aldosterone levels
were also slightly increased by dermorphin infusion (Degli-
Uberti et al. 1983c).
accord with the
The increase in PRA by dermorphin is in
known effect of other opioid peptides to
increase PRA (Cantalamessa et al. 1982) and such an increase in
PRA might generate sufficient angiotensin  II to account for the
pressor  response  observed  short ly  a f ter  dermorphin
administration (Degli-Uberti et al. 1983c). The reduction in
plasma cortisol and ACTH by dermorphin is also in accord with
the same response of plasma cortisol to enkephalin analog and
other opiates (Gold et al. 1980; Stubbs et al. 1978; Gaillard et
al. 1981). A role for opioid peptides in regulation of ACTH and
cortisol release is also indicated by the elevation of the
circulatory levels of these hormones by naloxone administered to
normal human subjects.
Catecholamines
Several opioid peptides were shown to stimulate the sympatho-
adrenomdullary axis and increase the circulatory levels of
norepinephrine, epinephrine, and dopamine (Feuerstein et al.
1983; Pfeiffer et al. 1982; Van-Loon and Appel 1981). Intra-
cerebroventricular administration of dermorphin to conscious
rats was likewise shown to produce a marked increase in plasma
levels of epinephrine (over twentyfold)
(sixfold) (Feuerstein et al. 1983). The site of the
and norepinephrine
sympatho-adrenal  act ivat ion  seems to  l i e  wi th in  the
hypothalmus, since microinjection of  dermorphin to the
anteroventral region of the hypothalamus produces similar
incraments in plasma catecholamines and, primarily, epinephrine
(Feuerstein and Faden 1983a). The increase in peripheral sympa-
thetic activity is considered to underlie the increase in heart
rate produced by dermorphin since adrenalectomy or propranolol
(a ß-adrenoceptor blocker) prevents the increase in heart rate
by dermorphin (Diz and Jacobowitz 1984). In addition, the
increase in sympathetic tone is probably the main stimulus for
the observed increase in PRA (Degli-Uberti et al. 1983c).
Table 2 summarizes the endocrinological effects dermorphin
obtained from animal and clinical research.
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TABLE 2
Endocrine and Metabolic Effects of Dermorphin
Epinephrine
Norepinephrine
Renin
Aldosterone
Glucagon
TSH
Growth Hormone
Increase No Change Decrease
Prolactin
Galcitonin
Insulin
Sumtostatin
Glucose
Cortisol
ACTH
TSH = thyroid stimulating hormone; ACTH = adrenorticotropic
hormone; * anesthetized rat; number of (+) or (-) denotes in-
tensity of increase or decrease in plasma levels, respectively.
BEHAVIORAL EFFECTS OF DERMORPHIN
Effects of dermorphin on the Electroencephalogram (EEG)
Injection of low doses (few nanomoles) of dermorphin into the
cerebroventricular system of the rabbit produces synchronous
patterns in the cortical EEG and disruption of hippocampal theta
waves. Higher doses reduce spike wave lexes (Aloisi and
Scotti De Garolis 1981). In the chick, dermorphin adminis-
tration into the third ventricle also caused total voltage power
increase and an EEG shift toward lower frequencies (Erspamer et
al. 1981). The EEG changes are all reversed by naloxone.
In rats, doses of dermorphin ranging from 5 to 2,500 ng produced
electroencephalographic seizures associated with grand mal motor
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manifestations: twitches and tremor with low doses; tonic-
clonic convulsion by higher doses. The convulsive patterns were
followed by high voltage slow waves and other abnormalities
(Aloisi et al. 1982).
Demorphin produces behavioral responsesn known for many opiates,
e.g., catatonia, rigidity, sedation. In the chick, “squating"
behavior was also observed. In mice, doses as low as 10 ng
produce the “Straub Tail Reaction” (tail elevation 906), rest-
lessness , and increased motor activity (runing fits); hi her
doses produce catalepsy. All these effects are also produced by
morphine at higher dose range. In the rat, higher doses of
dermorphin result first in reduced spontaneous movement, and
later in rigidity and catatonia. Exophthalmos, meiosis, and
hypothermia are also observed. In the rabbit, muscular
rigidity, catatonia, and loss of righting reflexes are always
seen at higher doses along with hypothermia, exophthalms, and
mydriasis. In the rabbit, high doses of dermorphin will result
in flaccid paralysis of the hindlimbs and, ultimately, death
(Aloisi et al. 1982). Topical administration of dermorphin over
the sensorimotor cortex in this species results in highly
disorganized EEG activity, characterized by exclusively slow
waves but no motor or EEG convulsive manifestations. Thus, it
appears that in the rat, dermorphin causes EEG; and behavioral
epileptic phenomena but is devoi of convulsant activity in the
STRUCTURE-ACTIVITY RELATIONSHIPS OF DERMORPHIN
The minimal peptidic sequence of dermorphin which possesses
biological activity is respresented by the N-terminal H-Tyr-
D-Ala-Phe-Gly-NH2 tetrapeptide (Broccardo et al. 1981; de
Castiglione et al. 1981b; Salvadori et al. 1982). However,
dermorphin (1-4) is only 2% to 5% as active as dermorphin in in-
hibiting GPI or MVD contraction in response to electrical
stimulation and is practically devoid of  analgetic and
cataleptic activity. dermorphin (1-3) has less than 0.5% of any
of the biological activities of dermorphin
However, modifications of the C-terminal of the dermorphin by
lipophilic substituents, e.g., Tyr-b-Ala-Phe-Gly-NH-CH2-C6H5,
markedly increase the opioid activity of the dermorphin tet-
rapeptide, and the biological activity; H-Tyr-D-Ala-Phe-Gly-NH-
Adamantyl results in over twentyfold increased potency in GPI
and MVD preparation, which strongly suggests a µ-receptor rather
than -receptor mediated effect (Broccardo et al. 1981;
Kosterlitz et al. 1980). A quantitive dependence of biological
activity on the lipophylic character of the C-terminus was also
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reported for a series of enkephalin like peptides (Do et al.
Profound changes in the biological activity of dermorphin can
also be seen by relatively minor changes in position 1 (H-Tyr).
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Replacement of Tye by D-Phe1 or Ala1 causes a 6-order decrease
in potency on the GPI; substitution of au Acetyl Tyr1 also
profoundly decreases the relative potency in GPI inhibition
test. The analog also display reduced capacity to displace
naloxone from binding sites on striatum homogenates (Darlak et
al. 1983). However, the capacity to displace naloxone from
opiate receptors might not alwayslcorrelate with the biological
activity of the analog; Tyr (Me)1-dermorphin for example, is
not less active in displacing naloxone from rat striatun
homogenates as compared to dermorphin but is >thirty fold less
potent than dermorphin in inhibiting of GPI contraction and
almost a hundredfold less active in producing analgesia in mice
(Darlak et al. 1983). Modifications of position 1 of dermorphin
analog also reveal some differential changes in the various
tests of biological activities. Phe1-dermorphin is only about
0.0001% as active as dermorphin on GPI, but has thus still 5%
analgetic activity as compared to the natural peptide. It is
also noteworthy lthat the introduction of a sulphate group on the
hydroxyl of Tyr1-residue of dermorphin completely destroyed all
of the opioid activity of dermorphin (de Castiglione and Perseo
1983).
Modification of enkephalins at position 2 by introducing D-Arg2-
residue produces analog with potent analgetic
(Takagi et al. 1982; Kubota et al. 1980). Similar modification
in the dermorphin tetrapeptide has also proved to produce potent
opioid tide analog (Sasaki et al .  1984).  Thus, D-Arg2-
dermorphin (1-4) is tenfold more potent than dermorphin tetra
peptide in the mice tail-flick test; replacing Gly4 by Sar4-
residue in the D-Arg2-dermorphin (1-4) further increases the
analgesic potency fourfold. Thus, it is clear that D-Ala2-
residue in dermorphin is not always necessary for the opioid
activity, as originally thought. Further modifications at the
C-terminus which increase the lipophilic character of the
peptide also increase the potency. This is due, in part, to an
increased resistance a against carboqieptidases. Resistance
against enzymatic breakdown might account for the prolonged
(several hours) action at relatively low doses injected
subcutaneously.
Several other modes of amino acid substitutjons yield various
potencies of the dermorphin molecules. Substitution of Tyr3 by
aromatic amino acid is well tolerated, but Gly dermorphin is
devoid of must activities. Substitution of Pro8 has little
effect on the overall opioid activity of dermorphin and this
applies also for position 7 (de Castiglione et al. 1981b). An
interesting finding is that the deaminated dermorphin maintains
its peripheral opioid activity but is devoid of effect on the
central nervous system.
Of special interest in the structure-activity relationships of
dermorphin analog are the differential activitiy displayed
by some analog. Thus, dermorphin (1-5) and Leu5 dermorphin
(1-5) demonstrate augmented potency (about twofold) in the GPI
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bioassay test but reduced activity (-80%) in the MVD bioassay
test; these dermorphin pentapeptides are virtually
inactive in the common analgesia and catalepsy tests. Another
example of differential preservation of opioid activity is
demonstrated by the benzylated-Tyr5-dermorphin which presents
about 50% of its inhibitory action on MVD bioassay but only 5%
in the GPI bioassay. In no case so far (of over 100 dermorphin
analog synthesized) has analgesia been preserved as a primary
property of a dermorphin analog. The main structure-activity
relationships of dermorphin are presented in table 3.
TABLE 3
Differential Opioid Activity of dermorphin Analog
GPI MVD ANALGESIC            CATALEPSY
Dermorphin 100 100 100 100
Bzl-Tyr5-Dermorphin <5 50 <1 <0.5
Des-Tyr5-Dermorphin <0.1 <0.1 <1 <l
Dermorphin (1-6) 50 40 20 <1
Dermorphin (1-5) 20 200 <5 <5
Leu5-Dermorphin (1-5) 15 175 <1
Dermorphin (1-4) <2 <5
Dermorphin (1-3) <0.3 <0.5
Numbers represent percent activity as compared to dermorphin
(100%). GPI = guinea pig ileum bioassay test; MVD = mouse vas
deferens bioassay test.
DERMORPHIN AS A µ-RECEPTOR AGONIST
The type of opiate receptor which mediates the biological
actions of dermorphin is still obscure. However, several
pharmacological properties of dermorphin effects in vitro and
in vivo strongly suggest the µ-opiate receptors are primarily
involved in dermorphin effects. The evidence underlying this
suggestion is: 1) Dermorphin is much more potent in blocking
the contraction of the electrically stimulated GPI rather than
the MVD; this bioassay test is considered to be a prototype for
morphine (µ) rather than enkephalin effect. 2) Dermorphin
is less potent than enkephalins in inhibiting the PGE1-stimu-
lated adenylate cyclase (accumulation of c-AMP) in neuroblastoma
x glioma hybrid cells (Glaser et al. 1981). 3) Dermorphin
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effects were shown to be easil and completely reversed by low
doses of naloxone administered peripherally or centrally. 4)
Dermorphin effects on the cardiorespiratory system are similar
to those of DAGO, which is a highly selective µ-receptor
agonist; the cardiovascular effects of dermorphin (pressor/
cardiac acceleration) are produced by doses which are one-
hundredth of those necessary to produce the same responses by
the relatively selective -receptor agonist DADLE (Feuerstein
and Faden 1983a, 1983b; Feuerstem et al. 1983).
SUMMARY
The biological activities of dermorphin summarized in this
chapter indicate that dermorphin possesses all known effects of
opiate/opioid peptides. It seems that dermorphin effects are
primarily mediated through a µ-receptor of high affinity. Since
none of the known endogenous opioid peptides displays high
potency and selectivity for µ-receptors, dermorphin like peptides
might be the endogenous selective ligands for such µ-receptors.
This hypothesis, however? awaits further investigation. The
structure-activity relationships of dermorphin and the unique
D-alanine at position 2 clearly indicate that the N-terminus of
the first four amino acids is crucial for the complete
biological activity. Systematic modifications of the dermorphin
sequence also reveal the potential for developing selective
agonists (or antagonists) for discrete opioid functions by
mdifying receptor selectivity.
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Design of Conformationally Constrained
Cyclic Peptides With High Delta and Mu
Opioid Receptor Specificities
Victor J. Hruby, Ph.D.
INTRODUCTION
Efforts to understand the conformational structure-biological
activity relationships for the endogenous opioid peptides, such as
methionine enkephalin, leucine enkephalin, and dynorphin, have
been difficult. Despite the preparation of at least a few thou-
sand peptide analogs (for reviews , see Miller and Cuatrecasas
1978; Morley 1980; Bajusz 1982; Olson et al. 1982, 1983), highly
receptor-selective and potent peptide analogs have been obtained
only recently. The reasons for these difficulties are many, but
basically they arise fran the intrinsic physical-chemical proper-
ties of most endogencus opioid peptides, the comlexity of the
biochemical events related to their biological activities, and the
existence of several different classes of receptors for these
molecules, each of which my mediate different biological respon-
SeS.
Most of the endogenous cpioid peptides that have been isolated
thus far are small or moderate size linear peptides which have a
high degree of conformational flexibility. These properties do
present certain advantages (table 1), many of which are undoubt-
edly utilized by the cpioid peptides in vivo. However, fran the
standpoint of understanding the physical-chemical basis for infor-
mation transfer and biological activity, these properties pose
several problems for many peptide hormones and neurotransmitters
which we (Meraldi et al. 1977; Hruby 1981a, 1982, 1984; Hruby et
al. 1983) and others Narshall et al. 1978; Veber 1979) have
discussed. For the purpose of this chapter, suffice it to say
that the high conformational flexibility of the opioid peptides
such as methionine enkephalin, H-Tyr-Gly-Gly-Phe-Met-OH, makes it
difficult to determine which of the multitude of possible confor-
mations are of biological significance.
A similar problem exists with regard to the complexity of biologi-
cal information transfer in the hormone-receptor complex. We have
pointed out Hruby 1981a, 1981b, 1984; Hruby et al. 1983; Hruby
and Hadley, in press) that binding, transduction, and reversal
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TABLE 1
Some Advantages of Conformational Flexibility
in Biologically Active Peptides
1.
2.
3.
4.
5.
Many Conformations Accessible at kT.
Different Conformational Structures Can Readily Be Utilized
at Different Receptors.
Easily Fit into Enzymes; Biological Degradation Facile.
“Zipper Model” Is Possible, Providing a Thermodynamically
Accessible Route to Peptide-Receptor Interaction.
Different Conformational Structures Available for Binding,
Transduction, and Reversal at Receptors.
probably each utilize different conformational structure proper-
ties of a peptide hormone or neurotransmitter. Thus, appropriate
ligands and biological assays are needed to help sort out this
complexity
Finally, as with most peptide hormones and neurotransmiters, the
endogenous opioid peptides appear to interact with several dif-
ferent receptors at different cell types. These include the delta
mu (µ), kappa epsilon and possibly other receptors
(Martin et al. 1976; Lord et al. 1977; Chang et al. 1979). These
different receptor types have biological significance, and in
several cases there is good evidence that they have different
structural requirements for cpioid peptides. Thus, the phar-
macophore for each receptor type is different, a fact which has
been largely ignored in previous attempts to understand the
“biologically active conformation” for opioids.
In an effort to resolve some of these problems, we have sought in
our studies to develop receptor-specific peptide analogs. Our
approach to obtaining such analogs has been via conformational
restriction (Marshall et al. 1978; Veber 1979; Meraldi et al.
1977; Hruby 1981a, 1982, 1984). In this chapter, we review how
this approach has led our laboratory to the design and synthesis
of cyclic, conformationally constrained peptides with high delta
and mu opioid receptor specificities.
CYCLIC DELTA RECEPTOR-SELECTIVE PEPTIDES
Oue starting point in 1981 for the development of receptor-spe-
cific enkephalin analogs was several observations related to
enkephalin structure-function studies. First, substitution of
Gly2 in methionine- or leucine-enkephalin by several D-amino acid
residues was compatible with high biological activity (e.g., see
Beddel et al. 1977). Second, substitution of Met5 or Leu5 by a
wide variety of L or D amino acid residues was compatible with
high potency (e.g., see Morley 1980). Third, the compact
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structural nature of many nonpeptide opioids suggested that, on
interacting with a receptor, the opioid peptides may assume more
compact conformations involving a turn conformation. With this in
mind, we decided to apply the concept of pseudoisosteric cycliza-
tion which we had applied successfully in the development of
superpotent cyclic melanotropins (Sawyer et al. 1982). In this
regard, the Gly2, Met5 residues in enkephalin were highly remi-
niscent of the Met4,
of Gly2,
GlylO residues in -MSH.
Met5 by D-Cys2, D(or L)-Cys5 to produce a 14-membered
Hence, substitution
cyclic structure appeared to be a reasonable starting point for
conformational restriction.
On examining the literature, we found that Sarantakis (1979) had
already prepared a [D-Cys2, L-Cys5]enkephalin analogue, and
though the compound was active, the bioassay results provide no
data on receptor specificity. We, therefore, decided to prepare
even more rigid analogs by utilizing geminal dimethyl groups for
restricting the conformation of these medium-sized peptide rings,
which we had demonstrated to occur in oxytocin antagonist analogs
(Meraldi et al. 1975, 1977; Mosberg et al. 1981; Hruby 1981b).
Thus, we prepared the enkelinamide (EA) analogs[D-Pen2,
Cys5]EA and [D-Pen2, D-Cys5]EA, and examined (Mosberg et al. 1982)
their delta versus mu receptor selectivity using the mouse vas
deferens (MVD) and guinea pig ileum (GPI) as the putative delta
and mu receptor-selective assays (Kosterlitz and Watt 1968;
Henderson et al. 1972). Fortunately, as we began our studies,
Schiller et al. (1981) also prepared the enkephalinamide compounds
of Sarantakis and examined their biological activities in the GPI
TABLE 2
Biological Activities (IC50) of Cyclic Enkephalin-
amide Analogs in the Guinea Pig Ileum and Mouse
Mouse Vas Defrens (MVD) Assays
Compounda
IC50(nM)
b
IC50(GPI)
GPI MVD IC50(MVD)
118 ± 19 3.6±0.67 32.4
117 ± 21 16.8±3.1 6.9
1.51 ± 0.03
0.78 ± 0.01
2.20 ± 0.40 3.75±0.04 0.59
Normorphinec 91 ± 19 540±113 0.17
aEA = enkephalinamide
bValues are the mean (± s.e.m.) of 3 to 4 determinations.
cMosberg et al. 1982
dSchiller et al. 1981
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assay and membrane binding assay system. The results from the
studies of Schiller and our studies are given in table 2. An
interesting result was observed. While the cyclic [D-Cys2, D(or
L)-Cys5]EA analogues of Schiller et al. and Sarantakis are
slightly µ receptor-selective (schiller et al. 1981), the [D-Pen2,
D(or L)-Cys5]EA analogs we prepared were somewhat delta selective
(Bosbsrg et al. 1982). Examination of the data in table 2
indicates that this delta receptor selectivity is primarily a
result of continued high potency of the D-Pen2 analogs at the MVD
receptor system but much lower potency at the GPI receptor
system (µ). Conformational analysis of the [D-Pen2, D(or L)-
Cys5]EA analogs and the D-Cys2, D(or L)-Cys5]EA analogs(Mosberg
and Schiller 1984) suggests that, whereas the D-Pen2 analogs are
the more conformationally constrained analogs, as expected, the
differences in biological activity may result from conformational
difference at the C-terminal portion of the peptides (possibly a
transanular effect of the geminal dimethyl groups of D-Pen2 in a
l4-membered ring).
These interesting results led us to examine this receptor specifi-
city of the carboxylate terminal analogs of D-Pen2-substituted
cyclic enkephalins (E) since previous structure-activity studies
(Morley 1980; Kosterlitz et al. 1980; Ronai et al. 1981) had indi-
cated that carboxylate terminal enkephalins were relatively more
reactive in the MVD assay ( receptor), while carboxamide terminal
enkephalins were relatively more reactive in the GPI assay (µ rec-
eptor). Indeed, as shown in table 3, [D-Pen2, L-Cys5]E and
[D-Pen2, D-Cys5]E are considerably more potent than their enkepha-
lynmnide counterparts in the MVD assay and, interestingly, they
are considerably less active in the GPI assay. Thus, these ana-
logs have exceptional delta receptor selectivity, and indeed
appeared to be the most delta-selective enkephalin analogs which
had been obtained up to that time.
TABLE 3
Biological Activities (IC50) of Cyclic Enkephalin
Analogs in the GPI and MVD Assays
aEa = enkephalinamide, E = enkephalin.
bvalues are the mean (± s.e.m.) of 3 to 4 detenninations.
cMosberg et al. 1982
dMosberg et al. 1983a
131
TABLE 4
Receptor Binding Affinities for Cyclic Enkephalin
Analogs in Rat Brain Preparation
Compounda
IC50(nM)
b
[3H]NAL [3H]DADLB
IC5O(NAL)
IC5O(DADLE)
73.4 ± 14.9 3.35 ± 0.15 21.9
178. ± 15.8 11.7 ± 1.20 15.2
16.2 ± 34.8 7.20 ± 1.80 22.6
157 ± 736 26.0 ± 0.50 6.0
23.3 ± 2.4 27.2 ± 1.2 0.9
53. ± 2.3 5.4 ± 0.10 9.8
22. ± 2.8 3.5 ± 0.8 6.3
aEA = enkephalinamide, E = enkephalin.bValues are the mean (± s.e.m.) of 3 to 6 determinations, each
done in triplicate.
cMosberg et al. 1982
dMosberg et al. 1983a
eMosberg et al. 1983b
In order to further evaluate the receptor specificity of these
cyclic enkephalin analogs, we (Mosberg et al. 1982) also have
examined their receptor binding to enkephalin (opiate) receptors
in rat brain membrane preparations in competition with the puta-
tive µ receptor-selective radioligand [3H]naloxone and the puta-
tive receptor-selective radioligand [3H]DADLE ([3H]-D-Ala2,
D-Leu5]E). Through neither of these ligands have particularly high
µ and receptor selectivity, respectively, they have served as
the prototypical ligands for these receptors. Thus, though the
results from these binding assays must be interpreted with
caution, they can provide insight into the structural and confor-
mational trends for receptor-specific ligands.
Interestingly, in these binding assays, the very high delta
selectivity for the cyclic D-Pen2 enkephalin analogs was less
striking. In fact, the enkephalinamide cyclic analogs appeared to
be slightly more delta selective than the corresponding enkephalin
analogs in this assay system. Thus, a lack of quantitative, and
in some cases qualitative, agreement between the muscle contrac-
tion assays and the receptor binding assays is observed. This
lack of agreement could be the result of one or more of the
following: a) species differences; b) different assay conditions;
c) lack of discrimination of receptor subtypes by competing
ligands; and d) heterogeneity of receptor subtypes. Nonetheless,
the high potency and significant selectivity of
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these compounds in all assay systems prompted us to attempt to
further increase this receptor selectivity.
Examination of possible conformational models for the D-Pen2-
and the D(or L)-Pen5-analogs suggested that the ß-hydrogens on the
half-cystine residues, L(or D)-Cys5 and D-Cys2, respectively, were
not sterically hindered, and that it thus might be possible to
prepare the more conformationally constrained bis-penicillamine
cyclic enkephalin analogs. Placing two geminal dimethyl substi-
tuents in a 14-membered ring would generally be considered very
difficult due to energetically unfavorable transannular interac-
tions. However, we felt that if our conformational model was
correct, and if the linear sulfhydryl peptides would assume a
similar conformation, ring closure might be possible. Therefore,
we decided to prepare [D-Pen2, Pen5]E (DPLPE) and [D-Pen2,
D-Pen5]E (DPDPE) (Mosberg et al. 1983c). The synthesis proceeded
well, and a good yield of the desired monomer was obtained after
purification by partition chromatography and gel filtration (Hurst
1984). The biological activities in the MVD, GPI, and binding
assays are shown in tables 5 and 6, and the results are compared
with those obtained for the D(or L)-Cys5 analogs and notmorphine.
Examination of the MVD and GPI bioassay data (table 5) and the
binding data (table 6) provide convincing evidence that DPLPE and
TABLE 5
Biological Activities (IC50) of Cyclic Enkephalin
Analogs in the GPI and MVD Assays
Compounda
(IC50)
b
IC5O(GPI)
GPI MVD IC5O(MVD)
2720 ± 50.1 2.50 ± 0.03 1088
213 ± 63 0.32 ± 0.03 666
6930 ± 124 2.19 ± 0.30 3164
1350 ± 340 6.27 ± 1.2 215
234 ± 85.6 0.70 ± 0.08 334
100 ± 19.6 0.58 ± 0.06 172
228 ± 52 0.60 ± 0.06 380
aE = enkephalin
bValues are the mean (± s.e.m.) of 3 to 4 determinations, each
done in triplicate.
cMosberg et al. 1983c
dMosberg et al. 1983b
eHurst 1984
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TABLE 6
Receptor Binding Affinities for Cyclic Enkephalin
Analogs in Pat Brain Preparations
Compounda
IC50(nM)
b
[3H]NAL
IC50(NAL)
[3H]DADLB IC50(DADLE)
3710 ± 740 10.0 ± 2.2 371.
178 ± 15.8 11.7 ± 1.2 15.2
2840 ± 670 16.2 ± 0.9 175.
157 ± 73.6 26.0 ± 0.5 6.0
Morphinec 23.3 ± 2.4 27.2 ± 1.2 0.86
H-Tyr-D-Ala-Gly-Phe-NHe
(CH2)12 96.3 1.06 91
H-Tyr-D-Ala-Gly-Phe-NH
[D-Ser2,Leu5,Thr6]Ec 88 ± 6.0 5.7 ± 0.4 15.4
[D-Thr2,Leu5,Thr6]Ec 36.3 ± 3.8 6.4 ± 0.6 5.7
146 ± 25 5.2 ± 0.70 28.1
aE = enkephalin
bValues are the mean (± s.e.m.) of 3 to 6 determinations, each
done in triplicate.
cMosberg et al. 1983c
dMosberg et al. 1983b
eShimohigashi et al. 1982
fHurst 1984
DPDPE are exceptionally delta receptor-specific peptides.
Interestingly, the DPDPE is more delta selective based on the MVD
versus GPI assays, while DPLPE is more selective based on the
binding assays. The reasons for this are that whereas both Pen5
diastereimeric analogs are much less potent in the GPI assay
than the corresponding D(or L)-Cys5-containing analogs, DPDPE is
more potent (almost threefold) than the corresponding D-Cys5 ana-
logs, and DPLPE is much less potent (about eightfold) than the
corresponding L-Cys5 analogs. Thus, the relative receptor speci-
ficity becomes much greater for DPDPE than for DPLPE in these
assays. On the other hand, while DPLPE has slightly better
binding potencies than DPDPE (table 6) against [3H]DALE (putative
ligand), the opposite relative binding potencies are seen versus
[3H]NAL (putative µ ligand). Thus, the DPLPE appears to be
slightly more delta selective than DPDPE in this assay system.
These results have recently been confirmed by James and Goldstein
(1984). Using what different assays and assay conditions,
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TABLE 7
Receptor Binding Affinities of Selected Enkephalin
Analogs in Neuroblastosm X-Glioma NG 108-15
Membrane Preparations
Compounda Ki (nm)b Hill Coefficient
1.95 ± 0.65 1.00 ± 0.08
1.78 ± 0.58 1.01 ± 0.06
[D-Ser2, Leu5, Thr6]E 1.59 ± 0.20 1.01 ± 0.06
[D-Thr2, Leu5, Thr6]E 1.42 ± 0.33 1.03 ± 0.04
aE = enkephalin
bvalues are the mean (± s.e.m.) of 3 to 6 determinations, each
done in triplicate.
they have examined the receptor selectivities of DPDPE, DPLPE,
and several other putative -selective analogs, and have found
that on the basis of their stringent requirements for selectivity,
only DPDPE and DPLPE are truly receptor specific. They also
found that these peptides have little or no kappa receptor acti-
vity. The bis-penicillamine cyclic enkephalin analogs also appear
to have considerably higher delta receptor selectivity than the
dimeric enkephalin analogs of Shimohigashi et al. (1982).
To further examine the delta selectivities and the receptor poten-
cies of our highly -selective cyclic analogs, we have done
several additional studies. We have examined their binding
affinities for receptors in neuroblastoma X-glioma NG 108-15 cell
membrane preparations (Mosberg et al. 1983d) using [3H]DADLE.
These opioid receptors have been suggested to be a single class of
receptors. The results given in table 7 clearly show that cur
-selective analogs are indeed highly potent at these receptors
(nmolar range). We have also prepared the delta-selective analogs
of Roques and colleagues, [D-Ser2, Leu5, Thr6]enkephalin (DSTLE)
(Gacel et al. 1980) and [D-Thr2, Leu5, Thr6]enkephalin (DTTLE)
(Zajac et al. 1983), for direct comparison in the two different
binding assays. As shown in table 7, these linear compounds have
similar binding properties as the cyclic bis-penicillamine
analogs. However, as seen in tables 5 and 6, the Thr6 analogs of
Rogues and colleagues are not highly delta selective based on
these assays, and similar results have been reported by James and
Goldstein (1984) using their assays.
Finally, we have made a number of analogs to test various aspects
of structure-function relationships in cur cyclic series using the
[D-Pen2, Cys5]E as the "standard" compound. First, we examined
whether other D-amino acid-containing diastereoisaner might be
more potent or selective. As seen in table 8, both the D-Tyr1 and
the D-Phe4 analogs lose considerable potency in all assay systems
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TABLE 8
Biological Activities of the Cyclic Enkephalin Analogs
in the GPI, MVP, and Rat Brain Binding Assaysa,b
aAssay results were determined as in tables 2 and 4.
bData from M.S. thesis of R. Burst (1984).
cE = enkephalin
and, in addition, their receptor specificities are not changed.
Second, Rogues et al. (1982) have suggested that hexapeptide enke-
phalin analogs may have higher delta receptor selectivity. We
first prepared [D-Pen2, Cys5, Thr6]enkephalin and found that
though it did retain high potency in delta receptor assays, its
selectivity was poorer than several other analogs.. We then
prepared [D-Pen2, Leu5, L-Pen6]enkephalin, a cyclic 17-membered
ring analog which is pseudoisosteric to the previously reported
-selective analog MTLE. However, this compound was quite
inactive (though it did retain some 6 receptor selectivity) and,
thus, it appears that the conformational restrictions impose by
the disulfides and geminal dimethyl groups do not permit this
analog to interact effectively with opioid receptors. Finally, we
increased the ring size one CH2 group (to 15-membered) by
pre ring [D-Pen2, ß-Ala3, Cys5]enkephalin, and we deleted the
Tyr1 residue in the cyclic 14-membered ring series. Both of these
compounds had little or no activity.
In summary, we have prepared a series of cyclic penicillamine-
containing l4-membered ring analogs of methionine enkephalin.
All have delta opioid receptor specificity, and some are the most
selective delta receptor ligands available to date. Based on our
results and the results of James and Goldstein (1984), [D-Pen2,
Pen5]E and [D-Pen2, D-Pen5]E would appear to be the ligands of
choice for exploring the physiological and pharmacological roles
of delta opioid receptors in the central nervouss system and in
peripheral tissue. Indeed, though it is not the subject of this
chapter, in collaboration with Prof. Tom Burks, Dr. Frank Porreca,
Dr. James Galligan, and Mr. Lane Hirning, we have examined several
aspects of this problem (Porreca et al. 1983, 1984; Galligan et
al., 1984; Burks et al., in press). Suffice it to say, these
studies suggest that highly delta-selective opioid peptides have
unique biological properties which make them candidates for
therapeutic applications.
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CYCLIC MU RECEPTOR-SELECTIVE PEPTIDES
Our success in designing -selective peptides prompted us to exam-
ine the possibility of preparing µ-selective cyclic peptides. At
the time we began this work (early 1983), the most µ-selective
peptide agonist analog appeared to be Tye-D-Ala-Gly-(Me)Phe-Gly-ol
(DAGO) (Handa et al. 1981), and this still appears to be the case
(James and Goldstein 1984). Schiller and coworkers (DiMaio and
Schiller 1980; Schiller and DiMaio 1982; DiMaio et al. 1982) have
prepared a series of cyclic enkephalin analogs of which
H-Tyr-cyclo-[N D-A2bu-Gly-Phe-Leu-] is the paradigm example.
These peptides all have µ receptor selectivity with an optimum
µ-selectivity value of 38.8 (as measured for H-Phe-cyclo[-N -D-
Lys-Gly-Phe-Leu]. However, by the criteria of James and Goldstein
(1984), this is not a sufficiently µ-selective analog for many
studies. Undoubtedly, Schiller and his coworkers will continue
to further develop this cyclic series for higher µ selectivity and
it is certain such will be learned in the process regarding the
conformational requirements for the µ receptor (Schiller 1984).
We have taken another starting point for the development of a µ-
selective peptide. Several years ago, it was reported (Terenius
1976; Razek et al. 1978) that sanatostatin can weakly inhibit the
binding of [3H]NAL and [3H]DADLE to rat brain homogenates and also
can give an analgesic response in mice. More recently, it was
reported that the much modified somatostatin analog
had an IC50 of 38 nM at a
putative µ receptor, and was capable of antagonizing the excitory
effects of a stable enkephalin analog in electrophysiological
experiments (Maurer et al. 1982). The compound also was a potent
antagonist of insulin release. We became interested in utilizing
this lead compound to develop conformationally constrained soma-
tostatin analogs with high potency and high receptor selectivity
with regard to glucagon release, growth hormone release, insulin
release, or µ opioid receptor interactions. We report here our
progress in developing a potent µ receptor-selective conforma-
tionally constrained sunatostatin analog (Pelton et al. 1985).
We began our studies by examining two parameters in the structure
of Maurer et al. We replaced the carbinol terminal group with a
carboxylate, and placed a geminal dimethyl group in the 20-mem-
bered ring by substituting either the Cyst or Cysll residue (the
numbering schema used in sanatostatin analogs) for a penicilla-
mine residue. The biological activity at mu and delta receptors
was assessed by examinating the binding of the analogs to opioid
receptors in rat brain membranes in competition with [3H]naloxone
([3H]NAL) and [3H] [D-Ala2, D-Leu5]enkephalin ([3H]DADLE), respec-
tively. The results are shown in table 9 along with the data
for sanatostatin (control), morphine-HCl (control), and the [Cys6,
Cys11]-analogue in which
only the carboxylate residue change is made (control). The Pen6
substitution greatly reduces potency relative to the cyclic soma-
tostatin5-12 analog and even relative to sanatostatin at both
137
TABLE 9
Receptor binding Affinities of Samatostatin Analogs
in Rat Brain Membrane Preparations
Compounda,c
IC5O(nM)
b IC5ODADLE
[3H]NAL [3H]DADLE IC5ONAL
27,400 ± 4,200 16,400 ± 8,500 0.60
23 ± 2.4 27 ± 0.9 1.17
51,500 ± 4,100 5,800 ± 1,000 0.11
2,600 260 3,100 720 1.21± ±
61,000 ± 17,500 38,100 ± 3,000 0.62
930 ± 72 5,400 ± 800 5.8
aS = somatostatin
bAssay values are the mean (± s.e.m.) of 5 to 6 determinations, each done in
cPelton et al. 1985
the mu and delta receptor sites. On the other hand, the Pen11
cyclic analog [D-Phe5, Cys6, D-Trp8, Pen11]somatostatin5-12 shows
increased binding potency at the µ receptor and slightly decreased
binding potency at the receptor and, hence, is slightly µ selec-
tive. It is interesting to note that the putative "active site"
peptide for sanatostatin, Ac-Phe-D-Trp-Lys-Thr-OH (Ac-D-Trp8-
somatostatin7-l0-OH), is somewhat less potent than sanatostatin at
the µ binding site, but somewhat more potent than somatostatin at
the delta binding site. Thus, it is quite delta selective, while
sanatostatin has very little selectivity for either the delta or
the mu binding site.
In an effort to further increase the selectivity and potency of
these somatostatin-based cyclic analogs, three different strate-
gies were followed. First, we further conformationally con-
strained the cyclic 20-membered ring by preparation of the bis-
penicillamine analog [D-Phe5, Pen6, D-Trp8, Pen11]-somitostatin5-12.
Second, we substituted the Phe7 residue for a tyrosine residue to
give and
Third, we replaced the
carboxylate terminal group with a carboxamide group. The bis-
penicillamine analog was intermediate in binding potency
between the Pen6 and Pen11 analogs at both the µ and receptor
(table 10), but had little discrimination for the µ or receptor.
Replacement of the Phe7 for a Tyr7 residue greatly increased the
binding potency of the compound at the µ receptor in both the
Pen6 and the Pen11 series and slightly increased potency at the
receptor as well. The differential effect was qreatest in the
Pen11 series and is now
quite µ receptor selective.
However, the most dramatic effect came by converting the car-
boxylate terminal to a carboxamide terminal group. This simple
change in the Pen11 series led to an analog H-D-Phe-Cys-Phe- D-
Trp-Lys-Thr-Pen-Thr-NH2 which was over 90 times more potent in
binding at the µ receptor, but only about 5 times more potent in
binding at the receptor. As a result, this compound now has an
EC50 of 10 nM at the µ receptor and is 110-fold selective for this
receptor versus the receptor. Addition of the Tyr7 residue in
place of the Phe7 residue led to an even more selective analog
which is our most potent
(EC50 3.5 nM) and most selective (270-fold) analogue for the µ
receptor system as measured in this assay system. Preliminary
studies show that these analogs act as µ receptor antagonists in
in vitro and in vivo experiments.
Careful analysis of the competitive
[3H]NAL gave Hill numbers near unity
binding experiments against
, suggesting that these ana-
logues were interacting with the receptor in a manner similar to
that of the labeled antagonist. However, the Hill number obtained
from binding experiments with [3H]DADLE were substantially less
than one, indicating that the somatostatin octapeptide analogs
were interacting with either multiple receptor sites or multiple
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TABLE 10
Receptor Binding Affinities of Somatostatin Analogs in Rat Brain Membrane Preparations
Compounda
IC50(nM)
b
[3H]NAL [3H]DADLE
IC50DADLE
IC50NAL
27,400 ± 4,200
61,000 ± 17,500
8,300 ± 1,000
470 ± 10
930 ± 72
290 ± 58
9.9 ± 1.6
3.5)± 0.20
2,500 ± 400
$6,400 ± 8,500
38,100 ± 3,000
11,000 ± 2,000
2,600 ± 410
5,400 ± 800
3,800 ± 610
1,100 ± 120
950 ± 210
13,500 ± 3,000
0.60
0.62
1.3
5.5
5.8
13.
110.
270.
5.4
aS = somatostatin
bAssay values are the mean (± s.e.m.) of 5 to 6 determinations, each done in duplicate.
cPelton et al. 1985
dPelton et al., unpublished results
TABLE 11
Inhibition of [3H]DADLE Binding to Bat Brain Homogenates by
Various Analogs Fitted to a Two-Receptor Site Model
Compounda
[3H] DADLE
IC50(1) IC50(2) BMax1 BMAX2
aS = Somtostatin
conformational states. The results of a computer analysis of the
latter data are given in table 11. The data can be fitted to a
two-site model with high- and low-affinity sites and approximately
equal nunbers of receptors (Pelton et al. 1985).
In an effort to establish the differential binding characteristics
of our analogs to somtostatin as compared to opiate receptors,
we have examined the ability of these analogs to inhibit the
binding of the biological1y stable 125I,labeled somtostatin ana-
logue GCP 23,996, [des-Ala1, Gly2] [desamincCys3, [Tyrll], di-
carba3,14]somtostatin. The results (table 12) show that the
TABLE 12
Binding Affinities of Somtostatin Analogs to
Somtostatin Receptors in Rat Brain Membrane Preparations
Compounda IC50(nM)
b,c
3.3 ± 0.30
170. ± 99
400. ± 200
690. ± 220
800. ±300
980. ± 480
1500. ± 470
1600. ± 460
4000. ± 780
aS = somatostatin
bDetermined by inhibitor 125I-labeled OGP 23,996.
cPelton et al. 1985
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selectivity of the cyclic octapeptide analogs extend to their
interaction with the sanatostatin receptor system in the brain.
However, the selectivities are much different than seen in the
opioid receptor systems. Indeed, our most potent µ receptor-
selective analogs, [D-Phe5, Cys6, Tyr7, D-Trp8, Pen11]-
somatosting5-12-NH2 and [D-phe
5, Cys6, D-Trp8, Pen11]-
somatostatin5-12-NH2, are respectively 210 and 450 times less
potent than sanatostatin in this somatostatin receptor binding
assay, but about 8,000 and 2,700 times more potent, respectively,
than sanatostatin in the µ receptor binidng assay. A discussion
of the data in the sanatostatin binding assay is outside the scope
of this chapter. Suffice it to say, these studies show that the
opiate and somatostatin receptor systems, at least in the rat
brain, have substantial differences in the structural and confor-
mational requirements of ligands for strong receptor interactions.
The structural and conformational features which lead to the high
and specific µ opioid receptor binding for the much modified soma-
tostatin analogs reported here are not clear as yet. The rela-
tively small effect of replacing Phe7 with Tyr7 in cur analogs
suggests that the increases seen may not be directly related to
the well-known requirement for a phenolic hydroxyl moiety in the
opiates and enkephalins. The much larger effect of substituting
the carboxylate terminal for a carboxamide terminal might suggest
that the increased potencies and selectivities are a result of a
general increase in lipophilicity. However, octanol-water par-
tition coefficients of the sanatostatin analogs do not correlate
well with receptor affinity or selectivity. Hence, other features
such as conformational changes or specific peptide-receptor inter
actions may be involved. Work is in progress in cur laboratory to
examine these questions.
C0NCLUSIONS
We have utilized principles of conformational restriction in con-
junction with careful examination of structure-biological activity
relationships to develop a series of highly receptor-selective,
potent cyclic peptide analogs of enkephalin and somatostatin
which have exceptionally high delta and mu receptor selective
respectively. Two of these compounds [D-Pen2, D-Pen5]enkephalin
and [D-Phe5, Cys6, Tyr7, D-Trp8, Pen11]somatostatin5-12-NH2 appear
to be, respectively, the most receptor-specific delta receptor
agonist and mu receptor antagonist reported thus far. These com-
pounds appear to have sufficient receptor selectivity, so that
they should be excellent tools for examining the physiological
roles of and µ receptors in peripheral and central nervous
system tissue. Indeed, considerable progress in this direction
has already appeared in the case of the delta-selective agonist.
In addition, since these compounds are cyclic, conformationally
constrained peptides, it may be possible to establish their pre-
ferred solution conformations and from this develop a model for
conformation-biological activity relationship of enkephalins and
sanatostatin at and µ opioid receptors, respectively. Confor-
mationally constrained peptides provide a more valid approach to
142
utilizing solution conformations for assessing the conformational
and topological properties of a peptide ligand which may be impor-
tant to biological activity, since in such constrained molecules
the overall conformational properties found in solution are more
likely to have relevance to the peptide-receptor complex. Thus,
insight into conformation-biological activity relationships are
more readily obtained using such analogs. Such insight should
lead to a rational design of more potent, more receptor-selective,
more biologically stable, etc., peptide analogs. There is still
much to be done utilizing this approach, and it is expected that
many important new insights regarding the physical-chemical basis
for the biological activity of peptide hormones and neurotransmit-
ters will follow fran these studies.
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Dehydro and Cyclopropyl Amino Acids
and Peptides
Charles H. Stammer, Ph.D.
In the recent past, there have been several excellent
reviews covering the synthesis of dehydro amino
acids and peptides (Stammer 1982; Schmidt et al.
1979; Noda et al. 1983). This review will cover
only the most recent literature on this subject
and is not intended to be exhaustive. The work
on cyclopropyl amino acids is quite new, coming
mostly from the author's laboratory, and the litera-
ture can be covered completely.
DEHYDRO AMINO ACIDS
Some of the latest work on dehydro amino acid synthe-
sis will be summarized here. -Phosphoryl glycine
esters have recently been synthesized in two dif-
ferent laboratories (Schmidt et al. 1982; Kober
and Steglich 1983). One procedure used an -methoxy
glycine derivative, previously prepared in Israel
(Zoller and Ben-Ishai 1975), in which the -methoxyl
function is replaced with the diethoxyphosphoryl
group. The other process replaces an -bromine
atom with the diethoxyphosphoryl group to give
the same intermediate. The N-acyl -phosphoryl
glycine exter was then used in a Wittig condensation
with aryl or aliphatic aldehydes to give, in one
step, the dehydro amino acid derivative. Both
of these methods appear to be imminently useful.
A new kind of specific synthesis of dehydro trypto-
phan has also appeared (Moriya et al. 1982). A
readily prepared pyrrolidino enamine of 3-indole
aldehyde was treated with N-fornyl glycine ester
to give the dehydro tryptophan derivative which
is easily N-deblocked with ethanolic HCl. In 1983,
a stereospecific synthesis of dehydro amino acids
was described (Somekh and Shanzer 1983) which pro-
ceeded through the dehydration of ß-hydroxy amino
acids synthesized by a previously reported method
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(Shanzer et al. 1979). The dehydration was accom-
plished using (diethylamino)sulfur trifluoride (DAST)
in pyridine.
DEHYDRO PEPTIDES
Only a few new ways to prepare dehydro peptides
have been reported recently. A series of communica-
tions describing the use of dehydro N-carboxy anhy-
drides (NCA'S) has appeared (Shin et al. 1981).
The synthesis of the NCA directly from an N-Cbz
dehydro amino acid using thionyl chloride proceeds
normally to give the desired product. This compound
undergoes alcoholysis to give N-free dehydro esters
or can be condensed with amino acid esters or peptide
esters to give N-terminal dehydro peptides.
Another novel approach to the synthesis of dehydro
peptides incorporates 2-aziridine carboxylic acids
(Azy) into a peptide chain followed by base-catalyzed
rearrangement of the aziridine ring to give a dehydro
amino acid moiety (Nakajima et al. 1982). The
method has been used to make several actinomycin
analogs.
Some years ago in the author's laborator, the
first dehydro peptide hormone, D-Ala2 ZPhe4,Met5-
enkephalin amide, was synthesized and shown to
be bioactive and stable to enzymatic attack (English
and Stammer 1978).
dehydro Phe4-
The in vivo activity of this
enkephalin was confirmed later (Chipkin
et al. 1979), and various other dehydro Phe4-enkepha-
line were prepared and their binding affinity to
the various opiate receptors were compared
(Shimohigashi et al. 1982b). The dehydro Phe moiety
in these compounds was prepared by two methods,
i.e., dehydrogenation of an azlactone with dicyanodi-
chlorobenoquinone (DDQ) (Konno and Stammer 1978;
Shimohigashi et al. 1983b) and by the more con-
venient dehydration of an azlactone formed from
-phenylserine. In all cases, the presence of
a dehydro amino acid was confirmed by double beam
ultraviolet measurements in which the peak(s) charac-
teristic of the dehydro moiety was isolated
(Shimohigashi et al. 1981b).
Ala3-, Leu5-enkephalins
The dehydro Ala2-,
and were all synthesized
and tested for binding and in vivo activity (Shimohi-
gashiet al. 1981a; Shimohigashi Stammer 1982a).
In general, these compounds were of somewhat reduced
biological activity, but showed a preference for
the delta receptor over the mu.
Leu5-enkephalin
The dehydro Ala3,
was particularly skewed in this
direction even though its activity was below that
of the naturalcompound (Shimohigashi and Stammer 1982d).
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Most impressive was the dehydro Leu5 -enkephalin
in this respect, since it was almost four times
more active than its D-Leu5 analog in the radioligand
binding assays and showed good delta selectivity.
More interestingly, it was very resistant to hydroly-
sis by carboxypeptidasey, showing that the presence
of the dehydro moiety again caused the peptide
to be incompatible with the enzyme active site
(Shimohigashi and Stammer 1983). An attempt to
prepare Tyr1-enkephalin was successful up to the
last step when the N-Boc group was removed and
gel chromatography in aqueous acetic acid was at-
tempted (Shimohigashi et al. 1983a). Hydrolysis
of the N-terminal enamine function was apparently
responsible for the loss of ninhydrin positive
material. Difference spectroscopy showed the
presence of the dehydro tyrosine residue in the
N-blocked peptide with a strong peak just above
300 nM. Later, quantitative amino acid analysis
was used to measure the stability, relative to
the saturated compound, of all the dehydro enkepha-
lins toward carboxypeptidase. They showed very
high stability to this enzyme (Shimohigashi et
al. 1982a).
The configurations of dehydro peptide moieties
have been determined in various ways (Stammer 1982;
Schmidt et al. 1979 ; Noda et al. 1983). X-ray
crystallography has been used to prove the configura-
tion of dehydro Phe and dehydro Leu (Chauhan et
al. 1979), but nuclear magnetic resolution (NMR)
methods have been used to infer the configurations
of the other unsaturated amino acids. When a deriva-
tive of dehydro E-Phe became available (Nitz et
al. 1981), nuclear Overhauser effect measurements
were carried out in which the N-H and the vinyl
protons were irradiated using a Nicolet NMC-500
NMR spectrometer (Shimohigashi et al. 1982c). Only
the E-form showed any effect at all.
Some recent work has been done to determine the
effect of a dehydro amino acid moiety on peptide
conformation. An NMR study of a di- and tri-peptide
containing a dehydro Phe residue showed that this
residue can occur in the i+2 position of a ß-
or -turn without greatly affecting the stability
of the turn (Bach et al. 1983).
More recently, dehydro E-Phe4-enkephalin has been
synthesized in the author's laboratory. Compared
with the Z-isomer, the E-compound showed a drastical-
ly reduced potency in the radioligand binding assays,
i.e., 260- and 150-fold loss of affinity toward
the and µ receptors, respectively (Shimohigashi
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et al. 1984). It is interesting to note that the
recently reported crystal structure of Leu5-enkepha-
lin (Camerman et al. 1983) showed the phenylalanine
side chain oriented toward the amino end of the
sequence, just as it appears in the Z-isomer of
the dehydro Phe residue.
A dehydro cyclic hexapeptide analog of somatostatin
containing a dehydro Z-Phe residue in the 2-position
has recently been prepared. The NMR spectra of
the saturated and unsaturated cyclic compounds
were very similar, even though the dehydro peptide
had only one-tenth the biological activity of the
saturated material (Brady et al. 19841. The dehydro
E-Phe isomer may have the preferred configuration
in this case.
CYCLOPROPYL AMINO ACIDS
The synthesis and incorporation of cyclopropyl
amino acids into various peptides is a new area.
These amino acids have a cyclopropane ring superim-
posed upon the bond of the amino acid moiety
just as the dehydro amino acids have a double bond
in this position. Similarly, the information carry-
ing ß-group of the cyclopropyl amino acid is fixed
in space, just as it is in the dehydro compounds
(figure 1). These two kinds of residues differ,
ZAmino Acid EAmino Acid
FIGURE 1
however, in that dehydro amino acid residues
are achiral while cyclopropyl moiety has two chiral
centers at the and ß-carbon atoms. This, of
course, means that all cyclopropyl amino acids
(except Ala, Val, and Pro) exist as four stereoiso-
mers, i.e., two diastereoisomeric pairs of racemates.
Thus, in order to determine the effect of such
a residue on the bioactivity of a peptide,
peptides must be prepared and tested.
four
It is clear,
also, that these rigid amino acids will have profound
effects on the overall conformation of a peptide,
especially in the space proximal to the rigid moiety.
It seems quite probable that one of the four stereo-
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isomers may cause the peptide to approximate a
shape which is most compatible with the enzyme
or receptor site normally occupied by the natural
peptide in question. Thus, at least one of the
four possible cyclopropyl peptides should be bioac-
tive and, most important, stable to indiscrimi-
nate enzymatic cleavage. Very stable peptide hor-
mones and/or enzyme inhibitors should then result.
We have recently published the synthesis of both
racemic cyclopropyl Phe isomers and have now resolved
these racemates and incorporated them into D-Ala2,
Leu5-enkephalin (King et al. 1982; Ximura et al.
1983). The amino acid synthesis requires the prepa-
ration of known azlactones followed by cyclopropana-
tion with diazomethane. The deblocking of this
material to give the free amino acids follows rela-
tively easily depending upon which amino acid is
being prepared. Cyclopropyl Phe requires relatively
mild deblocking conditions due to the ease with
which the cyclopropane ring is opened in hot acid.
To overcome this problem, another N-blocking group
has been developed (Suzuki et al. 1983b) in which
an incipient phthaloyl group is incorporated into
the azlactone molecule. A completely different
and more general approach was later used in the
synthesis of coronamic acid (Suzuki et al. 1983a).
In this case, a substituted diasomethane is added
to a dehydro alanine derivative followed by pyrolysis
or photolysis of the resulting pyrazoline. A halo
substituted cyclopropyl amino acid has also been
prepared by the azlactone method, but this is not
an analog of a protein amino acid (Bland and Stammer
1984).
CYCLOPROPYL PEPTIDES
Incorporation of a cyclopropyl amino acid residue
into a peptide chain will strongly affect the confor-
mation of the peptide. Examination of extended
conformations (figure 2) shows that the cyclopropyl
Z-residues will be most restrictive (+90° -90°)
Z-peptide
FIGURE 2
E-peptide
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of the (N-C ) angle while the E-residues restrict
the  (C -C') angle to small values. These effects
will most probably promote the formation ß- and
-turns in that area.
A preliminary account of the synthesis of the first
cyclopropyl peptide hormone has been published
by Kimura et al. (1983). This cyclopropyl enkephalin
incorporated cyclopropyl E-Phe in the 4-position.
As in the case of the dehydro Phe4 enkephalin,
the E-configuration of this rigid phenylalanine
residue was extremely deleterious to the binding
affinity of the peptide, with the more active isomer
being less active than its counterpart by a factor
of 3000. Most recently, both cyclopropyl Z-Phe4-
enkephalins have been prepared. These compounds
are more active by a factor of about 8000 than
the E-isomers, and they bind to rat brain receptors
with about the same affinity as the natural compounds
do. All of these compounds are stable in vitro
to enzymic attack and have not yet been assayed
in the muscle assays or in vitro. The synthesis
of cyclopropyl Tyr is under way and we hope soon
to see the effect of a rigid tyrosine residue on
the bioactivity of enkephalins.
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Affinity Labels as Probes for Opioid
Receptor Types and Subtypes
Phillip S. Portoghese, Ph.D., and A. E. Takemori, Ph.D.
Progress in most areas of pharmacology and medicinal chemistry depends upon
the availability of highly selective molecular probes. The opioid field is a case in
point. With the burgeoning evidence that the actions of opioids are mediated
through multiple receptor types and subtypes (Martin 1983). it has become
apparent that more selective ligands are required as tools. Thus, the narcotic
antagonist naloxone, which proved to be extremely useful in determining opioid
receptor involvement, is now considered to be inadequate for sorting out actions
mediated by different receptor types. This presentation reviews our approach to
addressing this problem through the design of highly selective, nonequilibrium
molecular probes for opioid receptors. Because such ligands become bound
covalently to opioid receptors, they are preferred where firm attachment of a
ligand is desirable. In this connection, they are finding utility in receptor
isolation, in mapping receptor distribution, in receptor binding paradigms, and in
determining the relative involvement of different opioid receptor types in
pharmacologic studies.
DESIGN RATIONALE
The original impetus for pursuing affinity labels for opioid receptors stemmed
from conclusions (Portoghese 1965, 1966) drawn from our stereochemical studies
on opioid ligands. In this connection, the divergent stereochemical requirements.
Convergent pharmacologica studies (Martin et al. 1976; Ward and Takemori 1976;
Lord et al. 1977) subsequently complemented and provided a detailed framework
for this concept. During that period, we had begun to investigate electrophilic
affinity labels as an alternative to stereochemical probes to explore opioid
receptors (Portoghese et al. 1971, 1977; Takemori et al. 1974).
The rationale for our approach was based upon studies of Baker (1967) who
pioneered the area of active-site, irreversible enzyme inhibitors. In theory, when
the affinity label contains an electrophilic center, high selectivity for opioid
receptors should be dependent on four parameters. These are: a) affinity of the
receptor for the ligand; b) equilibrium-controlled receptor selectivity; c) location
of electrophilic center in the ligand, and d) reactivity and chemical selectivity of
the electrophile.
In considering these parameters, it is evident that an electrophilic affinity label
may be involved in two consecutive recognition processes which lead to covalent
attachment to the receptor (figure I). The first recognition step is manifested by
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receptor affinity and the second recognition step involves proper alignment of
the electrophilic center of the ligand with a compatible receptor-based
nucleophile.
FIGURE 1
A schematic illustration of the principle of recognition amplification in the
covalent binding of receptor type A by affinity label containing a group-selective
electrophile X. Note that receptor types A-C have similar topographic features
which lead to reversible binding (1° recognition). However, the receptor types
differ with respect to the reactivity (G1
and C) of nucleophiles. Only in A is  the nucleophile G1, reactive with respect to
vs G1 in A and B) and location (G1 in A
X and within covalent binding distance (2’ recognition).
Because two recognition steps rather than one lead to covalent binding, enhanced
receptor selectivity (recognition amplification) is possible, particularly with
chemically selective electrophiles. On the other hand, if an affinity label
contains a highly reactive electrophilic group, such recognition amplification is
minimal and covalent binding selectivity is determined primarily by the first
recognition step. For example, since the promiscuity of the aziridinium ion
enables it to alkylate almost any nucleophile within covalent bonding distance.
the selectivity of a ligand which contains the active electrophilic group will be
determined primarily by its relative affinity for different receptor populations.
The concept of recognition amplification may be utilized for the design of
affinity labels that are highly selective for a single opioid receptor type among
multiple types if each receptor type contains a unique array of nucleophiles that
differs with respect to nucleophilicity and accessibility. This is illustrated
schematically in figure 1 where three receptor types with similar topographic
features (A, B, C) all are capable of associating reversibly with the affinity label.
However, the second recognition step takes place only with receptor type A
because the other receptor types contain nucleophiles that either are
insufficiently reactive (type B) or are not within covalent bonding distance (type
C) of the electrophile (X).
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EXPLORING THE FIRST RECOGNITION STEP
An important consideration in the design of opioid receptor affinity labels is the
nature of a ligand which will be modified with an electrophilic moiety. Since
our prior efforts and those of others with the modification of agonist ligands did
not yield compounds that have had wide utility, we turned our attention to the
antagonist pharmacophore as the recognition unit. A consideration in this choice
was based on the fact that antagonists, especially those without agonist activity,
have been extremely useful in pharmacologic investigations and in characterizing
opioid receptor involvement.
We therefore selected naltrexone 1 (table 1) for modification, as this pure
antagonist possesses high affinity for opioid receptors and contains convenient
functionality at the C-6 position for molecular modification. Moreover, C-6 was
chosen as a point of attachment for the electophilic group because it was
reported previously (Hahn et al. 1975) that a variety of C-6 substituents did not
destroy receptor affinity (first recognition step). In this connection, the 6-amino
derivative of naltrexone, beta-naltrexamine 2, possessed an affinity equal to that
of naltrexone (Jiang et al. 1977). This was relevant to our approach in that 6
beta-amino group was employed as a handle to attach various electrophilic
moieties. Our preference for the 6 beta-isomer rather than the 6 alpha-isomer
was based on the greater affinity of the former in the binding assay.
THE SECOND RECOGNITION STEP: RANGE-FINDING STUDIES
After it was established that the first recognition step was unimpaired by the
presence of a 6 beta-amino group, our design strategy involved the introduction
of a highly reactive electrophilic moiety (i.e., aziridinium ion) to assess the
availability of a proximal receptor-based nucleophile. In this case, it was
expected that the selectivity for different receptor types would be conferred
largely by the relative affinity (first recognition step) of the ligand at these sites.
Once nonequilibrium blockage was demonstrated, then less reactive and more
selective electrophilic groups were introduced in an effort to “fine-tune” the
ligand to allow a second recognition step to occur at one receptor type in a
population of multiple opioid receptors.
This rationale led first to the development of a nitrogen mustard derivative of
naltrexone, beta-chlornaltrexamine 3 (beta-CNA) (table 1) (Portoghese et al.
1978). Beta-CNA was found to be highly selective for opioid receptors and it
inhibited irreversibly the specific binding of opioids to brain membranes
(Portoghese et al. 1979). In both the guinea pig ileal (GPI) longitudinal muscle
and mouse vas deferens (MVD) preparations, beta-CNA produced irreversible
antagonism to opioids (Ward et al. 1982a; Caruso et al. 1979). This antagonism,
which was characterized by a shift of the concentration-response curve to the
right, followed by a decline in the maximum effect, is typical of classical
nonequilibrium antagonism involving spare receptors. The antagonism could be
prevented but not reversed by naloxone. Since nonopioid nitrogen mustards had
no selectivity for opioid sites, the data suggested that beta-CNA exerts its
sustained antagonism by alkylating opioid receptor nucleophiles. The selectivity
of its action was demonstrated by the fact that beta-CNA failed to block the
effect of norepinephrine in the GPI or block other binding sites (cholinergic,
prostaglandin, benzodiazepine) (Fantozzi et al. 1981). As beta-CNA was found to
be highly reactive toward nucleophilic reagents, it presumably reacts with
receptor nucleophiles via its aziridinium ion 4 (table 1).
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T a b l e  1
Naltrexone and Related Compounds
R1 = CH2CH(CH2)2 unless
otherwise indicated
1 = 0 (naltrexone)
2 NH2 11
3 N(CH2CH2Cl)2(ß-CNA)
4 N(CH2CH2)CH2CH2Cl 12 NHCOCH2N
5 N(CH2CH2Cl)2,R
1= CH3 (ß-COA)
6 NHCOC=CCOOMe (ß-FNA)
7 NHCOC=COOMe, R1-CH3 (ß-FOA)
15 NHCOCH2SS
8
9 NHCOCCl=CH2
13 N-C-S
14 NHCOCH2I
16 NHCOCH2HgCl
17 NHCOCOC6H5
18 NHCOCH2CH2COOMe
10 NHCOC-CCOOMe
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The ease with which beta-CNA blocked different opioid receptor types was mu >
kappa > delta, which paralleled its reversible binding affinity for these sites
(Sayre et al. 1983c; Goldstein and James 1984). This is in harmony with the idea
that little or no distinction between receptor-based nucleophiles occurs with a
highly reactive and promiscuous electrophile such as aziridinium ion.
The pharmacologic profile of beta-CNA in mice also was consistent with the
alkylation of opioid receptors, in that it produced ultralong antagonism (> 3 days)
of morphine-induced analgesia after a single (i.c.v.) injection (Caruso et al.
1980b). By comparison, naltrexone antagonism lasted less than 2 hours. It was
determined that the opioid binding capacity of brain membranes of beta-CNA-
treated mice was significantly decreased during this 3-day period, which
suggested covalent binding had occurred in vivo. When administered
intrathecally (i.t.), beta-CNA produced even longer antagonism (> than 13 days)
against it. morphine antinociception (Larson and Armstrong 1980).
In view of the potent nonequilibrium opioid antagonism displayed by beta-CNA,
we investigated the consequence of attaching a nitrogen mustard group to the
same position in oxymorphone. a potent agonist. This derivative, designated as
beta-chloroxymorphamine 5 (beta-COA) (table 1) (Caruso et al. 1979). was of
interest as a tool to test the generality of the rate theory of drug action proposed
by Paton (1961). According to this hypothesis, a characteristic feature of
antagonists is their slow dissociation from receptors when compared to agonists.
Beta-COA behaved as an irreversible agonist in the GPI. The fact that naloxone
protected against irreversible agonism, but could not reverse it, implicated the
involvement of opioid receptors. These results suggested that, at least in the
GPI, ligand receptor occupation rather than rate of dissociation is important for
agonist activity. Beta-COA administered i.c.v. in mice produced analgesia that
lasted 4 times longer than oxymorphone (Caruso et al. 1980a). The brains of
beta-COA-treated animals exhibited a decreased capacity to bind opiates,
suggesting covalent binding had occurred. Interestingly, beta-COA given i.c.v.
displayed a long-lasting antagonism (6 days) after the agonism had disappeared.
The antagonism was more pronounced (> 21 days) when beta-COA was
administered i.t. (Larson and Armstrong 1980).
BETA-CNA AS A TOOL
The irreversible nature of beta-CNA has made it useful as a research tool. [3H]-
beta-CNA has been employed to isolate opioid receptor components from brain
membranes (Caruso et al. 1980b). The elution profile suggested four covalently
bound fraction, two of which migrated as single-peak calibrated to be 590,000
daltons. These complexes may represent multiple forms of opioid receptors.
Since beta-CNA alkylates all opioid receptor types, it has been used in protection
studies. For example, in the MVD it has been used in the presence of a
protecting concentration of a delta agonist to irreversible block mu and kappa
receptors (Ward et al. 1982b). Such a preparation contains the highly enriched
population of delta receptors. Other protecting ligands have been employed with
beta-CNA in the smooth muscle preparations (Chavkin et al. 1982; Chavkin and
Goldstein 1981). Using the protection procedure, beta-CNA has been used to
enrich specific binding sites in brain membranes (Goldstein and James 1984;
James and Goldstein 1984). Beta-CNA has been employed to progressively block
dynorphin receptors in the GPI and MVD. It was concluded that the GPI has
more spare kappa receptors than the MVD (Cox and Chavkin 1983). An effort
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to estimate the dissociation constant of the normorphine-receptor complex in the
GPI using beta-CNA has been reported (Porreca and Burks 1983).
Beta-CNA also has been employed as a pharmacologic tool in vivo. These
include studies on the opioid nature of delta-tetrahydrocannabinol (Tulunay et
al. 1981) in rats and behavioral studies in mice (Quack and Lucas 1981), rats
(Messing et al. 1982), and chicks (Panksepp et al. 1982). The inhibition of
tolerance development to, and withdrawal from, morphine after i.t.
administration of beta-CNA also was investigated (DeLander and Takemori
1983).
THE SECOND RECOGNITION STEP: FINE TUNING
Since the pharmacologic characterization and binding studies of beta-CNA and
beta-COA suggested that these ligands selectively and irreversibly bind to opioid
receptors, it seemed likely that neighboring receptor-based nucleophiles were
involved in covalent bond formation with the aziridinium ion that was generated.
The reactivity and promiscuity of this electrophile minimize the importance of
the second recognition step. Consequently, the facility with which beta-CNA
alkylates different opioid receptor types is determined by the first recognition
step (affinity of reversibly bound ligand for the receptor type). Thus, based on
the assumption that different opioid receptor types contain different arrays of
nucleophiles, our strategy for enhancing selectivity of the second recognition step
was to employ electrophilic groups with a reactivity that is limited to only one or
two different nucleophiles. In this regard, Michael acceptors appeared to fulfill
this requirement because they react readily with sulfhydryl and sluggishly or not
at all with other nucleophiles. Another reason for selecting a Michael acceptor
groups was that studies with N-ethylmaleimide implicated the presence of a
receptor-based sulfhydryl (Simon et al. 1973).
BETA-FUNALTREXAMINE (BETA-FNA)
The fumarate methyl ester group was one of several Michael acceptor moieties
that were attached to the C-6 position of naltrexone (Portoghese et al. 1980).
This compound, which has been named beta-funaltrexamine (beta-FNA), was
the most selective ligand in the series (table 1).
In the GPI, beta-FNA is a reversible kappa agonist and irreversible blocks mu
receptors in a concentration- and time-dependent manner (Takemori et al. 1981).
The lack of inhibition of kappa agonists (e.g., ethylketazocine) revealed that this
antagonism was selective for mu receptors. It is noteworthy that beta-FNA did
not antagonize its own agonist effect (mediated through kappa site). The
inhibition of morphine antagonism was manifested as a parallel shift of the
morphine concentration-response curve with no diminution in the maximal
response. Using naloxone as an antagonist, PA2 analysis revealed that beta-FNA
depleted the GPI of functional mu receptors and that the residual opioid receptor
population was of the kappa type (Ward et al. 1982b). Thus, the presence of a
maximal response to morphine after mu receptor blockage was due to the fact
that morphine can act as a full agonist at kappa receptors. This pharmacologic
profile was in contrast to beta-CNA, which produced both a rightward shift and
a decline in the concentration-response relationship of morphine as a
consequence of blockage of both mu and kappa receptors (Caruso et al. 1979). In
the MVD, beta-FNA displayed all of the reversible kappa agonist and
irreversible mu antagonist features it exhibited in the GPI, and it did not
significantly inhibit delta agonists at concentrations employed for the blockage of
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mu receptors (Ward et al. 1982a). The binding characteristics of beta-FNA
binding appeared to be consistent with its profile in the GPI and MVD in that
the irreversible portion of beta-FNA binding demonstrated selectivity for mu
over delta binding sites, while the reversible component of beta-FNA binding
exhibited selectivity for kappa over mu or delta binding sites (Ward et al., in
press).
In mice, beta-FNA exhibited a pharmacologic profile similar to that observed on
smooth muscle preparations. It produced an antinociceptive effect of short
duration which appeared to be mediated by kappa receptors. In contrast. the
antagonist action was of remarkably long duration (> 4 days) (Ward et al. 1982c).
BETA-FNA AS A TOOL
Because of the high mu selectivity of beta-FNA, it has many applications as a
pharmacologic tool and opioid receptor probe. One of the initial uses was in
depleting the GPI of functional mu receptors, thereby affording a more
homogeneous population of kappa receptors (Ward et al. 1982b). This
preparation was useful in evaluating the kappa activity of so-called mu agonists.
It has been found that even mu agonists that were presumed to be highly
selective exhibited kappa activity at high concentrations (Takemori and
Portoghese, unpublished data). Since the high selectivity of beta-FNA obviates
the necessity of protection experiments involving mu receptors, the beta-FNA-
treated GPI has been employed to characterize dynorphin as a kappa agonist
(Huidobro-Toro et al. 1982) and to demonstrate the presence of cross-tolerance
to opioids in the GPI (Seidl and Schulz 1983).
A number of studies in vivo have made use of beta-FNA to study the relative
involvement of mu receptors in various opioid actions. These include opioid-
induced respiratory depression (Ward and Takemori 1983a). decrease in
gastrointestinal transit (Ward and Takemori 1983b). cardiovascular effects
(Holaday and Ward 1982; Pfieffer et al., in press), spinal analgesia (Hylden and
Wilcox 1983a. 1983b), antidiuresis (Zimmerman et al. 1984) and prolactin release
(Holaday et al. 1983). Beta-FNA also has been used to demonstrate the non-
involvement of mu receptors in certain opioid actions such as endotoxic shock
(Holaday et al. 1983) and post-ictal analgesia (Belenky et al. 1983). The mu
receptor involvement in analgesia (Hynes et al. 1384; Dystra 1984; Frederickson
et al. 1984; Leander et al. 1984; Schafer et al. 1984) produced by kappa and delta
agonists and the phenomena of tolerance and physical dependence (Aceto et al.
1984; DeLander et al. 1984; Gmerek and Woods, in press) also have been
investigated using beta-FNA.
An interesting application of the high mu selectivity of beta-FNA stemmed from
the finding that its N-methyl analogue 7 (table 1) derived from oxymorphone,
beta-FOA (Portoghese et al. 1980; Takemori et al. 1981). is reversibly acting mu
agonist in the GPI. No irreversible blockage of opioid receptors was observed.
The possibility that mu agonists and antagonists interact with separate recognition
sites was studied by evaluating a series of opioid agonists and antagonists for
their ability to protect against the irreversible mu antagonism by beta-FNA
(Portoghese and Takemori 1983). Antagonists afforded excellent protection
against irreversible blockage by beta-FNA, whereas most agonists were relatively
poor protectors. Moreover, the ability of the compounds to protect against beta-
FNA appeared to correlate with their antagonist potencies (Ke) but not their
agonist potencies (IC50). These results suggested that mu agonists and antagonists
interact at separate sites on the mu receptor system. It was proposed that the
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antagonist recognition site is a regulatory site which controls the agonist effect
mediated by mu receptors.
STRUCTURE-ACTIVITY RELATIONSHIP STUDIES
A number of Michael acceptor analogues of beta-FNA were synthesized in order
to delineate the steric requirements of covalent bond formation with opioid
receptors (table I) (Sayre et al. 1983a. 1984). In the beta-series, it was found
that the ketone 8 and acrylamide 9 exhibited irreversible blocking activity against
morphine but not ethylketazocine. This antagonism was in the range of that
displayed by beta-FNA. It is noteworthy that dihydro-beta-FNA 18 is a
reversibly acting compound, as would be expected for an unreactive ligand. The
fact that the Michael acceptors with cis double bonds (10, 11) were not active as
irreversible antagonists suggests that steric factors do play an important role in
the second recognition step. This is supported by kinetic studies which show that
the reactivities of the Michael acceptors toward cysteine do not parallel the rank
order of irreversible activities. Thus, it is plausible that proper alignment of the
electrophile with a receptor-based nucleophile is critical for covalent binding
with mu receptors in the GPI preparation. In support of this idea it was reported
that, even at high concentrations, alpha-FNA was incapable of irreversible
blockage of opioid receptors (Sayre et al. 1983b). The fact that irreversible
antagonism of beta-FNA could be blocked by protection with alpha-FNA
established that the electrophilic moiety is not properly oriented in the alpha-
series. Significantly, the C-6 stereospecificity observed for beta-FNA was not
found among the CNA C-6 epimers. as both beta-CNA and alpha-CNA (Sayre et
al. 1983c) are irreversibly acting ligands. This indicates that the second
recognition step is important only with relatively selective electrophilic groups.
It was noted that the placement of a spacer between the opiate and the Michael
acceptor group dramatically changed the pharmacologic profile. While the
maleimide 11 was devoid of irreversible antagonist activity, its N-acetyl analogue
12 selectively blocked my receptors in the MVD without a significant effect on
the GPI preparation (Sayre et al. 1984). The rationale for the synthesis of 12 was
based on the assumption that different receptor subpopulations contain a
different array of nucleophiles. Thus, by altering the distance of the electrophile
from the pharmacophore, opioid receptor selectivity can be altered to distinguish
opioid receptor subtypes.
Electrophiles other than Michael acceptors exhibited varying degrees of
selectivity in irreversibly blocking the effects of different agonists (Sayre et al.
1983c, 1984). Most notable was the isothiocyanate 13 which appeared to block
mu receptors in the GPI and mu and delta receptors in the MVD. Interestingly,
the alpha-isomer of 13 did not irreversibly block mu receptors in the GPI. Thus,
the stereoselectivity is similar to that of beta-FNA and other active Michael
acceptors in this preparation. The iodoacetamide 14 showed considerably less
cross-reactivity with different receptor types by selectively blocking the mu
receptors in the MVD. The pharmacologic profiles of 12 and 14 indicate that the
mu receptors in the MVD are different from those in the GPI.
Other compounds in this series (15 to 17) are electrophilic but produced no
significant blockage of morphine, ethylketazocine. or [D-Ala2-D-Leu6]enkephelin
(DADLE) in the smooth muscle preparations. The reason for the inability of
these compounds to act as irreversible antagonists is not well understood at this
time. However, it may be related to a deficient secondary recognition step.
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CONCLUSIONS
The extraordinary selectivity of beta-FNA for mu opioid receptors can be
viewed as arising from two sequential recognition steps leading to covalent bond
formation. While reversible binding to the mu receptor system is important, the
proper alignment of the electrophiles with a compatible receptor-based
nucleophile is critical for the selectivity of irreversible blockage. In this
connection, the fumarate moiety appears to possess a narrow spectrum of
reactivity and a geometry which permits facile access to the receptor-based
nucleophile. Refinement of this approach has led to development of subtype-
selective blockers of mu receptors. The enhanced selectivity of these probes is
proving to be very useful in the pharmacologic and biochemical characterization
of opioid receptors.
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Peptide Conformation and Biological
Activity: A General Review With Examples
of Approaches Relevant to Opioid Peptide
Function
Dan W. Urry, Ph.D.
INTRODUCTION
In this International Conference on the Medicinal Chemistry and
Molecular Pharmacology of the Opioid Peptides and the Opiates,
it is a challenge to respond to the invitation to give a review
of a general nature with examples of both methodological
approaches and conformational analyses of peptides, and to do so
in a manner that could have some relevance to the theme of the
conference. This is particularly so as it has been a number of
years since, working with my colleague M.A. Khaled, we were
directly concerned with the solution conformation of Met- and
Leu-enkephalins (Khaled et al. 1977, 1979). Nonetheless, it is
satisfying that the fundamental perspective of enkephalin con-
formational flexibility is retained and that the two confor-
mations considered in that work, a -chain conformation capable
of antiparallel association and a monomeric -turn conformation,
continue to be relevant to current considerations in solution
and in the crystalline states (Schiller 1984; Karle et al.
1983a). It is the conformational flexibility of the enkephalins
and the opioid peptides in general, coupled to the objective of
determining a receptor bound state, that makes the conformation-
function studies of opioid peptides so challenging.
An attractive approach is to impose structural restrictions on
conformational freedom which would allow probing of receptors
and which could lead to more selective binding at one of the
several receptors now recognized for the opioid peptides (Atweh
and Kuhar 1983; Paterson et al. 1983; Barnard and Demoliou-Mason
1983). Accordingly, amino isobutyric acid (Aib) and D•Ala ana-
logs have been synthesized with interesting results (Gorin et
al. 1978; Sudha and Balaram 1983; Beddell et al. 1977).
Enkephalins with restricted side chains have been prepared and
studied with delineation of different receptor activities and
with increased potency at particular receptors (English and
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Stammer 1978; Shimohigashi and Stammer 1982a, 1982b;
Shimohigashi et al. 1982; Deeks et al. 1983). Additionally,
cyclic enkephalin analogs have been synthesized and their activ-
ities determined. sometimes with strikina increase in activity
in one assay and decrease in activity in another (DiMaio and 
Schiller 1980; Schiller et al. 1981). It has been concluded
that "Activity profiles obtained with a cyclic enkephalin analog
and its linear correlate revealed that µ and -receptors differ
in their conformational requirements" (Schiller 1984). Such
approaches, coupled with graphic volume analyses such as those
of Marshall and colleagues (Gorin and Marshall 1977; Gorin et
al. 1980), can be expected to provide significant progress on
the conformation-activity problem of the opioid peptides and
receptors.
Much progress has been made in the characterization of the
opioid receptors and of the actions of opioid peptides. It has
been found that opioid receptors reside in the plasma membrane
of nerve cells and that they are protein in nature with a signif-
icant phospholipid component (Barnard and Demoliou-Mason 1983).
The opioid peptides alter membrane conductance (West and Miller
1983) with both pre- and post-synaptic actions in mammalian
parasympathetic ganglia (Katayama and Nishi 1984). It has been
reported that they hyperpolarize cells by means of increasing
potassium ion membrane conductance in the central nervous system
(Henderson 1983) and specifically by opening potassium ion chan-
nels in peripheral nerve cells (North and Egan 1983; Morita and
North 1981). A significant action in dorsal root ganglion cells
and peripheral nerve cells is the inhibition of neurotransmitter
release (Hughes and Kosterlitz 1983; North and Egan 1983;
Wouters and van den Bercken 1980; Werz and Macdonald 1982).
Additionally, opioid peptides stimulate hormone release
(Grossman and Rees 1983) and there are yet other actions
reported, including some which relate to the development of
tolerance and addiction (West and Miller 1983). What clearly
emerges, of course, is action at a membranous site with dominant
effects being on channel conductance and neurotransmitter
release.
This conformation-activity review with concern for methodologi-
cal approaches will attempt to address peptide channel activity
at a membranous site with some effort to note the wide-ranging
set of methodologies that are required to attack such a problem
effectively. Disciplines involved in a comprehensive approach
to the understanding of opioid peptide function include: 1)
synthesis of peptide analogs (Peptide Chemistry); 2) charac-
terization of molecular conformation by physical methods and by
molecular mechanics calculations (Molecular Biophysics); 3) iso-
lation and reconstitution of receptors and associated transport
components (Membrane Biochemistry); and 4) characterization of
opioid peptide and analog activities (Molecular Pharamacology,
Membrane Biophsyics. and Electrophysiology). These components
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for a comprehensive attack on the mechanism of action of opioid
peptides all have analogous components in determination of the
molecular structure and ionic mechanism of Gramicidin A channel
transport.
Accordingly, this chapter reviews a general conceptual and
experimental approach of considering cyclic conformations and
linear conformational correlates with use of the physical
methods of nuclear magnetic resonance (NMR), circular dichroism,
and dielectric relaxation. This will allow a conceptual deriva-
tion of the Gramicidin A channel structure, an experimental
development of a dynamic molecular structure wherein molecular
flexibility is an integral part of function, and the conceptual
derivation of a voltage-dependent channel structure. There will
be a brief consideration of channel transport phenomenology com-
bined with the utilization of an array of disciplines, with
similarity to those noted above for approaching the opioid pep-
tide structure-activity problem, to derive the molecular struc-
ture and mechanism of Gramicidin A channel transport. Finally,
there will be a few comments on the patch clamp methodology of
Neher and Sakmann and their colleagues (for an excellent review
of the subject, see Sakmann and Neher 1983) which is being used
in the Gramicidin A channel tranport study and which appears to
be particularly well-suited for the detailed study of opioid
peptide activity. This approach provides a means of studying
single whole cells or small membrane patches from cells, or of
reconstituted protein-membrane systems. It can be expected to
give rise to more detailed and less ambiguous demonstration of
activities and mechanisms related to ion transport across cell
membranes. It could also be used to follow, by means of cell
membrane capacitance changes, the fusion of neurotransmitter
loaded vesicles with plasma membrane in this mechanism of
neurotransmitter release (Neher and Marty 1982).
CYCLIC CONFORMATIONS WITH LINEAR CONFORMATIONAL CORRELATES
(CCLCC): AN ANALYTICAL CONCEPT AND AN EXPERIMENTAL APPROACH
The analytical concept of a cyclic conformation with a linear
conformational correlate (Urry 1972) derives from the realiza-
tion that, if a cyclic peptide with an adequate number of resi-
dues forms a definable conformation with reasonable stability,
then one can anticipate that a linear polymer comprised of the
repeating sequence of the cyclic structure could exist in a
related conformation. This is because, with two torsion angles
per peptide and with a substantial number of residues in the
cycle, only small changes in the torsion angles could result in
a left- or right-handed helical structure comprised of the
repeating unit. The resulting helical structure is particularly
favorable when the conformation gives rise to favorable inter-
turn interactions. This concept is relevant to the channel
structure of Gramicidin A (see below): it was originally
described in the first enunciation of voltage-dependent channel
formation using only dipole moments, in this case the dipole
171
moment of the peptide moiety (Urry 1972); it will be used as an
analytical concept below to derive two different channel struc-
tures; and it will be used as an experimental approach to derive
a particularly interesting helical conformation referred to as a
-spiral.
The Channel Conformation of Gramicidin A
If one considers the L•amino acid-Doamino acid (L-D) repeating
dipeptide unit contained in a cyclic hexapeptide, the relative
orientation of the peptide moieties would be as depicted in
figure 1A, pointing alternately up and down with respect to the
mean plane of the cyclic hexapeptide.
FIGURE 1
Representation of a cyclic conformation A, and a linear confor-
mational correlate B, comprised of repeating L-D dipeptides.
Part B is from Urry et al. 1971. Copyright 1971, National
Academy of Science.
The side chains (R groups) would be oriented in a radial manner.
This is closely the structure of the ionophore enniatin B
(Plattner et al. 1963), wherein the cation is held centrally by
peptide carbonyl oxygens that are librated inward with three
carbonyl oxygens above and three below the plane to achieve
coordi-nation of the cation. To convert this to a linear con-
formational correlate, the cyclic structure is ruptured; small
torsion angle changes are made to give a helical pitch of about
5A; the hexapeptide is repeated; and it is found that hydrogen
bond formation readily occurs between turns of the helix, as
schematically shown in figure 1B. The hydrogen bonding pattern
between turns exhibits the same pattern as between chains in the
parallel -pleated sheet. For this reason, the structure is
referred to as a single stranded -helix. In fact, the struc-
ture is also readily derived from a single -chain by
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FIGURE 2
A. and B. Spacefilling model of the Gramicidin A transmembrane channel in channel view (A) and in
side view (B). C. Wire model of the backbone and -carbons of the channel seen in side view as in B.
From Urry et al. 1975. Copyright 1975, New York Academy of Science.
interchanging backbone and side chain (i.e., converting from an
L-residue to a D-residue) at every other residue in the -chain.
The primary Structure of Gramiciden A is HCO-L•Val1-Gly2-L•Ala3-
D•Leu4-L-Ala5-D•Val6-L•Val-D-Val8-L•Trp9-D•Leu10-L•Trp11-
D•Leu12-L•Trp13-D•Leu14-L•Trp15-NHCH2CH20H (Sarges and Witkop
1964); that is, Gramicidin A could be a linear conformational
correlate of enniatin B which is a cyclohexapeptide with a
repeating L-D dipeptide sequence. The result is the channel
conformation of Gramicidin A (Urry et al. 1971) which is shown
in figure 2 (Urry et al. 1975). Note the pattern of hydrogen
bonding between turns of the helix in figure 2C. If two
chains were in either parallel or antiparallel association and
the same conversion of alternate residues from L to D were
carried out, the result would be double stranded -helices--a
structure proposed by Veatch et al. (1974). As will be noted
below, delineation of channel structure as between single and
double stranded -helices can be demonstrated in a simple way
using carbon-13 NMR of carbonyl carbon cation induced chemical
shifts.
The Polypentapeptide of Elastin --An Experimental Use of CCLCC
The precursor protein of the elastic fiber contains as a
repeating peptide sequence, L•Val1-L•Pro2-Gly3-L•Val4-Gly5
(Sandberg et al. 1981), referred to simply as VPGVG. When this
pentameric sequence is synthesized and the pentamer polymerized
and cross-linked either by chemical means (Urry et al. 1976) or
by y-irradiation (Urry et al. 1984c), the resulting matrix is
found to have elastomeric properties strikingly similar to those
of the native elastic fiber (Urry et al. 1985). The polypen-
tapeptide forms a relatively complex and dynamic structure. One
particularly interesting way in which its conformation was
approached involved a search for a cyclic analog which, by means
of various physical characterizations, exhibited a similar con-
formation to that of the linear high polymer. The solution con-
formational approaches are in large part the same as those that
have been used to study the opioid peptides (Schiller 1984),
particularly the enkephalins, and the result provides a clear
demonstrations of the sensitivity of the approaches to confor-
mation.
Comparison of physical characterizations of the cyclic and
linear structures: Figure 3 contains the circular dichroism
curves in water for the cyclopentapeptide, i.e., cyclo(VPGVG);
the cyclodecapeptide, i.e., cyclo(VPGVG)2; the cyclopen-
tadecapeptide, i.e, cyclo(VPGVG)3; and the linear polypentapep-
tide, i.e., H-(VPGVG) V-OMe. It is seen that the cyclopenta-
peptide exhibits a dramatically different conformation with the
right-hand ordinate being for this curve. The cyclodecapeptide
exhibits a significantly different conformation, and the cyclo-
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FIGURE 3
Circular dichroism spectra of cyclic analogs and the linear high
polymer. From Urry 1985a. Copyright 1985, Elsevier Science.
pentadecapeptide exhibits a conformation which is more similar
to that of the linear polymer. Thus, the cyclopentadecapeptide
is a candidate for the cyclic conformational correlate of the
linear polymer.
Using proton NMR, the temperature dependence of peptide NH pro-
ton chemical shift in dimethylsulfoxide was determined and is
shown in parts a, b, and c of figure 4 (Urry et al. 1981) for
the cyclic analogs. The dotted curves give the data for the
linear polymer. The cyclopenta- and cyclodecapeptides exhibit
very different patterns of temperature dependence of chemical
shift, whereas the patterns are very similar for the cyclopen-
tadecapeptide and the linear polypentapeptide. Since in each
case the sequence is the same, i.e., each residue has the same
nearest neighbor and next nearest neighbor etc., the differences
that appear must be solely due to differences in conformation.
This demonstrates that the approach is very sensitive to confor-
mation and that the cyclopentadecapeptide is a cyclic confor-
mational correlate of the linear polypentapeptide. The small
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FIGURE 4
Temperature dependence of amide proton in dimethylsulfoxide of
cyclic analogs of the elastin pentamer. Adapted with per-
mission from Urry et al. 1981. Copyright 1981, American
Chemical Society.
FIGURE 5
Solvent dependence of peptide carbonyls in dimethylsulfoxide
and water of cyclic analogs of the elastin pentamer. Adapted
with permission from Urry et al. 1981. Copyright 1981, American
Chemical Society.
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chemical shift in the Val1NH proton, which is essentially
constant with temperature, correlates with a small difference in
the Val1 coupling constant. Rotation of the 1    torsion
angle by a few-degrees in a direction that would make the
coupling constants similar would convert the cyclic structure to
a right-handed helical structure. This would also move the
Val 1NH peptide proton toward the edge of a peptide plane in a
manner that would lead to a downfield chemical shift due to the
magnetic anisotropy of the peptide moiety. Thus, the data not
only argues that the conformations of the cyclopentadecapeptide
and linear polymer are similar, but it also suggests that the
linear polymer forms a right-handed helical structure.
In figure 5, carbon-13 NMR is used to compare the solvent depen-
dence of peptide carbonyl carbon chemical shifts of the cyclic
and linear structures (Urry et al. 1981). The solvent pair is
dimethylsulfoxide and deuterated water and, again, dotted curves
are used for the linear polymer data to facilitate comparison
with each of the cyclic structures. The peptide C-0 chemical
shift dependence on solvent also shows the cyclopenta- and
cyclodecapeptides to be in conformations very different from
each other and very different from the linear polymer, whereas
again the cyclopentadecapeptide conformation is very close to
that of the linear polypentapeptide.
FIGURE 6
Solvent dependence of amide proton in dimethylsulfoxide and
water of cyclic analogs of the elastin pentamer. From Urry et
al. 1981. Copyright 1981, American Chemical Society.
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It is also interesting to look at the solvent dependence of the
peptide NH chemical shifts. This is shown in figure 6, using
the same Solvent pair as in figure 5 but for the six cyclic
analogs with n=1, 2, 3, 4, 5, and 6. As with the data of
figures 4 and 5, the data for the linear polypentapeptide is the
dotted set of curves superimposed on each of the sets of curves
for the cyclic analogs. Again, the patterns for the cyclopenta-
and cyclodecapeptides are dramatically different from each other
and from that of the linear polymer. The data for the cvclopen-
tadecapeptide, as before, closely follow that of the linear 
polypentapeptide. The data for the cycloicosapeptide (n=4) and
the cyclopentaicosapeptide (n=5) do not follow so closely. But
the data for the cyclotricosapeptide (n=6) follow extraor-
dinarily closely, even more so than for the cyclopentadecapep-
tide. This is thought to be due to a figure 8 type of structure
comprised of two pentadecapeptide moieties related by twofold
symmetry and differing from the cyclopentadecapeptide primarily
by the introduction of a helical pitch resulting from chain
crossing.
These results demonstrate the validity of such approaches as
sensitive monitors of conformation. The use of these methods is
particularly favorable for a sequence such as this pentamer,
where all side chains are aliphatic--having neither hydrogen
bonding capability nor magnetic anisotropies that can complicate
interpretation of temperature and solvent dependence data. The
interpretation of such data for the enkephalins is complicated
by the ring current effects of the Phe and Tyr side chains and
the hydrogen bonding capabilities of the Tyr OH and the amino
and carboxyl end groups.
Conformations of the Cyclic and Linear Structures of the
Polypentapeptides of Elastin
The solution derived conformations are shown in figure 7A, B,
and C for the cyclopentapeptide, the cyclodecapeptide, and the
cyclopentadecapeptide, respectively (Khaled et al. 1981, 1982;
Venkatachalam et al. 1981). These were derived using the above
type of NMR data to identify secondary structure, with coupling
constants to limit Hi-NHi torsion angles, and with the nuclear
Overhauser effects to limit the Hi-NHi+1 distances, all in
combination with conformational energy calculations to limit
further the allowed torsion angle ranges. Essentially the same
conformation for the more rigid cyclopentapeptide has been
determined in the crystal by X-ray diffraction (Einspahr et al.
1980), as has that of the more flexible cyclopentadecapeptide
which is shown in figure 8 (Cook et al. 1980). The molecular
structure of the cyclopentadecapeptide is analogous to a three-
footed stool with the Pro2-Gly3 -turns functioning as the feet
of the stool. The crystal structure of the cyclopentadecapep-
tide is particularly interesting since the threefold symmetry is
retained (see figure 8A); the intermolecular interactions are
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FIGURE 7
Crystal structures of cyclic analogues of the elastin pentamer.
A. The cyclopentapeptide; B. the cycle-decapeptide; C. the
cyclopentadecapeptide (stereo view). Reproduced with permission
from Khaled et al. 1981(A). Copyright 1981, Munksgaard,
Copenhagen. Khaled et al. 1982(B). Copyright 1982, Elsevier
Biomedical Press. Venkatachalam et al. 1981(C). Copyright
1981, American Chemical Society.
hydrophobic, and the substantial water in the crystal is within
the stack of cyclic molecules that are stacked exactly on top of
each other (see figure 8B).
It is a relatively simple conceptual process to take a stack of
cyclopentadecapeptide molecules and to convert them to a linear
left-handed or right-handed helix as described above for forming
the Gramicidin A channel from an enniatin E-like cyclic struc-
ture. When this is done by means of molecular mechanics, using
the potential functions of Scheraga and colleagues (Momany et
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FIGURE 8
Crystal structure of the cyclopentadecapeptide. A. molecular
structure; B. crystal packing. From Cook et al. 1980.
Copyright 1980, American Chemical Society.
al. 1974, 1975), a right-handed helical structure is found to be
preferred (see figure 9), whereas going left-handed disrupts the
conformational features of the cyclic structure (Venkatachalam
and Urry 1981). This is consistent with the analysis of the
small 3J( coupling constant difference and the small dif-
ference in chemical shift of the Val1NH as discussed relative to
figure 4 above. [It may be noted that the same potential func-
tions have been utilized in conformational energy calculations
of Met- and Leu-enkephalins and their analogs (Manavalan and
Momany 1979, 1980, 1981)]. The resulting linear structure
depicted in figure 9 is termed a -spiral, as the -turn is the
dominant repeating secondary structural feature. The term
spiral is used instead of helix to emphasize in the structure
that there is not the obligatory hydrogen bonding between
repeating units as in the classical helical structures of poly-
peptides. The interturn interactions are hydrophobic; there is
water within the -spiral; and the -turns function as spacers
between the turns of the -spiral. This is shown as stereopairs
for an all atom depiction in figure 9A and B and for an -carbon
only representation in figure 9C and D. The upper structures
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FIGURE 9
Representations of the proposed spiral for the polypentapeptide of elastin. A, B, C, and D from
Venkatachalam and Urry 1981. Copyright 1981, American Chemical Society. E and F from Urry 1983.
Copyright 1983, McGraw-Hill.
give the helix axis view. Figure 9E schematically shows the
helical nature and figure 9F shows the -turns functioning as
spacers between turns.
-Spiral Temperature Dependence and the Source of Elasticity
While the -turns are present at temperatures below 20 °C, they
are less stable at that temperature and become more stabilized
as the temperature is raised. Also, the hydrophobic Val-Pro
side chains come into closer association and the interturn
hydrophobic interactions develop. These hydrophobic interac-
tions are responsible for the -spiral formation. Particularly
on slight extension of the structure, as occurs on stretching,
the -turns are joined by a suspended segment, Val4-Gly5-Val1,
which is allowed a great deal of motional freedom as it is
largely surrounded by water and as the central residue is a gly-
cine without a sterically restricting side chain. The peptide
moieties of this suspended segment are able to librate, or to
rock, thereby providing motion and entropy. It is thought that
the damping of this motion is the decrease in entropy that
occurs on stretching and this is responsible for the entropic
elastomeric retracting force. This has been termed a peptide
librational entropy mechanism of elasticity (Urry et al. 1982b,
1983a). This proposed mechanism has been substantiated by
FIGURE 10
Temperature dependence dielectric relaxation spectrum of
polypentaprptide of elastin. Adapted from Henze and Urry 1985.
Copyright 1985, American Chemical Society.
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selected synthetic analogs (Urry et al. 1983a, 1983c), and by
the development of a motional mode on raising the temperature
that can be detected by means of dielectric relaxation studies.
As shown in figure 10, at 20 °C no resolvable relaxation is
observed in the real part of the dielectric permittivity in the
3 MHz to 1000 MHz range; but on raising the temperature, an
intense relaxation develops at 25 MHz as the -spiral forms
(Henze and Urry, unpublished data). This motional mode is due
to the motions of a dipole moment with the indicated frequency.
As the peptide is the only source of a dipole moment, this is
due to peptide motion. As the material is very viscoelastic,
the change is not whole molecule reorientation but rather a pep-
tide rocking motion. This experimental result provides direct
evidence for a structure-dependent peptide librational entropy
mechanism of elasticity. Whereas structural flexibility is a
problem in characterizing opioid peptide conformations, this
does not mean the absence of conformation and, as in the case of
the polypentapeptide of elastin, flexibility could be an essen-
tial aspect of function.
The Helical Rack Model and a Proposed Voltage-Dependent Channel
The concept of CCLCC described above was used to derive the
Gramicidin A channel conformation and, in the elastin study, it
was used experimentally to determine which of a series of cyclic
analogs had a conformation resembling the linear structure. In
the process of comparing cyclic analogs, the experimental
methods used--temperature and solvent dependence of peptide NH
and C-O nuclear magnetic resonance chemical shifts--were showii
to be very sensitive to conformation. In this section, the con-
cept of CCLCC is used to develop a structural motif for a
membranous protein which would function as a voltage-dependent
channel.
The classical helices, e.g., the helix and 310-helix, have
large dipole moments which could be used to orient in an
electric field or to induce helix formation on the application
of such a field. In 1975 (Urry 1975; Urry et al. 1975),
extending the use of peptide dipole moments to form voltage-
dependent channels (Urry 1972). a helical rack model was pro-
posed utilizing a classical helix cyclized head to tail by a
-chain segment continuing in sequence as shown in figure 11.
The dipole moments of the individual peptide moieties of the
helix sum to make a large dipole moment which, since the dipole
moment of a -chain is small, cause the cyclic molecules to
align across a membrane on application of a potential. A sche-
matic representation of the structure from a view perpendicular
to the membrane surface is given in figure 12 (Urry 1982).
Since all the -helices cross the membrane in the same direction
and the -chains do so in the opposite direction, all the
helices and -chains run in parallel and it is a simple matter
to convert from a series of cyclic subunits to the linear con-
formational correlate as shown in figure 13. This results in a
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protein structural motif of a -barrel surrounded by -helices.
This has been recognized by Richardson (1981) as the structural
motif for triosephosphate isomerase, the pyruvate kinase domain
I, and aldolase. A related structured motif has been derived by
Marshall and colleagues (Hall et al. 1984) from studies on ala-
methicin voltage-dependent channel formation. Obviously, such
a structural motif and the insiahts it provides aive rise to
numerous experimental approaches. Thus; we have a proposed
molecular structure for a voltage-dependent channel which could
possibly provide a point of reference for the consideration of
the effect of opioid peptides on increasing potassium ion con-
ductance.
b.
FIGURE 11
Helical rack model for voltage dependent channel formation.
From Urry 1975. Copyright 1975, John Wiley & Sons, Inc.
MOLECULAR STRUCTURE AND MECHANISM OF MEMBRANE CHANNELS: THE
GRAMICIOIN A CASE
As noted in the Introduction, the set of disciplines required in
an approach to the mechanism of action of opioid peptides is
closely similar to that required for a comprehensive approach to
the molecular structure and mechanism of Gramicidin channel
transport. Peptide synthesis is required to make analogs for
testing structural concepts and to prepare selectively isotope-
labeled molecules for determining elements of mechanism.
Characterization of conformations, interactions, and rate pro-
cesses by physical methods--such as circular dichroism, NMR,
ultraviolet, infrared, and fluorescence spectroscopies;
dielectric relaxation; etc.--provide an essential second com-
ponent. Molecular mechanics calculations are required to test
and refine proposed elements of mechanism and to add information
and insight not directly available from experiment. In addi-
tion, characterization of peptide or protein effected ion
transport across lipid bilayer membranes is by methods that pro-
vide the greatest sensitivity and time resolution, such as the
planar bilayer approach of Mueller and Rudin (1967) and the
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single channel recording techniques of Sakmann and Neher (1983).
The interplay and essential information exchange between each of
these components is extensive and the loss of any component
would mean a less well-characterized and less certain mechanism.
As an action of opioid peptides is to increase the opening of
potassium ion channels, a complete understanding of this mecha-
nism of action would require analogous approaches.
FIGURE 12
Voltage dependent channel formed from cyclic subunits with each
subunit containing an -helical and a -chain component. This
is the same structure as given in figure 11 from a different
perspective. The perspective of figure 11 is the cross section
indicated by the line labeled 3.
1.
2.
-barrel at center comprised of parallel -chains.
Right-handed -helices with positive end of dipole at top.
3. Horizontal line indicates cross section for figure 11.
4.
5.
Side chains on -helices are hydrophobic.
Alternate side chains on -chain determine character of
channel. Others may be hydrophobic.
6. Arrow indicates direction of chain
From Urry 1982. Copyright 1982, Alan Liss, Inc.
Phenomenology of Channel Transport
In its simplest terms, characterization of channel transport
involves a pair of electrodes separated by a small lipid bilayer
membrane of high resistance. Commonly, the salts in the aqueous
solutions on each side are equivalent and a potential is applied.
The presence of peptides or proteins that can form channels
across the lipid bilayer result in conductance events as a chan-
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FIGURE 13
Cyclic conformational correlate of the structures shown in
figures 11 and 12. Protein model for a voltage dependent chan-
nel.
1
2
-barrel at center.
Right-handed -helix with positive end of dipole at top.
3. Parallel aligned -chains.
4. Hydrophobic side chains of -helix.
5. Alternating side chains on -chains determine character of
the channel.
6. Arrow indicates direction of chain.
From Urry 1982. Copyright 1982, Alan Liss, Inc.
nel forms and disappears. This was first observed by Hladky and
Haydon (1970, 1971, 1972) with the Gramicidin peptides isolated
from bacillus brevis. Such single channel events have now been
observed for many different channels from higher organisms in
their natural cell membranes and reconstituted in model membranes
(see, for example, Sakmann and Neher 1983). The two basic chan-
nel characteristics are their single channel conductance given in
Siemens (channel current in coulombs/sec divided by applied
potential in volts) and channel mean lifetime, where a single
conductance event can last from milliseconds or less to seconds
or even minutes. Analgesics and anesthetics can be expected to
act indirectly or directly on a channel to alter one or both of
these two characteristics.
Figure 14 shows single channel current traces for Gramicidin A in
the upper trace and for N-acetyl desformyl Gramicidin A in part B
(Szabo and Urry 1979). The difference between these two channel
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FIGURE 14
Single channel current traces in the presence of 1M RbCl with an
applied potential of 1OOmV for Gramicidin A (A) and for N-acetyl
desformyl Gramicidin A (B). The step increase and decrease is
the turning on and off of a single channel. From Szabo and Urry
1979. Copyright 1979, American Association for the Advancement
of Science.
structures is simply the replacement of a formyl hydrogen by a
methyl moiety (i.e., acetyl for formyl), yet the effects on chan-
nel conductance and lifetime are dramatic. For the potassium ion,
the single channel conductance is reduced from a most probable
value of 45 pico Siemens (pS) to 27 pS and the channel mean life-
time is reduced from 3.3 seconds to 56 milliseconds. On a
macroscopic basis, this has the effect of reducing conductance to
1%. As will be briefly argued below, even the reorientation of
an amino acid side chain removed by some distance from the chan-
nel itself can have a similar dramatic effect in varying conduc-
tance.
This allows that even a most subtle binding effect of an opiate
or other effector could either greatly increase or decrease
effective conductance.
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Mechanism of Gramicidin A Channel Transport
Once structure is known, the major components of determining the
ionic mechanism of channel transport are to locate binding sites
in the channel, if indeed they exist, to determine binding
constants, and to estimate rate constants for each of the major
rate processes. When this is adequately achieved, a complete
free energy profile can be plotted and, when this is achieved
for different temperatures, complete enthalpy and entropy profi-
les should be obtained. With such information, the single chan-
nel currents would be calculable over wide ranges of ion
concentration, of applied potential, and of temperature. As
this is achieved, all of the obvious and subtle control mecha-
nisms will become apparent.
Location of Ion Binding Sites
From the conformation of the channel (see figures 1 and 2), it
is apparent that, as the cation passes through the channel, it
is coordinated laterally by the peptide carbonyl oxygens.
Accordingly, if an appreciable occupancy occurs, it should be
observable--using carbon-13 NMR--as an ion-induced carbonyl car-
bon chemical shift. This had previously been observed for the
cyclic conformation correlate, the enniatin B-K+ complex (Urry
1976). However, to determine the ion-induced carbonyl carbon
chemical shift for the Gramicidin A channel in lipid bilayers,
it is necessary to synthesize Gramicidin A molecules wherein
only the carbonyl carbon of a single residue is enriched with
carbon-13. This has been done in 10 syntheses, i.e., for 10
different peptide carbonyl. For each synthesis, the channel is
then packaged in lipid bilayers at 3 mM concentrations and the
presence or absence of a cation-induced carbonyl carbon chemical
shift is determined for one residue. The results, plotted as a
function of carbonyl location in the left-handed single stranded
6-helix, are given in figure 15 (Urry et al. 1982c). These
cation-induced carbonyl carbon chemical shifts, when plotted
with respect to other proposed structures, e.g., the double
stranded -helices (Veatch et al. 1974), can also be used to
determine unequivocally the channel structure (Urry et al.
1983b) and even to determine the helix sense (Urry et al.
1982c). The axiom utilized in delineating structures is that
helically (or structurally) equivalent carbonyls should show
similar ion-induced chemical shifts when equally proximal to the
ion.
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Wire Model and Ion Binding Sites of the
Gramicidin A Transmembrane Channel
FIGURE 15
Location of ion binding sites using carbon-13 NMR to observe
ion-induced carbonyl carbon chemical shifts. Adapted with per-
mission from Urry et al. 1982c. Copyright 1982, Springer-
Verlag, Inc.
Determination of Binding Constants
The ion-induced carbonyl carbon chemical shift can be used to
estimate binding constants and also to clarify the nature of the
binding process. Shown In figure 16 is the thallium ion-induced
carbonyl carbon chemical shift followed with carbonyl carbons of
the Trp and Trp residues and plotted as a function of log
[Tl+]. What is apparent is that there are two binding
constants--one for entry of the first ion (a tight binding pro-
cess) and one for entry of the second ion which, due to
repulsion from the first ion in the channel, is a weaker pro-
cess. A tight and a weak binding constant can also be estimated
using quadrupolar ion NMR and longitudinal relaxation time stu-
dies (Urry et al. 1980). Thus, in this twofold symmetric chan-
nel with two structurally equivalent binding sites, there two
binding constants--a tight one for single occupancy and a weak
one for double occupancy.
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FIGURE 16
Plot of thallium ion-induced carbonyl carbon chemical shifts as
a function of the logarithm of the ion concentration. This
clearly shows tight and weak binding processes, respectively,
for the entry of the first and second ions in the channel. From
Urry et al., unpublished data.
Estimation of Rate Constants
Ion NMR linewidths plotted versus chemical shift for spin l/2
ions or for situations that can so approximated and traverse
relaxation time studies of the spin 3/2 quadrupolar ions can be
used to estimate rate constants for ions leaving the channel
(Bull 1972; Venkatachalam and Urry 1980). The latter approach,
in particular, utilizes approximate expressions and arguable
assumptions to convert experimental relaxation times into corre-
lation times and finally to rate constants. Such estimates have
been made for the sodium ion, and the obtained rate constants
have been shown with the other data on binding constants and
site location to calculate single channel currents over wide
ranges of ion activity and applied voltage (Urry et al. 1980).
190
FIGURE 17
Dielectric relaxation spectrum of a suspension of malonyl-
Gramicidin A channels. The solid curve showing the additional
relaxation beginning just below 10 MHz is the case where there is
one Tl+ ion in the channel. From Henze et al. 1982. Copyright
1982, Springer-Verlag New York, Inc. Inset: Representation of
the dipole moment change attending an intrachannel ion transloca-
tion from one binding site to the other. From Urry 1985b.
Copyright 1985, D. Reidel Publishing Company.
A particularly notable means, when useable, for obtaining a rate
constant relevant to transport through the channel is dielectric
relaxation. There is a large change in charge distribution when
an ion jumps from one binding site to the other in the channel.
This is depicted in the inset of figure 17. When the frequency
at which the field reverses is faster than the ion can move, it
does not contribute to the dielectric permittivity of the medium
containing the channels. When the frequency is slower than the
rate for ion translocation, the ion can jump back and forth as
the field reverses and, as such, can contribute to the
dielectric permittivity of the medium. This is seen for
thallium ion in the channel in figure 17 where a relaxation is
observed giving a rate constant for jumping between sites of
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about 4 x 106/sec. (Henze et al. 1982). A particularly attrac-
tive aspect of this approach is that it requires no complicated
theory with arguable assumptions to estimate the rate constant.
Thus, dielectric relaxation has been seen to provide critical
information above in the elastin structure-function problem and
here in the development of the ionic mechanism of channel
transport. It could also be used to provide information on the
dipole moment of enkephalin molecules in solution.
Modulation of Single Channel Conductance and Lifetimes
Single channel conductance magnitudes and channel lifetimes are
readily modulated. The dramatic effect of replacing a hydrogen
by a methyl moiety, i.e., conversion N-formyl to N-acetyl, was
noted above in relation to fiaure 15. This resulted in a 99%
decrease in conductance. There are many examples of the marked
sensitivity of the amino (formyl) end to modification, but there
is a relative insensitivity to derivitization at the ethanolamine
OH. For example, the 0-pyromellityl derivative with its triple
negative charge has only a small counterion cloud effect (Apell
et al. 1977), whereas the N-pyromellityl derivative completely
destroys activity (Barnberg and Janko 1977). More subtly, the
D•Leu2-GA analog results in a marked decrease in lifetime with
essentially no change in conductance (Bradley et al. 1981a). As
external effects. addition of the anesthetic halothane at the
physiological dose reduces lifetime from 25% to 30% of normal
(Bradlev et al. 1981b); raising calcium ion concentration
decreases  conductance (Bamberg and Laüger 1977) by competitive
binding of calcium ion at the binding site even though divalent
cations are not conducted (Urry et al. 1982c); and increasing
membrane thickness decreases channel lifetime with no change in
conductance (Hladky and Haydon 1972).
An interesting analog is the des L•Va17-D•Val8-Gramicidin A which
is shorter by 3A due to the removal from the channel of two L-D
dipeptide units, one in each monomer of the dimeric channel. The
result, quite expectedly, is a shorter lifetime, but also, quite
instructively, the conductance is decreased to almost one-half
(Urry et al. 1984a). Since, by a diffusion-limited process, con-
ductance would be expected to be increased by 30% for this extent
of shortening, the result indicates the essential correctness of
an Eyring barrier-type description and indicates further that the
dominant conducting state is one with double ion occupancy.
Of particular interest with respect to control of conductance is
the multiplicity of conductance states. When single channel con-
ductance was mentioned above, the reference was actually to the
most probably conductance state. As shown in the histogram of
figure 18 by the dashed enclosure, while there is a most probable
conductance state for Gramicidin A at 100 mV, 20 °C, and 1M KCl
of 17 to 18 pS, there are other less probable states with lower
conductance (Urry et al. 1984c; Venkatachalam et al. 1984).
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FIGURE 18
A. Conductance histograms for Gramicidin A (...) and L•Leu5-Gramicidin A (-) at 100 mV, 1 M KCl and
20 °C in diphtanoyl lecithin/n-decane membranes. From Venkatachalam et al. 1984. Copyright 1984,
John Wiley & Sons, Inc. Single channel conductance traces for Gramicidin A (B) and
L•Leu5-Gramicidin A (C) under these conditions.
FIGURE 19
Stereo views of the sideview of the Gramicidin A channel (A) and
of a channel view taken from the solution end of a monomer (B).
For crosseye (close) viewing, cover the right-hand structures and
use the left-hand pair; for walleye (distance) viewing, cover the
left-hand structures and use the right-hand pair. These stereo
views show the orientation of side chains for a favorable in
vacuo distribution. This is one of a class of states with simi-
lar energy but with different side chain distributions. Adapted
from Venkatachalam and Urry 1983. Copyright 1983, John Wiley &
Sons, Inc.
This multiplicity of conducting states is a challenging issue to
resolve in connection with abundant data arguing that the same
channel backbone structure is responsible leading to the proposal
that the differing conductance states arise from different side
chain distributions with lifetimes on the order of seconds. One
preferred side chain distribution is seen in figure 19
(Venkatachalam and Urry 1983). In
mobility, it was found that the Trp
an analysis of side chain
side chain was especially
free to occur in different rotameric states, partly because it is
at the end of the helix but also because the residue on the
adjacent turn of helix,
small side chain.
residue-5, is an alanine residue with a
This allows the Trp side chain to reside
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over the Ala side chain, much as the Trp side chain is seen in
the distribution of figure 19 to lay up over the Ala side chain.
Thus, it was reasoned that replacement of Ala by a residue with
a bulkier side chain should restrict to a significant extent some
of the rotameric states available to the Trp side chain and
thereby decrease the multiplicity of states. To test this
perspective, the Leu -GA analog was synthesized. As shown in
figure 18, the probability of the most likely conductance state
has been doubled. This provides a demonstration of a most
intriguing and subtle means of modulation of conductance. Simply
by altering or restricting the orientation of a side chain not
directly involved in cation contact can markedly alter conduc-
tance. The mechanism is thought to involve the energetics of
peptide libration. As the ion enters the channel, the peptide
carbonyls must librate inward toward the channel center in order
to coordinate adequately the cation. The energetics of this pep-
tide libration are viewed as being dependent on the orientation
of the side chain of the involved carbonyl. Accordingly, there
are many ways to modulate the effective conductance of channels
and it will be interesting to see if any of those which are exhi-
bited by the Gramicidin A channel system will be analogous to the
manner in which opioid peptides increase potassium ion conduc-
tance in nerve tissue.
Further Comments on Mechanisms at a Membranous Site
The single channel conductance traces in figure 18B and C were
obtained using a cell with a teflon partition between two cham-
bers and with a small hole in the partition over which a planar
bilayer is formed. This is basically the Mueller and Rudin
(1967) approach. In order to improve signal to noise and
membrane stability to voltage ranges very small membrane areas
are desirable. These small areas can be obtained by using a
glass pipette drawn to a fine diameter of a few microns and by
further preparing the tip to decrease noise and make it suitable
for lipid bilayer coverage. This approach has been used by
Andersen (1983) in studies on Gramicidin A and is essentially
what has become known as the patch clamp technique so well de-
veloped by Sakmann and Neher (1983). This approach, which can
carry the Gramicidin A problem to the important refinement of
understanding side chain distribution issues, has found its
greatest application to cells and to small membrane patches from
cells. The mechanics of the process are schematically shown in
figure 20 (Hamill et al. 1981).
This means that channels of suitable nerve and other cells can be
studied much as the Gramicidin A channel has been studied and
that the response of these channels to neurotransmitters and
other effectors, such as the opioid peptides, can be assessed.
It is not unreasonable to expect in the future that the patch
clamp approach will provide more specific and informative assay
systems for opioid peptides and will also provide simpler systems
on which to dissect ionic transport mechanism.
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FIGURE 20
The patch clamp experiment (schematic representation). From
Hamill et al. 1981. Copyright 1981, Pflügers Arch.
A particularly intriguing use of the patch clamp pipette tech-
nique, which has relevance to the neurotransmitter release acti-
vity of opioid peptides, is the study of chromaffin cells by
Neher and Marty (1982). Patch clamp pipettes were used to
measure the cell membrane capacitance of small adrenal chromaffin
cells. Cell membrane capacitance was observed to exhibit step-
like changes (2 to 6 x 10-14+F) under conditions of enhanced
release of chromaffin granules. Quoting directly from the Neher
and Marty paper, "The size distribution of step-like capacitance
changes is well compatible with the idea that steps of capaci-
tance increase reflect individual events of exocytosis of chro-
maffin granules, whereas steps of the opposite polarity reflect
the formation of vesicles or vacuoles by endocytosis."
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It appears over the entire range, starting with the synthesis and
conformational studies of analogs and spanning to the emerging
means for studying mechanisms at membranous sites, that the study
of the mechanism of action of the opioid peptides and opiates is
entering a most challenging and productive period.
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Opioid Peptides: Analysis of Specificity
and Multiple Binding Modes Through
Computer-Aided Drug Design and
Structure-Activity Studies
Raoul D. Nelson, Ph.D.; David I. Gottlieb, Ph.D.;
T. M. Balasubramanian; and Garland R. Marshall, Ph.D.
I N T R O D U C T I O N
Analysis of the structure-activity data in the area of opioid
peptides and opiates is severely compromised by the presence of
multiple receptors, by incomplete pharmacological
characterization of compounds in the literature, and by
oversimplification of possible drug-receptor interactions. We
will use our efforts to determine the receptor-bound
conformation of morphiceptin and its relationship to enkephalin
to illustrate both the approaches we have developed (Marshall et
al. 1979) and the pitfalls which we have encountered.
Morphiceptin is a synthetic opiofd peptide, Tyr-Pro-Phe-Pro-NH2,
with moderate opioid agonist activity and extreme selectivity
for the mu opiate receptor. A mu receptor pharmacophore was
proposed for morphfceptin based on the structural homology with
enkephalin and other nonpeptide opioids. In order to
simultaneously test the pharmacophore hypothesis and increase
the potency and selectivity of morphiceptin, morphiceptin
analogs were synthesized with potentially important chemical
groups modified or eliminated, as well as conformationally
constrained analogs. Mu receptor agonist and antagonist potency
was determined in the stimulated guinea pig ileum (GPI)
bioassay. Mu receptor affinity and delta receptor affinity were
determined in receptor binding assays. The mu receptor agonist
potency and affinity correlated well.
The structure-activity relationships of the morphiceptin analogs
refined the pharmacophore hypothesis. The activity of the
analogs with potentially important chemical groups, modified or
eliminated, supported a three-group pharmacophore hypothesis.
There was a strict requirement for the Tyr-1 nitrogen group,
Tyr-1 phenolic group, and Phe-3 phenyl group. These groups are
similarly required for activity in enkephalin and nonpeptide
opiates. However, the Phe-3 phenyl of morphiceptin must either
bind to a different subsite on the mu opiate receptor or to a
similar subsite of the mu opiate receptor in a different
orientation than the corresponding group (Phe-4) of
enkephalin. Furthermore, there are strict conformational
requirements for the activity of morphiceptin.
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The study of the structure-activity relationships of
morphiceptln by computer analysis of conformation and computer
graphics further refined the pharmacophore hypothesis. The
active and conformationally constrained analogs of morphlceptin
can produce a common pharmacophore In three dimensions.
Morphiceptin cannot interact with the mu opiate receptor when
the pharmacophore groups are in the same relative orientation as
the corresponding groups in the nonpeptide opiates.
Morphfceptin can interact with the opiate receptor with the
pharmacophore groups in the same relative orientation as the
corresponding groups in enkephalin, but with a very different
backbone arrangement. The results of these computer studies
show that opioids with different overall constitution may
interact with the mu opiate receptor in very different modes.
METHODS
Molecular Modeling
The molecular modeling system consisted of a VAX-11/750 and an
NEC advanced personal computer as a color raster graphics
terminal. The system was equipped with SYBYL (Trfpos Assoc.,
St. Loufs, MO), a computer-aided drug design software package.
The peptide models were assembled with standard amino acid
fragments which were obtained by using the Empirical
Conformation Energy Program for Peptides (ECEPP) (Momany et al.
1975; Nemethy et al. 1983) and a standard amide bond geometry
Bendetti 1977). which represented averaged crystallographic
data. Unusual amino acids and nonamino acid groups were
constructed from standard fragments of chemical groups derived
from crystallographic data, and their geometry was optimized
using a molecular mechanics program with a standard force field
(White 1978; Labanowskf and Marshall, in preparation).
The computer program SEARCH systematically determined all
possible sterically allowed conformations of a molecule by
incremently changing the torsfonal angles of freely rotatable
bonds and discarding the conformations for which there were
repulsive van der Waals interactions (Bosshard et al. 1972). A
hard sphere potential model, with the van der Waals radii
calibrated against protein crystallographic data, was used to
calculate the repulsive van der Waals interactions (Marshall et
al. 1974). The program SEARCH also simultaneously determined
the specified distances that define each relative orfentatfon of
specified chemical groups for each sterically allowed
conformation of a molecule. The set of distances that define
the relative orientations of the specified chemical groups
produced by all the sterfcally allowed conformations of
molecules was defined as an orientation map. The program SEARCH
also determined the mathematical intersection of the orientation
maps for a set of different molecules with the corresponding
chemical groups, which represented the common orientations of
the specified chemical groups for the set of molecules. The
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orientation map was represented by a table of the observed
maximum and minimum distances, a table of vectors which
described the set of all possible distances, or three-
dimensional plots of three of the possible distances.
Conformations of molecules that produced the entries in
orfentation map were retrieved and examined by molecular
graphics.
The same SEARCH program also was able to determine all the
sterically allowed conformations of a molecule, as described
previously, and simultaneously output vectors produced by a
specified pair of atoms relative to a fixed aggregate of atoms
for each conformatfon of a molecule (Marshall et al. 1983). The
vector map common to a set of different molecules could also be
determined and it indicated that sterically allowed
conformations existed where the specified aggregate and pair of
atoms can be superimposed.
A molecular mechanics program MAXIMIN was used to minfmfze the
energy of a set of molecules with the options to simultaneously
superimpose specified aggregates of atoms common to a set of
molecules; and it also was used to fix the relative orientation
of aggregates of atoms within molecules (Labanowski and
Marshall, in preparation). The parameters of MAXIMIN were
derived from a literature valence force field (White 1978).
Radioligand Binding Assay
The saturation and competition binding assays for opiate
receptors were performed by a modification of literature methods
(Pert and Snyder 1973a; Chang et al. 1979; Chang and Cuatrecasas
1979; Gilian et al. 19791. The binding reaction was Initiated
by the addition of freshly thawed homogenate to a solution of
radfolfgand in the presence or absence of cold ligand in 50 mM
Tris-HCl, pH 7.5 at 24 °C with a total reaction volume of 1
ml. The reaction was incubated for 60 minutes at 24 °C and was
terminated by the addition of 4 ml of 50 nM Tris-HCl, pH 7.5 at
4 °C, and rapid filtration through a Whatman glass-fiber filter
(GF/F). The filters were washed twice with 4 ml 50 mM Tris-HCl,
pH 7.5 at 4 °C. The fflters were shaken in 5 ml scintfllatfon
cocktail and the radioactivity determined with an efficiency of
38% to 42%. The assay was performed using rat brain homogenate
(0.5 mg protein per ml assay volume), NMB cell homogenate (1.0
mg protein per ml assay volume), or NG108-15 cell homogenate
(0.25 mg protein per ml assay volume).
Saturation binding isotherms
homogenate and the radiolfgand [3H]-DADLE at eight
were performed using NMB cell
concentrations, from 0.1 to 20 nM, in the presence and absence
of 2.5 µM levorphanol. Saturation binding isotherms were also
performed using NG108-15 cell homogenate and the radioligand
[3H]-DADLE at efght concentrations. from 0.1 to 20 nM, in the
presence or absence of 2.5 µM DADLE. Similarly, saturation
binding isotherms were performed using rat brain homogenate and
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the radfoligand [3Hl-DADLE at eight concentrations. from 0.1 to
20 nM, in the presence and absence of 2.5 µM levorphanol.
Competition binding isotherms were performed using NMB cell
homogenate with the radfolfgand [3H]-DADLE at a concentration of
1.0 nM in the absence or presence of 6 to 10 concentrations of
cold competing lfgand and 2.5 µM levorphanol. Competition
binding isotherms were also performed using NGl08-15 cell
homogenate wfth the radfolfgand [3H]-DADLE at a concentration of
1.0 nM In the presence and absence of 6 to 10 concentrations of
cold competing lfgand and 2.5 µM DADLE. Sfmflarly, competition
binding isotherms were performed using rat brain homogenate and
the radfolfgand [3H]-DHM at a concentration of 0.24 nM in the
presence and absence of 6 to 10 concentrations of cold competing
lfgand and 2.5 µM levorphanol.
Nonspecific binding was defined as the binding in the presence
of 2.5 µM levorphanol or DADLE, and specific binding was defined
as the total binding minus the nonspecific binding. The
receptor binding assays were performed wfth each combination of
radfoligand and cold competing lfgand concentration in
triplicate within an experiment, and experiments were performed
in triplicate.
Receptor Binding Assay Data Analysis
Binding data from experiments wfth rat brain and NG105-15 cell
homogenate were analyzed with LIGAND (Munson and Rodbard
1980). This program fits a mass action-based mathematical model
for receptor binding, involving one or more lfgands and
receptors, by nonlinear regression to radfoligand binding
data. Binding affinity (Kq3) and capacity (Bmax) for [
3H]-DADLE
and NG1D8-15 cells, or [3H]-DHM and rat brain, were first
calculated for each saturation binding isotherm individually.
Similarly, Kd for each cold competing lfgand was calculated for
each conpetition isotherm, using the previously calculated
binding affinity of the radfolfgand. Nonspecific binding was
treated as a fftted parameter. The variance model for weighting
was for constant percent error. The data are reported for fits
with a single binding site model. The arlthmatfc mean and
standard error of the mean of Bmax and the geometric mean and
standard error of the mean of Kd were calculated for replicate
binding isotherms.
The data for the binding isotherms using the NMB cell homogenate
were treated in the traditional manner. Kd and Bmax were
calculated by linear regression of Scatchard plots for each
saturation binding isotherm (Scatchard 1949). The IC50 for each
cold competing lfgand was calculated for each competition
binding isotherm using SIGMOID (DeLean et al. 1978). SIGMOID is
a program which fits a four parameter logistic function to
radfoligand displacement data by nonlinear regression. and
interpolates the IC50. The (Ki) for each competing lfgand, in
each competition binding isotherm, was calculated according to
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the Prusoff equation, from the IC50 of the competing ligand. the
concentration of the radioligand, and the affinity of the
radioligand (Cheng and Prusoff 1973).
Guinea pig ileum bioassay
.
Opiate activity of potential opioid compounds was determined in
the coaxially stimulated GPI bioassay (Gyang and Kosterlitz
1966; Pert and Snyder 1973a, 1973b). Male albino guinea pigs
with an average weight of 350 g were killed by a blow to the
head and the small intestine was quickly removed. The distal 10
cm of the ileum and the duodenum were discarded and 3 cm strips
of ileum were hung via silk in a 15 ml organ bath from an F50
myograph microdisplacement transducer with a 1 g resting
tension. The organ bath contained Krebs-Ringer bicarbonate
solution (120 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4 2.5 mM CaCl2
1.2 mM KH2P04, 25 mM NaHC03. 10 mM dextrose) with 20 µM choline
chloride and 0.125 µM mepyramine maleate at pH 7.4 and 37 °C
bubbled with 95% 02/5% C02. The ileum was stimulated via silver
electrodes transmurally using a Grass SD9 stimulator with
supramaximal voltage (0.2 Hz, 1.5 ms). and the contractions were
monitored with a Physiograph DMP-4B recorder. The tissue was
allowed to equilibrate in the bath for 15 to 30 minutes.
The compounds to be evaluated were added to the bath in 10 to
100 µl aliquots, and were allowed to stay in the bath until
maximal inhibition of contraction occurred. Then the bath
contents were removed and the tissue was washed four times over
15 to 30 minutes. For a typical dose-response study of a
compound, a minimum of four doses which produced 10% to 90%
inhibition of contractions were used. Potency was defined as
the IC i.e the concentration of an agonist which produced
50% inhibition of contractions. The IC was calculated by
linear regression of the LOGIT transformation (Rodbard and
Frazier 1972) of percent inhfbftion of contraction
[LOGIT(%inhibition) = Ln(%inhibitionl(l%inhibition))] versus the
log of the concentration of the compound, and interpolation to
the concentration of the agonist that produces 50% inhibition of
contraction. The IC for DADLE was determined in each tissue
so that the %relative potency could be calculated for each
compound tested in the same tissue. The % relative potency was
defined as 100 x IC50 DADLE/IC50 compound. The geometric mean
and standard error of the mean of the IC50 and %relative potency
for each compound were calculated from dose-response studies
with at least three tissues. For each compound that an IC50
could be determined, a supramaximal dose was added to the ba
to demonstrate complete inhibition of contractions (i.e., full
agonist activity) and 200 nM naloxone was added to the bath to
demonstrate that the inhibitory activity was completely
reversed. In addition, compounds which exhibited little or no
inhibitory activity were checked at concentrations at which
little or no inhibitory activity was observed for their ability
to block or antagonize the inhibitory activity of DADLE.
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The sensitivity of the opiofd agonist, morphiceptin, to naloxone
antagonism was examined according to a modification of a method
described by Kosterlitz and Watt (1968). A dose-response study
was performed, and the IC50 calculated, for each agonist. both
without and with three concentrations of naloxone (4.12, 20.6,
103, and 515 nM). The pA2 Ke, and slope were calculated by
linear regression of a Schild plot of the log (dose ratio - 1)
versus the log ([naloxone]/nM), for each agonist. The
arfthmatfc mean and standard error of the mean of the slope and
pA2. and the geometric mean and standard error of the mean of
the Ke, were calculated for replicate experiments. The opiofd
agonists used were Met5-enkephalin, ethylketocyclazocine, and
morphiceptin.
Chemistry of morphiceptin analogs
All solvents were HPLC grade and chemicals were reagent grade.
Free and protected amino acids were purchased except for 2-
aminoindane-2-carboxylate (Mauger and Ross 1962), trans-3-
phenylproline (Cox et al. 1964; Sarges and Tretter 1973), and 2-
methylproline (Ellington and Honigberg 1974) which were prepared
by methods reported in the literature. Benzhydrylamine
polystyrene 1%-crosslinked divinlybezene resin was synthesized
by the method of Pietta et al. (1973); p-methylbenzhydrylamine
polystyrene 1%-crosslinked divinylbenzene resin was purchased.
Melting points were determined on a Hoover capillary apparatus
and microanalyses were performed by Robertson Laboratory of
Florham Paris, New Jersey. Optical rotations were performed
using a Perkin-Elmer 241 automatic polarimeter with a 1 dm
cell. Proton magnetic resonance spectra were recorded at 60 MHz
using a Perkin-Elmer T60 spectrometer or at 100 MHz using a
Varian XL100 spectrometer. The IR spectra were recorded on a
Perkin-Elmer 7108 spectrometer for compounds as a KBr pellet.
Fast atom bombardment mass spectra were recorded on a Finfgan
3200 mass spectrometer equipped with a FACS fast atom bom-
bardment gun using Xe gas at 6 to 8 Kev. Two to ten µg of each
sample in 1 µl MeOH was applied to a glycerol matrix of the
probe for analysts. Twenty five to fifty µg of each peptide was
examined for homogeneity by thin-layer chromatography (TLC)
using precoated silica plates. The peptides were visualized
with iodine vapor, chlorox/starch-KI, and/or ninhydrin. All
peptides showed a single spot on TLC. Hydrogenations were
carried out on a low pressure Parr hydrogenator at room
temperature. Selected protected peptides were purified by
medium pressure liquid chromatography on Lobar silica columns
(E. Merck) with various solvent systems.
For amino acid analysis, the peptides were hydrolyzed at 110 °C
for 24 hours in deaerated tubes in 6N HCl and 0.5% phenol with
Nle as an internal standard. Amino acid analysis was performed
using one of the following methods: a procedure described by
Benson and Hare (1975) and modified to include a Glenco MM amino
acid analyzer equipped with a dual beam photometer (570 nm and
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440 nm), and Hewlett-Packard 3390A and Spectra-Physics
Minigrator integrators; or the procedure of Bohlen and Mellet
(1979) using a Waters amino acid analyzer equfpped with a filter
fluorometer optimized for o-phthalaldehyde amino acid
derivatives, and a digital integrator; or a modified PTC
procedure (Henrickson and Meredith 1984).
Selected analogs of morphfceptin were synthesized by the solid
phase method. Some analogs were synthesized by this method
because of the side reactions encountered in the initial
solution phase synthetic strategies. The peptides were
synthesized on the benzhydrylamine (Pietta et al. 1973) and p-
methylbenzhydrylamine (Matsueda and Stewart 1981) polymers,
which afford a C-terminal amide. Standard initial attachment
and elongation protocols were used, with DCC for coupling, BOC
groups for N-terminal protection, Bzl groups for side-chain
protection of tyrosine, and TFA for BOC removal. Extended
coupling times and double coupling cycles were used in the
syntheses with the sterically hindered amino acids: 2-
methylproline, N-methyl-D-alanine, N-methylphenylalanine, 2-
aminoaminoindan-2-carboxylate, and cycloleucine. The final
peptide was deprotected and cleaved from the polymer by either
the high HF or high/low HF (Tam et al. 1983) procedures, and was
worked up by standard procedures.
Selected analogs of morphiceptin were synthesized by solution
methods, including those substituted wfth sterfcally hindered
amino acids and C-terminal phenyl alkyl amides that are not
easily incorporated by solid phase methods. Multiple synthetic
strategies were chosen to take advantage of common fragments and
afford the peptides in high yield and purity. The synthetic
strategies used common coupling reagents and protecting
groups. DCC with HOBT (Konig and Geiger 1970). EDCI with HOBT
(Sheehan et al. 19651, PPA (Wissmann and Kleiner 19801, and DPPA
(Hamada et al. 1977) were the coupling reagents used. EDCI and
PPA were preferable because no purification other than the
standard workup was usually necessary.
Preparative RP-HPLC is becoming a standard analytical and
preparative technique that is extremely valuable in purification
and analysis of synthetic peptides. The preparative techniques
at the time this work was begun were either for large gram scale
purifications using the Waters Prep-500 HPLC equipment (Rivier
et al. 19841 and very expensive columns, or for the smaller mg
scale purifications using the conventional HPLC equipment and
small semipreparative columns. This prompted the development of
an intermediate scale preparative RP-HPLC methodology. Twenty
to eighty mg of each deprotected peptide was chromatographed on
a 22 x 250 mM Zorbax 5 µM ODS column. The peptides were eluted
with isocratic conditions at 5% B for 10 minutes, a concave
gradient between 5% and 20% to 35% B over 10 to 30 minutes, and
isocratic conditions at 20% to 35% B for 1 to 2 hours, at 8.0
ml/minute while monitoring absorbance at 280 nM. A was 1.1 N
HCOOH in H20 with the pH adjusted to 3.0 with TEA, and B was
210
MeOH. The homogenous fractions demonstrated by analytical RP-
HPLC were subsequently desalted by chromatographing on a Waters
4.6 x 250 mM µBondapack ODS column. The peptide was applied to
the column, the salts eluted with isocratfc conditions of 100%
A, and the peptide eluted with a sharp linear gradient of 0% to
75% B, where A is 0.1 N CH3COOH and B is MeOH. Lyophflization
from dilute CH3COOH afforded homogeneous peptides as acetate
salts with yields of 30% to 90%.
RESULTS
Structure-Activity of Morphiceptin Analogs
The analogs prepared are shown in figures 1 and 2. Figure 1
concentrates on analogs useful in testing the pharmacophore
hypotheses. Figure 2 shows compounds designed with different
conformational constraints necessary to determine the receptor-
bound conformation. The opiate activity of the synthetic
morphiceptin analogs was measured in the stimulated GPI bioassay
FIGURE 1
Selected Structures of Morphiceptin Analogs The numbering
scheme corresponds with that in the tables of biological data.
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for each morphiceptin analog, DADLE and morphine. The analogs
of isorphiceptin produced parallel dose-response curves in the
bioassay, consistent with their interaction at a common receptor
and full agonist activity (table 1).
The sensftfvfty of morphiceptin to naloxone antagonfsm was
studied in order to determine whether the agonist activity of
morphfceptin was mediated by the µ or opiate receptor.
Typically, µ agonists are more sensitive to naloxone than
agonists. but both are antagonized by high doses of naloxone, in
the GPI bioassay (Lord et al. 1977). Dose-response studies were
performed with Met-enkephalin, a µ agonist in this bfoassay;
ethylketocyclazocine. a agonist in this bioassay; and
morphiceptin, with and without three concentrations of
naloxone. Parallel shifts in the dose-response curves were
observed for morphfceptin with increasing concentrations of
naloxone, i.e., the same slope and maxima, as well as Met-
enkephalin and ethylketocyclazocine, and a Schild plot of the
data were linear with a slope that was not significantly
different from unity.
These results are consistent with naloxone acting as a
competitive antagonist of morphiceptin (Lord et al. 1977). The
pA2, and Ke for naloxone antagonism of the agonist activity of
morphiceptin were not significantly different-from that of Met-
enkephalin (P<O.O5), a µ agonist in this bioassay, but were
significantly different from that of ethylketocyclazocine
(P<O.O5), a agonist in this bioassay. The activity of
morphiceptin is mediated by a receptor that has a similar
affinity for naloxone as the receptor that mediates the activity
of Met-enkephalin, but a different affinity from the receptor
that mediates the activity of ethylketocyclazocine.
A competition binding assay was used to determine the affinity
of the synthetic morphfceptin analogs for the µ and 8 opiate
receptors. The appropriate combinations of opiate receptor
selective radioligands and sources of opiate receptor were used
to obtain the most accurate measure of affinity for each
receptor. µ-Receptor affinity was measured in a competition
binding assay using [3H]-DHM, a relatively specific µ ligand
(Chang and Cuatrecasas 1979; Gillan et al. 1979), and rat brain
homogenate, which contains a mixed populatfon of opiate
receptors (Chang and Cuatrecasas 1979; Chang et al. 1981).
Receptor affinity has often been measured in a competitive
binding assay using  [3H]-DADLE, a moderately -specific lfgand
(Kosterlitz et al. 1981), and rat brain homogenate.
However, since [3H]-DADLE has an affinity for the receptor
that is only fivefold to tenfold greater than the affinity for
the µ receptor at concentrations required for a reasonable
signal in a competition binding assay, a significant proportion
of the ligand occupies the µ receptor as well as the receptor
at the concentrations required for the competition
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binding-assay. As a result, competition binding assays with
highly µ- specific competing ligands, such as morphfceptin.
produce shallow or biphasic displacement curves and afford
inaccurate estimates of the true -receptor affinity (Chang et
al. 1981a, 1981b). Since more selective radiolfgands are not
yet commercially available. an alternative technique was
chosen. [3H]-DADLE was used, but with NG108-15 murine
neuroblastoma x rat glioma and NMB human neuroblastoma cell
homogenates, both homogeneous sources of receptors (Chang et
al. 1978; Simantov and Snyder 1976; Ard and Gottlfeb, in
preparation).
FIGURE 2
Selected Structures of Morphiceptin Analogs The nunbering
corresponds with that in the tables of biological data.
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TABLE 1
Summary of Biological Activity of the Morphiceptin Analogs as
Determined in the Stimulated Guinea Pig Ileum Bioassay
Compound IC50/nM
a SEM %Rel.Pot.b SEM
aAll compounds for which the IC was determined were full agonists, and
their activity was fully reversible by 200 nM naloxone.
b%Relative potency (%Rel.Pot.) was normalized to morphiceptin.
cCompounds for which an IC could not be determined were also
inefiective in antagonizing DA The IC50 and %Rel.Pot. are expressedE.
as the geometric mean and standard error of the mean (SEM). The IC50
and %Rel.Pot. were determined according to the described experimental
methods.
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Competition binding isotherms were performed with each
morphiceptin analog, DADLE and morphine, using each combination
of radfolfgand and receptor preparation. The Kd was calculated
with the computer program LIGAND (Munson and Rodbard 1930) for
each analog from the competition binding assays using  [3H]-DHM
and rat brain homogenate, and using [3H]-DADLE and NG108-15 cell
homogenate. The competition binding isotherms were monophasic
and were best fit by the single site model (data not shown).
The structure-activity relationships for morphiceptin analogs in
the GPI bioassay and the µ-receptor binding assay will be
discussed together since there was such a strong correlation
between agonist potency and affinity. The correlation of the
log of the %relative potency and the log of the %relative
affinity for the morphiceptin analogs produced a correlation
coefficient of 0.93. This suggests that the changes in agonist
potency for this series are due to changes in affinity. In no
cases were partial agonists or antagonists encountered in the
bioassay. A partial agonist would be expected to show a
decrease in potency without a decrease in affinity, and would
lie off the line of correlation of affinity and potency. This
correlation also suggests that the receptor in the bioassay and
binding assay are very similar, even considering that they are
from different species and different parts of the nervous
system.
The structure-activity relationships for morphiceptin at the mu
opiate receptor support the µ-receptor pharmacophore hypothesis
stated previously for morphiceptin. The smallest fully active
fragment of morphiceptin is Tyr-Pro-NH(phenethyl) [11],
suggesting that the terminal Pro-NH2 is not required for
activity. This indicates that pharmacophoric groups are limited
to this fully active fragment of morphiceptin.
The Tyr1 tyramine group of morphiceptin is very important for
activity. The elfmination [2] or methylation [5] of the
phenolic hydroxyl and the N-acetylation of the nitrogen [4]
results in a dramatic loss in activity. The effects of these
modifications suggest that the phenolfc hydroxyl could be
interacting with the receptor via a hydrogen bond or ionic
interaction.
The Phe3 phenyl group of morphiceptin is also very important for
activity. Reduction of the phenyl group to a cyclohexyl
derivative [6] results in a dramatic loss of activity,
suggesting an important role for a flat hydrophobic and,
perhaps, aromatic group. Nitratfon of the phenyl group [7] also
results in a dramatic loss in activity, possibly as a result of
negative steric or electronic interactions with the receptor.
In additfon, nitration of the D-Phe [9] and truncated phenethyl
amide [13] analogs of morphfceptin also resulted in a dramatic
loss in activity, suggesting that even analogs with different
possible conformational freedom can not fold to accommodate the
nftro group on the phenyl ring. Clearly, the activity of
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morphiceptin is particularly sensitive to modificatfons of the
Phe3 phenyl group.
The remainder of the morphiceptin structure besides these three
critical groups, the phenol group of Tyr1, the amine group of
Tyr1, and the phenyl group of Phe3, probably serves as a linker
and orients these three pharmacophoric groups relative to each
other. The loss of activity for the D-Tyr1 analog of
morphiceptin [3] is interesting and probably represents a form
of stereospeciffcity much like that seen with the classical
opioids (Pert and Snyder 1973a, 1973b; Cox and Weinstock 1966;
Kosterlftz et al. 1973). The relative diastereomeric
selectivity for the -carbon of the morphiceptin Tyr1 is about
50. With a minimum three receptor subsites, the receptor would
be expected to be able to recognize the chfralfty in a ligand.
The remainder of the backbone may interact with the receptor
directly, but the direct interaction is not necessary for
activity. This is difficult to prove, but a few analogs are
consistent with this conclusion. The high activity of the D-
NMeAla2 [22], D-Ala2 [21]. NMePhe3 [19], and tPhpro3 [17]
analogs of morphiceptin suggests that the µ receptor is somewhat
tolerant of changes in steric volume of the backbone of
morphiceptin. Furthermore, the high activity of the NMePhe3
[l9] and tPhpro3 [17] analogs of morphiceptin suggests that the
amide nitrogen is not functioning as an important hydrogen bond
donor in the interaction with µ opiate receptor. There is a
requirement for a nontyramine phenyl group for the activity of
morphiceptin similar to enkephalin and selected nonpeptfde
opiates (Morley 1980; Fournie-Zaluski et al. 1981; Gacel et al.
1981; Simon et al. 1981; Ophefm and Cox 1976), suggesting that
the nontyramine phenyl groups are also interacting with a common
subsfte of the opiate receptor. However, the loss of activity
upon nitration of the phenyl group in morphiceptin, as opposed
to the enhancement of activity upon nitration of the
corresponding phenyl group in enkephalin (Fauchere et al. 1983;
Schiller et al. 1983), suggests that either the phenyl group of
morphiceptin binds to a different subsfte of the µ opiate
receptor than does the corresponding phenyl group of enkephalin,
or the phenyl group binds in an entirely dffferent orientation
to the same subsite of the µ opiate receptor. In addition, the
nitration of the D-Phe3 [9l and phenylamfde [13] analogs of
morphiceptin also decreases activity. Since these analogs might
be expected to have different conformational possibflfties that
would allow a unique orientation of the phenyl group relative to
the tyramine group, and a decrease of the repulsive interactions
between the receptor and the nftro group. the inactivity of the
nitrated analogs of morphfceptin is more likely a result of
interaction with a unique receptor subsite. It would be
interesting to examine the activity of the meta-NO2 Phe
3 and
ortho-N02Phe
3 analogs of morphiceptin and enkephalin to further
test the possibility that the phenyl group of morphiceptin is
interacting with a unique opiate receptor subsite.
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Many constraints in conformation that were imposed in
morphiceptin analogs by substitution for the Phe3 also
maintained or enhanced activity at the µ opiate receptor. Most
importantly, the 2-aminoindanyl amide analog of morphiceptin
[15] was much more active than morphiceptin. It is possible
that this increase of activity is a result of the favorably
constraint of the torsional angle equivalents of the x1 and x2
of the Phe3 of morphiceptin, since the indan ring has limited
flexibility. It is interesting that the 2-indanylamide analog
of morphiceptin [15] was active, but the homologous Ain3 analog
of morphiceptin [20] was inactive. Ain would be expected to be
able to mimic the 2-indanylamide. However, the extra Pro-NH2 in
the Ain3 analog [20], which was not present in the 2-
indanylamide analog [15], could be fixed in a region of space
that sterically disallows interaction the opiate
receptor. The trans-2-phenylcyclopropyl amide analog of
morphiceptin [23] was also as active as morphiceptin. In this
analog, the torsion angle equivalent to the x1 of the Phe of
morphiceptin is constrained by the cyclopropyl ring.
The tPhpro3 analogs of morphiceptin turned out to be very
interesting. One of the diastereomers was 200-fold more active
[l7] than the other [18]. Again, it is likely that the
difference in the activity of these diastereomers is a result of
the conformational constraints imposed. By analogy with
proline, the
Phe3, and x1
torsional angle equivalents of morphiceptin at
should be relatively fixed (Balasubramanian et
al. 1971; Madison 1977; Delaney and Madison 1982). and tPhpro is
likely to restrict the freedom of preceding torsional angle   of
Pro2 (Marshall and Bosshard 1972; Tonelli 1976). The two
isomers should differ significantly in the position of the
phenyl group relative to the tyramine group. Perhaps, the
different allowed positions of the phenyl relative to the
tyramine in the two isomers is the factor which determines
activity. It is also possible that one isomer is inactive
because of another repulsive interaction of a nonessential group
with the receptor. Unfortunately, the absolute configuration of
tPhpro in the active or inactive isomers is not yet known.
Certainly, the active diastereomeric tPhpro analog of
morphfceptin will be most important in defining the active
conformations of morphiceptin by conformational analysis.
Only selected analogs of morphiceptin were examined for
receptor binding affinity using the two different sources of
receptors. The major objective was to determine if the analogs
of morphiceptin that had a high affinity for the µ receptor had
an increased or decreased -receptor affinity, and therefore,
decreased or increased µ selectivity, relative to morphiceptin.
The tPhpro3 analog of morphiceptin [17]. which had hfgher
affinity for the µ receptor, had lower affinity for the
receptor than morphfceptin [1], and potentially increased
selectivity for the µ receptor, although an exact measure could
not be determined because of the extremely low affinity for the
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receptors. It is important to recognize that few opiofds
exhibit the extreme ectfvfty shown in table 2 for the mu
receptor as the tPhpro3 analog of morphiceptin [17], without
the sacrifice of affinity and potency at the µ receptor. It
will be important to demonstrate that this analog also exhibits
a very low affinity for the opiate receptor. as well as low
agonfst potency for the and receptors. This analog of
morphfceptin could prove to be most valuable as a selective tool
in the study of the role of the mu opiate receptor in mediating
the biological responses to opiofds.
TABLE 2
Summary of Morphiceptin Analog Binding Selectivity
for the µ and Opiate Receptor Sites
Compound Ki /Kd(µa) Kd /Kd(µa) Ki /Kd
1. Tyr-Pro-Phe-Pro-NH2 >49 >2,210
15. Tyr-Pro-NH(2-indanyl) 366 338 1.083
17. Tyr-Pro-Pro(trans phenyl)-  >558 >7,480 --
22. Tyr-D-NMeAla-Phe-Pro-NH 2
N(CH3)2 *HPLC fraction 1
25. Tye-D-Ala-Gly-Phe-D-Leu2
251 --
0.196 0.358 0.547
26. Morphine 155 155 0.998
aDHM in rat brain homogenate.
bDADLE in NG108-15 cell homogenates
cDADLE in NMB cell homogenates
Molecular Modeling
Opioid agonists and antagonists are recognized and bound by the
opiate receptors via important chemical groups, and in addition,
agonists activate the opiate receptors. There is a particular
bound conformation of an agonist or antagonist that is the most
thermodynamically stable for the receptor complex as a whole, with
noncovalent interactions between the receptor and the agonist or
antagonist optimized. Binding energy may be consumed in the
deformation of the agonist or antagonist conformation from the most
stable solution conformation. Therefore, it would seem to be
important to define this receptor-bound conformation in order to
design agonists and antagonists with the receptor-bound
conformation prestabilized in solution. The result should be an
increase in the thermodynamic stabflity of the receptor-bound
agonist or antagonfst complex and, thus, an increase in potency and
affinity. Furthermore, it should be possible to design agonists
and antagonists which take advantage of the subtle differences in
the conformational requirements of the subtypes of opiate receptors
and exhibit receptor-subtype selectivity.
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It is also important to realize that it is difficult to compare
noncongeneric molecules in terms of conformation, because their
chemical constitution is so different. For this reason, it is
important to define the chemical groups that are dominant in the
interaction with the receptor, i.e., the pharmacophore. Then the
noncongenerfc molecules can be compared in terms of the possible
orientations of the pharmacophore groups, rather than their
possible conformations. Again, it is likely that the different
subtypes of receptors may preferentfally interact with different
pharmacophoric groups and/or different relative orientations of the
pharmacophoric groups.
For rigid compounds, the relative orientation of the pharmacophoric
groups is envfronmentally independent, and, therefore, the relative
orientation of the pharmacophoric groups in states for which
conformational analysis can be performed (NMR, X-ray, etc.) will
not differ from that in the receptor-bound state. However, for
flexible compounds, e.g., opioid peptides and many nonpeptide
opioids, there are many possible orientations of the pharmacophorfc
groups populated to varying degrees, and the possible orientations
are also environmentally dependent. Without knowledge of the
environment or structure of the receptor site, it is difficult to
choose from the many possible receptor-bound orientations of the
pharmacophore groups, if, indeed. there is a single one. The most
likely orientation(s) of the pharmacophoric groups in states where
the conformational analysis is performed may not resemble that when
bound to the receptor.
It was originally thought that structure-activity studies of
morphiceptin would provide further insight into the recognition and
activation requirements at the µ opiate receptor involving
enkephalin, Tyr-Gly-Gly-Phe-(Leu,Met). Structural homology to
enkephalin suggested that morphiceptin interacted with the µ
receptor in the same way as enkephalin. If this was the case, the
structure-activity studies of morphiceptin could be combined with
those of enkephalin, further refining the pharmacophore model for
the highly flexible enkephalin analogs. Alternatively, if
morphiceptin did not interact with the opiate receptor in the same
way as enkephalin, structure-activity studies would have to proceed
independent of enkephalin.
Initially, a pharmacophore was proposed by considering the
structural homology of morphiceptin to enkephalin, and possibly to
the representative nonpeptide opioids, morphine, GPA1657 and PEO.
The Tyr1 tyramine of morphiceptin could potentially be equivalent
to the corresponding Tyr1 tyramine of enkephalin and the tyramine
of morphine, GPA1657, and PEO. In addition, the Phe3 phenyl of
morphiceptin could be equivalent to the Phe4 phenyl of enkephalin
and perhaps the nontyramine phenyl of GPA1657 and PEO. The Pro2
probably functions as a linker to orient the tyramine and the
phenyl relative to each other in the same way as the Gly2-Gly3 of
enkephalin, or the D-Ala2-Gly3 of the most potent enkephalin
analogs--perhaps the same way as the core structures of GPA1657 and
PEO. In order to determine if morphiceptin was simply an
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enkephalin analog and whether the Pro2 of morphiceptin was a
surrogate for the D-Ala2-Gly3 segment of enkephalin. the model
fragments N-acetylproline methylamide [I] and N-acetyl-D-alanine
methylamide [II] were examined using SEARCH. Sterically allowed
conformations were determined and, simultaneously, the vectors
produced by the methylamide nitrogen and carbon of [I] and [II]
were plotted relative to the fixed acetyl group. There was clearly
no intersection of the vector maps produced by the model peptides,
indicating that the N-acetyl and methyl amide groups of the model
peptides [I] or [III] were not superimposable in any of the
sterically allowed conformations. Clearly, the Pro of morphiceptin
is not a surrogate for the D-Ala-Gly segment of enkephalin. This
is consistent with the idea that if the tyramine and phenyl groups
of morphlceptin and enkephalin are interacting with the µ opiate
receptor in the same relative orientation, the backbones must be
very different, or the phenyl and tyramine groups are interacting
with the µ opiate receptor in a very different relative
orientation.
To further address the issue of whether the tyramine and phenyl of
morphiceptin and enkephalin can interact with the µ opiate receptor
in the same relative orientation, SEARCH was used in the same way
as for morphlceptin by creating orientation maps. Preliminary
results suggest that it may be possible for enkephalin to adopt a
conformation in which the relative orientation of the tyramine and
phenyl are similar to the corresponding constrained morphiceptin
analogs [15] and [l7/18]. However, further studies are required,
especially with the more rigid analogs of morphiceptin.
The conformationally constrained analogs of morphlceptin. Tyr-Pro-
NH(2-indanyl) [15], and Tyr-Pro-tPhpro-N(CH3)2 [17/18] exhibit high
activity at the µ opiate receptor. It was assumed that the
tyramine and phenyl groups of these analogs, like their parent
compound, morphlceptin [1] were similarly important for activity
and interact with the same subsites of the µ opiate receptor as
morphiceptin [1]. In other words, it was assumed that these
compounds have a common µ-receptor pharmacophore.
SEARCH was used to determine the common relative orlentations of
the tyramine and phenyl groups produced by the sterically allowed
conformations of [15] and [17/18]. The studies followed four
possible pathways in order to consider the possibility for the
cis/trans isomerization for the Tyr-Pro amide bond in both [15] and
[17/18] (Liakopoulou-Kyriakiades and Galardy 1979; Deslauriers et
al. 1979). As a result, there were four possible orientation maps
describing the common relative orientations of the tyramine and
phenyl groups produced by the sterically allowed conformations of
[15] and [17/18].
The conformational analysis was simplified by assuming that the
tyramine of morphiceptin interacts with the µ opiate receptor with
the same relative orientation of the amine and phenol groups as for
the rigid opioids, morphine, GPA1657, and PEO. This conformation
of tyrosine does not invoke any strong repulsive van der Waals
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contacts. A similar assumption was made in molecular modeling
studies of enkephalin (Gorin and Marshall 1977) and was actually
supported by the high activity of enkephalin analogs in which the
tyrosine was substituted with conformationally rigid subpieces of
morphine (Shaw and Turnbull 1978; Deeks et al. 1983; Cardinaux and
Pless 1984). According to molecular mechanics calculations and
molecular graphics comparisons, these constrained tyrosine
substitutes do constrain the tyramine to a low energy conformation
which places the phenol and amine in the same relative orientation
as observed in morphine, GPA1657, and PEO.
Using SEARCH, four orientation maps were determined according to
the four strategies. Six distances were used to define the
relative orientations of the phenyl relative to the tyramine
(figure 3). All four pathways produced orientation maps that were
circumscribed by maximum and minimum distances that differed by one
to five angstroms (table 3). The orientation maps were visualized
by graphical plots of dimensions 1-3 and 4-6 where the axes
represent the defined distances (figure 4). These orientation maps
demonstrate that these analogs of morphiceptin may interact with
the opiate in four possible sets of common relative orientations of
the tyramine and phenyl groups produced by conformations that were
energetically reasonable, i.e., no repulsive intramolecular van der
Waals contacts. It is important to observe that the superimposed
orientation maps 1 and 2, and similarly 3 and 4, for the different
tPhpro3 diastereomeric morphiceptin analogs did not intersect
significantly, suggesting that the difference in activity between
these analogs is a result of the different allowed orientations of
the phenyl group relative to the tyramine group. Identification of
the active configuration of tPhPro will determine which of the
orientation maps describes the relative orientations of the
tyramine and phenyl groups of morphfceptin required for activity at
the µ opiate receptor.
.
Conformations of [l51] and [17/18] derived from each of the
orientation maps were selected, and MAXIMIN was used to determine
four possible conformations of [l5] and [17/18] in which the
tyramine and phenyl groups were superimposed with the least energy
of deformation. This is desirable because of the increment used in
SEARCH which may not optimize overlap of pharmacophoric groups.
Again, there were four unique possibilities because of the
cis/trans Tyr-Pro isomerism and the ambiguity in the absolute
configuration of the tPhpro of [17/18] (figure 5). Identification
of the absolute configuration of tPhpro in [17/18] and the amide
configuration which is required for activity at the µ receptor will
determine which conformation or relative orientation of the
tyramine and the phenyl is most important for activity at the µ
opiate receptor.
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FIGURE 3
The Opiofd Pharmacophore and the Defined
Orientation Map Distances 1-6
TABLE 3
Orientation Map Distance Ranges
Defined Distance
Number
Distance Range
(Minimum and Maximum in Angstroms)
Orientation Map*
1 2 3 4
1 9 2 9 8 10 4-11 1 6.9-87 7 2 9 1
2 10.1-10.7 11.1-12.2 9.2-11.7 8.2-10.9
3 10.4-11.8 12.0-13.1 7.9-10.8 9.3-10.7
4 7.9-9.7 10.5-11.5 5.6-9.4 7.7-9.8
5 9.2-12.0 11.5-13.1 6.0-12.4 7.8-11.4
6 9.6-12.0 12.2-15.9 6.2-11.8 9.2-11.4
*Map 1 = Pro2-trans, L-tPhpro3; Map #2 = Pro2-trans, D-tPhpro3; Map #3 =
Pro2-Cis, L-tPhpro3; Map #4 = Pro2-Cis, D-tPhpro3.
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FIGURE 4
Orientation Maps for Morphiceptin Analogs
The orientation maps are plotted as distances #1-3 (left) and distances
#4-6 (right). The top set of maps correspond to Map 2 of table 3 and
the bottom set to map 1.
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FIGURE 5
Conformations of Tyr-Pro-NH(2-indanyl) and
Tyr-Pro-L-tPhpro-N(CH3)2, with the Tyr-Pro
Amide in the Trans Configuration Superimposed
If one examines the four possible conformations of [15] and [l7/l8]
previously calculated in relation to GPA1657 and PEO, it is
possible to conclude that morphfceptin may not interact with the
opiate receptor in the same way as enkephalin. Gorin and Marshall
(1977) proposed that enkephalin interacted with the µ opiate
receptor in a conformation in which the tyramine and phenyl groups
were superimposed over the corresponding groups of GPA1657.
Clearly, the constrained analogs of morphiceptin cannot adopt a
conformation in which both the tyramine and phenyl are superimposed
over the corresponding groups of GPA1657. This suggests that the
tyramine of morphfceptin and enkephalin interact with the same
subsites of the µ opiate receptor, and that the phenyl of
morphiceptin and enkephalin may interact with a different subsite
of the µ opiate receptor.
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The suggestion that the corresponding tyramine groups of
norphiceptin and enkephalin interact with a common primary binding
site and that the corresponding phenyl groups interact with dif-
ferent secondary sites of the µ opiate receptor is also consistent
with the previously described structure-activity relationships of
morphiceptin and enkephalin. The activity of morphiceptin and
enkephalin at the µ opiate receptor is generally sensitive to the
chemical modification of the tyramine and phenyl groups. However,
the activity of morphfceptin decreases dramatically with the
nitration of the phenyl group, whereas the activity of enkephalin
increases with the nitration of the phenyl group. It will be
important in the future to actually see if the nitration of the
constrained analogs of morphiceptin also decreases activity at the
µ receptor in order to insure that these analogs themselves
interact with the receptor in the same way as morphfceptin, an
underlying assumption in all these molecular modeling studies.
Also, it will be important to determine if nitration of the ortho
and meta positions of Phe3 or morphiceptin, perhaps, increases the
activity of morphfceptin, as does paranftration of Phe4 of
enkephalin. This would suggest that the phenyl groups of
morphiceptin and enkephalin interact with the same sites, but in a
different  orientation.
CONCLUSIONS
The structure-activity studies of morphfceptin clearly demonstrated
that the minimal active structure of morphfceptin for µ-receptor
activity, i.e.. binding affinity and agonist potency, was Tyr-Pro-
NH(phenethyl). Furthermore, unmodified tyramine and phenyl groups
were required for activity at the µ receptor. These requirements
paralleled the similar requirements for the unmodified tyramine and
phenyl groups in the enkephalin. the requirements for the
unmodified tyramine in the nonpeptide opioids PEO and GPA1657, and
the requirement of the phenyl group of PEO for superpotency.
However, the activity of morphiceptin would not tolerate the
nitration of the phenyl group, whereas the activity of enkephalin
was enhanced by the nitration of the phenyl group.
The possibility of multiple divergent modes of interaction of
molecules with opiate receptors has been described as accounting
for the structure-activity relationships of the multitude of
structurally dissimilar nonpeptide opiofds. It is possible that
the phenyl group of these different opioids may bind to a variety
of subsites or accessory sites of the µ opiate receptor, in order
to confer significant activity through sufficient binding energy.
Thus, a µ-receptor pharmacophore for morphiceptin analogs
consisting of tyramine and phenyl groups oriented in one of several
specific orientations relative to each other was suggested from the
computer modeling studies of morphiceptin structure-activity
relationships.
The computer-modeling studies of morphfceptin, although in the
preliminary stages, helped to refine the pharmacophore hypothesis
in three dimensions and suggested some possible relationships
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between morphiceptin, enkephalin, and selected nonpeptide
opiates. The systematic analysis of the conformations of the most
conformationally constrained analogs of morphiceptin demonstrated
that there were a limited number of possible common relative
orientations of the phenyl and tyramine groups in which there were
no intramolecular repulsive van der Waals contacts. The common
orientations of these groups as determined by the conformational
analysis are candidates for the receptor-bound orientation, i.e.,
the µ-receptor pharmacophore for morphiceptin.
R E F E R E N C E S
Ard. M., and Gottlieb, D. In preparation.
Balasubramanian, R.; Lakshminarayanan. A.V.; Sabesan, M.N.; Tegoni,
G.; Venkatesan, K.; and Ramachamdran, G.N. Studies on the
conformation of amino acids. VI. Conformation of the proline
ring as observed in the crystal structure of amino acids and
peptfdes. Int J Protein Res 3:25-33, 1971.
Benedetti, E. Structure and conformatfon of peptides: A critical
analysis of crystallographic data. In: Goodman, M., and
Meienhofer, J., eds. Peptides Proceedings of the 5th American
Peptide Symposium. New York: Wiley, 1977. pp. 257-273
Benson, J.R.; and Hare, P.E.; Phthalaldehyde: Fluorogenic
detection of primary amines in the picomole ranae. Comparison
with fluorescamine-and ninhydrin. Proc Natl Acad Sci USA
72:619-622,  1975.
Bohlen, P., and Mellet, M. Automated fluorometric amino acid
analysis: The determination of proline and hydrovproline. Anal
Biochem 94:313-321, 1979.
Bosshard, H.E.; Barry, C.D.; Fritsch. J.H.; Ellis, R.A.; and
Marshall, G.R. Burlesk:The use of systematic conformational
searches- in chemistry. In: Proceedings of the 1972 Summer
Simulation Conference. ????, 1972. p. 58
Cardinaux, F., and Pless, J. In: Ragnarrson, U., ed. Peptides
1984: Proceedings of the 18th European Petide Symposium Stock
holm: Almquist & Wiksell, 1985. pp. 18-22.
Chang, K.-J.,' and Cuatrecasas, P. Multiple opiate receptors.
Enkephalins and morphine bind to receptors of different
specificity. J Biol Chem  254:261O-2618, 1979.
Chang, K.-J.; Miller and Cuatracasas. P. Interaction of
enkephalin with opiate receptors in intact cultured cells. Mol
Pharmacol 14:961-970, 1978.
Chang, K.-J.; Cooper, B.R.; Hazum, E.; and Cuatrecasas, P.
Multiple opiate receptors: Different regional distribution in
the brain and differential binding of opiates and opioid
peptides. Mol Pharmacol 16:91-104, 1979.
Chang. K.-J.;Hazum, E.; and Cuatrecasas, P. Novel opiate binding
sites selective for benzomorphan drugs. Proc Natl Acad Sci
78:4141-4145, 1981 USA.
Chang, K.-J.; Killian, A.; Hazum. E.; Cuatrecasas, P.; and Chang.
J.K. Morphiceptin (NH4-Tyr-Pro-Phe-Pro-CONH2): A potent and
specific agonist for morphine (µ) receptors. Science 212:75-77,
1981B.
226
Cheng. Y.-C., and Prusoff. W.H. Relationship between the
inhibition constant (KI) and the concentration of inhibitor
which causes 50 percent inhibition (I50) of an enzymatic
reaction. Biochem Pharmacol 22:3099-3108, 1973.
Cox. B.M.. and Weinstock. M. The effect of analgesic drugs on the
release of acetylcholine from electrically stimulated guinea-pig
ileum. Br J Pharmacol 27:8l-92. 1966.
Cox. D.A.; Johnson, A.W.; and Mauger, A.B. A modified proline
synthesis. J Chem Soc,  Organic: 5024-5029, 1964.
Deeks, T.; Crooks.; and Waigh, R.D. Synthesis and analgesic
properties of two Jeucine-enkaphalin analogues containing a
conformationally restrained N-terminal tyrosine residue. J Med
Chem 26:762-765, 1983.
Delaney, N.G. and Madison, V. Novel conformational distributions
of Rethylproline peptides. J Am Chem Soc 104:6635-6641, 1982.
DeLean, A.P.; Munson, P. J.; and Rodbard, D. Simultaneous analysis
of families of sigmofdal curves: Application to bioassay,
radioligand assay, and physiological dose-response curves. Am J
Physiol 235:E97-E102, 1978.
Des-Jauriers. R.; Becker. J.M.; Steinfeld. A.S.; and Naider. F.
Sterfc affects of cis-trans isomerism
proline oligopeptides A 13C-NMR:
heterogeneity in linear tripeptides.
1979.
Ellington, J.J., and Honigberg, I.L.
methylproline and 2-methylornithine.
1974.
Fauchere, J.-L.; Pfenninger, S.; Do,
Schfller, P.W. Synthesis and opiate
on neighboring residues in
study of conformational
Biopolymers 18:523-538,
The synthesis of 2-
J Org Chem 39:104-106,
K.Q.; Lemieux. C.; and
activity in vitro of five
Acta 66:1053-1060, 1983
new p-nitrophenylalanine4-enkephalin-like petides. Helv Chim
Fournie-Zaluski, M.-C.; Gacel, G.; Mafgret, B.; Premilat, S.; and
Roques, B.P. Structural requirements for specific recognition
of µ or 8 opiate receptors. Mol Pharmacol 20:484-491, 1981.
GaceJ, G.; Fournie-Zaluski, M.-C Fellion, E.; and Roques, B.P.
Evidence of the preferential involvement of receptors in
analgesia using enkephalins highly selective for peripheral µ or
8 receptors. J Med Chem  24:1119-1124, 1981.
Gillan, M.G.C.; Kosterlitz,  H.W.; and Paterson, S.J. Comparison of
the binding characteristics of tritlated opiates and opiofd
peptides. Br J Pharmacol 70:481-490, 1980. pp. 3.9.
Gorin, F., and Marshall G.R Proposal for the biologically active.
conformation of opiates and enkephalins. Proc Natl Acad Sci USA
74:5179-5183, 1977.
Gyang, E.A.. and Kosterlitz, H.W. Agonist and antagonist actions
of morphine-Jike drugs on the guinea pig isolated ileum. Br J
Pharmacol 27:514-527, 1966.
Hamada, Y.; Shioirf. T.; and Yamada, S. Application of diphenyl
phosphorazidate (DPPA) to the synthesis of the N-terminal
hexapeptide of the vasoactive intestinal peptfde. Chem Pharm
Bull (Tokyo) 25:221-223, 1977.
Heinrickson, R.L., and Meredith, S.C. Amino acid analysis by
reverse-phase high-performance liquid chromatography: Precolumn
derivitization with phenylisothiocyanate. Anal Biochem 136:65-
74, 1984.
227
Konfg, W., and Geiger, R. Eins neue Methode zur Synthesis von
Peptiden: Aktiviering der Carboxylgruppe mit
Diccyclohexylcarbodiimide unter Zusatz von 1-Hydroxy-
benzotriazolen. Chem Ber 103:788-798, 1970.
Kosterlitz, H.W., and Watt, A.J. Kinetic parameters of narcotic
agonists and antagonists with particular reference to N-
allylnoroxymorphone (Naloxone). Br J Pharmacol 33:266-276,
1968.
Kosterlitz, H.W.; Lord, J.A.H.; and Watt, A.J. Morphine receptor
in the myenteric plexus of the guinea pig ileum. In:
Kosterlitz, H.W.; Collier. H.O.J.; and Villarreal. J.E.. eds.
Unisveristy Press, 1973. pp. 45-61
Agonist and Antagonist Actions of Narcotic Drugs.. Baltimore:
Kosterlitz,  H.W.; Paterson, S.J.; and Robson, L.E.
Characterization of the K-subtype of the Opiate receptor in the
guinea-pig brain. Br J Pharmacol 73:939-949, 1981.
Liabanawski, J., and Marshall, G.R. In preparation.
Liakopoulou-Kyriakiades, M., and Galardy, R.E. S-Cfs and s-Trans
isomerism of the His-Pro peptide bond in angiotensin and
thyroliberin analogues. Biochemistry 18: 1952-1957, 1979.
Lord, J.A.H.; Waterfield. A.A.; Hushes, J.; and Kosterlitz. H.W.
Endogenous opiofd peptides:. Multitiple agonists and receptors.
Nature 267:495-499, 1977.
Madison, V. Flexibiity of the pyrrolidine ring in proline
peptides. Biopolymers 16:2671-2692, 1977.
Marshall, G.R., and Bosshard. H.E. Angfotensin II: Studies on the
biologically active conformation. Circ Res (Supp. 30/31):143-
150, 1972.
Marshall, G.R.; Bosshard, H.E.; Vine, W.H.; Glfckson, J.D.; and
Needleman. P. Angfotensin II: Conformation and interaction
with the receptor. In: Fanelli. G-M.. and Wesson. L.G.. eds.
Baltimore University Recent Advances in Renal Physiology and
Pharmacolgy. Park Press, 1974, pp. 215-256
Marshall. G.R.; Barry, C.D.; Bosshard, H.E.; Dammkoehler, R.A.; and
Dunn,- D.A. The conformational parameter in drug design: The
active analog approach. In: Olson, E.C.. and Christoffersen.
R.E., eds.
Washinqton.
Computer Aided Drug Design. ACS Symp. Vol. 112
Marshall, G.R,; Humblet, C.; Van Opdenbosch,  N.; and Zabrockf, J.
Peptide bond modification and its effect on conformational
mimicry. In: Rich, D., and Gross, E., eds. Peptides: Syntesis
Structure Function. Springfield: Pierce, 1985. pp. 559-673
Matsueda, G.R., and Stewart, J.M.  A p-metylbenzhydrylamine resin
for improved solid-phase synthesis of peptide amides. Peptides
2:45-50, 1981.
Mauger, A.B.. and Ross, W.C.J. The preparation and properties of
some Di-2-chloroethylaminoaryl substituted hydantoins and
related amino acids. Biochem Pharmacol 11:847-858, 1962.
Momany, F.A.; McQuire. R.F.; Burgess, A.W.; and Scheraga, H.A.
Energy parameters in polypeptfdes. VII. Geometric parameters,
partial atomic charges, nonbonded interactions, hydrogen bond
interactions, and intrinsic torsional potentials for the
naturally occurring amino acids. J Phys Chem 79:2361-2382,
1975.
228
Morley, J.S. Structure-activity relationships of enkephalin-like
peptides. Annu Rev Pharmacol Toxicol 20:81-110, 1980.
Munson, P.J.. and Rodbard, D. Ligand: A versatile computerized
approach for characterization of ligand-binding systems. Anal
Biochem 107:220-239, 1980.
Nemethy, G.; Pottle, M.S.; and Scheraga, H.W. Energy parameters in
polypeptides. 9. Updating of geometrical parameters, nonbonded
interactions, and hydrogen bond interactions of the naturally
occurring amino acids. J Phys Chem 87:1883-1887, 1983.
Opheim, K.E., and Cox, B.M. Stereaspecific interaction of the
quaternized opiate, -N-methyllevorphanol, with opiate receptors.
J Med Chem 19:857-858,  1976.
Pert, C.B.,and Snyder, S.H. Properties of opiate-receptor binding
in rat brain. Proc Natl Acad Sci USA 70:2243-2247, 1973a.
Pert, C.B., and Snyder, S.H. Opiate Receptor: Demonstration in
nervous tissue. Science 179:1011-1014, 1973b.
Pietta, P.G.; Cavallo, P.F.; Marshall, G.; and Pace, M.
Benzhydrylamino polymers for the preparation of C-terminal
peptide amides. Gazzetta Chimica Italiana 103:483-489, 1973.
Rivfer, J.; McClintock, R.; Galyean, R.; and Anderson, H.
Reversed-phase high-performance Jfqufd chromatography:
Preparative purification of synthetic peptides.
288:303-328, 1984.
J Chromatogr
Rodbard, D., and Frazfer, G.R. Statistical analysis of radioligand
assay data. In: O'Malley, B.W., and Hardman, J.G., eds. Meth
Enzymol XXXCII, Hormone Action, Part B. Peptide Hormones. New
and Tretter, J.R.
c Press, 1972. pp.3-22.
Sarges, R., Synthesis of aryl-substituted 1,3-
and 1,4-diazocine derivatfves. J Org Chem 39:1710-1716, 1973.
Scatchard, G. The attraction of proteins small molecules and
ions. Ann NY Acad Sci 51:660-672, 1949.
Schiller, P,W,; Nguyen, T.M.-D.; DiMaio. J.; and Lemfeux. C.
Comparison of mu-, delta-, and kappa-receptor binding sites
through pharmacological evaluation of p-nftrophenylalanine
analogs of opioid peptides. Life Sci 33:(Supp. 1): 319-322,
1983.
Shaw, J., and Turnbull, J. In vitro profile of some opiofd
pentapeptide analogues. Eur J Pharmacol 49:313-317, 1978.
Sheehan, J.C.; Preston, and Crufckshank, P.A. A rapid
synthesis of olfgopeptfde derivatives without isolation of
intermediates. J Am Chem Soc 87:2492-2493, 1965.
Sfmantov, R., and-Snyder, S.H. Morphine-like peptides, leucine
enkephalin and methionine enkephalin: Interactions with the
opiate receptors. Mol Pharmacol 12:987-998, 1976.
Simon. L.D.; Simon, F.R.; Mohasci, E.; Berger, L.; and Simon, E.J.
Effect of the position of the phenolic group in morphinans on
their affinity for opiate receptor binding. Life Scf 28:2769-
2772, 1981.
Tam, J.P.; Heath, W.F.; and Merrifield, R.B. SN2 deprotectfon of
synthetic peptides with a low concentration of HF in dimethyl
sulfide. Evidence and application in peptide synthesis. J Am
Chem Soc 105:6442-6455, 1983.
Tonelli, A.E. The effects of isolated N-methylated residues on the
conformational characteristics of polypeptfdes. Biopolymers
15:1615-1622, 1976.
229
White, D.N.J. Mol Struct Diff Meth 6:38-62, 1978.
Wissmann, H., and Kleiner, H. New peptide synthesis. Angew Chewm
Int Ed Engl 19:133-134, 1980.
ACKNOWLEDGMENTS
Dr. Duane Goldman synthesized and made available the trans
phenyl-proline analog used in this study. This work was supported
in part by a grant from the Monsanto Fund and by grants GM24483 and
2-T32-GM07200 from the National Institutes of Health.
AUTHORS
Raoul D. Nelson, Ph.D.
David I. Gottlieb, Ph.D.*
T.M. Balasubramanian, Ph.D.
Garland R. Marshall, Ph.D.
Department of Physiology and Biophysics, and
Department of Anatomy and Neurobiology
Washington University School of Medicine
St. Louis, Missouri 63110
230
Mechanistic Structure-Activity Studies of
Peptide and Nonpeptide Flexible Opioids:
An Interdisciplinary Approach
Gilda H. Loew, Ph.D.; Lawrence Toll, Ph.D.; Edward
Uyeno, Ph.D.; Alice Cheng, Ph.D.; Amrit Judd, Ph.D.;
John Lawson, Ph.D.; Christopher Keys, B.S.; Peter
Amsterdam, B.A., B.S.; and Wilma Polgar, M.S.
SUMMARY
In this chapter, results obtained using an interdisciplinary
approach to investigate opioid narcotic analgesic agonism and
antagonism are presented. In particular, this approach is
illustrated by studies conducted on two specific classes of
flexible opioids: peptides and 3-phenylpiperidines. For each
class, the work discussed is a continuation of the two major themes
of our past theoretical studies complemented by more recent
experimental efforts involving medicinal chemistry and receptor and
animal pharmacology.
One major focus of our past activities has been the use of theo-
retical chemistry techniques to characterize common molecular fea-
tures among diverse classes of fused-ring and flexible opioids
leading to high µ-receptor affinity and analgesic activity. A
second major theme has been the identification of molecular deter-
minants which modulate the extent of analgesic agonist and
antagonist activity in a given opioid, and the design of analogs
with mixed agonist/antagonist activity.
Continuing these themes, we report here theoretical calculations,
analog synthesis, receptor binding, and in vivo animal studies of a
series of 3-pheoylpiperidines and peptide opioids. In addition, we
report, for the first time, preliminary attempts to ideotify
peptide conformers leading to high affinity at -receptors.
2 3 1
THEORETICAL AND EXPERIMENTAL STUDIES OF 3-ARYLPIPERIDINES:
DETERMINATION OF MOLECULAR FEATURES LEADING TO µ-RECEPTOR SITE
AFFINITY AND MODULATION OF ANALGESIC AGONIST/ANTAGONIST ACTIVITY
The discovery of opioid analgesic properties in meperidine aroused
interest in other classes of phenylpiperidines. In particular, 3-
arylpiperidins congenere have been synthesized and tested in
several laboratories (Kugita et al. 1964, 1965; Iorio and Casy
1978; Jacoby et al. 1981; Cheng et al. 1984). The known structure-
activity data for two representatives of this class of compounds,
3R=CH3 and COOC2H5-( meperidines),are summarized in table 1
(Kugita et al. 1965; Iorio and Casy 1978; Jacoby et al. 1981). As
seen in this table, this class of opioids exhibits structure-
activity profiles markedly different from those of the rigid
opiates, with antagonist activity absolutely requiring a phenolic-
OR, and being further modulated by 2-CH3, and 3-R groups, without
the requirement of N-substituent variation.
Using the semiempirical quantum mechanical method Perturbative
Configurstion Interaction using Localized Orbitals (PCILO) (Diner
et al 1969), we have calculated the energy-conformation behavior
and electronic structure of analogs in this class of opioids in an
attempt to explain their structure-activity profile in terms of
fundamental opiate-receptor interactions.
The results of these calculations, also briefly summarized in table
1, together with their known activity profiles, led to postulated
pharmacophores, i.e., conformations and orientations at the µ-
receptor site that could initiate analgesic agonist and antagonist
activity.
TABLE 1
Calculated Low Energy Isomers and Observed
Pharmacological Activity for N-CH3-3-
Phenylpiperidines
Activity (Agonist/Antagonist)
Low Energy
3-R 2-R Conformer No OH (m+ H ) (p-OH)
CH3 H ND wk ag/ND N D
-CH3 N D inact/ant N D
-CH3 EQ N D inact/ant N D
COOEt H
-CH3
EQ ag/inact ag/ant wk ag/inact
ND N D N D
-CH3
EQ
EQ N D N D ND
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Specifically, for all the -aeperidines studied, only one low
energy conformer was found. This conformer is a piperldine-chair,
with the pheoyl group equatorial. No stable conformer with the
pheoyl axial or piperidine boat form could be found. Thus, as
shown in figure 1, we have proposed that this conformer could
initiate both analgesic agonist and antagonist activity by binding
to a µ-receptor in two diffareot (bimodal) orleotations. In this
figure, the proposed antagonist pharmacophore (I) satisfies our
hypothesized minimum requirement for antagonism: an orientation in
which its (m-OH)-pheoyl group can interact at the µ-opiate receptor
in a manner similar to that of fused-ring opiates (shown in dotted
lines for comparison). The agonist pharmacophore II satisfies the
minimum proposed requirement for analgesic activity: interaction
of the protonated piperidine amine group with an anionic receptor
subsite as in fused ring opiates. In both of these pharmacophores,
the ester chain can provide additional polar interactions with
cationic receptor sites.
I . Antagonist I I . Agonist
FIGURE I
Calculated Molecular Electrostatic Potential Minima
(kcal/mol) Around Meperidine Oxygen Substituents in
Proposed Agonist and Antagonist Pharmacophores
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To model receptor interaction in the agonist and antagonist modes,
molecular electrostatic potentials (Weinstein et al. 1973) in the
vicinity of the (m-OH) and ester substituents were calculated with
and without a protonated amine interaction with a model anionic
receptor site. The negative potentials calculated in the plane of
the phenol ring and in the ester group are a measure of the
electrostatic energy of interactions with cationic receptor
sites. The results shown in figure 1 indicate that without the
initial protonated amine-model anionic receptor site interaction,
postulated as crucial to agonist activity, the (m -OH)-phenyl group
has the larger minimum negative potential and could, therefore,
more effectively bind at cationic receptor sites. This result is
consistent with the hypothesis that pharmacophore I leads to antag-
onism and that the (m-OH)-phenyl group contributes important
receptor interactions for such antagonist activity.
The results also show that, in the presence of an initial inter-
action of the protonated amine with a model anionic receptor site,
(OH), while both polar groups are activated, the augmented
negative potential around the two ester oxygen atoms is larger than
that around the phenol group, thereby favoring their binding to
cationic receptor sites. These results are consistent with the
hypothesis that pharmscophore II binding of meperidines at the
receptor site could be responsible for their agonist activity.
Substitution of a 3-CH3 group for the 3-COOC2H5 substituent of B-
meperidine yields more flexible analogs. Specifically, extensive
energy-conformation studies indicated the presence of three low
energy conformers: two piperidine chair conformers, one with the
phenyl-group equatorial and the other with the phenyl-group axial;
and a piperidine boat conformer. While the two chair forms had the
lowest energy, a boat form was also a stable conformation, with
calculated activation energies of 9.5 to 16.5 kcal/mol and
conformational energies of 5.5 to 6.5 kcal/mol, low enough to be a
candidate conformation at the receptor site. Experimental values
of chair-boat activation energies and conformational energy
differences for the related ring system cyclohexane are in the same
range as the calculated values, i.e., 9 to 11.5 kcal/mol and 4.8 to
6.0 kcal/mol, respectively (Komornicki and McIver 1973), confirming
the validity of the calculated values.
Thus, for the 3-CH3,3-phenylpiperidines, but not for B-meperidines,
results of energy-conformation studies imply two possible modes of
receptor binding which could initiate mixed agonist and antagonist
activity. As indicated in figure 2, one is a bimodal interaction,
similar to that proposed for the -meperidines, in which antagonist
activity is initiated by pharmscophore I and agonist activity is
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initiated by pharmacophore II binding to the receptor. If this
bimodal interaction is responsible for mixed agonist/antagonist
activity, then N-substituent variation should not modulate such
activity as it does in fused-ring opiates.
Pharmacophore I Pharmacophore II Pharmacophare III
Possible Mixed
Antagonist Agonist Agonist/Antagonist
FIGURE 2
Postulated 3-Phenyl Piperidine Modes of Initiating
Agonist/Antagonist Activity
Alternatively, for these 3-methyl-3-phenyl compounds, the boat
conformation of the piperidine ring in pharmacophore III can have
simultaneous overlap of both the protonated amine group and (m -OH)-
phenyl group with fused-ring opiates. If this is the mode of
interaction at the receptor, N-substituent variation should modu-
late agonist/antagonist activity in a manner similar to fused-ring
opiates.
To determine the effect of varying N-substituents, we undertook an
experimental effort involving the synthesis, optical resolution, in
vitro receptor binding and in vivo pharmacological activity of four
N-R-substituted 3-methyl-3(m-hydroxyphenyl)piperidine analogs shown
in table 2. The synthesis of racemic analog 1 followed a modified
procedure of Kugita et al. (1964). The resolution of the
enantiomers and their N-alkylation were reported for the first time
by our laboratory and are described elsewhere (Cheng et al.
1984, 1985).
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Opioid-receptor binding assays on rat brain homogenates were per-
formed essentially as described by Pasternak et al. (1975). In the
present studies, self- and cross-competition experiments were con-
ducted for four labeled ligands: [H]naloxone, D-Ala2-D-Leu5-
enkephalin (DADL), ethylketocyclarocine (EKC), and dihydromorphine
(DHM) at two different concentrations of labeled ligand. This
yielded a 4 by 4 “matrix” of competitive inhibition behavior. For
each pair of enantiomers, inhibition of binding of each of the four
labeled ligands was performed.
TABLE 2
Resolved Isomers of 3-Phenylpiperidines Studied
Compound R R
(+) and (-)
1 H
2
m-OCH3
CH3 m-OH
3 Allyl m-OH
4 Cyclopropylmethyl m-OH
5 Phenethyl m-OH
Data obtained from binding studies of each enantiomeric pair were
analyzed simultaneously with that from the 4 by 4 matrix using a
modified version of the program LIGAND (Munson and Robard 1980),
which predicts the receptor binding affinities and capacities
using weighted nonlinear, least squares regression analysis. The
five-receptor-site model, shown in table 3, yielded a self-
consistent set of receptor binding affinities and capacities that
was statistically much more significant than a one-, two-, three-,
or four-site model. A six-site model was not statistically more
significant than the five-site model.
As can be seen in table 3, a site was identified which has high
affinity for all the ligands, and was labeled µl. Sites “µ2” and
were labeled as those of high affinity for DHM and DADL,
respectively. The fourth site with high affinity for EKC and
naloxone, but low affinity for DHM and DADL, was labeled The
fifth residual site with large capacity has apparent low affinity
for all labeled ligands and could be a composite site.
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Also seen in table 3, all 3-phenylpiperidine analogs have highest
receptor affinity at the µl site and in general are n-selective
compounds. While there are not dramatic differences in affinity at
µ between pairs of enantiomers, the N-allyl and N-cyclopropylmethyl
analogs differ most in this respect. Relative affinities at the µ)
site vary from about 2% to 10% of the values for DHM and
naloxone.
TABLE 3
Receptor Affinities and Maximum Binding Capacities
for a live-Receptor-Site Model
“µl”
KD(nM)
"µ2" 5th Site
Naloxone 0.4 5.0
DADL 0.9 22
EKC 0.5 6.7
DHM 0.2 10
3-Phenylpiperidines
(-)N-CH3
(+)N-CH3
(-)N-ally1
(+)N-ally1
(-)N-CPM
(+)N-CPM
(-)N-phenethyl
(+)N-phenethyl
Bmax(pmol/g)
114 1,170
132 1,000
24 110
100 370
32 43
120 256
13 130
5.0 6.2
3.0 30.0
18 1.0 154
2.1 625 10,000
14 0.3 4,160
100 830 200
30,000
15,900
4,000
4,000
4,350
2,700
2,170
588
7.8
625 8,330
714 19,200
370 1,720
137 3,700
122 1,700
83 833
625 1,390
179 26,300
4.2 233
The similarity in receptor-site affinities between the enantiomeric
pairs is in contrast to the striking differences obtained in in
vivo activities. As noted in table 4, determination of agonism as
shown by inhibition of mouse acetic acid writhing (Koeter et al.
1959), and antagonism of morphine-induced tail-flick analgesia
(D’Amour and Smith 1941; Harris et al. 1969), revealed that all (-)
isomers are- pure agonists, while (+) isomers are mixed
agonist/antagonists.
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TABLE 4
Analgesic and Narcotic Antagonist Potencies of
Resolved 3-Methyl-3-m-hydroxypheaylpipcrldine
with N-Substituent Variation
Mouse Writhing Testa Mouse Tail-Flick TestD
ED50
(95% Con. limits) AD50 (95% Con. limits)
Compound µmol/kg i.p µmol /kg  i . p .
N-Methyl
( - ) - 2 25.69 (14.68 - 44.96) c
(+ ) -2 41.36 (21.55 - 79.42) 1 0 1 . 3 4  ( 7 1 . 3 5  - 143.90)
N-Ally1
( - ) - 3 14.34 (8.96 - 22.94) c
( + ) - 2 160.94 (106.58 - 243.02) 112.O2 (69.58 - 180.36)
N-Cyclopropylmethyl
( - ) - 4 12.23 (2.63 - 21.41) c
( + ) - 5 d 1 3 9 . 3 2  ( 8 3 . 9 3  - 231.27)
N-Phenethyl
( - ) - 5 18.38 (11.08 - 30.52) c
(+ ) -5 11.53 (7.21 - 18.44) 13.07 (8.71 - 19.58)
Morphine Sulfate
0.81 (0.51 -  1 .29)
N-Allylnormorphine
Hydrochloride
2.04 (1.44 - 2.8 7)
aInhibition of acetic acid induced writhing (Koster et al 1959)
bAntagonism of tail-flick inhibition induced by morphine sulfate
(21.08 µmol/kg, s.c.) (D’Amour and Smith 1941, Harris et al
1969).
cCompounds showed no significant antagonist activity up to dose
of SO mg/kg.
dShowed no significant agonist activity at a dose of 707.21
µmol/kg.
In general, the relative affinities of the analogs at the µl-
receptor site correspond to their relative agonist activity,
lending credence to the hypothesis of Pasternak et al. (1980) of a
common high-affinity site for all types of opioids initiating
analgesic activity.
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The results presented are most consistent with the hypothesis that
different receptor binding modes lead to agonism and antagonism.
All (-) isomers are pure agonists and thus would seem to bind to n-
receptors only in an orientation without a (m-OH)-phenyl overlap
(pharmacophore II), preventing antagonist activity. By contrast,
the (+) isomers appear to bind in a bimodal fashion with
agonist activity initiated by binding in a pharmacophore II mode
and antagonist activity initiated by binding in a pharmacophore I
mode.
The N-R aubatituents do not modulate agonist/antagonist activity as
in fused-ring opioids. In fused-ring opiates, N-methyl compounds
rarely show antagonist activity, and N-phenethyl compounds have
never been shown to possess antagonist activity. Also, the N-allyl
and cyclopropylmethyl substitutions in this series do not increase
antagonist activity as they do in the fused-ring opiates. Thus,
pharmacophore III with simultaneous cationic amine and hydroxy-
phenyl overlaps is probably not involved in the binding.
The surprising finding of strict etereoapecificity for antagonism,
but not agonism, provides clues to additional spatial requirements
for antagonist activity of 3-phenylpiperidines, other than (m -OH)-
phenyl overlap with morphine at the µ-opioid receptor. Comparing
the two different enantiomers in a pharmacophore I orientation
(figure 3). it is seen that the amine-N of the piperidine ring
differs in its spatial relationship to the crucial (m -OH)-phenyl
group. Apparently, only one of the amine positions is compatible
with local receptor subsite interactions.
(+) Enantiomer (-) Enantiomer
FIGURE 3
Proposed Antagonist Pharmacophore for the Two 3-Phenyl-
piperidine Enantioners (m-OH)-phenyl Overlap with Morphine
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Preliminary X-ray structure determination of the (+)-enantiomer of
the m-OCH3 nor-analog, 1 (Cheng et al. 1984), reveals that the
series of active antagonists derived from this compound have an S-
configuration, as shown in figure 3. Moreover, it was found, as
shown, that the piperidine ring has a chair conformation and the
phenyl ring is equatorial. These X-ray results support the con-
clusion that bimodal piperidine chair pharmacophores (I and II),
rather than a boat conformation (pharmacophore III), are involved
in receptor interactions. The X-ray determination of the absolute
configuration of the active enantiomer further defines the relative
position of the crucial amine and phenyl groups in the antagonist
b i n d i n g  m o d e .
IDENTIFICATION OF OPIOID PEPTIDE CONFORMERS LEADING TO HIGH
AFFINITY AT µ-RECEPTORS
Although the µ-site is traditionally associated with morphine and
the fused-ring opiates, a number of peptides have also been found
to show specificity for binding to the µ-site as measured by
tissue-specific assays and in vitro receptor binding assays (Morley
1980). Of these peptides, the first found were analogs of enke-
phalins which had been synthesized in an attempt to produce
opioids that were protected against proteolytic breakdown and thus
increase in vivo activity. The structural modifications made in
these analogs included substitution and modification of residues as
well as lengthening and shortening of the peptide chain. A
decrease in in vivo degradation did result, but at the same time,
the µ-6 binding specificity of the peptide was often altered.
Initial energy-conformational studies made in our laboratory were
designed to identify peptide conformations leading to µ-receptor
affinity and focused on three of the first Met-enkephalin analogs
synthesized as shown in table 5A (Pert et al. 1976, Walker et al.
1977). Subsequent studies were made of tetrapeptide analogs shown
in table 5B. The tetrapeptide analogs were found to be even more
potent than morphine as in vivo analgesics (Terenius et al. 1976,
McGregor et al. 1978).
Of more recent interest are structure-activity studies of a series
of analogs in which modifications have been systematically made in
order to explore the structural requirements for specificity. In
this regard, morphiceptin, an amidated tetrapeptide (Tyr-Pro-Phe-
Pro-NH2) fragment of casomorphin, a naturally occurring peptide
in milk (Henschen et al. 1980), is of interest because it was found
to have morphinelike physiological activity, as well as bind with
high specificity to the µ-receptor (Chang et al. 1981). A series
of morphiceptin analogs has subsequently been synthesized in which
the second, third,, and fourth residues were modified, leading to
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more potent, highly µ-selective analogs (Chang et al. 1983).
In a continuing effort to identify µ-selective opioid peptide con-
formers, energy conformation studies of the morphiceptin analogs,
shown in table 5C, have begun in our group. Specifically, in this
series we have examined the conformational effects of substitution
of D-Pro for L-Pro in the second and fourth positions, and the
addition of a methyl group to the backbone nitrogen of the
phenylalanina residue at the third position.
TABLE 5
Three Types of µ-Selective Peptide Opioids Studied
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In all of these studies, we have used the methods and procedures
outlined in table 6 to identify µ-selective peptide conformers.
Underlying these procedures are the assumptions that: (1) different
conformations are associated with optimum binding at µ- and -receptor
sites; and (2) differences in affinity between peptide analogs at each
site are related to the relative energy required to obtain a favorable
conformation.
TABLE 6
Methods and Procadures Used to Identify µ-Peptide
conformations
I . SELECI A SET OF µ-ACTIVE/INACTIVE ANALOGS.
USE: Receptor affinity
Guinea pig ileum (G.P.I.) activity
Antinociceptive activity
I I . PERFORM ENERGY-CONFORMATION CALCULATIONS.
USE: Different methods
Quantum mechanical
Empirical energy
Different search strategies
Aufbau: From single amino acids
Use standard secondary structures
III. SELECT A SET OF PUTATIVE ACTIVE CONFORMERS. CRITERIA:
Low energy in active analogs/High energy in
inactive analogs
Relative energy parallels relative affinity in a
series of analogs
IV. REFINE SELECTIONS USING RESIDUE SUBSTITUTION/ENERGY
CALCULATIONS:
Active analogs "accommodated"
Inactive analogs "not accommodated"
V. COMPARE CANDIDATE CONFORMERS WITH µ-SELECTIVE, FUSED-RING
OPIOIDS (MORPHINE-LIKE). LOOK FOR:
Crucial tyramine overlap
Other regions of overlap
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At the time of our first study, extensive energy conformation
studies had already been made of Met-enkephalin using the
Empirical Conformational Energy Program for Peptides (ECEPP)
(Isogai et al. 1977, Momany et al. 1975). In addition, a number
of conformational comparisons with rigid opiates had been made by
model building and comparison of overlaps of different assumed
critical regions of Met-enkephalins and rigid opiates. Of
particular interest were the p-OH phenethylamine (tyramine) moiety
formed by the terminal amino group and the tyrosine residue
(Bradbury et al. 1976; Horn and Rodgers 1976).
While valuable in describing numerous low and medium energy con-
formers of Met-enkephalin, none of the optimized conformers
previously reported had significant spatial overlap with several
functional groups in morphinelike opiates. On the other hand, the
conformers proposed by overlap with rigid opiates were based on
model building with no estimate of their relative energies.
Deviations from minimum energy conformations of the isolated
molecule could occur by an induced fit at the receptor site,allow-
ing enhanced resemblance to rigid opiates, but with some energy
required.
In order to determine the most likely conformers for interaction
at the receptor site, we have made systematic energy-conforma-
tional studies by both empirical and quantum mechanical methods.
The aim was to determine the energy of Met-enkephalin conformers
with varying degrees of similarity to rigid opiates and select as
most likely those conformers with modest energy expenditure and
significant overlap with rigid opiates. In keeping with the
protocol outlined in table 6, an additional requirement in our
selection strategy was the accommodation of D-Ala2, but not L-
Ala , in the place of the Gly residue. This second criterion is
consistent with the retention of activity when Gly is replaced by
D-Ala (Walker et al. 1977), and with a large decrease of receptor
affinity upon replacement by L-Ala (Pert et al. 1976).
The conformational energy calculations were performed using the
ECEPP and the PCILO methods. While the empirical and quantum
mechanical energy calculations did not give identical results, a
number of likely candidates common to both methods were
obtained.
As shown in table 7, both methods showed a trend toward higher
energies for conformers with increasing resemblance to rigid
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opiates. A conformer constructed to have maximum overlap with 7-
[l-phenyl-3-hydroxybutyl-3]-endothenotetrahydrothebaine (PET), and
not energy optimized, gave extremely high energies by both the
ECEPP and PCILO methods. These high energies are due to the
crowding of the terminal nitrogen and hydrogen atoms with the Gly2
carbonyl carbon and oxygen atoms. Relaxation of the Tyr1 and Gly2
backbone angles to a local minimum decreased the energy
significantly. Step-wise relaxation of a starting structure with
w angles ~180° yielded a series of lower and lower energy
structures by both methods.
TABLE 7
Energy of Met-Enkephalin Analogs with Increasing
Overlap with Fused-Ring Thebaine Opiate (PET)
Descr ip t i on
(ECEPP) (PCILO)
(kcal/mol)
Gly2, no tyramine overlap 0 0
D-Ala2, no tyramine overlap 1.5 -0.5
D-Ala2, tyramine overlap 9.6 2.3
D-Ala2, minimal PET overlap 14.55 3.8
Increased PET Overlap
1 = 180°) 25.2 14.4
Maximum Constrained
PET overlap 1 = 0°) 135.0 25.0
In another approach, it was assumed that a minimum viable overlap
of Wet-enkephalin with rigid opiates should involve the tyramine
0H)moiety of both opiates. Imposition of this con-
straint on optimized Met-enkephalin conformers resulted in 22
conformers with relative energy 9 to 20 kcal/mol by ECEPP and 1.0
to 8.5 kcal/mol by PCILO, above the lowest energy conformer
without the imposed overlap. The further condition that D-Ala2
be accommodated more readily than L-Ala in place of Gly reduced
the number of viable conformers from 22 to 12. These 12
conformers were optimized with the constraint of accommodating
both the Gly and D-Ala residues and the tyramine overlap with
morphine.
The results of this procedure were that the minimum energy con-
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formers calculated by both the ECEPP and PCILO methods did not
have any overlap with rigid opiates beyond the imposed tyramine
overlap. On the other hand, the lowest energy conformer with
significant additional rigid opiate overlap was the same by both
methods: a bend with a hydrogen bond between the carbonyl
group of tyrosine and the amine group of phenylalanine. This is a
particularly viable candidate for interaction at the receptor
site since it is only 3 kcal/mol above the minimum energy form as
calculated by the PCILO method.
Figure 4 shows the overlap of this structure with the potent
agonist PET. Not only do the important phenethylamine moieties
overlap, but the phenylalanine side chain overlaps with the
phenethyl C19 substituent of PET. In addition, the methionine
backbone C=O group and side chain are in the region of the C6
rethoxy group of PET. This conformer is quite similar to the one
previously proposed by model building (Bradbury et al 1976) and is
confirmed by these studies as a very likely candidate at the
r e c e p t o r  s i t e .
FIGURE 4
A Candidate Active Conformer for Met-Enkephalin
Analogs: Turn
interact with the opiate receptor is provided by the first
published X-ray crystal structure determination of Leu-enkephalin
(Smith and Griffith 1978), shoving a G-G bend stabilized by
hydrogen bonding between the tyrosine and phenylalanine
residues. While a subsequent crystal structure determination
yielded extended structures (Karle et al. 1983), indicating the
conformational flexibility of these peptides, a turn remains
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a viable candidate conformer.
In the second study, the conformational behavior of the five
tetrapeptide enkephalin analogs given in table 5B were examined to
continue identification of peptide opioid conformations leading to
high and low affinity at the µ-receptor site.
Using the same empirical energy method (ECEPP) and semi-empirical
quantum mechanical method (PCILO), conformational energies vere
obtained for a large number of optimized geometries of each
tetrapeptide. Two methods of selecting candidate active
conformations from low-energy conformers mere used. In the first
method, inactive conformers were designated as those having low
energy in the very weak tetrapeptide, Tyr-Gly-Gly-Phe-OH, and high
energy in the more potent ones. These candidate inactive con-
formers had geometries resembling or “random” peptide
conformations. Conversely, candidate active conformers selected
were low-energy conformations for both Tyr-D-Ala-Gly-Phe-NH2 and
Tyr-D-Ala-Gly-(NMe)Phe-NH2, but not low-energy conformers for Tyr-
Gly-Gly-Phe-OH. In the second method of selection, conformers
with relative energies in the active and inactive peptides that
followed the potency order Tyr-Gly-Gly-Phe-OH << Tyr-D-Ala-Gly-
Phe-NH2 < Tyr-D-Ala-Gly-(NMe)Phe-NH2 were chosen as candidate
active conformers. By using both methods of selection, a
bend geometry, shown in figure 5, was found as the active
conformer.
FIGURE 5
Candidate Active Conformer for Enkephalin like
Tetrapeptides: A II' Bend (---) Superimposed on PET
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While very similar in structure to that found for the penta-
peptides, this conformer is not stabilized by a 1-4 hydrogen
bond, but instead is stabilized by hydrogen bond between the
tyrosine amine hydrogen atom and the phenylalanine carbonyl oxygen
atom. Thus, our results show that such conformers can exist
as relatively low-energy forms for active peptides with an N(CH3)
group on the fourth residues of the bend.
The candidate active forms have a greater degree of spatial over-
lap with the fused ring opiate PET than do the inactive ones,
suggesting that the extent of this overlap may be important in
high-affinity µ-receptor binding and in analgesic activity. The
identification of a -type conformer as an inactive form of these
peptide opiates is in agreement with proposed inactive conforma-
tion of Tyr-Gly-Gly-Phe based on crystallographic (Prange and
Paecard 1979) and NMR data (Fournie-Zaluski et al. 1977).
The morphfceptin analogs under current study, listed in table 5C,
are among the most µ-specific linear peptides found and should,
therefore, add considerable insight into the continued search for
µ-selective opioid peptide conformers. In these energy conforma-
tion studies, we have used only the empirical energy method ECEPP
and began with an “aufbau” search strategy. Starting with low
energy derivitized single amino acid conformers, these were
optimized and combined to form dipeptidee which were in turn
optimized. A number of unique low energy conformers of the
dipeptides were then combined to form tetrapeptide conformers
which were then optimized. The results obtained for these analogs
are summarized in table 8A-C.
Despite two proline residues, 38 different conformers of morphi-
ceptin (Tyr-Pro-Phe-Pro-NH2) vere found within 10 kcal/mol of the
lowest energy conformer (table 8A). However, addition of a methyl
group to the nitrogen backbone atom of the phenylalanine residue
greatly diminished the flexibility, yielding only 12 conformers in
this same energy range (table 8B). Moreover, while the low energy
conformers found for morphiceptin varied widely, those for Tyr-
Pro-NMe-Phe-Pro-NH2 (NMePheMorphiceptin) were very similar to each
other, falling into two basic classes: one class roughly equi-
valent to a turn, and the other shoving backbone and
angles similar to those in the repeating C7 structure.
Since both of these analogs have similar µ-receptor affinities, it
is reasonable to assume that similar peptide conformers would be
involved in such receptor binding. Yet, there was no significant
overlap between any of the low energy < 10 kcal/mol) morphi-
ceptin and NMePheMorphiceptin analogs found by the aufbau search
strategy. Thus, a different strategy was used to find common
conformations for the two peptides.
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TABLE 8
Calculated Energies of Optimized Conformers for Three
Morphiceptin Tetrapeptides Using an Empirical Energy
Method (ECEPP)
In the second procedure, low energy conformers of each analog were
examined for their ability to accommodate each other. The result
was that no low energy conformer of morphiceptin could accomodate
the N-methyl analog. The energy required to maintain the N-methyl
analog in these conformers was of the order of hundreds of
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kcal/mol and no constrained conformer vas a local minimum. By
contrast, when morphiceptin was constrained to overlap with the
low energy conformers of NMePheMorphiceptin, the energy required
ranged from 4 to 14 kcal/mol. Some of these conformations were
additional local minima for morphiceptin not found by the aufbau
search strategy, while others were not local minima at all.
Figure 6 shove the
conformation (33’)
energy for each.
two analogs in an overlapping
which is a local minimum with
II-type
relatively low
FIGURE 6
Overlap of Similar Optimized Conformers of
Morphiceptin = 6.5 kcal/mol) and N-Me-Phe3-
Morphiceptin = 2.8 kcal/mol)
The morphiceptin analog Tyr-Pro-NMePhe-D-Pro-NH2 (PL017) is the
most potent and µ-selective analog and can be considered the
template for µ-specific morphiceptins. Thus, D-Pro4 was
eyetematically substituted into all the lov energy conformers of
Tyr-Pro-N(Me)Phe-L-Pro-NH2, given in table 8B. The relative
energy of the D-Pro4 conformers, optimized from this initial set
and labeled by their initial similarity to the L-Pro analogs from
which they were formed, are given in table 8C.
The effect of D-Pro4 substitution was large on some conformers and
small on others. Because the effect on activity was small, we
eliminated as candidates those conformers which would not incor-
porate D-Pro in the fourth position without a large energy cost.
The -type conformer 33’ best accomodated D-Pro4 with very
little geometry or energy change (figure 7) although it was not
the conformer with lowest energy for NMePhe-Morphiceptin or its D-
Pro4 analog.
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FIGURE 7
Overlap of Similar Optimized Conformers of N-Me-Phe3
L-Pro = 2.8 kcal/mol) and N-Me-Phe-D-Pro -
Morphiceptin = 2.4 kcal/mol)
As indicated in figure 6, it was also one of the conformers
which best accommodated morphiceptin, and thus is our candidate
conformation for morphiceptin like compounds.
Finally, we examined the effects of substituting a µ-Pro for an L-
Pro in the second position of morphiceptin. In contrast to the
fourth position, a D-Pro substitution produces an inactive analog
(table 5C). Consistently, we found that forcing the Tyr-D-Pro-
Phe-Pro-NH2 analog to conform to any low energy conformer of N-
Me-Phe-Morphiceptin required an energy of 25 to 400 kcal/mol
compared to its lowest energy conformer. Moreover, none of these
constrained conformations were local minims (figure 8A), nor did
local minima of the D-Pro overlap with L-Pro2-morphiceptin
(figure 8B).
In contrast to destruction of activity by substituting a D-Pro2
residue in morphiceptin, a number of modified L-Pro2 residues can
be substituted in the 2 position without significant effect on µ-
affinity and in vitro activity. Among these analogs, the most
significant decrease in bioactivity was found with the substi-
tution of a 4-hydroxy-proline into the second position of PL017.
Conformational analysis revealed that there was virtually no
energy cost for adding a 4-OH group to proline in any candidate
conformers of PL017. This result indicates that the decrease in
the observed bioactivity results from adverse electronic
interactions at the receptor site rather than from conformational
differences in these analogs.
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A. D-Pro2morphiceptin conformer constrained to overlap with
L-Pro2 analog = 249 kcal/mol)
B. Optimized D-Pro2 conformer = 8.9 kcal/mol). Little
overlap with L-Pro2
Comparison of L-Pro2 and D-Pro2 Morphiceptin Conformers
FIGURE 8
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Conclusions and Future Directions
The three types of studies made thus far indicate a “universal”
type of µ-selective opioid peptide conformer involving a o r
turn. In enkephalin-type analogs, a conformer is a
likely candidate, while µ-selective morphiceptin analogs, appear
to prefer a turn. As shown in figure 9, these two types of
turns have a considerable overlap.
Studies are currently under way to investigate the effects of
other subatitutions in the second position of morphiceptin
analogs. Work is also currently proceeding on conformational
analysis of the cyclic µ-selective compounds of Schiller et al.
These authors have synthesized Leu-enkephalin analogs in which the
aliphatic side chain (CH2)n of the second residue has been
extended to various lengths (n=1,4) and cyclized with the C-
terminal carboxyl group through an amide linkage (DiMaio et al.
1982). While the the degree of n-specificity varied in the four
cyclic analogs of
this type synthesized, all shoved greater µ-specificity than their
linear counterparts in binding assays, although diacrepanciea with
tissue-specific assays did exist. The increased µ-specificity
appeared to be due generally to a decrease in -receptor
aff inity.
FIGURE 9
Tyr-D-Ala2-Gly-Phe-NH2 Shown in
and Conformations
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Comparing the candidate conformers of the most µ-selective and
highest potency morphiceptin analog (PL017) with the lowest energy
conformers of the most µ-specific cyclic compounds (with n=2,4),
should provide a further probe of µ-selective opioid conformers.
It will also be interesting to compare these conformers with the
-selective linear and cyclic analogs which we are also currently
studying.
PRELIMINARY STUDIES OF -SELECTIVE OPIOID PEPTIDE CONFORMERS
LEADING TO HIGH AFFINITY AT -RECEPTOR SITES
Although the -receptor site was first identified by its pre-
ference for peptide compared to nonpeptide opioids, moat opioid
peptidea synthesized have been found to bind and act with
comparable or higher affinities at the µ-receptor.
Among the first molecules rationally designed for specificity
were the hexfpeptide Tyr-D-Set-Gly-Phe-Leu-Thr (DSLET), and its
related DThr2 (DTLET) analog (David et al. 1982). It was thought
that this sequence would lead to -specificity since structure
activity studies of peptidea had previously shown that: (a) Phe
at position 4 plays a crucial role in µ- versus -selectivity;
(b) lengthening of Met-enkephalin by Thr enhances MVD potency
while decreasing GPI activity; (c) Leu-enkephalin shows increased
MVD potency relative to Met-enkephalin; and (d) replacement of
Gly2 by a D-amino acid inhibits degradation and reinforces µ-
selectivity if the residue is hydrophobic.
As summarized in table 9, GPI versus MVD studies indicate that
DSLET and DTLET are 4 to 10 times more -selective than DADL,
while binding studies indicate that they are only somewhat more
selective than DADL.
Thus, while the linear peptides DSLET and DTLET seem to be some-
what more -selective than DADL, the extent of this selectivity is
unclear from the existing data. Since these linear peptidea are
quite flexible, it is not surprising that they would not be over-
whelmingly selective for a particular receptor.
As discussed above, Schiller and coworkers (DiMaio et al 1982)
demonstrated that reduction of flexibility by cyclization could
modulate the extent of µ- and -selectivity and lead to µ-
selective Leo-enkephalin type peptides. These investigators have
also synthesized another series of cyclic analogs baaed on a Tyr-
Cys-Gly-Phe-Cys pentapeptide cyclized by a diaulfide bridge
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TABLE 9
Receptor Binding and In Vitro Activity of
-Selective Opioid Peptides
Enkephalin
Analog
D-Ser2-Leu5Thr6a
D-Thr2-Leu5-Thr6a
[D-Pen2-L-Pen5]a
[D-Pen2-D-Pen5]a
[D-Pen2-L-Cya5]b
[D-Pen2-D-Cys5]b
[D-Cys2-L-Cya5]
[D-Cys2-D-Cys5]
[L-Cys2-L-Cys5]
IC50 nM
[3H]Nalox [3H]DADL
DADLa
Morphinea (normorphine)
88 5.7
36 6.4
3710 10
2840 16
178 12
157 26
2 .0 c 0 .8 c
3 .5 c 1 .6 c
16 4
23 27
ED50 nM
G.P.1 MVD
234 0.70
100 0.58
2720 2.5
6930 2.2
213 0.32
1350 6.3
1.5d 0.80d
0.80d 0.30d
210d 950d
24 0.72
91 541
aMosberg et al. 1983a; bMosberg et al. 1983b, cSchiller et al. 1981;
dSchiller and DiMaio 1983.
between the second and fifth reaiduaa (Schiller et al. 1981,
Schiller and DiMaio 1983). As shown in table 9, of thrae such
analogs synthesized, all were relatively unselective. By analogy
with oxytocin analogs, Mosberg and coworkers (1983a. 1983b)
reasoned that gem-dimethylation of the cysteine -carbons would
greatly rigidify this cyclic structure. As shown in table 9, the
resulting two analogs [D-Pen2-L-Pen5]enkephalin and [D-Pen2-D-
Pen5]enkephalin, while retaining affinity and activity at
receptors, had greatly diminished activity at µ-receptors,
yielding the most -selective peptides yet found.
We have begun energy conformation studies of both the linear
peptide DTLET and the cyclic peptide [D-Pen2-L-Pen5]enkephalin, in
order to identify, for the first time, peptide opioid conformers
leading to high affinity at but not µ-receptors.
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For the hexapeptide, DTLET, the aufbau search strategy was used
with the empirical energy program ECEPP. Each of approximately 10
low energy derivatized single amino acid conformers was combined
to give about 100 initial conformations for the Tyr-D-Thr and Phe-
Leu dipeptides. Each of these dipeptide conformers were then
optimized. To the optimized Tyr-D-Thr peptides were added low
energy conformers of Gly to form tripeptides. A similar procedure
was used to obtain Phe4-Leu5-Thr6 tripeptidea. Finally, optimized
tripeptide fragments were combined to form 64 initial hexapeptide
conformers which were once again optimized. These 64 conformers
spanned an energy range of 14 kcal/mol relative to the lowest
energy conformer obtained. Fifty conformers had energies in the
range of < 10 kcal/mol.
This considerable effort resulted in characterization of the
energy-conformational profile and indicated a high degree of
flexibility of this linear peptide. This flexibility makes it
difficult to identify a probable selective conformer baaed
solely on studies of linear peptides.
To help alleviate the problem of extensive flexibility, we have
begun a systematically study of the more conformationally restricted
[D-Pen2-L-Pen5] cyclic enkephalin. In order to perform this study,
we have recently modified our structure-generating and empirical
energy programs to incorporate and recognize diaulfide
bonds between cyateinelike residues. The search strategy we are
using involves:
1) Starting with the linear analog formed by breaking the
diaulfide bond, and constructing a number of standard
secondary structures as initial geometries.
2) Generating an initial cyclic structure by rotating side
chain and backbone torsion angles to form a diaulfide
bond with an S-S distance of 2.04 A.
3) Optimizing all initial structures.
Using this strategy, torsion angle optimization of an -hel ical
initial conformation was made, leading to a low energy minimum,
the first geometry-optimized cyclic structure of this analog to be
reported. This conformation of D-Pen -L-Pen was then used as a
template to which DTLET was maximmly overlapped. Maximum overlap
includes exactly matching the Tyr1 and Phe4 side chain angles of
both the cyclic and linear analogs. Partial optimization of the
DTLET conformation was then performed, allowing only torsion
angles in DTLET, with no counterparts in the cyclic analog to
vary. The resulting structure (figure 10) had an energy only 11
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FIGURE 10
Overlap of Optimized (D-Pen2-L-Pen5)Enkephalin
Conformer with Partially Optimized DTLET Conformer
DTLET = 11 kcal/mol)
kcal/nol higher than the lowest energy DTLET conformer obtained
from the previoua aufbau search. Moreover, unconstrained opti-
mization of this conformer caused only small departures from
maximal overlap, as shown in figure 11, and resulted in a gain of
4 kcal/mol. Thus, the maximumly overlapped conformer of DTLET is
near a local minimum of the potential energy surface, only 7
kcal/mol above the global minimum. Therefore, the conformer of
DTLEI and [D-Pen2-L-Pen5]enkephalin shown in this figure are
plausible candidates for a -selective peptide opioid conformer.
This conformer of DTLET was not among the minima found from the
aufbau search strategy and illuatratea the usefulness of a cyclic
template in sorting out candidate -selective conformers.
We are continuing these studies, searching for additional low
energy conformers of this and other cyclic analogs, to further aid
in selecting the most probable conformer responsible for high-
affinity binding at -receptors.
DESIGN OF µ-SELECTIVE OPIOID PEPTIDE ANTAGONISTS
The synthesis of opioid peptide antagonists has been repeatedly
attempted since the initial discovery of the enkephalina. Moat
previous attempts have, by analogy to fused-ring opiates, relied
upon the addition of one or two N-alkyl moieties to Met- or
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FIGURE 11
Overlap of Optimized DTLET with Optimized [D-Pen2-L-
Pen5]Enkephalin Conformer DTLET = 7 kcal/mol)
Leu-enkephalin analogs. Initial studies with Met- or Leu-
enkephalina and their N-allyl analogs revealed alight antagonism
to morphine’s inhibition of amooth muscle contraction (Hahn et al.
1977), but no antagonism to analgesia after intracerebral
ventricular (i.c.v.) administration (Pert et al 1977). The
addition of N,N-diallyl to Leu-enkephalin analogs has produced
potent -selective antagonists. ICI 154,129 (Shaw et al. 1982)
and, more recently, ICI 174,864 (Cotton et al. 1984) have been
shown to be Nghly selective in their inhibition of agonist
actions in the field-stimulated MVD preparation. ICI 154,129 was
also shown to inhibit the slowing of the head-turn time induced by
etorphine, the model uaed to investigate -receptors in vivo by
Gormley et al. (1982). These compounds, however, being
selective, showed no inhibition of morphine-induced analgesia.
Conformational studies of enkephalin analogs and comparisons with
flexible, rather than fused-ring, nonpeptide opiates led us on a
different path to peptide antagonists, and produced compounds with
µ-selectivity. Previous energy calculations, described above,
indicated that, in low energy conformations of Met-enkephalin, the
amino-terminal phenethylamine moiety could overlap with the 3-
phenylpiperidine class of flexible opiates (figure 12A).
Moreover, these two types of flexible opioida share only a
phenethylamine overlap with fused-ring opioida (figure 12B). Also
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as diacuaaed in detail above, our own and previous atudiea of the
3-phenylpiperidinea indicate that they are moderately potent µ-
selective opioid agonists, in which addition of an -OH group to
the phenyl ring induces antagonist activity, and thus generates
mixed agonist/antagonist compounds. A p-OH group produces very
weak antagonism and an m-OH group greatly increases antagonist
activity (Jacoby et al. 1981). Furthermore, in the 3-CH3-3(m-
OH)phenylpiperidine series, N-aubatitutiona did not influence
relative agonist/antagonist activity as in fused-ring opiates
(Cheng et al. 1984, 1985).
A. L-Tyr superimposed on
3-phenylpiperidine
B. L-Tyr superimposed on portion
of morphinan nucleus
FIGURE 12
Comparison of 3-Phenylpiperidine and Peptide Opioids,
A) With Each Other and B) With Morphinan
Thus, the two enkephalin analogs with modified tyroaine residues,
showo in figure 13, were chosen for synthesis and testing along
with D-Ala -Met-enkephalin amide. The synthesis of these peptides
is described elsewhere (Loaw et al. in press). As shown in
this figure, the modified tyroaine residues consisted of a m-OH
tyroaine and a (m-OH) -CH3 tyroaine chosen to correspond to the
( m-OH) and 3-CH3 groups of the 3-methyl-3-(m-OH)phenylpiperidines,
respectively. Binding affinities as well as in vivo, i.c.v.
agonist and antagonist activity were determined for the three
peptides.
As seen in table 10, the parent compound D-Ala2-Met-enkephalin
amide (p-Tyr) is a potent agonist in the tail-flick teat when
administered i.c.v. in mice, being about one-third as potent as
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morphine. This compound also showed significant antagonist
activity in inhibiting a morphine-induced increase in tail-flick
latency, but was only one-tenth as potent an antagonist as an
agonist. Displacement of the hydroxy group on the tyrosine to the
meta position produced striking changes in the relative activities
TABLE 10
Analgesic and Narcotic against and Antagoniat
Potencies of (D-Ala2, Met5)Enkephalin Amide Analogs
Evalueted in the Mouae Tail-Flick Teat
COMPOUND
p -Tyr
m-Tyr
-Ch3-m-Tyr
Nalorphine
Morphine
AGONISMa ANTAGONISM
b
K D 5 0
µmol/kg
95% Conf. Lia. Ant.AD50 95% Conf. Lia.
µmol/kg µmol/kg µmol/kg
0.214 0.074 ± 0.616 2.283 1.512 ± 3.453
10.302 5.630 ± 18.854 1.684 0.785 ± 3.596
2.394 1.203 ± 4.764 3.530 2.263 ± 5.507
19.320 7.963 ± 46.754 0.322 0.184 ± 0.563
0.063 0.026 ± 0.151
aA modification of tail-flick teat of Li et al. (1978).
bAntagonism against 21.08 µmole/kg (s.c.) of morphine sulfate was
measured 2, 5, 10, 20, 30, 45, 60, 90, and 120 min. after i . c . v .
administration of enkephalin amide analogs.
FIGURE 13
Peptides Selected for Synthesis
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of the compound. The (m-OH)Tyr analog is 50 times weaker as an
agonist, but slightly stronger as an antagonist, than its p-OH
counterpart. This produces a compound six times more potent as an
antagonist than as an agonist, and corresponds well with relative
changes in potencies when 3-phenylpiperidines are modified from p-
OH to m-OH (Jacoby et al 1981). The -CH3- m-Tyr analog has an
activity profile between that of the other two compounds with
approximately equal agonist and antagonist activity.
Competitive binding studies of these compounds were made using the
four labeled ligands [H] naloxone, [E]DADL, [E]EKC, and
[H]DHM. Also conducted were self- and cross-competitive binding
of the labeled ligands themselves, as decribed above. The
resulting 4 by 7 matrix of competitive inhibition experiments was
analyzed simultaneously using the computer curve fitting program,
LIGAND.
As shown in table 11, all of the peptides exhibited high affinity
at the site designated as µl. Furthermore, the relative analgesic
potency of the three peptides corresponds to their relative
affinities at “µ l-” The affinity at µ1 and analgesic activity of
the p-Tyr analog are 20 to 50 times higher then either of the two
novel peptide analogs. This observation lends support to the
evidence presented by Pasternak that the µ1 receptor is
responsible for opiate-induced analgesia (Pasternak et al.
1980). Also evident from table 11 is the n-selectivity induced by
the (m-OH)Tyr. While the p-Tyr analog is very potent at
receptors, both m-Tyr and -CH3-m-Tyr have quite low affinities at
consistent with the 3-phenylpiperidine templates.
Thus, it appears that (m-OH)Tyr and methyl-(m-OH)Tyr-Met-
enkephalin-amide analogs are the first µ-selective enkephalin-type
peptides with demonstrated antagonism to whole animal analgesia.
Moreover, requirements for potent antagonism of Met-enkephalin
analogs appear similar to that for 3-phenylpiperidines, possibly
indicating similar binding conformations.
To continue to explore this similarity, we are in the process of
synthesizing two more novel tyrosine analogs, an N-phenethyl-(m -
OH)-tyrosine and a dimethyl-(m-OH)-tyrosine to incorporate
into Met-enkephalin-amide peptides. If they behave as 3-phenyl-
piperidines do, then both of these modifications should enhance
antagonist potency.
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TABLE 11
Receptor Affinities and Maximum Binding Capacities of
(D-A1a2-Met5)Enkephalin Amide Analogs Assuming a
5-Receptor-Site Model
S i t e  1
"µ1"
KD(nM)
Site 2 Site 3 Site 4 Site 5
“µ2"
Naloxone 0.60 3.0 20.8 0.5 100
DADL 1.80 14.9 1.3 312 0,333
EKC 0.60 4.3 15.0 0.003 588
DHM 0.30 12.7 119 1.515 83
p-Tyr 0.53 5.0 0.40 1600 476
m-Tyr
-CH3-m-Tyr
Bmax pmol/g
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Conformations of Opioid Peptides as Deter-
mined by Nuclear Magnetic Resonance and
Related Spectroscopies
M. Abu Khaled, Ph.D.
INTRODUCTION
The peptides that possess opiate like biological properties are
called “opioid peptides.” Known members can be divided into
three main groups according to their sources. 1) Endorphins:
These peptides have been found to occur naturally in the central
nervous sys tern. -Endorphin is the largest in this group,
followed by dynorphin, neoendorphins, and the enkephalins which
are the smallest pentapeptides in the family (Hughes and Koster-
litz 1977). 2) Exorphins: These peptides are obtained as a
result of partial enzymatic digestion of proteins derived from
food stuffs (Loukas et al. 1983). For example, -casomorphins
have been isolated from the bovine milk protein, -cesein. 3)
Kyotorphins: These are synthesized small peptides (Takagi et
al. 1979) whose opiate like properties do not arise from direct
interaction vith opiate receptors,but perhaps act by releasing
enkephalina and/or by inhibition of  enkephalin degradation
( M o r l e y  1 9 8 3 ) .
Since the discovery of enkephalins, much attention has been
dravn to this area. The enkephalins are distributed over wide
areas of the CNS, specific parts of the brain, spinal cord, and
in certain nerve plexi of intestines. Because of the inter-
action of enkephalina at the same receptor site as that of
morphine, numerous structural analosa of  nkephalins have been
prepared and tested for their opioid activity, their propenaity
to cause tolerance and physical dependence,their susceptibility
to degradation by brain enzymes,and for their behavioral effects
on laboratory animals and on schizophrenic patients. The iso-
lation, identification, characterization, and structure-activity
relationships of two naturally occurring enkephalins, namely
H-L. Tyr-Gly-Gly-L•Met-OH([Met5]-Enk) and H L•Tyr-Gly-Gly
L•Phe-L•Leu-OH ([Leu5]-Enk), are covered in detail in some
recent reviews (Hughes and Koaterlits 1977; Miller and Cautre-
casas 1978; Morley 1980; and Schiller 1984).
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Structural similarities between the morphine derivatives and the
enkephalins must exist if they share common receptors. Exten-
sive research efforts have, therefore, been made to predict the
enkephalin structures compatible with the rigid morphine struc-
ture. The main approaches utilized in these studies are: 1)
speculation as to the conformation of the enkephalins at the
opiate receptor resulting from model building and comparison
with models of narcotic drugs, 2) conformations of enkephalins
in solution as derived from various spectroscopic data, and 3)
conformational energy calculations.
Recently, in an elegant review article, Schiller (1984) has
exhaustively summarized all the previously reported conformation-
activity relationships of enkephalin molecules. Data from
various spectroscopic methods, nuclear magnetic resonance (NMR)
in particular, have been discussed. In order to avoid repeti-
tion of the similar subject matters, a different approach will
be taken in this review article as outlined in the folloving
sections.
1. Definitions of various conformational states of a
peptide/polypeptide backbone.
2. Descriptions of various NMR methods that are used in
obtaining conformational information.
3. Use of such NMR methods in relation to A) backbone and
B) side-chain conformations of enkephalin molecules.
4. Concluding remarks.
PEPTIDE  CONFORMATIONS
The backbone of a polypeptide or protein is formed from a
repeating peptide unit, as depicted in figure 1.
It can be seen that the overall conformational characteristics
of the peptide unit are determined by rotations about the
C'-N, and bonds (R is the side-chain of an amino
acid). A convenient description of the conformation about each
bond is in terms of the torsion angles -C ' ) , (N- (C'
-N), and -R) as shown in figure 1: refers to the torsion
angle of sequence of atoms to the se-
quence N1,  C'1, N2; and to the sequence
negat ive ( - )according as when the system (figure 1) is viewed
Torsion angle is considered positive (+ )or
along the central bond N2- in the direction N2 C ' 2
quires to be rotated to the right or to the left, respectively,
(or C'2       N2), the bond to the front atom C'1 (or C'2) re-
in order that it may eclipse the bond to the rear atom C'2 (or
C'1). Similarly, a n d can be determined by viewing along
the central bond Torsion angle is either zero (for
cis peptide bonds) or 180 (for trans peptide bonds).
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Side-chain torsion angles designated by are specified by two
(or three) superscripts, the first one (or two) indicating the
central bond about which the angle is measured and the last one
indicating whether the angle measured is relative to any
branched chain atom. By the sequence rule (IUPAC-IUB 1970),
when =0, is in the eclipsed position relative to
N. Positive or negative angles can be generated by viewing
along the central bond in the direction and
rotating right or left, respectively,in order to
eclipse with N. A fully extended polypeptide chain is charac-
terized by +180° (IUPAc-IUB 1970).
Rotations at the above mentioned bonds give rise to various con-
formations that are stabilized by intra- and/or inter-molecular
hydrogen bond (H-bond) formations between the C=0 and N-H groups,
as shown in figure 2.
An H-bonded ring between the N-H of an amino acid sequence
number m and the C=0 of another residue of the sequence number n
is designated as m n which encompasses a certain number of
atoms of the backbone chain. The possible H-bonded structuree
in a system of 4 linked amino acids are shown in figure 2. A 2
2, 3 3, or 4 4 H-bond encompassee 5 atoms; the 3 1 or 4
2 contains 7 atoms; similarly, 2 3 or 3 4 and 4 1 H-bonds
contain 8 and 10, respectively; while a 2 4 H-bonded ring con-
sists of 11 atoms. These aforementioned intramolecular H-bonded
rings are also indicated by C5, C7, C8, C l0, and C l1
conformations, respectively.
FIGURE 1
A Peptide Backbone Showing Various Torsion Angler
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The conformation is extended and usually occurs in conjunction
with an antiparallel -pleated sheet structure that is formed by
intermolecular H-bonds, as shown in figure 3.
FIGURE 2
Possible Intramolecularly H-Bonded
Rings in a Peptide System with Four
Linked Amino Acids
Both the C7 and C8 conformations are also known as short-
range interactions and usually occur with other dominant confor-
mational features, such as helices or higher ring structures.
For example, C7 always coexists with C11, as shown in figure
4. Following the -turn, which is a 10-membered H-bond, chrono-
logically, an 11-membered H-bonded ring (figure 4) should be
termed as -turn (Nemethy and Printz 1972; Matthews 1972).
Unfortunately, however, controversy remains in literature re-
garding the designation of this structure. The structure in
figure 4 happens to contain one 7-membered (C7)ring which some
research workers prefer to call -turn, while the C11 is
referred to as -turn.
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FIGURE 3
Antiparallel -Sheet Structure with C5 H-Bond
FIGURE 4
A -Turn Conformation in Peptides
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The -turn, a 10-membered intramolecular H-bonded ring, just
mentioned above, will be further discussed here since the occur-
rence of this conformational feature in enkephalin analogs is
most abundant. The reader should, therefore, be adequately
familiar with conformational properties of a -turn. The main
characteristic of a -turn is to reverse the backbone chain, con-
taining a suitable dipeptide moiety, in the same plane where it
thus differs from a 310-helix. It was, therefore, previously
termed as 4 1 intramolecularly H-bonded nonhelical confor-
mation (Venkatachalam 1968; Benedetti et al. 1976). Conforms-
tions related to -turns have also been called earlier as: 3
(or 3-10) bond (Kuntz 1972), folded -conformation or -fold10
(Shields et al. 1968), -turn (Urry and Ohnishi 1970), -bend
Chandrasekaran et al. 1973), hairpin bend (Kuntz 1972;
Chandrasekaran et al. 1973), -loop (Kuntz 1972), 1 4 bend
(Nemethy and Prints 1972), chain reversal (Lewis et al. 1973),
U-bend (Chandraeekaran et al. 1973), lo-membered H-bonded ring
(Deber 1974), 1,4 turn (Hruby 1974), -twist (Benedetti et al.
1976), and tight turn (Richardson et al. 1978).
Various foldings of a peptide backbone chain into different
forms or types of -turns are depicted in figure 5. Venkata-
chalam (1968) classified the -turns into conformational types:
I, II, III, and their mirror images I', II', III'. The torsion
angles and that define these types are given in table 1.
It can be seen in table 1 that the -turn type III is actually a
helix. Because of sterical hindrance, it is necessary that
the two residues within the H-bonded ring should be with L-con-
f iguration,  i .e . , L-L arrangement is preferred for a type I
-turn, while an L-D arrangement is preferred for a type II
-turn. The mirror images, D-D and D-L, are obviously required
to form type I' and II' -turns, respectively. There configur-
ational arrangemente are clearly shown in figure 5 by the dif-
ferent projections of R2 and R3 on side-chains. A glycine
residue can be conveniently accommodated in place of a D-substi-
tuted amino acid , particularly in type II and II' -turns. A
convenient way of distinguishing type I and type II -turns is
to consider the orientation of the peptide moiety between
residues 2 and 3 (see figure 5). In type I -turn, the -H
proton of residue 2 is oriented opposite to the N-H proton of
residue 3, as indicated by a double-headed arrow in figure 5A.
In type II -turn, however, the same two protons are on the same
side which is also indicated by a double-headed arrow in figure
5B. These are the simple descriptions of intra- and/or inter-
molecular H-bonded structures that will be mentioned frequently
in section 3, which deals with the backbone conformations of
various enkephalin analogs.
NUCLEAR MAGNETIC RESONANCE METHODS
NMR is the most powerful technique which can provide all the
necessary information needed to describe a peptide conformation.
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A. TYPE I B. TYPE. II
Type
I
I '
I I
II'’
III
I I I '
FIGURE 5
-Turn Structures in Peptides
TABLE 1
Torsion Angles of Various Types of -Turns
Residues
2 3
2 2
-60 - 30 -90 0
60 30 90 0
-60 120 80 0
60 -120 -80 0
-60 - 30 -60 -30
60 30 60 30
3 3
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Resolution of NMR signals and their assignment to individual
amino acid residues are the first steps in conformational
analysis of peptides and proteins. Usually, the assignments are
carried out from the inspection of the side-chain spin pattern
of a particular amino acid residue by using spin decoupling tech-
nique. This is true when a molecule contains different amino
acid residues occurring only once in the backbone with well-
resolved NMR signals. However, it becomes more complicated when
a molecule contains a recurring amino acid residue such as in
enkephalin molecules where two glycyl residues are involved in
positions 2 and 3. Selective isotope enrichment of one of such
residues either by C, H, or N is the usual way for
unequivocal assignments of NMR resonances. The two glycyl
residues in [Leu5]enkephalin were thus assigned by the partial
C13 enrichment (Tancrede et al. 1978). Recently, however, a
combined use of 1H and 13C resonances has been made to
both 1H and 13C signals of a particular amino acid in
peptide system (Khaled and Urry 1981; Khaled et al. 1981;
Khaled and Watkins 1983). The basic principle of this technique
is to selectively irradiate the -H. and N-H. protons,
across a peptide bond. These two protons are coupled to
hauser enhancement (NOE) for this carbonyl carbon nucleus.
=O carbon which also provide almost all the nuclear Over-
Once
two such protons are located and one of the amino acid residues
is identified, either from its side-chain spin pattern or by
perturbing the end groups in case of a linear peptide, the rest
of the residues in the molecule can be assigned by stepwise
irradiation of the 1H resonances. Thin method ultimately
allows the unequivocal NMR signal assignments without involving
an expensive and time-consuming synthetic iaotope enrichment.
After having assigned all the resonances, conformational
analyses are carried out by using the well-established NMR
methods as described next.
Identification of H-Bonds
The intra- and inter-molecular H-bonds are usually delineated
from the temperature dependence of peptide N-H proton chemical
shifts . An intramolecularly H-bonded peptide N-H proton has
less temperature dependence compared to an intermolecularly
H-bonded or an exposed N-H proton. The temperature coefficient
of an intramolecularly H-bondgd N-H proton typically
varies from 2 x 10-3 to 5 x 10-3 ppm/°C depending on the
stability of the H-bond (Kopple et al. 1969; Ohnishi and Urry
1969). However, there exists a controversy regarding the temper-
ature dependence of peptide N-H protons. Stevens et al. (1980)
reported value of the order of 2.4 ppm/°C which they
attributed to the N-H proton that is exposed to nonpolar
solvents, such as chloroform. The               values higher than 2.4
ppm/°C are interpreted as the indications of change of N-H
protons from bound to free state, i.e., from H-bonded to exposed
to nonpolar solvents.
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The rates of peptide N-H proton exchange with the labile hydro-
gens or deuteriums in the medium can also provide information on
the H-bonded and nonbonded N-H protons (Molday et al. 1972;
Stern et al. 1968). This can be achieved either by adding a con-
trolled quantity of D2O into a protonated medium or by the
saturation transfer of the labile proton of the solvent by a
double resonance NMR method (Redfield 1978). The N-H protons
which are exposed to the solvent experience reduced signal inten-
sity according to the extent of their exposure to solvent. The
difficulty with this method is that the proton exchange rates
are the kinetic parameters which reflect the properties of the
transition state of rate determining step in the protolysis
r e a c t i o n  i . e . , a state which may not resemble the preferred
equilibrium state of the peptide. However, it is generally
desirable to confirm intramolecularly H-bonded peptide N-H
protons by as many methods as possible. There is, therefore,
another method where the peptide N-H protons show differential
dependence on the composition of a solvent mixture (Pitner and
Urry 1972). The advantage of this method is that both the pep-
tide N-H protons and peptide C=O carbons can be classified as an
appropriate H-bonded pair, i.e., N-H...O=C pairing can be estab-
lished. There is, however, one very essential requirement in
this method which requires that the molecule should retain the
same conformation(s) in both the solvents, which can be verified
by coupling constants and temperature studies as stated above.
Such an experiment is performed by monitoring the chemical shift
changes of peptide N-H protons and peptide C=O carbons from a
weak basic solvent, such as dimethyl sulfoxide, to a protic
solvent, such as trifluoroethanol. Very recently , Khaled and
Watkins (1983) have developed a new 13C(1H) NOE method to
detect simultaneously an H-bonded pair, i.e., N-H...O=C, in
peptides.
Estimation of Torsion Angles and
A conformation is completely described when the angle of rota-
tion about each bond of a peptide is specified (see figure’ 1 and
section 1). In peptides and amino acids, vicinal coupling be-
tween N-H and H protons provides information about the peptide
torsion angle using a Karplus relationship (1959) of the type
( 1 )
where is the dihedral angle formed between the H-N-
and planes.
The dihedral angle is related to the peptide torsion angle
by the equations
= -60 for L-amino acids
= +60 for D-amino acids (2)
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Empirically, Bystrov et al. (1969) have established the
following equations:
(3)
and for glycine residues
(4)
The above expressions give several possible angles for each ex-
perimental coupling constant. One of the possible angles would
be approximately correct, if there were no torsional motion.
Since, virtually in every case for a biological peptide, there
would be some toreional flexbility, it is important to realize
that the observed value is obtained from a summation of states
properly weighted according to its energy dependent probability.
Therefore, if the values ranging from 5.5 to 7.5 Hz were ob-
served, then this could imply either a single state, , or
nearly unrestricted rotation about the N-E bond. However, if a
value of 4 Hz or 8 Hz is obrerved, then these values indicate
substantially restricted angles. Similarly , if the residue is a
glycine, then the greater the nonequivalent the
NB-NHX coupling constants, the stronger the argument is for
limited rotation about the N- bond. If the coupling constants
are equivalent, it may be due to essentially unrestricted rota-
tion or, looking along the N- bond, due to the N-H line segment
bisecting the H- -H bond angle. The same considerations may
also apply to H-CbH2 for the determination of angle X, as
described below.
For the torsion angle of glycine residues, Barfield et al.
(1976) have determined an expression for the geminal coupling,
2J, which is also a function of the of equation 4.
= -13.91-1.55 ( 5 )
For L- and D-amino acid residues, NOE can be used as long as the
peptide moiety remains approximately planar, becaure the H i
to NHi+1 interproton distance is a function of the angle
(Leach al. 1977).
Side-Chain Conformations (X)
The conformational properties of amino-acid side-chain sometimes
restrict the allowed range of and angles if there  is an
intramolecular interaction with the adjacent amino acid. For a
complete understanding of the conformation of peptides it is
important to determine the conformation about the bond. A
correlation has been observed between 3J(HH) coupling constant
and the dihedral angle for the CH-CH system using again a
Karplus-like relation: 3J = B cos2 -C, were B + 10.4 for
0< <90, and B = 13.5 for 90< <180 and C = 0.
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FIGURE 6
Possible Side-Chain Conformations of Amino
Acids Rl= R2 = H for Ala, R1 = R2
= CH3 for Val, and Rl = H, R2 = aryl or
alkyl group representing Phe, Tyr, Leu, etc.
For most amino acid residues,there is considerable rotational
freedom about the bond. It is assumed that the three
staggered conformations (I, II, and III depicted in figure 6)
have relative populations, PI, PII, and PIII such that
P I  + P I I  + P I I I
(6)
For rotation about the bond that is rapid on the NMR time
scale
3J(HH)obs = J tP I I+J8P I+J8P I I I ( 7 )
assuming Jg has the same magnitude for conformers I and III.
For free rotation (P I  - P I I  = P I I  the observed 
3J is
given by
3J(HH)free = 1/3 (J t + 2Jg) (8)
From experimental coupling values and assuming J = 13.6 Hz
and J
rotamer
= 2.56 Hz, obtained by Pachler (1964), the relative
populations can be calculated for different amino acid
side-chains, such as valine, leucine, phenylalanine, aspartic
acid, and tyrosine. The torsion angles can also be estimated by
using the equation of Abraham and McLauchlan (1962):
10.5 cos2 X1 - 0.28 for X1 = 0 - 90°
(9)
10.7 cos2 X1- 0.29 for X1 = 90 - 180°
The relative population of trans and gauche, isomers can be
calculated, but it is not possible to distinguish between the
two possible gauche conformers (I and III in figure 6) unless
Rl and R2 have been unequivocally assigned, e.g., for valine
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(R1 = R2 = CH3) and phenylalanine (Rl or R2 = H). For
phenylalanine and tyrosine, the assignments of the two -CH2
protons could be made by stereospecific deuterium labeling.
This has been accomplished in enkephalin molecules by Kobayashi
et al. (1979, 1980). As mentioned above, a large or small
coupling constant or nonequivalence, involving a CH2 moiety ,
provides direct evidence for restricted torsion angles. Where
it becomes important to resolve the ambiguity of midrange
coupling constants and equivalent coupling to CH2 moieties.
synthetic enrichment with 13C and/or 15N can be carried out
and the additional heteronuclear coupling constants can be used
to resolve the ambiguity experimentally. This has recently been
done for the H2 torsion angles of enkephalins (Stimson
et al. 1979; Garbay-Jiurequiberry et al. 1982) and will be
discussed further in section 3.
Nuclear Magnetic Relaxation Times (Tl and T2)
The longitudinal or spin-lattice relaxation time (Tl) and the
trsnsversal or spin-spin relaxation time (T2), particularly the
Tl, have been used to study the dynamic behavior of enkephalin
molecules by many research workers.
In practice, T2 is measured from the line width of a single
signal by using the equation
(10)
where W is the line width at half height of a signal.
Various molecular dynamics can be well characterized by a time
factor called correlation time,which serves as a measure of the
average time that two nuclei remain in a given orientation and is
designated as Tc. For molecular rotation, the Tc is the average
length of time that the molecule requires to rotate through an
angle of a radian, while for translation, the Tc is the time it
takes to move the molecule to one molecular diameter. The rota-
tional process is related to the intramolecular relaxation,
while the translational process is related to the intermolecular
relaxation. In general, both processes depend on the viscosity
of the medium and vary critically on the size and shape of the
molecule involved. If the molecule being studied tumbles iso-
tropically and behaves like a spherical rigid rotor (having
only rotational motion),
given by (Levy and Nelson 1972).
the equation to derive Tc from T1 is
(11)
Where is the gyromagnetic ratio, w is the angular frequency,
and r is the distance between the two coupled nuclei. This is
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the relsxstion for one IH attached to a I5C; for I3C-IH,
the right-hand side of the equation will have to be multiplied
by n (n is the number of protons attached to a carbon atom).
Nuclear Overhauser Effect
As mentioned in the preceding section, besides providing the
estimate of torsion angle NOE can, in principle, be used in
determining the spatial relationships between nuclei that are
not covalently linked. It is the fractional change, f i  (j),
in intensity by cross-relaxation of one resonance, i, when
another resonance, j, is perturbed (Noggle and Schirmer 1971).
Simple mathematical derivations of fi (j) are given by Roques
et al. (1980) and, therefore, the repetition of such expressions
here is unwarranted. The change in intensity of the signal of
spin i on saturation of spin j reflects the relative proximity
of i and j. The NOE, fi(j), is, therefore, a function of both
the molecular geometry if a molecule and the molecular dynamics.
Two-Dimensional (2-D) NMR
In the event that the NMR spectra are too complex to be resolved
in normal NMR experiments, 2-D NMR in such cases appears to be an
invaluable tool. The basic principle of the experiment involves
two successive precession periods, t1 and t2. The first
time tl, is called the evolution period an the second time,d
t2,  is called the detection period. The spectral resolution
is characterized by two frequency coordinates, one with chemical
shift information and the other with the coupling constant infor-
mation. A large variety of experiments is possible, depending
on the phase or frequency of Rf irradiation, decoupling level,
and so on, that are applied to the nuclear spins during the
intervals t1 and t2.
These experiments include 2D J-resolved spectroscopy, 2D cor-
related spectroscopy (COSY) and 2D cross-relaxation spectros-
copy. In  enkephslin systems both the 2D-J-resolved and COSY
have been utilized by a few research workers (Gidley et al.
1981; Kessler et al. 1983, in press).
CONFORMATIONS OF ENKEPHALINS
Various physical methods, such as NMR, UV, CD, IR, and Laser
Raman spectroscopy have been used to derive the conformations of
enkephalin molecules. NMR, however, remains the most informa-
tive, as discussed. In this section, therefore, most of the NMR
work will be discussed along with other spectroscopic methods.
Since it is desirable to describe the backbone and side-chain
conformations separately, this section is divided into two
subsections.
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Backbone Conformations
From the structural modifications of enkephalin,the stereo-
specificity and the structure-activity relationships of each
residue have been established. Tyrosine at position 1 is the
most sensitive one; a slight alteration, even in its  aromatic
side-chain, drastically reduces the biological activity.
Clycine at position 2 can conveniently be replaced only by any
D-substituted amino acid residue. Positions 3 and 4 are fixed
for the glycine and L-phenylalanine residues, respectively,
while position 5 is quite open to any amino acid residue with
either L or D configurations. Based on these findings, Beddell
et al. (1977) have suggested various H-bonded conformations of
enkephalin whose general definitions and terminologies have
already been described. All such possible H-bonded conforma-
tions of enkephalin molecules are described below. Each of
these structures as observed by NMR and either supported or
refuted by other physical techniques has also been discussed.
Phe4 N-H 0=C Tyr1 (4 1 -turn, Bradbury et al (1976)
first predicted this -turn, formed between the Phe4 N-H and
Tyr1 C=0 groups from the application of the empirical rules
for predicting secondary structure from amino acid sequence.
Smith and Griffin (1978) also found this H-bond in crystalline
state of [Leu5] enkephalin grown from an aqueous methanol
solution. In all the previously reported studies in solution,
the occurrence of such H-bond could not be found. Only very
recently Beretta et al. (1984), for the first time, have pre-
dicted the formation of this -turn in complexes of [Met5] and
[Leu5] enkephalin amides with 18-crown-6-ether in chloroform
using high temperature dependence of Phe4 N-H proton
resonance, measured at 500 MHz, as the indication of H-bond for-
mation. As mentioned previously , there exists the controversy
of using parameter; accordingly, this report is one such
example. The lowest values reported in this study are for
Leu5 and Met5 N-H protons which, based on the other criterion
(see the indentification of H-bonds), should give rise to a
-turn involving the [Met5] N-H and Gly2 C=0 groups. This
conformational feature is discussed next.
Met5 or Leu5 N-H 0=C Gly2 (5 2 -turn), This is the
most commonly observed conformational feature of enkephalins
reported by many research groups. Roques et al. (1976) and
Jones et al. (1976) were the first to report the occurrence of 5
2 turn in DMSO-d6 based on the coupling constants and the
low values of Met5 or Leu5 N-H proton. Almost at the
same time , Bleich et al. (1976) reported a normal value
for the Met5 N-H proton and suggested that a folded conforma-
tion might be stabilized by a nonbonded interaction. Jones et
al. (1977) later came out with an explanation for this discre-
pancy showing that the cationic and switterionic forms of
enkephlin gave different NMR parameters. In all NMR studies
involving 1H, 13C and 15N nuclei in DMSO, the same 5 2
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-turn was observed (Khaled et al. 1977; Garbay-Jaureguiberry et
al. 1977; Stimson et al. 1979; Marion et al. 1981; Zetta and
Cabasai 1982). The controversy, however, remaineder for sometime
on the type of the turn. This -turn contains Gly3 - Phe4
peptide moiety within the 5 2 H-bonded ring. Since a glycine
residue could be substituted for a D-amino acid residue, thus
forming a D-L peptide moiety, this D-L configurational arrange-
ment should then be designated by a type II' -turn (see section
1) The 13C NMR studies by Stimson et al. (1979), however,
vere found to be beat compatible with a type I -turn vith pre-
sumably uncharged terminal groups. Laser Raman studies (Han et
al. 1980; Rapaka et al. 1984) supported a compact -turn struc-
ture, but the exact type could not be delineated. The proton
T1 measurement by Niccolai et al. (1980) also revealed the
occurrence of a type I -turn. The unequivocal determination of
the type of -turn by NOE (Khaled  and Urry 1976) was impeded by
the complex spin pattern of the Gly3 methylene protons. More
recently, however, mearurement of 3J1H(Gly3)1 5N ( P h e 4 )
by Garbay-Jaureguiberry et al. (1982) finally indicated the
occurrence of a type II' -turn which is also energetically more
favorable, as previously proposed by Isogai et al. (1977).
Associated form. The  associated form with an antiparallel
cross -structure was, first reported by Khaled et al. (1977)
from combined 1H and 13C NMR data. In this structure, four
intermolecular H-bonds were found to occur bet
and Gly3 C=0 groups and between the Met5
ween the Gly3 NH
or Leu5 NH and
Tyr1 C=O groups. A “head-to-tail” interaction was also pro-
posed and later supported by Anteunis et al. (1977). Occurrence
of such associated form in crystalline state was first noted by
Blundell and Wood (1982) but later completely described by Karle
et al. (1983).
Conformational equilibrium. Enkephalins are  small molecules
and, therefore, it is likely that there could be a number of con-
formations that these molecules may adopt in solution. The
variety of conformers discuessed above confirms the existence of
such molecular flexibility. Using 1H, 13C, CD, and UV spec-
troecopies, Khaled et al. (1977) demonstrated that different con-
formations may occur, depending on the nature of solvents and
concentration. They even proposed (Khaled et al. 1979) a confor-
mation resulting from the inversion at central Gly3 carbon
atom which is similar to a V-conformation (Beddell et al. 1977).
The results of subsequently performed 13C and 15N T1
studies (Tancrede et al. 1978; Marion et al. 1981) supported
such folding since Gly3 residue was found somewhat more re-
stricted than the Gly2 residue. Using sterochemically deuter-
ated Gly2 and Gly3 residues Fischman et al, (1978) also
showed the averaging of Gly2 and Gly3 angles in both
DMSO and D2O solvents. In addition, Higashiiima et al. (1979)
suggested that the zwitterionic form of [Met5] enkephalin in 
DMSO at low concentration may exist in an equilibrium of
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extended and folded conformations. Later, Miyazawa and Higashi-
jima (1981) used IR absorption spectroscopy to distinguish
cationic, zwitterionic, and anionic forms of N- and C-terminal
free enkephelins in DMSO and once again supported the existence
of a folded = extended conformational equilibrium. Although a
folded form was stabilized by an electrostatic interaction between
the free N- and C-terminals, the results from an NOE experiment
ruled out the possibility of a 5 2 -turn formation (Higashi-
jima et al. 1979).
Many different conformational equilibria vere also predicted
from the CD results as a function of temperature and pH (Spirtes
et al. 1978; Rollosi et al. 1980). Soos et al. (1980) used the
CD spectra of  enkephalin to determine structure-activity rela-
tionship. Based on the increased negative ellipticity at 225 nm
as indicative of folded conformation, they obtained a good cor-
relation betveen the degree of folding and the potency in the
GPI but not in the MVD, thus reflecting the requirement of folded
form at the µ-receptor sites. Conformational flexibility of
[Met5] enkephalin amide was also observed in methanol and tri-
fluoroethanol by using CD spectroscopy (Sudha and Balaram 1981).
The Laser Raman spectroscopic results reported by Ran et al.
(1980) also showed different conformers of [Leu5] enkephalin
in D20 in zwitterionic form.
(1982) used Raman spectroscopy to show that the occurrence of
Most recently, Rapaka et al.
-turn in [Leu5] enkephalin in vater is more predominant than
in [Met5] enkephalin. This interpretation was
the observation of a strong band at 1263 cm-1 for [Leu5]
derived from
enkephalin in comparison with a shoulder at 1265 cm-1 for
[Met5] enkephalin.
In an effort to minimize the conformational freedom, several
cyclic analogs of enkephalin have been Synthesised with re-
rtric ed
D+Cys5] and [D-Pen2, D+Cys5] enkephalinamides, cyclired
backbone. Two sush cyclic analogs are: [D-Cys2,
via S-S bond. Pen stands for penicillamine and is equivalent to
-dimethylcyeteine. The former peptide showed the preference for
the µ-receptor (Schiller et al. 1981), while the latter
displayed significant -receptor specificities (Hosberg et al.
1982). The only difference between these two peptides is the
side-chain of the amino acid at position 2. Recently the 1H
NMR studies by Mosberg and Schiller (1984) revealed a common con-
formational characteristic for both peptides. Although they did
not indicate any particular conformational feature, it appears
from the parameter of the amide protons that the NH proton
of the L or D-Cys5 is the most shielded one, thus indicating
the formation of a 5 2 -turn. Another interesting group of
cyclic analogs of enkephalin reported by Kessler et al.
(in press) are the Tyr-Cyclo (-N-Xxx-Gly-Phe-Leu-) where Xxx =
L-Orn, L-Lys, or D-Lys. The D-Lys2 analog is 10 times more
active in the GPI assay, i.e., µ-receptor specific, than the
D-Orn2-compound. Use of 2D 1H and 15N-1H COSY, 3J, and
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parameters have all been used in order to understand the
conformational properties of these peptides. The D-Orn2-
analogs showed a Leu5 N-H O-C Gly3 H-bond which they
designated as -turn (please see the first section and note the
discrepency) and an intramolecularly bifurcated H-bond between
the Orn2 N-H and Orn2 C=0 groups. The D-Lys compounds, on
the other hand, have been found to possess another bifurcated
10-membered intramolecular H-bond between the D-Lys N-H and the
Gly3 C=O groups which they called a -turn (See the definition
o f -turn that appeared above and note again the discrepancy).
The D-Lys2 compound is rather flexible and the µ-receptor
specificity has been attributed to this reduced rigidity. How-
ever, contrary to this finding, Mosberg and Schiller (1984)
correlated the increased flexibility of [D-Pen2, L-Cys5]
enkephelinamide with the stronger preference for the -receptor
sites.
Side-Chain Conformational (X)
An extensive effort has been made to  elucidate the side-chain
conformations of Tyr1, Phe4, and Met5/Leu5 amino acid
residues in enkephalin molecules. NMR remained to be the sole
spectroscopic method for providing information in this  area.
However, various ways of interpreting NMR data have made it dif-
ficult to reach any concensus on the ride-chain conformetions.
As mentioned earlier (see the section on side-chain conforma-
tions), there are two ways of analyzing 3J couplings. The
usual way is to obtain the weighted average of three populations
(see figure 6) in case of free rotation along the bond.
If , however, there is any indication of restricted rotation
either from the nonequivalent appearance of H2 protons or
from the relaxation time measurements of the side-chain, the
interpretation becomes more complicated. Some of these complica-
tions  wil now  be discussed in reletion to Tyr1, Phe4, and
Met5/Leu5 side-chain conformations in enkephalins.
Tyr1 Side-Chain
Since an unsubstituted tyrorine residue at position 1 is abso-
lutely necessary for opioid activity in enkephalinlike mole-
cules) the determination of its side-chain conformations drew
considerable attention. Horn and Rodgers (1976) first suggested
that the N-terminal of enkephalins may be serving the same role
as found in several narcotics, such as levorphenol, metazocine,
and profadol. All such drugs contain en important hydroxyl (OH)
group and a tertiary amino group within the molecule. The dis-
tances between these two groups in various opiate agonist and
antagonist molecules varies from 6.89 to 7.08 A. Loev and Burt
(1978) attempted to gain insight into this problem by comparing
enkephalin conformations vith rigid opiate 7-[1-Phenyl-3-bydroxy-
butyl-3] endoetbano-tetrahydrotbebeine (PET) and found that
there is an excellent overlap of tyramine moiety of PET with the
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Tyr1 side-chain when = -90°, although it was not the
lowest energy conformation. In the first crystgllographic study
by Smith and Griffin (1978), tvo values (-43° and -86°)
for Tyr1 were reported. a l .
(1983), hovever,
In a second X-ray study,Karle et
reported four sets of values, i.e.,
177° 70°, 53°, and 169°. The = -86 reported by
Smith and Griffin (1978) for [Leu5] enkephalin in its folded
form seems to bear a good resemblance with the postulation of
Loew and Bert (1978).
The solution conformations of Tyr1 side-chain remained most
controversial and confusing. Following a Pachler-like (1964)
analysis of the 1H NMR data obtained in
DHSO-d6 (Jones et al. 1976; Garbay-Jaureguiberry et al. 1976,
1977; Robayashi et al. 1980; Zetta and Cabassi 1982) and in
D20/DMSO-d6 (Anteunis et al. 1977) shoved that all three
ride-chain rotamers are equally populated; in another word, the
bond is freely rotating. The problem associated in this
kind of NMR data analysis in the averaging of the two
a n d  3 J values. For example,
one of the Tyr1 values is ca. 5 Hz and the other is
ca. 8 Hz; the mean value is 6.5 Hz, which is essentially an indi-
cation of free rotatio Whereas, as discussed previously, this
nonequivalency, i.e., 3JAX = 5 Hz and 
3JBX= 8 Hz,
should be considered as indicative of some kind of restricted
motion at the bond. Bleich et al. (1976, 1979) reported
the 1H and 13C relaxation parameters, confirming such
restricted rotationlof the Tyr1 ride-chain. They even con-
cluded that the Tyr1 side-chain alternates between the g+ and
states  at  a  s low rate of  400 sec .  Careful  analysis  of
values of 2.7 and 1.0 Hz obtained by Stimson et
gave a number of values, out of which = -60 or
-90 has been considered most favorable. It appears from all the
NMR studies that the Tyr1 side-chain prefers a more populated
tg conformation, reflecting one of the above mentioned values
ranging from -60° to -90°. Interestingly, however this
side-chain conformation of tyroeine is more compatible with the
tyramine moiety of an opiate.
Phe4 Side-Chain Conformation
Folloving again the method of Pachler (1964), the three rotamer
populations of Phe4 side-chain were found to be equally pre-
ferred (Jones et al. 1976; Carbay-Jaureguiberry et al. 1976,
1977; Anteunis et al. 1977) both in DMSO-d6 and D2O. Koba-
yashi et al. (1979) and Zetta and Cabassi (1982), however, sug-
gested the predominance of a tg conformation which is also
strongly supported by Stimson et al. (1979). The 1H and 13C
T1 values, on the other hand, indicted a rapid internal motion
relative to the peptide backbone (Bleich et al. 1976; Niccolai et
al, 1980). It appears, therefore, that there still exist dis-
agreements in the case of for L-Phe4 residue in enkephalin
molecules.
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Met5/Leu5 Side-Chain
This is the only residue in all enkephalin molecules that seems
to enjoy a common agreement on its side-chain conformation,
1H NMR data analysis using the Pachler (1964) method gave a
free rotating bond both in DMSO-d6 and D3O (Jones et
al. 1976; Garbay-Jaureguiberry et all
1977; Zetta and Cabasei 1982). The 1H and 13C relaxation
1976; Anteunis et al.
parameters in this case are also in excellent agreement, i.e.,
they shov a rapid internal rotation (Bleich et al. 1976; Combris-
son et al. 1976; Niccolsi et al. 1980). Leu5 side-chain, to
the contrary, adopts a conformation that exists predominantly in
the tg state (Garbay-Jaureguiberry et al. 1977, 1982; Stimson
et al. 1979).
CONCLUDING REMARKS
Numerous applications of theoretical and physical methods have
at least established the fact that the enkephalins are extremely
flexible molecules. By introducing the cyclization constraint
in the backbone, it was possible to define a particular conforma-
tion. The question remains, hovever, why one molecule prefers a
µ- and the other a -receptor vhile both the molecules seem
to adopt a similar backbone conformation? Recently, Deek et al.
(1983) have synthesized tvo analogs of [Leu5] enkephalin,
namely [(2-Amino-5-hydroxy-2-indanyl)carbonyl] and [(2-Amino-6-
hydroxy-2-tetralinyl)carbonyl]Gly-Gly-Phe-Leu-OMe, with re-
stricted Tyr1 side-chain where the latter has been found to be
7 to 8 times more active than the [Leu5] enkephalin at the µ-
receptor site. Although no conformational studies have been
reported, the Dreiding model of this constrained side-chain of
Tyr1 favors = -90, which is compatible with the tyramine
moiety of an opiate (vide supra). Possibly, this means that the
tyroeine alone can mimic the opioid activity if appropriately
carried to the receptor site(s). To test this hypothesis, L Tyr
was linked with dodecalamine and its activity vas tested using a
mouse seizure model (Khaled and Beaton 1985). Surprisingly,
this molecule was found to possess analgesic activity similar to
other opiates, as previously reported (Snead and Bearden 1982).
These findings, therefore, resffirm the notion that the deriva-
tion of the actual bioactive conformation(s) of enkephalins will
have to wait until such time as the receptor sites are identified,
isolated, and characterized.
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Conformational Analysis of Opioid Peptides
and the Use of Conformational Restriction
in the Design of Selective Analogs
Peter W. Schiller, Ph.D.
INTRODUCTION
The discovery of the enkephalins by Hughes et al. (1975) was
a lmos t  imed ia te ly  f o l l owed  by  e f f o r t s  t o  de te rmine  the
conformation of there pentapeptider and to correlate it with the
three-dimemlonal structurer of the more rigid opiates. The
conformational   analysis of small linear peptides like the
enkephelins is not without problems. There is a strong
poss ib i l i t y  tha t  ra ther  than  assuming  a  s ing l e  p re f e r red
conformation in solution, they may exist in a conformational
equilibrium. It is quite likely that their conformation(s) may
be determined to a large extent by the molecular environment.
Furthermore, the bioactive conformation may not preexist in
solutlon, but may only be adopted when the peptide interacts
with the receptor, perhaps in a step-wise binding process
similar to  the “zipper”-type model propored by Burgen et al.
(1975). In the part 8 years, the c o n f o r m a t i o n  o f  t h e
enkephalins and of other opioid peptides has been studied
extensively by means of nearly all theoretical and experimental
methods avai lable  to  date . A wealth of information about
conformational features of there peptide in the isolated state,
in cryrtalline form, and in solution has been obtained and will
be reviewed in the first part of this chapter. Ideal ly ,  the
bioactive conformation should be studied with the peptide bound
to a purif ied receptor.  Since purif ied opioid receptors are
still unavailable at this time, insight into the receptor-bound
conformation of opioid peptides ten only be obtained indirectly
through analysis of conformationally constrained analogs which
are biologically active. Moreover, in the case of the opioid
peptides, the situation is  further complicated through the
existence of multiple opioid receptors etc.) which
dif fer  from one another In their structurel requirements.
Therefore, i t  w i l l  be  necessary  t o  de te rmine  a  d i s t inc t
receptor-bound conformation for each type of receptor capable of
interacting with a particular opioid peptide. The pharmacologic
and conformational characterization of conformationally
rertricted opioid peptide analogs wil l  be dercribed in the
second part of this chapter.
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A review covering the early literature on conformational studies
of enkephalin has been published by Gorin et al. (1978). A more
recent comprehensive review dealing with the conformational
analysis  o f the enkephalins and with conformation-activity
relationship has been w r i t t e n  b y Schiller (1984).
Confonnational features of the endorphins have been reviewed by
Yamashiro and Li (1984).
HYPOTHETICAL MODELS OF THE BIOACTIVE CONFORMATION OF ENKEPHALIN
Structural comparisons between opioid peptides and opiates
require first of all the identification of structural elements
which may play analogous roles in the interaction with opioid
receptors. Subsequently, a pharmacophoric conformation of the
peptide has to be postulated such that spatial overlap between
corresponding functional groups in the peptide and in the more
rigid opiates is achieved. The  fa c t  tha t corresponding
modifications of the tyramine moiety in morphine and of the N-
terminal tyrosine residue in enkephalin produce similar changes
in the activity profile (cf. Schiller 1984) strongly suggeste
that the tyramine moieties contained in the peptide and in the
alkaloid are functional correlates. This correspondence formed
the basis for nearly all hypothetical models of the bioactive
conformation of enkephalin which have been proposed to date.
Essentially two different proposals have been made concerning
t h e  f u n c t i o n a l  r o l e  o f the Phe4 residue in  enkephal in in
relation to structural elements of morphine-related analgesics.
Bradgury et al. (1976) suggested that the Phe4 side-chain of
[Met5]enkephalin and the phenethyl substituent attached to
carbon-19 of the potent morphine derivative PEO1 might bind to
an identical receptor subsite. Consequently, an appropriate
pharmacophoric
accossaodate
conformation of  enkephalin would have to
the tyramine segment of Tyr1 and the Phe4 aromatic
r i n g  i n  a  r e l a t i v e  s p a t i a l  d i s p o s i t i o n  a n a l o g o u s  t o  t h a t
existing between the corresponding moieties in PEO (phenol-phenyl
separation of about 10 Å). Proposed confonnational models which
fulfil this condition include a 4 1 hydrogen-bonded -bend
conformation (Bradbury et al. 1976), the 5 2 hydrogen-bonded
II'-bend (Clarke et al. 1978), and a bent conformation centered
on Gly2-Gly3 lacking an intramolecular hydrogen bond (Hudson et
a l . 1980). In an alternative proposal, the atoms in para and
meta position of the Phe4 residue in enkephalin were considered
as functional correlates of atoms C5 and C6 contained in the C-
ring of morphine, again under the assumption of functional and
spatial correspondence between the tyramine moieties contained
in the two molecules. A systematic computer search performed
with the active tetrapeptide H-Tyr-D-Ala-Gly-Phe-OH resulted in
a single s t e r i c a l l y allowed conformation in which the meta
p o s i t i o n  o f the Phe4 aromatic ring nearly coincided with the
s p a t i a l  p o s i t i o n  o f the carbon-6 atom in morphine. I n  t h e
latter conformation, the intramolecular distance between the two
aromatic rings is much shorter (about 5) than in t h e -bend
models (see above). Aside from these two major proposals, a
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number of other suggestions concerning corresponding functional
moieties in enkephalin and opiates have been made and, obviously,
no general consensus has been reached to date.
CONFORMATIONAL ANALYSIS OF OPIATES
Theoretical Energy Calculations
The f irst  conformational  energy study of  [Met5]enkephal in
performed by Isogai et al. (1977) using the ECEPP program
resulted in a lowest energy conformation characterized by a type
II-bend centered on Gly3-Phe4 and stabilized by a hydrogen bond
between the tyrosyl hydroxyl group and the carbonyl group of
Gly3. This conformer permits substitution of Gly2 by L-Ala but
not by D-Ala and, therefore, it is unlikely to represent the
receptor-bound conformation, since it is well known that D-Ala2
analogs of enkephalln retain high potency and L-Ala analogs are
only weakly active. Performing a different type of
conformational energy calculation, DeCoen et al. (1977) obtained
a number of different olded and extended structures as low
energy conformers of [Met5]enkephalin and it was suggested that
an equilibrium of such different conformations might also exist
in  so lut ion. The results of a study based on the use of the
Monte-Carlo method in conjunction with a clustering analysis
al so indicated that a limited number of different structural
classes might best represent the conformational behavior of
enkephalin in solution (Maigret and Premilat 1982). In a
subsequent study dealing with enkephalin analogs, Humblet and
DeCoen (1977) found a folded structure with a turn centered on
residues 2 and 3 as lowest energy conformer of [D-Ala2,Met5]en-
kephalin which was considered as a likely candidate f o r  t h e
bioactive conformation of enkephalln.
Ala 2 ,Met5]enkephal in
Based on the results of a
semi-empirical conformational analysis of [Met5]enkephalin, [D-
al.  (1978) proposed a 4 1 hydrogen-bonded I-turn as the
and [D-Ala3,Met5]enkephalin, Balodis et
receptor-bound conformation. Using the ECEPP program, Manavalan
and Momany (1981) performed an analysis of seven enkephalin
analogs and found that several different low energy conformers
common to the group of analogs studied exist. Furthermore, it
became obvious that conformers with significantly different
backbone structures may st i l l  have a very s imilar  spatial
disposition of the side-chains in positions 1, 4, and 5 and, in
fact, the existence of only three major categories of side-chain
configurations was indicated by the results of this study. Loew
and Burt (1978) used the ECEPP program as well as a quantum
chemical method to determine the energy content of enkephalin
conformers which display various degreea of spatial overlap with
PEO. A II'-bendlike structure showing spatial overlap of the
Tyr1  tyramine segment and the Phe 4  s ide-chain with the
corresponding moieties in PEO was found to be only 3.5 kcal/mol
higher in energy than the lowest energy conformer and thus
represents a plausible candidate for the active conformation.
More recently, Loew et al. (1982) used a similar approach to
study N-terminal tetrapeptide analogs of enkephalin and obtained
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two structures of the II'-bend type, stabilized by a hydrogen
bond between the N-terminal amino group and the Phe4 carbonyl
group, which showed good rpatial overlap with PEO. In a similar
approach, M a i g r e t  e t  a l . (1981) determined minimum energy
conformers of H-Tyr-D-Ala Gly-Phe-OH by imposing a somewhat
different rpatial overlap with structural elements of morphine
and obtained a putative pharmacophoric conformation which
d i f f e red  s i gn i f i cant ly  f r om that  des c r ibed  by  Loew e t  a l .
(1982).
Grystal Structure Determinations
In a first X-ray study. the interpretation of the diffraction
pattern obtained with crystals of [Leu5]enkephalin grown from
aqueous methanol  led to  the proposal  of  a -bend structure
stabilized by two antiparallel hydrogen bonds between the amino
group of Tyr and the carbonyl oxygen of Phe and between the
amide proton of Phe and the carbonyl group of Tyr (Smith and
Griffin 1978). Moreover, the data indicated the existence of
two different conformations of the Tyr1 reasidue. Essentially
the same crystal  structure was recently obtained with the
analog [4'-Br)Phe4,Leu5]enkephalin as the result of an X-ray
study carried out by Ishida et al. (1984). In the meantime.
examination of improved diffraction patterns obtained with the
original [Leu5]enkephalin c rys ta l s  l ed  t o  the  de te c t i on  o f
additional weak spots. indicating that the crystals balonged to
space group A2 rather than C2, as had originally been assumed.
The recently completed analysis of there patterns revealed the
existence of four conformationally distinct [Leu5]enkephalin
molecules per unit cell. Whereas the four molecules have very
similar backbone conformations closely resembling the originally
proposed -bend structure, they differ from one another
significantly in the orientation of the ride-chains (G.D. Smith,
personal communication, 1983). Karle et al. (1983) performed an
X-ray analysis with [Leu5]enkephalin crystals grown from DMF in
the presence of water which turned out to belong to space group
P 2 1 .  A g a i n ,  t h e  u n i t  c e l l  c o n t a i n e d  f o u r  m o l e c u l e s  o f
[Leu5]enkephalin. each having a distinct conformation, but
all of them showing similar extended backbones, in sharp
contrast to the folded conformations existing in the crystals
belonging to apace group A2. The major differences between the
four molecules are again observed in the orientation of the
side-chains. Preliminary results of an X-ray study recently
performed with [Met5]enkephalin also provided evidence for an
extended backbone structure (Ishida et al. 1984). The folded
and extended structures observed with the enkephalins i n  t h e
crystalline state moat likely represent conformers of comparably
low energy; however. there is no compelling reason to assume
that they represent bioactive conformations (cf. Schiller 1984).
Conformational Studies in Solution
Numerous studies on the solution conformation of the
enkephalins have been performed by spectroscopic techniques
under various solvent conditions. These experiments provided
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information concerning the aggregation behavior of enkephalin,
the backbone conformation(s) of the peptide, intramolecular
distances in analogs. and side-chain orientations.
Both Khaled et al. (1977) and Higarshijima et al. (1979) observed
a concentration dependence of Shemica shifts in NMR studies
performed with [Met5]- and [Leu5]-enkephalin in DMSO which was
interpreted to indicate a molecular assoc ia t i on  process .  In
contrast to these results, Bleich et al. (1976), Stimson et al.
(1979). and Marion et al. (1981) found no evidence for self-
aggregation in DMSO. On the other hand, there is general
agreement that enkephalin does not self-associate in aqueous
solution (Bleich et al. 1976; Levine et al. 1979; Higashijima
et al. 1979; Schiller et al. 1978).
Baaed on the results of NMR and other studies, several propoeals
for a preferred backbone conformation of the enkephalins have
been made. NMR data obtained with [Met5]enkephalin in DMSO were
interpreted to indicate the existence of  a  5 2 hydrogen-
bonded I-turn stabilized by a hydrogen bond between the amide
proton of Met5 and the carbonyl oxygen of Gly2 (Roques et al.
1 9 7 6 ;  J o n e s  e t  a 1 .  1 9 7 6 ) .  T h i s  t y p e  o f  c o n f o r m a t i o n  c a n
accommodate the Tyr1 residue and the Phe4 side-chain in a
relative spatial disposition similar to that existing between
the corresponding moiet ies  in PEO and,  therefore,  i t  was
suggested that it might represent the bioactive conformation of
[Met5]enkephalin. However, the fact that the analog
[Leu(NMe)5]enkephalin is active indicates that a hydrogen bond
involving the amide proton in position 5 is not an absolute
requirement for the receptor-bound conformation (Schiller and
St.-Hilaire 1980). Performing an NMR study with the cationic
form of [Met5]enkephalin in DMSO, Bleich et al. (1976) found no
evidence for a 5 2 hydrogen bond and suggested that a
p r e f e r r e d  c o n f o r m a t i o n  m i g h t  b e  s t a b i l i z e d  b y  s o l v e n t
interactions. Based on the results of yet another NMR study in
DMSO, Khaled et al. (1977) proposed a 5 2 hydrogen-bonded
turn model of the monomeric form of enkephalin containing a
second  hydrogen  bond between the amide proton of Gly3 and the
carbonyl oxygen of Tyr1 and a third one between the Tyr1
hydroxyl group and the Gly3 carbonyl group. Similar results
were obtained by Zetta and Cabassi (1982). The conformation of
[Leu5]enkephalin in DMSO was also investigated by NMR
spec t ros copy .  Or ig ina l l y  ob ta ined  1 H NMR data  (Garbay -
Jaureguiberry et al. 1977) led again to the proposal of a 5 2
hydrogen-bonded -bend model which was subsequently revised in
favor of a 2-5 II'-bend structure on the basis of 15N NMR data
obtained by the same group (Garbay-Jaureguiberry et al. 1982)
The results of a 13C NMR study performed by Stimson et al.
(1979)
centered on Gly3-Phe4. Based on NMR data obtained in D20,
were interpreted to be compatible with a type I -bend
severa l  p roposa le  f o r  a  p re f e r red  con fo rmat i on  o f  the
enkephaline in aqueous solution were made. Roquee et al. (1976)
and Jones et al. (1976) suggested that the 2-5 I-bend model
they proposed for [Met5]enkephalin in DMSO might also represent
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the predominant conformer in water. The studies performed by
Bleich et  al .  (1976) .  Levine et  al .  (1979) ,  and Zetta et  al .
(1979) also suggested the existence of a preferred conformation
in aqueous solution but  did not  provide any evidence for
intramolecular hydrogen bonding. Finally, 1H and 13C NMR data
obtained by Higashi j ima et  al .  (1979)  were interpreted to
indicate that [Met5 lenkephalin in D20 predominantly exists in an
extended conformation devoid of intramolecular hydrogen bonds.
In contrast  to  the proposals  in favor of  a  s ingle  preferred
back bone conformation of enkephalin discussed so far, several
other studies produced results which were more in tune with a
conformational equilibrium involving a number of different
conformers. Fishman et al. (1978) measured 3J(H’-H ) coupling
constants at positions 2 and 3 of the peptide sequence with two
isomers of [Leu5]enkephalin containing stereochemically
deuterated glycine residues. The obtained results indicated
that averaging of the and angles is taking place both in
2H6-DMSO and in D20 and, therefore, provide strong evidence
against a single preferred backbone conformation in the central
part of the peptide. NMR data obtained by Higashijima et al.
(1979) with the zwitterionic form of [Met5]enkephalin in 2H6-
DMSO were taken to indicate an equilibrium of extended and
folded conformations. Analysis of CD spectra obtained with
[Met5]enkephalin in H20 and trifluoroethanol (Spirtes et al.
1978) and of a Raman spectrum recorded with [Leu5]enkephalin in
D 20 (Han et  al .  1980)  also  led to  the conclusion that  the
e n k e p h a l  i n  m o l e c u l e s  e x i s t  a s  a n  e n s e m b l e  o f  d i f f e r e n t
conformers.
In a number of Studied, intramolecular distances between side-
chains in enkephalin analogs were determined. A fluorescence
energy transfer experiment performed with the active analog
[Trp4,Met5]enkephalin in H20 resulted in an average
intramolecular distance between the phenol ring of Tyr1 and the
indole  moiety of  Trp 4  o f  9 .3  ±  0 .4  Å (Schi l ier  1977) .  This
distance would be compatible with the Tyr1-Trp4 separation
observed in the various -bend models and with the distance
between the two aromatic rings in PEO. However, it is quite
possible that the measured value represents an average of
distances present in several different conformers participating
in a conformational equilibrium and, in fact, the results of a
Monte-Carlo type calculation were found to be in agreement with
the latter  interpretation (Demonté et  al .  1981) .  In further
energy tranefer studies, no gross difference in the average
Tyr1-Trp4 intramolecular distance was observed within a series
of nine [Trp4lenkephalin analogs which differed widely from one
another in their  µ-receptor  af f inity (Schil ler  et  al .  1978;
Schiller and St.-Hilaire 1980). Interestingly, a much larger
Tyr1-Trp4 intramolecular distance (> 15 Å) was determined with
the potent dynorphin analog [Trp4]dynorphinI(1-13) (Schiller
1983a). This marked difference in the Tyr1-Trp4 separation
between the [Trp4]analogs of enkephalin and dynorphin may be
related to the different receptor selectivity profiles of the
two peptides. A close proximity between the methyl groups of the
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Ala2 and Met5 side-chain in [D-Ala2,Met5]enkephalin was
indicated by the results of an NOE1 experiment (Niccolai et al.
1980).
Numerous studies on side-chain conformations in enkephalin have
been performed (for a detailed review, see Schiller 1984).
Side-chain rotamer populations were mainly determined by Pachler
analysis of 1H NMR data. There is some agreement that the tg-
rotamer may represent the favored conformation of the Tyr1 side-
chain under a variety of conditions (Kobayaehi et al. 1979;
Zetta and Cabassl 1982; Stimson et al. 1979). Interestingly.
the tg - rotamer shows closer conformational resemblance with the
tyramine segment in morphine than the other two side-chain
rotamera (tg+ and gg+). Furthermore, the results of most spin-
l a t t i c e  r e l a x a t i o n  t i m e  m e a s u r e m e n t s  i n d i c a t e d  a  f i x e d
conformation of the Tyr1 residue relative to the peptide
backbone (Bleich et al. 1976; Combrisson et al. 1976; Garbay-
Jaureguiberry et al. 1977). Evidence to indicate that the Tyr1
hydroxyl group of enkephalin in H20 or DMSO/H20 mixtures does
not participate in an intramolecular hydrogen bond with a
backbone carbonyl group was obtained from a fluorescence study
(Schiller 1977). a UV titration etudy (Spirtes et al. 1978).
laser Raman experiments (Han et al. 1980). and a4
 1H NMR study
(Zetta and Cabassi 1982). In the case of the Phe4 side-chain,
all three rotamers were found to be significantly populated
according to the results of reveral studies, with the exception
of that performed by Stimson et al. (1979) which indicated that
in 2H6-DMSO the Phe
4 tg- rotamer is exclusively populated.
Furthermore, it has been well established that the Phe4 side-
chain in the natural enkephalins undergoes rapid internal
rotation relative to the peptide backbone. In 2H6-DMSO, all three
rotamers of the Met5 side-chain in [Met5]enkephalin were found
to be populated to some extent, where as in [Leu5]enkephalin the
L e u 5  s i d e - c h a i n  a p p e a r s  t o  e x i a t  e x c l u s i v e l y  i n  t h e  t g -
conformation (Garbay-Jaureguiberry et al. 1977;
1979). With [Met5]enkephalin, rapid internal motion of the Met5
Stimson et al
side-chain was again indicated by the reaults o f  sp in - la t t i ce
relaxation time measurements.
CONFORMATIONALLY RESTRICTED OPIOID PEPTIDE ANALOGS
Insight into the receptor-bound conformation can be obtained
from structural analysis of conformationally restricted analogs
t h a t  r e t a i n  b i o l o g i c a l  a c t i v i t y .  H o w e v e r ,  u n a m b i g u o u s
conclusions cannot be drawn in the case of conformationally
constrained analogs which are inact ive,  s ince the loss  of
activity could be due either to an incompatible conformation or
to a lack of the necessary molecular flexibility required in a
step-wise binding process.  A further interesting aspect  of
introducing conformational constraints into biologically active
peptides is the possibility of obtaining selective analogs in a
situation of receptor heterogeneity.
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Conformational constraints have been built into the peptide
backbone of  enkephal  in  by subst itut ion of and
methylamino acids in various portions (for a review, see Gorin
et al. 1978). Local conformational restrictions of the peptide
backbone through insertion of 5- or 6-membered cyclic structuree
resulted in mostly inactive analogs (for a review, see Schiller
1984). Several enkephalin analoge containing conformationally
restricted side-chains have been reported. Restriction of the 
r o t a t i o n a l  f r e e d o m  o f  t h e  T y r 1  s i d e - c h a i n  i n  e n k e p h a l i n
substitution of 2-amino-6-hydroxy-tetralincarboxylic acid in
position 1 resulted in an active compound, whereas an analog
with 2-amino-5-hydroxy-2-indancarboxylic acid in that same
position was found to be inactive (Deeks et al. 1983). The
relatively flexible tetralin residue can assume conformations
corresponding to the tg - or tg+ rotamer of tyrosine but not to
the gg+  rotamer, whereas the latter rotomer is the only one
accessible to the rigid indan structure. This observation is of
in teres t  in  v i ew  o f  the  fa c t  ths t  the  tg -  r o tamer  shows
resemblance with the conformation of the tyramine moiety in
morphine. Conformational restriction of the Phe4 side-chain was
achieved through substitution of l-aminoindan in H-Tyr-D-Ala-
Gly-Phe-OH (Gorin et al. ,1980) and of dehydrophenylalanine with
Z-configuration in [D-Ala2,Met5]enkephalimide (Chipkin et al.
1979). In both cases, the obtained analog showed good activity.
More drastic restrictions of the overall conformation of opioid
peptides has been achieved through synthesis of cyclic analogs.
Cyclic enkephalin analogs obtained through direct head-to-tail
cyclitation between the terminal amino and carboxyl group
(Kessler and Holzemann 1981) or through linkage of the termini
via a glycyl residue or a 2-aminoethyl group as bridging element
(Hudson et  al .  1980)  were found to  be  e ither  insoluble  or
inactive.
In an alternative approech. cyclic opioid peptide analogs were
synthesised through ring closure between a side-chain group and
the C-terminal carboxyl group or through covalent linkage of two
side-chains. A common characteristic of these analogs is an
exocycl ic  Tyr1  residue.  A f irst  family of  cycl ic  enkephalin
analogs was obtained through substitution of a D- -diamino
acid residue in position 2 of enkephalin and cyclication of the
-amino group to the C-terminal carboxyl group (DiMaio and
Schiller 1980; DiMaio et al. 1982a) (figure 1, compounds I-IV).
A n a l o g s  w e r e  t e s t e d  i n  b i o a s s a y s  b a s e d  o n  i n h i b i t i o n  o f
electrically evoked contractions of the GPI and of the MVD1,
w h i c h  a r e  r e p r e s e n t s t i v e  f o r  µ -  a n d -opioid receptor
i n t e r a c t i o n s ,  r e s p e c t i v e l y  ( t a b l e  1 ) .  I n  c o m p a r i s o n  t o
[Leu5]enkephalin, the prototype of this series, H-Tyr-c[-N -D-
A2bu-Gly-Phe-Leu-] (II) was shows to be 17 times more potent in
the GPI assay and 7 times less potent in the MVD assay.
Therefore. this cyclic analog shows preference for µ-receptors
over -receptors, as indicated by its IC50(MVD)/IC50(GPI) ratio
of 5.77. No such preference is shown by the corresponding
open-chain analog, H-Tyr-D-Abu-Gly-Phe-Leu-NH2 (IIa), which is
dist inguished from its  cycl ic  counterpart  II  merely by the
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FIGURE 1
Structural Formulas of Cyclic Opioid Peptide Analogs
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TABLE 1
Potencies of Cyclic Enkephalin Analogs in the GPI and MVD-Assaya
Compound
GPI MVD
ICSO [nM] IC50 [nM]
MVD/GPI
IC50-ratio
I
II
IIa
IIb
IIc
III
IV
IVa
IVb
IVc
IVd
IVe
IVf
H-Tyr-c[-N -D-A2pr-Gly-Phe-Leu-] 23.4 ± 4.2
H-Tyr-c[-N -D-A2bu-Gly-Pht-Leu-] 14.1 ± 2.9
H-Tyr-D-Abu-Gly-Phe-Leu-NH2 28.7 ± 1.3
H-D-Tyr-c[-N -D-A2bu-Gly-Phe-Leu-] 3'230 ± 760
H-Tyr-c[-N -L-A2bu-Gly-Phe-Leu-] 1'450 ± 350
H-Tyr-c[-N -D-Orn-Gly-Pht-Leu-] 48.0 ± 4.3
H-Tyr-c[-N -D-Lye-Gly-Phe-Leu-] 4 . 8 0  ± 1.79
H-Tyr-D-Nle-Gly-Phe-Leu-NH2 24.6 ± 1.6
H-Tyr-c[-N -D-Lye-Gly-Phe-D-Leu-] 2 . 3 9  ± 0.57
H-Tyr-c[-N -D-Lye-Gly-Phe-Met-] 1 . 2 0  ± 0.26
H-Tyr-cc-N -D-Lye-Gly-Phe(pN02)-Leu-] 0.504 ± 0.138
H-Tyr-c[-N -D-Lye-Gly-Leu-Phe-] 3.36 ± 0.04
H-Phe-c[-N -D-Lye-Gly-Phe-Leu-] 105 ± 19
[Leu5]enkephalin 246 ± 39
73.1 ± 14.5
81.4 ± 5.8
45.6 ± 9.1
330 ± 102
475 ± 99
141 ± 28
25.2 ± 7.9
17.5 ± 5.7
34.3 ± 5.5
13.4 ± 6.3
41.6 ± 9.4
4'070 ± 200
11.4 ± 1.1
3.12
5.77
1.59
0.102
9.90
29.4
1.02
7.32
28.6
26.6
12.4
38.8
0.0463
a Mean of three determinations ± SEM.
opening of a single carbon-nitrogen bond. This result indicates
t h a t  t h e  µ - r e c e p t o r  s e l e c t i v i t y  o f  c y c l i c  a n a l o g  I I  i s
exclusively due to the conformational constraint introduced
through ring closure, and, furthermore, permits the unambiguous
conclusion that  µ-  and -opioid receptors differ in their
conformational requirements (Schiller and DiMaio 1982). Within
the series of cyclic analogs I-IV, the number of methylene
groups in the 2-position side-chain increases from 1 to 4 and,
therefore, subtle variation in the degree of conformational
restriction is achieved. All members of this series were found
to be µ-receptor selective and the IC50(MVD)/IC50(GPI) ratio
increased gradually  with lengthening of  the s ide-chain in
position 2, reaching a value of 29.4 with H-Tyr-c[-N -D-Lys-Gly-
Phe-Leu-] (IV) (table 1). The latter analog was 51 times more
potent than [Leu5]enkephalin in the GPI assay and 12 times less
potent in the MVD assay. The corresponding open-chain analog
(IVa) again showed no selectivity. Structure-activity studies
with linear enkephalin analogs had shown that L-configuration in
position 1 and D-configuration in position 2 are required for
activity, whereas in position 5 either L- or D-configuration is
tolerated. The results of potency determinations performed with
cycl ic  analogs IIb,  IIc ,  and IVb (table  1)  indicate that  the
cyclic analogs have the same configurational requirements in
posit ions 1 ,  2 ,  and 5 as  l inear enkephalins.  Furthermore,
introduction of a nitro substituent in para position of the
Phe4 aromatic ring in cyclic analog IV (compound IVd) results in
approximately a tenfold potency increase in both essays, as is
the case with noncyclic enkephalins (Schiller et al. 1983).
Based on these results, it can be assumed that the mode of bind-
ing to opioid receptors is the same for cyclic and linear enke-
phalin analogs. Using cyclic analog IV as parent compound,
further structure-activity studies were undertaken. In most
cases, corresponding modifications in the cyclic analog and in
linear enkephalins had the same effect on potency (cf. analogs
IVc and IVd). However, two interesting exceptions were noticed.
Transposition of the Phe and Leu residues in the cyclic peptide
(compound IVe) resulted in a small potency increase in both
assays, whereas that same modification in the corresponding
open-chain analog lowered potency quite drastically (DiMaio of
al .  1982b) .  Even more interest ingly ,  omission of  the Tyr1
hydroxyl group in the cyclic analog results in a compound (IVf)
still more than twice as potent as [Leu5]enkephalin, whereas
linear enkephalin analogs containing Phe in position 1 show very
low potency. These two observations may reflect a difference in
the binding process between cyclic and linear analogs. It is
possible that the semi-rigid cyclic analogs may bind to the
receptor according to Fischer's "lock-and-key" model, whereas a
zipper-type interaction may take place in the case of the more
flexible linear analogs. Certain moieties may no longer be
absolutely required for efficient binding in a lock-and-key-
type interaction. Whereas in a zipper-type interaction certain
modif ications (e .g . ,  Phe 4-Leu 5  transposit ion)  may increase
the step-wise binding process. The results obtained with the
c y c l i c  e n k e p h a l i n  a n a l o g s  i n  b i n d i n g  a s s a y s  b a s e d  o n
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d i s p l e c e m e n t  o f  [ 3 H ] n a l o x o n e  a s  a  µ - r e c e p t o r - s e l e c t i v e
radioligand and of [3H][D-Ala2,D-Leu5]enkephalin as a
-receptor-selective radiolebel from rat brain membrane
preperations were in general  agreement with the act ivity
profiles determined in the GPI- and MVD-asssys. However,
unexpected results were obteined in a comparison of the cyclic
analogs with their linear correlates in the GPI bioassey and the
[3H]naloxone binding assay, which are both representative for µ-
receptor interactions. For example. cyclic analog IV is five
times more potent than its corresponding open-chain analog IVa
in the GPI assay. whereas en almosf txectly reversed potency
relat ionship is  observed in the [3H]naloxone binding essay
(DiMaio et el. 1982a). This discrepancy can be interpreted to
indicate that the conformational restriction introduced in IV
through ring closure slightly reduces µ-receptor affinity, but
significantly increases the ability of the bound peptide to
activate the receptor ("efficacy" enhancement). High resistance
of cyclic analog II to enzymatic degradation was demonstrated in
vitro (DiMeio and Schiller 1980), and intracerebroventricular
administrstion of compound IV (20 nanomoles) produced a long-
lasting analgesic and catatonialike effect in rats (Schiller et
al. 1981a). The rigid 13- and 14-membered ring structures
contained in cyclic analogs I and II exclude formation of a 4-
1 or 5 2 hydrogen-bonded -bend and are also incompatible
with the crystal structures described by Smith (personal
communication. 1983) and by Karle et al. (1983). Kessler et al.
i n  p r e s s )  i n v e s t i g a t e d  t h e  c o n f o r m a t i o n s  o f  c y c l i c
analogs III and IV by performing a lH NMR study in [2H6]DMSO.
In the case of compound III, the obtained data indicated a rigid
conformation stabilized by two transannular hydrogen bonds
(Leu5-NH OC-Gly3 and Orn2-NH OC-Orn2). On the other hand,
cyclic peptide IV showed a somewhat more flexible conformation
than III,and evidence for only a siqnle intramolecular hydrogen
bond between the group of D-Lys2 and the carbonyl group of
Gly3 was obtained. Since analogs III and IV are both µ-
receptor selective, these interesting results suggest that at
least two different backbone conformations of enkephalin are
tolerated et the µ-receptor, provided that conformational
changes of these semi-rigid analogs do not occur upon binding.
It should be noted, however, that compound IV is about 10 times
more potent then analog III in the GPI assey (DiMaio et al.
1982a).
A family of side-chain to side-chain cyclized opioid peptide
analogs was obtained through substitution of an -diamino acid
and a glutamic or aspartic acid residue in appropriate positions
followed by amide bond formation between the side-chein amino
and carboxyl groups (e.g., compound X, figure 1) (Schiller and
Nguyen 1984). Potencies of such annalogs are presented in table
2. Compound V WAS found to be 250 times more potent then
[Leu5]enkephalin in the GPI assay, but turned out to be non-
selective since it showed high potency on the MVD as well.
Inversion of the configuration in position 2 (compound Va) again
produced a drastic drop in potency. Transposition of the Glu
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TABLE 2
GPI and MVD Assay of Side-Chain to Side-Chain Cyclised Analogs
Compound
GPI MVD
IC50 [nM] IC50 [nM]
MVD/GPI
IC50-ratio
V 1 . 1 3  ± 0.14 0.648 ± 0.132 0.573
V A 1 ' 5 8 0  ± 420 1 0 ' 6 0 0  ± 300 6.71
VI 42.7 ± 6.5 699 ± 146 16.4
VII 24.1 ± 2.8 256 ± 36 10.6
VIII 2.93 ± 0.30 5.21 ± 0.88 1.78
IX 7.99 ± 0.78 101 ± 18 12.6
X 43.8 ± 4.4 4'690 ± 1'020 107
XI 631 ± 123 10'400 ± 4'300 16.5
XII 8'750 ± 2'520 > 40'000 > 4
XIII 55'000 20'600 ± 4'700 0.375
246 ± 39 11.4 ± 1.1 0.0463
a Mean of three determinations ± SEM.
and Lye residue in V resulted in an analog (VI) which was 6
times more potent then [Leu5]enkephalin on the GPI but 60 times
less potent on the MVD and, therefore, is µ-receptor selective.
The di f ference in potency and receptor  select ivity  between
compounds V and VI may be due to the different position and
d i r e c t i o n  o f the side-chain connecting amide bond which is
likely to produce dissimilar transannular hydrogen bonding and
thereby different ring conformations. Shortening of the side-
chain in position 2 of analog VI results in a twofold to
threefold potency increase with little change in  se l e c t i v i ty
(compound VII). The des-Gly3 analogs of V and VI (analogs VIII
and IX) show activity profiles similar to those of their perent
peptides. Extraordinary µ-receptor selectivity is displayed by
H-Tyr-D- -NH2 (X), which is 6 times more potent then
[Leu5]enkephalin on the GPI and 400 times less potent on the
MVD. Its IC50(MVD)/IC50(GPI) ratio of 107 is comparable to that
of the highly µ-receptor selective ligand H-Tyr-D-Ala-Gly-MePhe-
NH(CH2)2OH (DAGO) (Kosterlitz and Peterson 1981). Transposition
of the Orn and Asp residues results in a less potent and less
selective analog (XI). Compound XII showed week potency, in
contrast to the significant activity which had been reported for
the related linear analog H-Tyr-D-Met-Gly-NH-CH(CH3)-CH2-
CH(CH3)2 (Roques et el. 1979). Analog XIII was also foun to bed
weakly active, which is surprising in view of the relatively
high potency observed with 1 linear [D-Ala2]enkephalin analogs
containing a side-chain with L-configuration in the 3-position.
A second type of side-chain to side-chain cyclized enkephalin
analog was prepared by substitution of a D-Cys residue in
position 2 and of a D- or L-Cys residue in position 5 followed
by oxidative disulfide bond formation (figure 1; anologs XIV,
XV,  XXII ,  and  XXII I )  (Sch i l l e r  e t  a l .  1981b ) .  The  cyc l i c
enkephalinamide analogs XIV and XV were found to be highly
potent in both the GPI and MVD assays and, therefore, showed no
s i g n i f i c a n t  r e c e p t o r  s e l e c t i v i t y  ( t a b l e  3 ) .  T h e  r e c e p t o r
binding mode of these analogs again seems to be similar to that
of linear enkephalins, since they showed the same
configurational requirements et the individual residues (cf.
analogs XV, XVI, XVII, and XIX). This assumption was again
supported by the potency increase observed upon substitution of
p-nitrophenylalenine in position 4 of XV which resulted in a
compound (XVIII) having five times the potency of dynorphin A-
(1-13) in the GPI assay and an IC50 value of about 20 picomolar
in the MVD assay. Substitution of Phe in position 1 and of Trp
in position 4 of compound XV produced Active analogs (XX and
XXI) showing considerable µ-receptor selectivity. In contrast
to the nonselective cystine-bridged enkephalinamide analogs (XIV
and XV), the corresponding analogs with a free C-terminal
carboxyl group (XXII and XXIII) were shown to be moderately
receptor selective. The same difference in receptor selectivity
is in general observed between linear enkephalins and
enkephalinamides. Thus, cyclic enkephalins XXII and XXIII
display about the same -receptor selectivity as
[Leu5]enkephalin but are about two orders of magnitude more
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TABLE 3
Potencies of Cystine-Containing Enkephalin Analogs in the GPI and MVD Assaya
Compound
GPI MVD
IC50 [nM] IC50 [nMl
MVD/GPI
IC50-ratio
XIV
XV
XVI
XVII
XVIII
XIX
XX
XXI
XXII
XXIII
1.51 ± 0.03
0.780 ± 0.010
210 ± 58
135 ± 13
0.0351 ± 0.0100
483 ± 112
48.6 ± 6.05
0.842 ± 0.185
3.06 ± 0.52
1.48 ± 0.18
246 ± 39
0.760 ± 0.086 0.503
0.298 ± 0.037 0.382
950 ± 160 4.52
891 ± 139 6.60
0.0187 ± 0.0023 0.533
582 ± 113 1.20
456 ± 159 9.38
14.1 ± 1.1 16.7
0.190 ± 0.035 0.0621
0.122 ± 0.016 0.0824
11.4 ± 1.1 0.0463
a Mean of three determinations ± SEM.
potent  then  the  ne tura l  pep t ide .  Subs t i tu t i on  o f  a  ha l f -
penici l lamine (Pen)  residue for  the hel f -cyst ine residue in
position 2 and/or 5 of the cystine-bridged enkephelin analogs
resulted in compounds with high preference for -receptors over
µ-receptors (Momberg  al. 1983). A conformational comparispn
of corresponding Pen2- and Cys2-containing cyclic analogs by 1H
et
NMR spectroscopy in D20 indiceted a somewhet enhanced rigidity
of the ring structure contained in the [Pen2]-analogs as
compared to the [Cys2]-analogs, which  may be the cause of the
observed selectivity difference (Mosberg and Schiller 1984).
The results of fluorescence studies performed with analogs XV
and XXI in H20 indiceted a close interaction between the Tyr
1
aromatic ring and the  d i su l f i de  b r idge ,  and  an average
intramolecular distance between the Tyr1 and Trp4  aromatic rings
in XXI of 9.7 ± 0.2 Å, which is close to the corresponding
distance of 9.5 ± 0.3 Å determined with the linear analog H-Tyr-
D-Ala-Gly-Trp-Met-OH (Schiller 1983b).
CONCLUSIONS
The  resu l t s  f r om theore t i ca l  energy  ca l cu la t i ons ,  c rys ta l
structure determinations, and spectroscopic studies in solution
indicate that the enkephelins art flexible molecules which can
exist in several different conformations of comperatively low
energy. It appears that the molecular environment is likely to
have an important influence on the conformation(s) of these
peptides and there is good evidence to indicate that at least in
aqueous solution they exist in a conformational  equilibrun. The
molecular flexibility of the enkephalins complicates the task of
determining their bioactive conformation(s) and presumably is
the cause of their lack of specificity in the interaction with
different opioid receptor types. In view of this situation. the
pr inc ip l e  o f  c on fo rmat i ona l  r e s t r i c t i on  has  emerged  as  a
promising new tool i n  o p i o i d  p e p t i d e  a n a l o g  d e s i g n .  I n
particular, synthesis of cyclic enkephelin analogs during the
pest  few years has resulted in potent ,  stable ,  and highly
selective µ- and -receptor agonists. More extensive studies
on the conformation of these cyclic analogs can be expected to
lead to a better definition of the conformational requirements
of the different opioid receptor types in the near future.
FOOTNOTES
1 Abbreviations : CD, circular dichroism; ECEPP, empirical
conformational energy program for peptides; GPI, guinea pig
ileum; MVD, mouse vas deferens; NMR, nuclear magnetic resonance;
NOE, nucleer Overhauser enhancement; PEO, 7- -(1-(R)-hydroxy-1-
methyl-3-phenylpropyl)-6,14- endo-ethenotetrehydrooripavine.
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Stereochemically Constrained Enkephalin
Analogs Containing -Aminoisobutyric Acid
and I-Amino-Cyclopentane-I-Carboxylic Acid
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INTRODUCTION
S m a l l  b i o l o g i c a l l y  a c t i v e  a c y c l i c  p e p t i d e s  l i k e  e n k e p h -
a l i n s  a r e  c o n f o r m a t i o n a l l y  v e r y  f l e x i b l e .  A s  a  c o n s e -
q u e n c e ,  I t  i s  d i f f i c u l t  t o  e s t a b l i s h  u n a m b i g u o u s l y  t h e
" b i o l o g i c a l l y  a c t i v e "  c o n f o r m a t i o n  w h i c h  i s  r e c o g n i z e d
b y  t h e  i n  v i v o  r e c e p t o r .  T h e  r e l a t i o n s h i p  b e t w e e n  s t a b l e
solution conformations and structures bound to receptors
i s  o f t e n  n o t  c l e a r .  T h e  s y n t h e s i s  o f  c o n f o r m a t i o n a l l y
r e s t r i c t e d  a n a l o g s  a n d  a n  e v a l u a t i o n  o f  t h e i r  r e c e p t o r
a f f i n i t i e s  o r  b i o l o g i c a l  a c t i v i t y  a f f o r d  a  p o s s i b l e
a p p r o a c h  t o  t h e  d e l i ne a t i o n  o f  b i o a c t i v e  c o n f o r m a t i o n s .
I m p o s i t i o n  o f  b a c k b o n e  a n d  s i d e - c h a i n  c o m f o r m a t i o n a l  c o n -
s t r a i n t s  m u s t ,  i n  p r i n c i p l e ,  b e  a c c o m p l i s h e d  b y  c o v a l e n t
m o d i f i c a t i o n s ,  w h i c h  d o  n o t  d i r e c t l y  i n f l u e n c e d  i n t e r a c -
t i o n s  w i t h  r e c e p t o r s ,  b u t  m o d u l a t e  p e p t i d e - r e c e p t o r  b i n d -
i n g  i n d i r e c t l y ,  b y  l i m i t i n g  t h e  r a n g e  o f  a c c e s s i b l e
t i d e  c o n f o r m e t i o n s  ( S p a t o l a  1 9 6 3 ;  M a r s h a l l  e t  a l . 1 9 7 6 :
T h i s  c h a p t e r  b r i e f l y  r e v i e w s  a n  a p p r o a c h  t o  r e s t r i c t i o n
o f  p e p t i d e  b a c k b o n e  c o n f o r m a t i o n a l  f l e x i b i l i t y ,  b y  i n t r o -
d u c t i o n  o f  a c h i r a l dialkyl residues (figure 1) in
e n k e p h a l i n s  l a  p l a c e  o f  G l y  r e s i d u e s  a t  p o s i t i o n s  2  a n d  3 .
Conformational Restrictions by - A l l s y l a t i o n
Two degrees of torsional freedom about the N-C
and b o n d s  d e t e r m i n e  t h e  b a c k b o n e  c o n f o r m a t i o n s
of individual r e s i d u e s  i n  p e p t i d e s . T h e  p e p t i d e  b o n d  i s
g e n e r a l l y  l i m i t e d  t o  a  t r a n s geometry =  1 8 0 ° ) .  A s  a
c o n s e q u e n c e ,  p e p t i d e  c o n f o r m a t i o n s  a r e  c o n v e n i e n t l y  m a p p e d
on the two-dimensional  Remachandran plot (Rama-
c h a n d r a n  a n d  S a s i s e k h a r a n  1 9 6 8 ) .  F i g u r e  2  i l l u s t r a t e s
the theoretically computed maps,for L-ALa and D-Ala
residues.  The map for the Aib  residue is shown in
f i g u r e  3 .  I t  i s  e v i d e n t  t h a t  s u b s t i t u t i o n  a t l i m i t s
t h e  e n e r g e t i c a l l y  a c c e s s i b l e  r e g i o n s  o f space. In
t h e  c a s e  o f  s y m m e t r i c a l -dialkyl residues, exempli-
f i e d  b y  A i b ,  o n l y  a  v e r y  l i m i t e d  r e g i o n  o f  c o n f o r m a t i o n a l
s p a c e  i s ,  i n d e e d ,  s t e r i c a l l y  a n d  e n e r g e t i c a l l y  f a v o r e d
(Marshall  and Bosshard 1972:  Prasad and Balaram 1984) .
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FIGURE 1
S t r u c t u r e s  o f -dialkylated residues having acyclic
and cyclic sidechains.
FIGURE 2
Pamachandran (Steric) map for N-acetyl-L-Ala-N'-methyl-
amide and N-acetyl-D-Ala-N'-methylamide.  The  continous
and broken lines enclose regions allowed by normal and
extreme contact limits, respectively.
FIGURE 3
a )  Po tent ia l  energy  map  f o r  N -ace ty l -A ib -N ' -methy lamide .
The  contours  a re  drawn  wi th  respec t  t o  the  innrmost
c o n t o u r  e n c l o s i n g  t h e  m i n i m u m .  T h e  i d e a l  3 1 0 and
hel ical  confomations are marked.  These conforma-
t i o n s  a r e  c o m p a t i b l e  w i t h  A i b  r e s i d u e s  i n  T y p e  I  o r  I I I
-turns. Crystal structure observations o f  A i b
r e s i d u e s  i n  n o n h e l i c a l  r e g i o n s  a r e  m a r k e d . Cryrtallo-
g r a p h i c  o b s e r v a t i o n s  f o r  A i b  r e s i d u e s  i n  p e p t i d e s  i n  t h e
r i g h t  ( b )  a n d  l e f t  ( c )  h a n d e d  h e l i c a l  r e g i o n s  o f  t h e
map .  T ips  o f  a r row  ind i ca te  i dea l  3 1 0  a n d -helices.
N - te rmina l  r e s idues  in  pro te c ted  pept ides Nonterminal
r e s i d u e  x  C - t e r m i n a l  A i b  p r e s e n t  a s  e s t e r  o r  a c i d .
E x t e n s i v e  c o n f o r m a t i o n a l  s t u d i e s  o f  A i b - c o n t a i n i n g  p e p -
t i d e s  i n  t h e  s o l i d  s t a t e  a n d  i n  s o l u t i o n  h a v e  b e e n  r e p o r t -
e d .  T h e  c o n f o r m a t i o n a l  a n g l e s  d e t e r m i n e d  b y  X - r a y  d i f -
f r a c t i o n  f o r  A i b  r e s i d u e s  i n  a  l a r g e  n u m b e r  o f  p e p t i d e s
a r e  s u m m a r i z e d  i n  f i g u r e  3 .  W i t h  v e r y  f e w  e x c e p t i o n s ,
A i b  r e s i d u e s  a d o p t  c o n f o r m a t i o n s  i n  t h e  r e g i o n  o f  
±60°  ±20°  and =  ± 3 0  ± 2 0 ° .  T h e s e  v a l u e s  o f a r e
c o m p a t i b l e  w i t h  t h e  p r e s e n c e  o f  A i b  r e s i d u e s  a t  p o s i t i o n s
i + 1  o r  i + 2  o f  T y p e  I ( I ' )  o r  I I I  ( I I I ' ) - t u r n s  o r  a t
p o s i t i o n  i + 2  o r  a  T y p e  I I  ( I I ' ) -turn (Venkatachalam
1 9 6 8 ;  S m i t h  a n d  P r e s s  1 9 8 0 ) . - T u r n  c o n f o r m a t i o n s  i n
p e p t i d e s  a r e  g e n e r a l l y ,  t h o u g h  n o t  a l w a y s ,  s t a b a i l i z e d
b y  i n t r a m o l e c u l a r  4 1 hydrogen bonding between the C=0
group  o f  r e s idue  i  and  the  NH group  o f  r e s idue  i+3
( f i g u r e  4 ) .  T h e  c o n f o r m a t i o n a l  p a r a m e t e r s  f o r  t h e  i d e -
a l i z e d  T y p e  I - I I I - t u r n s  a r e  l i s t e d  i n  f i g u r e  4 .  T h e
i n t r o d u c t i o n  o f  A i b  r e s i d e s  i n t o  A c y l i c  p e p t i d e s  t h u s
e n h a n c e s  t h e  p r o b a b i l t y  o f - t u r n s  f o r m a t i o n  i n v o l i n g
A i b - X  o r  X - A i b  s e q u e n c e s .  T h i s  t e n d e n c y  i s  a m p l y  d e m o n -
s t r a t e d  i n  c r y s t a l  s t r u c t u r e s  o f  s e v e r a l  A i b - c o n t a i n g
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FIGURE 4
Schematic representation of a -turn conformation  stabili-
z e d  b y  a  4 1 (C10) hydrogen bond. Conformational
a n g l e s  f o r  i d e a l i z e d  T y p e  I ,  I I  a n d  I I I - turns  are
indicated.  The enantiomeric - t u r n s  ( T y p e s  I ,  I I ,  a n d
I I I ' )  a r e  g e n e r a t e d  b y  r e v e r s i n g  t h e  s i g n s  o f  a l
a n g l e s .
m o d e l  p e p t i d e s  ( N a g a r j  a n d  B a l a r a m  1 9 8 1 ;  P r a s a d  a n d
ance (NMR) studies of proteceted peptides in organic
Parlaram 1983. 1984) and also in nuclear magnetic reson-
solvents  (Nagaraj  et  al .  1979;  Iqbal  and Balaram 1981) .
The presence of  successive Aib residues in a  sequence,
i . e . ,  an  A ib -A ib -X  segment ,  o r  a l t e rnated  A ib  r e s idues ,
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i . e . ,  a n  A i b - X - A i b - X  s e g m e n t ,  g e n e r a l l y  l e a d s  t o  f o r m a -
t i o n  o f  c o n s e c u t i v e  B - t u r n  s t r u c t u r e s  o f  t h e  T y p e
I I I - I I I  o r  I I I ' - I I I '  a s t e g o r i e s .  S u c h  c o n f o r m a t i o n s
are incipient right- or left-handed 310-helical structures
( I q b a l  e t  a l .  1 9 8 1 ;  V i j a y a k u m a r  a n d  B a l a r a m  1 9 8 3 a ,  l 9 8 3 b ) .
T h e  1 - a m i n o c y c l o a l k a n e c e r b o x y l i c  a c i d s  ( f i g u r e  1 )  a r e
s t r u c t u o l l y  a n a l o g o u s  t o  A i b .  T h e o r e t i c a l  s t u d i e s  o f
t h e  c y c l o p e n t a n e  ( A c c 5 )  a n d  c y c l o h e x a n e  ( A c c b )  c o n t a i n i n g
N-ace ty l -aminoac id -N-methy l  amides  sugges t  tha t  these
r e s i d u e s  a l s o  s t r o n g l y  p r e f e r  r i g h t -  o r  l e f t - h a n d e d
3 1 0 / x - h e l i c a l  c o n f o r m a t i o n s  ( P r a s e d ,  u n p u b l i s h e d
r e s u l t s ) . T h e  e x t e n d e d  r e g i o n s  o f space are, in
f a c t ,  e v e n  l e s s  f a v o r a b l e  t h a n  i n  t h e  c a s e  o f  A i b .  T h e s e
c o n c l u s i o n s  a r e  b o r n e  o u t  b y  t w o  r e c e n t  c r y s t a l  s t r u c -
t r u r e s  o f  m o d e l  p e p t i d e s  c o n t a i n g  A c c 6  r e s i d u e s .  I n
A i b - A c c 6 - N H M e 6 ,  a  t y p e  I I I  ( I I I ' ) B - t u r n  c o n f o r m a -
t i on  was  observed  w i th = +68.4°, = ±15° for the Acc6
r e s i d u e . M o l e c u l e s  o f  b o t h - h a n d e d n e s s  w e r e  p r e s e n t  i n
t h e  a c h i r a l  c r y s t a l s . In Boc -Aib-Acc6-OMe, where an
i n t r a m o l e c u l a r  4 1  h y d r o g e n  b o n d  i s  n o t  p o s s i b l e ,  a
semiextended conformation is  observed
    = ±143°), but the Acc6 r e s i d u e  h a d
a t  A i b =  + 6 2 . 2 °
= ±48°, = ±42.6°.
s t r o n g l y  s u p p o r t i n g  t h e  n o t i o n  t h a t  t h e  c y o l o a l k y l  s i d e -
c h a i n  i m p o s e s  e v e n  g r e a t e r  r e s t r i c t i o n s  o n  c o n f o r m a t i o n a l
f r e e d o m  ( B a r d i  e t  a l . ,  i n  p r e s s ) .  I n t r i s t i n g l y ,  r e c e n t
studies by Italian and English groups suggest that the use
of -dialkyl residues like -diethylglycine (Deg)
or -di-n-propylglycine (Dpg) can result in a stabi-
l ibat ion of  extended peptide  conformations (Barone et  al . ,  in
press [1984a, 1984b]) may thus be possilble to modulate the
f o l d i n g  t e n d e n c y  o f  a c y c l i c p e p t i d e s  b y  i n t r o d u c t i o n  o f
A i b  o r  1 - a m i n o c y c l o a l k a n e c a r b o x y l i c  a c i d s  o n  t h e  o n e  h a n d
o r  t h e  h i g h e r -dialkyl amino acids on the other.
T h e  i n t r d u c t i o n  o f  e a c h -dialkyl residues into
b i o l o g i c a l l y  a c t i v e  p e p t i d e s  c o u l d  t h e n  p r o v i d e  a  m e a n s
o f  s e l e c t i v e l y  s t a b i l l z i n g  c e r t a i n  b a c k b o n e  c o n f o r m a t i o n s .
I n  p r i n c i p l e , the use of schiral amino acids could be most
a p p r o p r i a t e  w h e n  G l y  r e s i d u e e  p r e s e n t  i n  t h e  n a t u r a l
s e q u e n c e  a r e  r e p l a c e d  i n  t h e  a n a l o g  s t r u c t u r e .
T w o  c o m p l i c a t i n g  f a c t o r s  m u s t  b e  c o n s i d e r e d  w h e n  a n a l y z -
i n g  s t r u c t u r e - a c t i v i t y  d a t a  g e n e r a t e d  b y  u s i n g  s u c h
analogs.
1) Enhanced hydrophobicity of the analog peptides may
i n f l u e n c e  b i n d i n g  t o  a p o l a r  r e c e p t o r  s u r f a c e s .
2) T h e  a l k y l  s u b s t i t u e n t s  m a y  a f f e c t  p e p t i d e - r e c e p t o r
in te rac t  i ons  by  v i r tue  o f  the  new  s t e reochemica l
c o n t a c t s  i n v o l v e d .
T h e  r e p l a c e m e n t  o f  G l y  r e s i d u e s  b y  A i b  i m p o s e s  a  c o n s i d e r a -
b l e  r e s t r i c t i o n  o n  b a c k b o n e  f l e x i b i l l t y .  T h e  r e p l a c e m e n t
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of hydrogen atoms by methyl groups at may be viewed
a s  a  m i n i m u m  s t e r i c  p e r t u r b a t i o n .  S t e r i c  e f f e c t s  a t
r e c e p t o r  b i n d i n g  s i t e s  m a y  b e  m o r e  s i g n i f i c a n t  w h e n
b u l k y  c y c l o a l k y l  g r o u p s  l i k e  A c c 5   o r  A c c 6  a r e  u s e d
I f  t h e  a n a l o g  p e p t i d e s  r e t a i n  f u l l  b i o l o g i c a l  a c t i v i t y
o r  e x h i b i t  e n h a n c e d  a c t i v i t y ,  t h e n  i t  i s  l i k e l y  t h a t  t h e
c o n f o r m a t i o n s  p o s s i b l e  i n  t h e  s t e r e o c h e m i o a l l y  c o n -
s t r a i n e d  a n a l o g s  a r e  i n d e e d  r e c o g n i z e d  b y  t h e  r e c e p t o r .
F u r t h e r m o r e ,  a n y  d i r e c t  e f f e c t  o f  t h e  s u b s t i t u e n t  ( n o t e d
a b o v e )  i s  m i n i m a l  o r  p r o m o t e s  r e c e p t o r - p e p t i d e  a s s o c i a -
t i o n .  I f  t h e  a n a l o g  p e p t i d e  i s  i n a c t i v e ,  t h e n  t h e  c o n f o r -
m a t i o n s  f a v o r e d  i n  t h e  a n a l o g  a r e  n o t  r e c o g n i z e d  b y  t h e
receptor . A l t e r n a t i v e l y ,  t h e  s u b s t i t u e n t  h a s  a  d i r e c t
i n h i b i t o r y  e f f e c t  a n  r e c e p t o r  i n t e r a c t i o n s  b y  i m p e d i n g
c l o s e  c o n t a c t  o f  t h e  p e p t i d e  w i t h  t h e  b i n d i n g  s i t e .
STUDIES ON ENKEPHALIN ANALOGS
In the case of the enkephalins (Tyr-Gly-Gly-Phe-Met/
Leu), the presence of the Gly-Gly segment results in
c o n s i d e r a b l e  c o n f o r m a t i o n a l  f l e x i b i l i t y  ( F i s h c h m a n  e t  a l .
1 9 7 8 ) . S o l u t i o n  s p e c t r a l  s t u d i e s  h a v e ,  t h e r e f o r e ,  g e n e r -
a l l y  f a i l e d  t o  p r o v i d e  e v i d e n c e  f o r  a  d o m i n a n t  c o n f o r m -
t i o n  i n  t h e  n a t i v e  s e q u e n c e s , a l t h o u g h  e v i d e n c e  f o r  f o l d e d
( B l e i c h  e t  a l .  1 9 7 7 ;  K h a l e d  e t  a l .  1 9 7 7 )  s t r u c t u r e s  h a v e
R o q u e s  e t  a l .  1 9 7 6 ;  J o n e s  e t  a l .  1 9 7 6 )  a n d  e x t e n d e d
been  presented . T h e  b a c k b o n e  c o n f o r m a t i o n a l  f l e x i b i l i t y
o f  t h e  e n k e p h a l i n s  i s  a l s o  d r a m a t i c a l l y  i l l u s t r a t e d  b y
X - r a y  d i f f r a c t i o n  studies, w h e r e  o n e  c r y s t a l  f o r m  h a s
yielded a Gly2Gly5 Type I' -turn structure (Smith and
G r i f f i n  1 9 7 8 ;  B l u n d e l l  e t  a l .  1 9 7 9 ) ,  w h i l e  a n o t h e r  i s  c o m -
p o s e d  o f  e n k e p h a l i n  m o l e c u l e s  i n  a n  e x t e n d e d  B - s h e e t  c o n -
f o r m a t i o n  ( K a r l e  e t  a l .  1 9 3 3 :  C a r m e m a n  e t  a l .  1 9 8 3 ) .
Conformations Determined by NMR
T h e  G l y  r e s i d u e s  a t  p o s i t i o n s  2  a n d  3  i n  M e t -  a n d  L e u -
enkephal in  amides have been separately  or  s imiltaneously
r e p l a a e d  b y  A i b  o r  A c c 5  r e s i d u e s  a n d  t h e  c o n f o r m a t i o n  o f
t h e  r e s u l t i n g  e n k e p h a l i n  a n a l o g s  h a v e  b e e n  i n f e r r e d  f r o m
NMR studies in (CD3)2SO (Sudha and Balaram 1983; Kiahore
a n d  B a l a r a m  1 9 8 4 ) .  T h e  p r e s e n c e  o f  i n t r a m o l e c u l a r l y
h y d r o g e n - b o n d e d  c o n f o r m a t i o n s  i s  e s t a b l i s h e d  b y  d e l i n e a t i n g
so lvent - exposed  and  - sh i e lded  NH groups ,  us ing  t emperature
c o e f f i c i a n t  o f  N H  o f  c h e m i c a l  s h i f t s  ( d 8 / d t )  i n  ( C D 3 ) 2 S O  a s
a  d i a g n o s t i c  c r i t e r i o n .  T h e /dT values <0.003) ppm/k  may
b e  g e n e r a l l y  c o n s i d e r e d  t o  r e p r e s e n t  s t r o n g l y  s o l v e n t -
sh i e lded  NH groups ,  wh i l e  va lues  <0 .005  ppm/K  are  charac -
t e r i s t i c  o f  s o lvent - exposed  NH groups .  In termed ia te /dT
v a l u e s  ( 0 . 0 0 3  t o  0 . 0 0 5  p p m / K )  a r e  h a r d e r  t o  i n t e r p r e t
d e f i n i t i v e l y ,  b u t  a r e  o f t e n  i n d i c a t i v e  o f  m o d e r a t e l y
s o l v e n t - s h i e l d e d  N H  g r o u p s  ( R a v i  e t  a l .  1 9 3 3 ;  I q b a l  a n d
Balaram 1981) .
The chemical  shifts and temperature coefficients
/dT) of nine enkephalin analogs incorporating Aib or
A c c 5  r e s i d u e s  a r e  s u m m a r i z e d  i n  t a b l e  1 .  T h e  c o r r e s p o n d i n g
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TABLE 1
NMR Parameters of NH Groupsa in Enkephalinamide Analogs in Dimethylsulfoxide
Chemica l  Sh i f t s  ( 8  ppm) /dT x 10 3  ppm/K
P e p t i d e s X 2  Y 3  P h e  M e t 5 / L e u 5 Y 3  P h e  M e t 5 / L e u 5
Tyr-Aib-Gly-Phe-Met NH2
Tyr-Gly-Aib-Phe-Met NH2
Tyr-Aib-Aib-Phe-Met NH2
Tyr-Alb-Gly-Phe-Leu NH2
Tyr-Gly-Aib-Phe-Leu NH2
Tyr-Aib-Aib-Phe-Leu NH2
Tyr-Aco5-Gly-Phe-Leu NH2
Tyr-Gly-Aco5-Phe-Leu NH2
Tyr-Aco5-Aco5-Phe-Leu NH2
Tyr-Gly-Gly-Phe-Met NHd2
Tyr-Gly-Gly-Phe-Leu NH2
7 . 1 5 8.21 7 . 9 3 7 . 9 8 5 . 5  2 . 8 4 . 6
8 . 5 0 8 . 4 3 7 . 8 6 7 . 6 3 6 . 5  4 . 6 1 . 8
b 8 . 2 8 7 . 7 8 7 . 8 1 6 . 5  1 . 8 1 . 8
b 8 . 2 4 7 . 9 4 7 . 7 6 4 . 5  1 . 9 3 . 9
b 8 . 4 2 7 . 7 8 7 . 6 2 5 . 9  3 . 5 1 . 8
b 8 . 1 3 7 . 7 8 c 7 . 7 1 c 6 . 3  2 . 0 0 2 . 3
b 8 . 1 2 7 . 8 0 7 . 8 5 4 . 5  1 . 8 4 . 9
b 8 . 4 4 7 . 7 8 7 . 5 7 5 . 9  3 . 7 1 . 9
b 8 . 0 9 7 . 6 7 c 7 . 6 1 c 6 . 2  1 . 9 2 .1
8 . 2 4 8 . 1 3 8 . 1 5 8 . 0 5 4 . 6  4 . 9 5 . 6
8 . 2 0 8 . 0 5 8 . 1 0 7 . 9 0 a 3 . 7 4 . 6
a )  T h e  N H  o f  r e s i d u e  2  g e n e r a l l y  b r o a d e n e  o n  h e a t i n g  i n  ( C D 3 ) 2 S O ; /dT  was  there fo re
not  measured.
b )  NH resonance obscoured due to  overlap with aromatic  protons or  due to  broadening.
c) Not assigned due to overlap.
d )  V a l u e s  t a k e n  f r o n t  H i g a s h i j i m a  e t  a l .  1 9 7 9 .
Parameters  f o r  Met 5 / L e u 5  e n k e p h a l i n a m i d e  a r e  a l s o  l i s t e d .
the  f o l l ow ing  f ea tures  o f  the  NMR data  a re  no tewor thy .
1 )  T h e  a n a l o g s  w i t h  A i b / A c c 5  r e s i d u e s  a t  p o s i t i o n  2  s h o w
low /dT values for the Phe NH, oharectieristiac of a
so lvent  - sh i e lded  pro ton .  A l l  o ther  NH groups  appear
t o  b e  s o l v e n t  e x p o s e d .
2 )  I n  t h e  p o s i t i o n  3  a n a l o g s ,  t h e  M e t  N H  h a s  a  v e r y  l o w
/dT value, indicative of its sting shielding from
t h e  s o l v e n t .  O t h e r  N H  g r o u p s  a p p e a r  t o  b e  s o l v e n t
e x p o s e d ;  a l t h o u g h  i n  t h e  A i b  a n d  A c c 5  a n a l o g s  o f  L e u -
enkephalinamide, the Phe NH has a moderate /dT value,
s u g g e s t i v e  o f  a  m o d e r a t e  d e g r e e  o f  s h i e l d i n g  f r o m
s o l v e n t .
3 )  I n  t h e  a n a l o g s  v h e r e  b o t h  G l y  r e s i d u e s  a r e  r e p l a c e d  b y
Aib /Acc 5  r e s i d u e s ,  b o t h  P h e  a n d  M e t  N H  r e s o n s n c e s  h a v e
v e r y  l o w /dT values, characteristic of solvent-shield-
ed NH groups.
4 )  A l l  N H  g r o u p  i n  t h e  G l y - G l y  a n a l o g s  h a v e  r e l a t i v e l y
h i g h /dT values.
I n  s m a l l  a c y l i c  p e p t i d e s ,  i n v o l v e m e n t  o f  N H  g r o u p s  i n
i n t r a m o l e c u l a r  h y d r o g e n  b o n d i n g  g e n e r a l l y  r e s u l t s  i n
t h e i r  s h i e l d i n g  f r o m  t h e  s o l v e n t .  D i r e c t  s t e r i c  s h i e l d i n g
w i t h o u t  h y d r o g e n  b o n d i n g  i s  u n l i k e l y .  T h e  N M R  r e s u l t s
t h e r e f o r e  l e a d  t o  t h e  f o l l o w i n g  i n f e r e n c e s .
1)  The Phe NH is  intramolecularly  hydrogen bonded in
p o s i t i o n  2  a n a l o g s ,  i n c o r p o a t i n g  A i b  o r  A c c 5
r e s i d u e s .
2   The Met NH is  hydrogen bonded in the posit ion 3
a n a l o g s .
3) Both Phe and Met NH groups are hydrogen bonded in 
a n a l o g s  s u b s t i t u t e d  s i m u l t a n e o u s l y  w i t h  A i b  o r  A c c 5
r e s i d u e s  a t  p o s i t i o n s  2  a n d  3 .
T h e  s t r o n g  t e n d e n c y  o f  A i b  r e s i d u e s  t o  p r o m o t e - turn
fo rmat i on ,  t oge ther  w i th  the  NMR resu l t s ,  sugges t s  tha t
i n t r a m o l e c u l a r l y  h y d r o g e n - b o n d e d  c o n f o r m a t i o n s  a r e  s t a b i -
l i z e d  i n  t h e  A i b  a n a l o g s .  T h e  c o n f o r m a t i o n s  c o m p a t i b l e
with HMR data and the known stereochemical  preferences of
A i b  r e s i d u e s  a r e  i l l u s t r a t e d  i n  f i g u r e  5 .  I t  t h u s  a p p e a r s
that  conformations involving a -turn centered at positions
2  a n d  3  ( r e s i d u e s  i + 1  a n d  i + 2 ,  r e s p e c t i v e l y )  a r e  h i g h l y
p o p u l a t e d  i n  ( C D 3 ) 2 S O  f o r  t h e  A i b ( 2 )  a n a l o g s ,  w h i l e  a
-turn at positions 3 and 4 is sugested for the Aib(3)
analogs. In the Aib(2)-Alb(3) analogs, a consecutive
Type III-III -turn structure is compatible with the
s p e c t r a l  d a t a .  S u c h  c o n f o r m a t i o n s  a r e  a l s o  l i k e l y  t o  b e
f a v o r e d  i n  t h e  A c c 5  a n a l o g s ,  i n  v i e w  o f  t h e  s i m i l a r i t i e s
i n  t h e  s p e c t r a l  c h a r a c t e r i s t i c s  o f  t h e  A i b  a n d  A c c 5
a n a l o g s .  F u r t h e r m o r e ,  m o d e l  b u i l d i n g  a n d  t h e o r e t i c a l
e n e r g y  c a l c u l a t i o n s  s u g g e s t  t h a t  A i b  a n d  A C C 5  r e s i d u e s
h a v e  s i m i l a r  s t e r e o c h e m i c a l  p r e f e r e n c e s .
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FIGURE 5
P r o p o s e d  b a c k b o n e  c o n f o r m a t i o n s  o f  A i b  a n a l o g a  o f  L e u -
e n k e p h a l i n a m i d e  a )  T y r - A i b - G l y - P h e - L e u + N H 2  b )  T y r - G l y -
A i b - P h e - L e u - N H 2 ,  c )  Tyr -A ib -Phe -Leu -NH 2 .
T h e  c r y s t a l  s t r u c t u r e s  o f  t h e  p r o t e c t e d  f r a g m e n t s
Boc-Aib-Phe-Leu-OMe (Prasad,  unpublished)  and Boc-Aib-Aib-Phe-
M e t - N H 2  ( P r a s a d  e t  a l .  1 9 8 3 )  p r o v i d e  f u r t h e r  s u p p o r t  f o r
t h e e e  c o n c l u s i o n s .  I n  t h e  f o r m e r ,  a  T y p e  I  A i b - P h e -turn
i s  o b s e r v e d  ( f i g u r  6 ) ,  w h l l e  t h e  l a t t e r  a d o p t s  a  c o n s e c -
u t i v e  T y p e  I I I - I I I  ( i n c i p l e n t  3 1 0  h e l i c a l )  c o n f o r m a t i o n
i n  t h e  s o l i d  s t a t e  ( f i g u r e  6 ) .
Circular Dichroism (CD) Studies
CD s tud ies  o f  Met (5 ) - enkepha l inamide ,  Boc -Tyr -G ly -G ly -
Phe-Leu-NH 2 ,  and the fragment Boc-Gly-Gly-Phe-Met-NH 2
demonst ra te  a  pronounced  so lvent  dependence  o f  spec t ra
i n  s o l v e n t s  l i k e  2 , 2 , 2 - t r i - f l u o r e t h a n o l  ( T F E )  a n d  m e t h a -
n o l ,  i n d i c a t i v e  o f  s t r u c t u r a l  t r a n s i t i o n s  ( f i g u r e  7 ) .
R e p l a c e m e n t  o f  t h e  G l y  r e s i d u e s  b y  A i b  r e s u l t s  i n  a n  a b o -
l i t i o n  o f  t h e  s o l v e n t - d e p e n d e n t  s i g n  r e v e r s a l  o f  t h e  C D
band at  215 to  220 nm (Sudha and Balaram 1981) .  These
o b s e r v a t i o n s  h a v e  b e e n  i n t e r p r e t e d  b y  t h e  a u t h o r s  a s
indicaitve of the role of Aib residues in stabilizing
s p e c i f i c  f o l d e d  c o n f o r m a t i o n s  i n  t h e s e  s e q u e n c e s .  I n  t h e
above  s tudy ,  p ro te c ted  t e t rapept ide  f ragments  were  used
t o  e x a m i n e  t h e  e f f e c t  o f  A i b  r e s i d u e s  o n  s o l v e n t - d e p e n d e n t
c o n f o r m a t i o n a l  t r a n s i t i o n s .  T h i s  a p p r o a c h  h a s  s u b s e q u e n t l y
b e e n  e x t e n d e d  t o  a  s t u d y  o f  t h e  e n k e p h a l i n  a n a l o g s  t h e m -
s e l v e s .  T h e  C D  s p e c t r a  o f  t h e  t h r e e  A i b  a n a l o g s  o f  L e u ( 5 ) -
enkephalinamide in MeOH, H20, and dioxane are shown in
figures 8 to 10, respectively. The spectra of the corres-
ponding Acc 5  analogs  in  MeOH and dioxane are  shown in
f i g u r e  8  a n d  9 ,  r e s p e c t i v e l y .
T h e  f o l l o w i n g  C D  s p e c t r a  c l a s s e s  m a y  b e  r e c o g n i z e d :
A )  P o s i t i v e  C D  b a n d  a t  ~ 2 2 0 n m ,
B) Negative CD band at ~,215 to 217 nm,
C) Two negative CD bands at 230 nm and 220 nm.
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FIGURE 6
Perspec t i ve  v i ew  o f  the  mo le cu lar  c on fo rmat i ons  o r  two
p e p t i d e  f r a g m e n t s  r e l a t e d  t o  A i b  a n a l o g s  o f  e n k e p h a l i n s .
L e f t :  B o c - A i b - A i b - P h e - M e t - N H 2  ( P r a s a d  e t  a l .  1 9 8 3 ) .
N o t e  3 1 0  h e l i c a l  s t r u c t u r e s  f o r m e d  b y  r e p e t i t i v e  4 1
h y d r o g e n  b o n d s .  R i g h t :  B o c - A i b - P h e - O M e  ( P r e s a d
u n p u b l i s h e d ) .  A  T y p e  I -turn with A i b  =  - 5 8 . 3 ° ,
A i b  =  - 2 9 . 8 ° , = -84.7°, P h e  =  1 . 3 °
C l a s s  A  C D  s p e c t r a  a r e  e x h i b i t e d  b y  t h e  p o s i t i o n  2
a n a l o g s  ( A i b  o r  A c c 5 )  i n  M e O H  a n d  H 2 O.  These  spec t ra
a r e  c h a r a c t e r i s t i c  o f  a -turn conformation, tentatively
a s s i g n a b l e  t o  e i t h e r  T y p e  I '  o r  T y p e  I I I '  c a t e g o r i e s ,
c ons i s t ent  w i th  the  c lass  C '  spec t ra  o f  Woody  (Woody  1974 ;
S m i t h  a n d  P e a c e  1 9 8 0 ;  C r i s m s  e t  a l .  1 9 8 4 ) .  S u c h  s p e c t r a
h a v e  b e e n  a s s i g n e d  t o  T y p e  I I  B - t u r n s  i n  m o d e l  p e p t i d e s
with Pro-X sequences (Criama et al. 1984; Rao et al.
1 9 8 3 ) .  H o w e v e r ,  t h e  o c c u r r e n c e  o f  A i b  o r  A c c 5  r e s i d u e s
a t  p o s i t i o n  i + 1  o f  a  T y p e  I I -turn = -60°, = 120°)
is sterically unfavorable. Is is, therefore, more
a p p r o p r i a t e  t o  a a s i g n  t h e  c l a s s  A  s p e c t r a  t o  T y p e  I '  o r
Gly(2)-Aib/Acc5(3) or Aib/Acc5 (2)-Aib/Acc5(3)  analogs in
III' -turns. The class B ectra obtained for the
M e O H  c a n  b e  a s s i g n e d  t o  t h e  c o n s e c u t i v e -turn (Type
I I I - I I I '  s t r u c t u r e ) .  F o r  t h e  G l y - A i b  ( A c c 5 )  a n a l o g s  i n
H 2 O  b o t h  t h e  n e g a t i v e  b a n d  a t  ~ 2 1 7 n m  a n d  t h e  p o s i t i v e
b a n d  a t  ~ 2 2 4  n m  a r e  o b s e r v e d ,  s u g g e s t i n g  a n  e q u l i b r i u m
m i x t u r e  o f  c o n f o r m a t i o n s  y i e l d i n g  b o t h  c l a s s  A  a n d  c l a s s
B  s p e c t r a .  i n t e r e s t i n g l y ,  i n  t h e  A i b - A i b - ( A c c 5 - A c c 5 )
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ana logs ,  there  i s  a  ra ther  dramat i c  change  in  CD pat te rns ;
a class B spectrum is observed in MeOH, whereas a class A
spec t rum i s  s een  in  H 2 O ( f i gures  8  and  10 ) .  The  NMR
e v i d e n c e  s u g g e s t s  t h a t  a  c o n s e c u t i v e -turn conformation
( f i g u r e  5 c )  i s  f a v o r e d  i n  p o l a r  s o l v e n t s  l i k e  d i m e t h y l
s u l f o x i d e .  T h i s  c o n f o r m a t i o n  i s  e x p e c t e d  t o  b e  a d o p t e d
in  MeOH a l so  and  cou ld  a c count  f o r  the  c lass  B  spec t rum
I n  H 2 O ,  o n e  o f  t h e - t u r n s - - p r o b a b l y  A i b ( 3 ) - P h e ( 4 ) - -
m a y  b e  d e s t a b i l i z e d ,  r e s u l t i n g  i n  a  s i n g l e  T y p e  I '  ( I I I ' )
Aib(2) -Aib(3) -turn. This would be similar to the
s t r u c t u r e s  p r o p o s e d  f o r  t h e  A i b  ( 2 )  ( A c c 5 ( 2 ) )  a n a l o g s  a n d
m a y  a c c o u n t  f o r  t h e  o b s e r v e d  c l a s s  A  C D  p a t t e r n .  I n  t h e
relatively apolar solvent, dioxane, all six analogs
e x h i b i t  d i s i n c t l y  d i f f e r e n t  C D  s p e c t r a  a s  c o m p a r e d  t o
M e O H  o r  H 2 0 .  An  unusua l  f ea ture  o f  these  spec t ra  i s  the
2 3 0  n m .  A  d e f i n a t i v e  c o n f o r m a t i o n a l  a s i g n m e n t  i n  d i o x -
p r e s e n c e  o f  a  r a t h e r  l o n g  w a v e l e n g t h  n e g a t i v e  b a n d  a t
a n e  i s  n o t  f e a s i b l e  a t  p r e s s n t .  A g g r g a t i o n  e f f e c t s  m a y
a l s o  p l a y  a  r o l e  i n  t h i s  s o l v e n t .  T h e  C D  s t u d i e s  s u g e s t
t h a t  e v e n  i n  t h e  A i b  o r  A c c 5  a n a l o g s  o f  L e u - e n k e p h a l i n
t h e r e  a r e  s o l v e n t  d e p e n d e n t  s t r u c t u r a l  c h a n g e s .  I t  i s
l i k e l y  t h a t  w e l l - d e f i n e d  c o n f o r m a t i o n a l  s t a t e s  l i k e  T y p e
I '  ( I I I ' )  o r  c o n s e c u t i v e -turn structures are populated
f o r  t h e m  p e p t i d e s ,  i n  s o l u t i o n .  H o w e v e r ,  e q u l l l b r i a
be tween  them con fo rmat i ons  must  be  c ons idered .
T h e  b i o l o g i c a l  a c t i v i t y  o f  a l l  t h e s e  a n a l o g s  h a s  n o t
y e t  b e e n  d e t e r m i n e d . H o w e v e r ,  a n  i n  v i v o  b e h a v i o r a l
a s s a y  i s  m i c e  f o l l o w i n g  i n t r a c e r e b r a l  i n j e c t i o n  o f
p e p t i d e  h a s  b e e n  c a r r i e d  o u t  o n  t h e  t h r e e  A i b  a n a l o g s
of Met-enkephalinamide. This study established the
f o l l o w i n g  o r d e r  o f  a c t i v i t y :  A i b - A i b  A i b - G l y  G l y - G l y
Gly-Aib (Nagaraj et al. 1970; Sudha and Balaram 1983).
w h i l e  r e s i s t a n c e  t o  e n z y m a t i c  d e g r a d a t i o n  ( P e r t  e t  a l .
1 9 7 6 )  l i k e l y  t o  e n h a n o e  t h e  a c t i v i t y  o f  t h e  A i b  a n a -
l o g s ,  r e l a t i v e  t o  t h e  n a t i v e  s e q u e n c e  i n  a n  i n  v i v o
a s s a y ,  t h e  o b s e r v e d  a c t i v i t y  d o e s  s u g g e s t  t h a t  f o l d e d
e n k e p h a l i n  c o n f o r m a t i o n s  a r e  i n  f a c t ,  r e c o g n i z e d  b y
a p p r o p r i a t e  r e c e p t o r s .  T h i s  c o n c l u s i o n  i s  b a s e d  o n  t h e
assumption that extended conformations are unlikely to
b e  p o p u l a t e d  i n  t h e s e  a n a l o g s  s e v e n  a t  t h e  r e c e p t o r  s i t e ,
s i n c e  f a v o r a b l e  b i n d i n g  i n t e r a c t i o n s  a r e  u n l i k e l y  t o
offset unfavorable conformational energies.
Th i s  chapter  has  des c r ibed  an  approach  used  in  the
a u t h o r s '  l a b o r a t o r y  t o  r e s t r i c t  b a c k b o n e  c o n f o r m a t i o n a l
f l e x i b i l i t y  o f  t h e  e n k e p h a l i n s .  T h e  u s e  o f  a l k y l a t i o n
at as a means of  limiting peptide backbone freedom
( S p a t o l a  1 9 8 3 )  i s  a  p r o m i s i n g  a p p r o a c h  t o  t h e  d e v e l o -
m e n t  o f  c o n f o r m a t i o n a l l y  c o n s t r a i n e d  a n a l g o s  o f  b i o l o g i -
c a l l y  a c t i v e  p e p t i d e s .  T h e  u s e  o f  1 - a m i n o c y o l o a l k a n e
carbox ly i c  a c ids  o f  vary ing  r ing  s i ze  may  permi t  a l t e re -
a t i o n s  i n  t h e  s t e r i c  b u l k  a n d  h y d r o p h o b i c i t y  o f  t h e  r e s i d u e
b e i n g  u s e d  t o  l i m i t  c o n f o r m a t i o n a l  f l e x i b i l i t y .  T h e  p o t e n -
tial of this approach is indicated by the observation that
replacements of Leu(2) in the chemotactic peptide (Formyl-
Met-Leu-Phe) by Aib, Acc5, and Acc6 leads to biologically
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FIGURE 7
L e f t :  C D  s p e c t r a  o f  B o c - G l y - P h e - M e t - N H 2  ( 1 . 9 6 )  i n
a) TFE b) MeOH c) TFE MeOH, 1:1 (v/v). Right: CD spectra
o f  Tyr -G ly -G ly -Phe -Met -NH 2  ( 1 . 7 4 )  i n  a )  M e  O H ,  b )  T F E
Boc-Tyr-Gly-Phe-Lue-NH2 (1.53) in c) MeOH and d) TFE.
(From Sudha and Balaram 1981, Copyright 1981, Elsevier/
North-Holland Biomedical Press).
FIGURE 8
CD spectra of  Tyr-X-Y-Phe-Leu-NH 2  in  MeOH. Left :  -Aib-Gly-
- G l y - A i b - , -Aib-Aib- O. Right: -Ace5-Gly-
- G l y - A c c 5 - , Acc5-Acc5- O.
FIGURE 9
CD spec t ra  o f  Tyr -X -Y-Phe -Leu -NH 2  i n  d i o x a n e .  L e f t :
- A i b - G l y - - G l y - A i b - -Aib-Aib- O. Right:
- A o c 5 - G l y - - G l y - A c c 5 - -Acc5-Acc5- O.
FIGURE 10
C D  s p e c t r a  o f  T y r - X - Y P h e - L e u - N H 2  i n  H 2 O .  - A i b - G l y -
- G l y - A i b - - A i b - A i b -  0 .
3 2 7
a c t i v e  a n a l o g s .  T h e  A c c 6  a n a l o g  i s  a  h u n d r e d  f o l d  m o r e
a c t i v e  t h a n  t h e  p a r e n t  p e p t i d e  ( I q b a l  e t  a l .  1 9 8 4 ;
Sukumer  e t  a l .  1985 ) .
T h e  s t u d i e s  d e s c r i b e d  i n  t h i s  c h a p t e r  o u t l i n e  a  m e a n s
o f  i m p a r t i n g  s p e c i f i c  f o l d e d  c o n f o r m a t i o n s  t o  a n a l o g s  o f
e n k e p h a l i n s .  A d i t i o n a l  r e s t r i c t i o n s  i m p r o e d  o n  s i d e -
c h a i n  f l e x i b i l i t y  s h o u l d  c o m p l e m e n t  t h e s e  s t u d i e s  a n d  l e a d
t o  a  b e t t e r  d e f i n i t i o n  o f  t h e  s t r u c t r a  r e q u i r e m e n t s
f o r  r e c o g n i t i o n  b y  b i o l o g i c a l  r e c e p t o r s .
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Enkephalin Conformation in Solution: A
Perspective From Vibrational Spectroscopic
Studies
V. Renugopalakrishnan, Ph.D.; T. W. Collette, Ph.D.;
L. A. Carreira, Ph.D.; and R. S. Rapaka, Ph.D.
The conformations of enkephalins have been assiduously explored
since their discovery by Hughes et al. (1975). Numerous
studies, often resulting in conflicting conclusions, have been
reported in the literature (see Schfller 1984 for a review). A
broad spectrum of physical methods has been utilized in
derivin the solid and solution phase conformations of
enkephalins. The central goal of the numerous studies has been
to determine the bfoactfve conformation of enkephalins in their
free state and, from the results obtained, derive the plausible
conformation at the receptor site whose topography can at best
be inferred. Many spectroscopic studies have been performed in
organic solvents (Schiller 1984), which have provided much
useful information but are of little direct relevance to the
conditions likely to prevail at the receptor site. Of the
numerous studies reported in the literature, only theoretical
conformational analysis and molecular graphics have enabled
researchers to postulate the receptor site conformations of
enkephalins (Gorin et al. 1978).
In this study, FT-IR, Raman, and 2D-NMR spectroscopic methods
were chosen to investigate the enkephalin conformations in
solution, as these methods are suitable for obtaining fresh
insight in the somewhat tedious and frustrating search for the
elusive bfoactfve conformations of enkephalins. 2D-NMR studies
and, in particular, 2D-NOE studies are still in progress; there-
fore, a perspective of enkephalin conformations from FT-IR and
Raman spectroscopic studies (Renugopalakrishnan et al. 1985) is
presented in this review. Previously, a Raman study of
Leu5-enkephalin was reported in the literature (Han et al.
1980). The present study differs in many respects from the
previous Raman study of Leu5-enkephalin. In the present
study, the conformations of both Leu5- and Met5-enkephalins
are investigated in aqueous and dimethyl sulfoxfde (DMSO)
solutions. The latter solvent was used in order to compare the
results of the present study with earlier studies (Schiller
1984). The FT-IR study of enkephalins in aqueous solutions
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discussed here is the first of its kind and has utilized
state-of-the-art advancements In this field. These studies
were performed typically with millimolar concentrations of
enkephalins in solution and, at this concentration level, the
molecular aggregation of enkephalins can be expected to be
minimal. The final answers to the bioactive conformations of
enkephalins must await the isolation and purification of
receptors in whose presence the conformations of enkephalins
have to be determined using physical methods.
VIBRATIONAL SPECTROSCOPY AS A WINDOW ON SECONDARY STRUCTURE ON
POLYPEPTIDES AND PROTEINS
Recent developments in vibrational spectroscopy have placed
this technique in the forefront of physical methods for the
elucidation of secondary structures of polypeptides and
proteins. IR and Raman spectroscopic methods are based on the
principles of vibrational spectroscopy, but differ on the
fundamental mechanisms by which they arise: IR absorption
occurs only when the dipole moment changes during the
molecular vibration, whereas the Raman effect occurs through
the induced dipole moment, namely the polarizability term when
the incident light Interacts with the molecular system.
Therefore, the two methods provide complementary information on
a molecular system. For a general review of the application of
FT-IR and Raman spectroscopy to biological molecules, see
Parker (1983) and Tu (1982). Recently, the two methods and
their variants have been applied to the elucidation of
secondary structures of polypeptides and proteins
(Renugopalakrishnan et al. 1984; Renugopalakrishnan and
Bhatnagar 1984; Diem et al. 1984).
MID-IR AND RAMAN SPECTRA AS A BLUEPRINT OF THE PDLYPEPTIDE
BACKBONE CONFORMATION
Most of the IR and Raman spectra of polypeptides and proteins
reported in the literature contain much useful information in
the mid-IR and Raman frequency region of 1000 to 2000 cm-1,
which can be broadly divided into the following three regions:
I. 1600 to 1700 cm-1
II.
III.
1500 to 1600 cm-1
1200 to 1300 cm-1
These regions are usually designated as amide I, II, and III
regions since they contain the three important vibrational
modes of the peptide moiety, as shown in figure 1. The amide I
vibrational mode consists of carbonyl bond stretching with a
minor contribution from NH in-plane bending; the amide II mode
consists of C'-N and N-C bond stretchings with a minor
contribution from NH in-plane bending;  whereas the amide III
mode consists of C'-C and C'-N bond stretchings with a
minor contribution from NH in-plane bending. The amide II mode
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is usually either Raman inactive or weak in intensity. The
three amide modes are generally sensitive to the secondary
structures of the polypetide backbone, but it has been
difficult to derive reliable secondary structural information
from the observed frequencies. Part of the difficulty in
deriving useful secondary structural information has been due
to the absence of accurate IR and Raman data on polypeptides
with well-characterized secondary structures. Much of the IR
data reported in the literature before the introduction of the
FT technique contained broad bands which lacked sufficient
resolution to derive precise frequencies for secondary
structural interpretation.
The introduction of lasers in the late sixties as the source of
excitation in Raman spectroscopy (Lord and Yu 1970) has made
it relatively easier to record Raman spectra of polypeptides
and proteins, which was quite difficult with the older
generation Raman spectrometers equipped with mercury arc
lamps. Therefore, in recent years, a wealth of data on
polypeptides and proteins has been reported in the literature
setting the stage for a qualitative and quantitative
interpretation of their IR and Raman spectra.
VIBRATIONAL FREQUENCIES OF SOME PROTEIN STRUCTURES RELEVANT TO
ENKEPHALIN CONFORMATIONS: AMIDE I AND III FREQUENCIES OF
-SHEET AND -TURN STRUCTURES
Synthetic polypeptfdes and proteins containing -sheets,
determined by other physical methods, manifest characteristic
amide I frequencies ranging from 1669 cm-l to almost 1690
cm-1. For example, phosvitin (a phosphoglycoprotein from hen
egg yolk containing more than 50% O-phosphoserines) assumes
largely a -sheet
band at 1690 cm-1 and a Raman active band at 1672 cm-1
structure at pH 2 and manifests an R active
(Renugopalakrishnan et al. 1985b). The amide I bands
typical of -sheets cluster at the higher frequency range,
while those characteristic of -helical structures cluster at
the lower frequency range of the amide I region. The amide III
frequencies characteristic of -sheet and -helical structures
occur in the lower and higher frequency ranges of the amide III
region respectively.
Amide I and III frequencies characteristic of -turns have been
calculated from normal vibration analysis of a tetrapeptfde,
CH3CO-(Ala-Ala-Ala-Ala)-NH-CH3 by Bandekar and Krimm
(1979). For effective transition dipole coupling perturbation,
eff between 0.35 and 0.45D, characteristic frequencies
around 1640 to 1645 cm-1 and 1685 to 1690 cm-1 for type I
-turns and around 1660 to 1665 car and 1685 to 1690 cm-1
for type II -turns were observed from these calculations.
Antiparallel -sheet structures manifest amide I frequencies
near 1690 cm-1 (Miyazawa and Blout 1961) which partly overlap
with the type I -turn frequencies (Bandekar and Krimm 1979).
Therefore, caution must be exercised in the interpretatlon of
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Amide I
Amide II
Amide III
FIGURE 1
Amide I, II, and III vibrational modes of a peptide
moiety. From Tu 1982. Copyright 1982, John Wiley and
Sons.
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the amide I frequencies. The amide II modes of the type I
-turn structures occur near 1550 to 1555 cm-l and 1567
cm-1, whereas type II e-turn structures exhibit amide II
bands around 1545, 1555, and 1560 cm-1 respectively,
corresponding to eff=0.27D (Bandekar and Krimm 1979). From
the calculations, the amide III modes were found to occur in
the 1290 to 1330 cm-1 region.
In general, a number of IR and Raman studies on -turn
structures have reaffirmed the theoretical calculations of
Bandekar and Krimm for amide I and II frequencies. However,
their observations on amide III frequencies, in general, are
not corroborated by experimental observations (Tu 1982). Since
the amide I frequencies of -turn and -sheet structures
sometimes conflict with each other by occurring in the same
region of IR and Raman spectra of polypeptides and proteins,
caution must be exercised in drawing secondary structural
interpretations.
From this wealth of information, the frequency range for
different types of secondary structures commonly present in
polypeptides and proteins is presented in figure 2, which was
adapted from Tu (1982).
As may be observed from figure 2, the region designated as
"random coil" is relatively smaller in area than the -helical,
-sheet, and -turn structures. In fact, this region contains
the regions where -turns, -turns, and collagenlike
polyproline II structures manifest characteristic vibrations
and, therefore, its definition remains quite arbitrary.
Interferences in the Amide I Region
The amide I region is usually obscured by bands arising from
the solvents comnonly used in vibrational spectroscopic
studies. Althouah diaital subtraction of solvent bands is
possible, in reality it becomes difficult to completely
subtract the solvent backaround. Therefore. sufficient caution
must be exercised in assigning secondary structural
significance to amide I bands. Fortunately, the introduction
of the Fourier self-deconvolution technique (Kauppinen et al.
1981) has made possible the resolution of complex overlapping
bands and has initiated a new era in the application of Raman
and FT-IR spectroscopic methods to the determination of
secondary structures. The interference of solvent in the amide
II and III regions is less severe than in the amide I region,
but the former vibrational modes are mixed modes involving the
stretching of multiple bonds, making them less dependable as
conformational probes.
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FIGURE 2
The range of observed amide I and III frequencies for
-helical, -turn, -sheet, and "random coil"
structures. From Tu 1982. Copyright 1982, John Wiley
and Sons.
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RELATIONSHIP BETWEEN AMIDE I, II, AND III FREQUENCIES WITH THE
SECONDARY STRUCTURE OF POLYPEPTIDE BACKBONE
The secondary structural dependence of amide I, II. and III
vibrational modes are based on the concept that the vibrational
frequencies of the peptide moiety are dampened to an extent
dependent on their spatial orientation in the polypeptide
backbone; peptide moieties with similar spatial constraints
give rise to somewhat similar vibrations. For example, the
amide I vibrational mode, figure 1, can be expected to depend
on the orientation of the it peptide unit with respect to
the preceding polypeptide backbone, figure 3, described by
Ramachandran angle. The -helical and -sheet structures
differ in, their value, and if the amide I frequency for these
two structures depend on , then one would expect to see marked
differences in their respective frequencies, as observed from
figure 2. It is at present difficult to distinguish between
and structures, as well as between e-sheet and -turn
structures, and -sheet and collagenlike polyproline II
structures based on amide I frequencies. It was recently
suggested that the low-frequency vibrational modes where
torsional interactions dominate are much more useful in
providing a clearer distinction between various polypeptide
structures (Renugopalakrishnan et al., in press [1985a]). It
was demonstrated by Lord (1977) that the amide III frequencies
of -helical and -sheet structures differ markedly and, hence,
a correlation between amide III frequencies and, was
proposed. From numerous observations, this proposal has been
further substantiated, although the amide III frequency is
sensitive to the nature of side chain which makes Its use as a
conformational probe quite difficult (Hsu et al. 1976). Raman
and IR spectroscopic studies can provide a qualitative estimate
o f , which at best can complement a time averaged value for
from NOE studies in solution phase (Leach et al. 1977; Urry et
al. 1978).
With the introduction of FT technique in IR spectroscopy, FT-IR
method is slowly gaining increasing popularity in protein
structural studies. The previous disadvantage of utilizing
aqueous solutions in IR studies has been largely overcome. The
technical problem of fluorescence overshadowing the weak Raman
lines has also been resolved by the introduction of the
coherent anti-Stokes Raman technique (CARS), the use of pulsed
lasers with electronic time gating to capture Raman photons,
and the prolonged exposure of the sample to the laser beam
which presumably bleaches the fluorescent moiety (Hudson
1977). The two methods, i.e., FT-IR and Raman spectroscopy,
are well suited for structural investigations of the solid and
solution phase of polypeptides and proteins and, therefore,
offer a rapid method for the determination of their secondary
structures.
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FIGURE 3
Ramachandran angles about and
bonds for two peptide units linked at the atom.
From Tu 1982. Copyright 1982, John Wiley and Sons.
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A PERSPECTIVE OF ENKEPHALIN CONFORMATION FROM FT-IR AND RAMAN
SPECTROSCOPIC STUDIES IN SOLUTION PHASE
Conformation of Leu5-Enkephalin in Aqueous Solution
The FT-IR deconvoluted spectrum of Leu5-enkephalin in aqueous
solution is presented in figure 4. The amide I and II regions
only are shown in figure 4 where the amide I bands occur at
1663 cm-1 with two shoulders at 1 58 cm-1 and 1675 cm-1
in addition to a peak at 1632 cm-1. We have assigned the
1663 cm-1 band to a type II -turn, whereas it is somewhat
difficult to assign conformational significance to the
shoulders at 1658 cm-1. The shoulder at 1675 cm-1 and the
peak at 1632 cm-1 can be assigned to the -sheet structure.
The amide I frequencies for the -sheet structures also exhibit
satellite bands in the 1630 to 1640 cm-1 region (Renugo-
palakrishnan et a1. 1985b), which is not shown in
figure 2. The IR active band at 1663 cm-1 for Leu5-
enkephalin is quite close to the 1665 cm-1 band observed in
the Raman spectrum of Leu5-enkephalin presented in figure 5,
and its frequencies are tabulated in table 1. Raman spectrum
of Leu5-enkephalin in aqueous solution shows a multiplet
structure in the amide I and III regions with the amide II mode
being weak in this case. The most prominent amide I band
occurs at 1665 cm-1, whereas the amid
1263 cm-1 with a shoulder at 1255 cm-1 and a second peak at
III band occurs at
1275 cm-1. The amide III band at 1263 cm-1 is
characteristic of -turns, probably a type II -turn (Bandekar
and Krimm 1979). The shoulder at 1275 cm-1 is in the range
observed for -helical structures.
-turn structure for Leu5-enkephalin
Further support for the 
in aqueous solution is
provided by the intense amide II band at 1547 cm-1 in the
FT-IR spectrum of Leu5-enkephalin (figure 4). The FT-IR
spectrum of Leu5-enkephalin (figure 4) shows somewhat less
secondary structure than the Raman spectrum of
the same (figure 5). but the frequencies of the observed bands
in both are reasonably close to one another. The Raman bands
at 1648 cm-1 and 1275 cm-1, which are typical of -helical
structures, have no counterpart in the FT-IR spectrum.
Conformation of Leu5-Enkephalin in Dimethyl Sulfoxide
The Raman spectrum of Leu5-enkephalin in DMSO solution
(figure 6) shows very few bands in the amide I and III regions,
unlike the Raman spectrum of the same in aqueous solution,
which was shown in figure 5. The amide I band occurs at 1616
cm-1 and 1686 cm-1. While the origin of the band at 1616
cm-1 is not certain, the 1686 cm-1 is typical of the
-sheet structure (Renu opalakrishnan et al. 1985b).
The conformation of Leu5enkephalin in DMSO is
quite different from that observed in aqueous solution.
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FIGURE 4
The FT-IR deconvoluted spectrum of Leu5-enkephalin
solution  at a concentration of 0.37 mg/ml in water. The
spectrum was recorded at room temperature. From
Renugopalakrishnan et al. 1985. Copyright 1985,
Academic Press.
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FIGURE 5
Raman spectrum of Leu5-enkenphalin solution at a
concentration of 0.95 mg/50 µl in water (top) and of
Met5-enkephalin solution at a concentration of 1.05
mg/50 µl in water (bottom). The spectra were recorded
at room temperature using the 488 nm excitation line of
an argon ion laser at a laser power of 600 mW.
From Renugopalakrishnan et al. 1985. Copyright 1985,
Academic Press.
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FIGURE 6
Raman spectrum of Leu5-enkephalin solution at a
concentration of 1.2 mg/50) µl of DMSO (top) and of
Met5-enkephalin solution at a concentration of
1.55 mg/50 µl of DMSO (bottom). The spectra were
recorded at room temperature using the 488 nm excitation
line of an argon ion laser at a laser power of 600 mW.
The amide I and III regions only are shown. From
Renugopalakrishnan et al. 1985. Copyright 1985,
Academic Press.
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The amide III region shows one intense peak at 1210 cm-1 with
a shoulder (on DMSO peak) at 1274 cm-1. The amide III peaks
are hard to interpret in terms of the secondary structures and
provide little conformational information.
Conformation of Met5-Enkephalin in Aqueous Solution
The FT-IR spectrum of Met5-enkephalin in aqueous solution is
presented in figure 7 and the frequencies of amide I, II, and
III mode
1636 cm-1 and 1678 cm-1. The 1678 cm-1 is typical of
are listed in table 1. The amide I mode occurs at
-sheet structure (Renugopalakrishnan et al. l985b).
In contrast, the amide III exhibits a triplet structure with
bands occurring at 1246, 1273, and 1296 cm-1 respectively.
The 1246 cm-1 band arises from the -sheet structure
the 1273 cm-1 band is typical of -helical structure.
whereas
Bandekar and Krimm (1979) have predicted the 1290 to 1330
cm-1 region as characteristic of type I -turns, but none
have been reported to occur at this high frequency.
Further work is necessary to assign the 1296 cm-1 band.
From the Raman studies, a somewhat different perspective of its
conformation in aqueous solution emerges (figure 5) The amide
I mode exhibits a multiplicity of bands: 1613 (sh) 1623, 1633
(sh), 1649, and 1665 (sh) cm-1. An unequivocal assignment of
the bands is certainly quite difficult. The 1633 (sh) cm-1
could well be a satellite band characteristic of -sheet
structure, but if this is true, its higher frequency component
in the 1669 to 1690 cm-1 region is not observed in figure 5.
The 1665 cm-1 band which is only a shoulder, unlike a peak at
1665 cm-1 in the case of Leu5-enkephalin, is in the range
typical of type II -turn structures. The 1649 cm-1 band is
against typical of
(sh) cm-1 and the 1623 cm-1 peak are hard to interpret.
-helical structures. The shoulder at 1613
The amide III region shows three bands at 1252, 1265 (sh), and
1276 cm-1; whereas the 1252 (sh) cm-1 is too high for
µ-sheet structure, the other two can be assigned to the -turn
and -helical structures.
1265 cm-1 is only a shoulder in contrast to Leu5-enkephalin.
But, again, the -turn frequency of
Conformation of Met5-Enkephalin in Dimethyl Sulfoxide
As mentioned earlier, the Raman spectrum of Met5-enkephalin
in DMSO solution is shown in figure 6. The spectrum manifests
a doublet in the amide I region with bands occurring at 1616
cm-1 and 1686 cm-1. The band at 1686 cm-1 is typical of
-sheet structure. The conformational flexibility of Met5-
enkephalin is greatly reduced in DMSO solution, which is
similar to the observations on Leu5-enkephalin in DMSO.
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FIGURE 7
The FT-IR deconvoluted spectrum of Met5-enkephalin
solution at a concentration of 0.17 mg/ml in water. The
spectrum was recorded at room temperature. From
Renugopalakrishnan et al. 1985. Copyright 1985,
Academic Press.
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TABLE 1
The Amide I, II. and III Frequencies of Leu5- and Met5-enkephalins in Solution Phase
From FT-IR and Raman Spectroscopic Studies
FT-IR RAMAN ASSIGNMENT
H2O H20 DMSO
Leu5 EnkEphalin
1217 cm-1
1255(sh)
1263
1275
1210 cm-1
1274(sh on DMSO
peak)
1516 cm-1
1547
1632
1658(sh)
1675(sh)
1623
1648
1655
AMIDE III
AMIDE II
1616
1686
AMIDE I
Met5-Enkephalin
1246
1373
1296
1217
1252
1265(sh)
1276
1210
1274(sh on DMSO
peak AMIDE III
1512 AHIDE II
1551
1578
1636
1678
1613(sh)
1623
1633(sh)
1649
1665(sh)
1616
1686 AMIDE I
CONCLUSIONS
Numerous studies on enkephalins using theoretical conforma-
tional analysis, X-ray diffraction studies on crystalline
Leu5- and Met5-enkephalins, and spectroscopic studies of
enkephalins in solution have led to widely divergent perspec-
tives on the bioactive conformations of enkephalins. Un-
fortunately, none of the studies could be directed toward the
bioactive conformations of enkephalins at the receptor site 
except for the theoretical conformational analysis of Gorin et
al. (1978) and the 500 MHz 1H NMR study of Beretta et al.
(1984).
From the earlier studies, enkephalins have been postulated to
be flexible molecules (Schiller 1984). This conclusion should
not be surprising if one considers the absence of long-range
stabilizing interactions in the pentapeptide. Hence, its
conformation is likely to be determined by short-range inter-
actions. It is plausible that the peptide exists in a
conformational equilibrium modulated by the nature of the
solvents, ionic strengths, etc. Among the structures commonly
encountered for pentapeptide are and -turns; and, If
molecular aggregation occurs, larger structures can be
envisaged.
The FT-IR and Raman spectroscopic studies of enkephalins are
Indicative of a conformational equilibrium prevailing in
aqueous solution, whereas in DMSO, the conformational
flexibility is greatly reduced. In DMSO, enkephalins form
either -turn or -sheet structures or a combination of both;
while, in aqueous solutions, both structures definitively
coexist. While Leu5-enkephalin in aqueous solution shows a
-turn structure, Met5-enkephalin shows a less marked
tendency to form turn structures. The occurrence of amide I
bands at 1648 cm-1 in Leu5-enkephalin and at 1649 cm-1 in
Met5 enkephalin (typical of -helical structures) can
probably be explained by the occurrence of values at the
N- or C-terminal ends characteristic of -helical structures.
The peptides are too short to cause nucleation of -helical
structures (Chou and Fasman 1974). An equally valid
explanation for the above bands is the likely presence of a
type I -turn structure which, according to the calculations of
Bandekar and Krimm (1979). have low amide I frequencies in the
region 1640 to 1645 cm-1. At the present time, the results
from this FT-IR study are more conclusive since it was possible
to deconvolute the bands in the amide I and II regions. Han et
al. (1980) concluded that Leu5-enkephalin forms a -turn
structure in DMSO-d6 with an amide I band occurring at 1691
cm-1. This is slightly different from the frequency observed
in our study, namely 1686 cm-l. While an ambiguity probably
exists in the interpretation of -turn and
with frequencies of 1686 cm-1 and 1691 cm-1, we would like
-sheet structures
to interpret this band as arising from s-sheet structure based
on numerous observations (Renugopalakrishnan et al. 1985b).
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Unfortunately. the earlier Raman study of Han et al. (1980)
indicated a broad band centered around 1640 cm-1 for
Leu5-enkephalin in aqueous solution from which little
conformational information could be derived. From their
observations, Han et al. concluded that an ensemble of
conformations existed in aqueous solution which is
qualitatively similar to the conclusions
study. The IR spectrum of Leu5-enkephalin in DMSO-d6 (Han
reached in the present
et al.) showed an intense band of 1666 cm-1 which was typical
of a type II -turn structure. This IR band at 1666 cm-1 is
quite close to the 1663 cm-1 band observed in the present
study of Leu5-enkephalin in aqueous solution.
For Met5-enkephalin, the propensity of the -turn is reduced
and evidence points to the presence of -sheet structure as one
of the prominent conformations. To date the observed
difference in biological activity of Leu5- and
Met5-enkephalins has not been explained based on
conformational requirements. Even though the present study
points toward differences in conformational populations in
solutions of Leu5- and Met5-enkephalins, further studies
are required to draw any definitive conclusions on the
relationship between the conformational requirements and
biological activity, such as µ/ specificity.
It is tempting to speculate that each opioid receptor subtype
obviously interacts with a single conformation from an ensemble
of enkephalin conformations based on the topography and
stereochemistry of both the receptor and the ligand. The rules
which govern this selectivity are as yet unknown. However,
Met5-enkephalin, as compared to Leu5-enkephalin, has higher
affinity for binding at µ-receptor sites as compared to receptor
sites, and, from our studies, it appears to preferentially
exist as a -sheet structure, over the -turn. It might be
that the -sheet conformation interacts at the µ-receptor site,
whereas as a -turn structure (as in Leu5-enkephalin), it
interacts at the -receptor site. The present progress in the
isolation and purification of opioid receptors (Demoliou and
Barnard 1984), and the degree of sophistication in physical and
theoretical studies attained, will pave the way in the future
for understanding the rationale of enkephalin structure
dynamics function relationships, in particular, and for
polypeptides and proteins, in general.
R E F E R E N C E S
Bandekar, J., and Krimm, S. Vibrational analysis of peptides,
polypeptides, and proteins: Characteristic amide bands
of -turns. Proc Natl Acad Sci USA 76:774-777, 1979.
348
Beretta, C.A.; Parrilli, M.; Pastore, A.; Tancredi, T.; and
Temusi, P.A. Experimental simulation of the environment of
the opioid receptor. A 500 MHz study of enkephalins in
CDCl3. Biochem Biophys Res Commun 121:456-462, 1984.
Chou, P.Y., and Fasman, G.D. Prediction of protein conforma-
tion. Biochemistry 13:222-245, 1974.
Demoliou, C.D., and Barnard, E.A. Solubilization in high yield
of opioid receptors retaining high affinity
binding sites. FEBS Lett 170:378-382, 1984.
Diem, M.; Bhatnagar, Druyan, M.E.; and Renugo-
palakrishnan, V. Solution phase Raman spectroscopic studies
on synthetic collagen analogs: Prolyl-prolylqlycine and
(prolyl-prolyl-glycine)lO. Biopolymers 23:2955-2961 1984.
Gorin, F.A.; Balasubramanian, T.M.; Barry, C.D.; and Marshall,
G.R. Elucidation of the receptor-bound conformation of the
enkephalins. J Supramol Structure 9:27-39, 1978.
Han, S.-L.; Stimson, E.R.; Maxfield, F.R.; and Scheraga, H.A.
Conformational study of [Leu5] enkephalin by laser Raman
spectroscopy. Int J Pept Protein Res 16:173-182, 1980.
Hsu, S.-L.; Moore; W.H.; and Krimm, S. Vibrational spectrum of
the unordered polypeptide chain: A Raman study of feather
keratin. Biopolymers 15:1513-1528, 1976.
Hudson, B.S. New laser techniques for biophysical studies.
Annu Rev Biophys Bioeng 6:135-150, 1977.
Hughes, J; Smith, T.W.; Kosterlitz, H.W.; Fothergill, L.A.;
Morgan, B.A.; and Morris, H.R. Identification of two related
pentapeptides from the brain with potent opiate agonist
activity. Nature 258:577-579, 1975.
Kauppinen, J.K.; Hoffatt, D.J.; Mantsch, H.H.; and Cameron,
D.G. Fourier self-deconvolution: A method for resolving
intrinsically overlapped bands. Appl Spectroscopy
35:271-276. 1981.
Leach, S.J.; Nemethy, G.; and Scheraga, H.A. Use of proton
nuclear Overhauser effects for the determination of the
conformations of amino acid residues in oligopeptides.
Biochem Biophys Res Commun 75:207-215, 1977.
Lord, R.C. Strategy and tactics in Raman spectroscopy of
biomolecules. Appl Spectroscopy 31:187-194, 1977.
Lord, R.C., and Yu, N.-T. Laser-excited Raman spectroscopy of
bianolecules. I. Native lysozyme and its constituent amino
acids. J Mol Biol 50:5O9-524, 1970.
Miyazawa, T., and Blout, E.R. The IR spectra of polypeptides
in various Conformations: Amide I and II bands. J Am Chem
Soc 83:712-719, 1961.
Parker, F.S. Applications of IR, Raman, and Resonance Raman
Spectroscopy in Biochemistry. New York: Plenum Press, 1983.
Renugopalakrishnan, V., and Bhatnagar, R.S. Fourier transform
infrared photoacoustic spectroscopy: A novel conformational
probe. Demonstration of helical conformation of poly
-benzyl glutamate). J Am Chem Soc 106:2217-2219. 1984.
Renugopalakrishnan, V.; Kloumann, P.H.B.; and Bhatnagar, R.S.
L-Alanyl glycylglycine: FT-IR and Raman spectroscopic
evidence for tripeptide packing in a collagen-like
arrangement. Biopolymers 23:623-627, 1984.
349
Renugopalakrishnan, V.; Rapaka, R.S.; Collette, T.W.; Carreira,
L.A.; and Bhatnagar, R.S. Conformational states of Leu5-
and Met5-enkephalins in solution. Biochem Biophys Res
Commun 126:1029-1035, 1985.
Reniiakrishnan, V.; Collette, T.W.; Carreira, L.A.; and
Bhatnagar, R.S. Low frequency Raman spectroscopy as a
conformational probe. Macromolecules in press (1985a).
Renugopalakrishnan, V.; Horowitz, P.M.; and Glimcher, M.J.
Structural studies of phosvitin in solution. J Biol Chem,
260:11406-11413, 1985b.
Schiller, P.W. Conformational analysis of enkephalin and
conformation-activity relationships. In: Udenfriend, S. and
Meienhofer, J., eds. The Peptides Vol. 6. New York:
Academic Press, 1984. pp. 219-268.
Tu. A.T. Raman Spectroscopy in Biology: Principles and
Applications. New York: Jon Wiley and Sons, 1982,
Urry, D.W.; Khaled, M.A.; Renugopalakrishnan, V.; and Rapaka,
R.S. Proton magnetic resonance and conformational energery
calculations of repeat peptides of tropoelastin. The
hexrpeptide. J Am Chem Soc 100:696-705, 1978.
ACKNOWLEDGMENTS
FT-IR experiments were performed at the National Center for
Biomedical IR Spectroscopy at Battelle Columbus Laboratories,
Columbus, Ohio, supported by NIH grant 1-P41 RR 0137. The help
of Ms. Katrina B. Smith with FT-IR experiments is gratefully
acknowledged.
AUTHORS
V. Renugopalakrishnan, Ph.D.
Laboratory of Skeletal Disorders and Rehabilitation
Department of Orthopaedic Surgery
Harvard Medical School
Children's Hospital, Enders-1220
300 Longwood Avenue
Boston, MA 02115
T.W. Collette, Ph.D. and L.A. Carreira, Ph.D.
Department of Chemistry
University of Georgia
Athens, Georgia 30602
R.S. Rapaka, Ph.D.
National Institute on Drug Abuse
Rockville, Maryland 20857
350
Conformational Features of the Opioid
Peptides in the Solid State: A Review of
X-Ray Crystallographic Research
Arthur Camerman, Ph.D., and Norman Camerman, Ph.D
INTRODUCTION
lsolation and characterization of the enkephalins led very
quickly to attempts to elucidate their three-dimensional
conformations. A variety of approaches, including model
bullding experiments (Gradbury et al. 1976), high resolution
nuclear magnetic resonance (NMR) (Roques et al. 1976; Jones et
el. 1976), and empirical energy calculations (Isogal et al.
1977) were interpreted to suggest a folded conformation with a
-bend between either Gly2-Gly3 or Gly3-Phe4 as the most
stable enkephalin structure. However, more comprehensive
studies util izing NMR, ultraviolet spectroscopy (UV) and
circular dichroism (CD) data (Khaled et al. 1977), and
sophisticated energy considerations (De Coen et al. 1977)
demonstrated that fully extended enkephalin conformations are
also consistent with spectroscopic data and with energy
minima. From these studies, the existence of both folded and
extended enkephal in molecules in solution was postulated.
Seversl X-ray crystallographic investigations of leucine end
methlonine enkephalins and enkephal in analogs in the solid
state have recently been described. They have confirmed the
occurrence of both types of conformation and have al loved us
to observe direct ly the intra- and inter-molecular bondings
which help to stablize them.
FOLDED CONFORMATIONS
Three crystal structure determinations--of an enkephalin, a
substituted enkephalin, and an enkephalin analog--all have
pentapepide molecules which exhibit folded conformations in
the sol id state. Despite the differences between the
molecules themselves and in crystal environments (see table
1), the three molecular conformations are remarkably similar.
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TABLE 1
a
b
c
z
Space
Group
Crystal Data for Enkephalins and Analogs whIch Have Been Crystallized
Leucine Methionine
1a 2b 3 c 4d 5 e 6
c , d
7d
31.87 (31.93) 18.72 11.46 31.58 8.59 11.61 11.55
8.54 (17.08) 24.73 15.59 8.63 30.27 17.99 11.58
12.47 (24.86) 20.31 16.73 12.58 15.02 16.52 12.95
90.0 90.0 90.0 90.0 90.0 90.0 90.0 93.77
96.53 (95.54) 115.86 92.20 97.74 96.94 91.20 95.96
90.0 90.0 90.0 90.0 90.0 90.0 90.0 86.96
4 (16) 8 4 4 4 4 2
C 2 ( A 2 ) C 2 P 1
aSmith and Griffin 1978; (Blundell et al. 1979). Leucine enkephalin; folded conformation.
bCamerman et al. 1983 Leucine enkephalin; extended conformation.
cBlundell and Wood 1982 Leucine and methionine enkephalins; unsolved but.
likely both are extended.
d Ishida et al. 1984. [p-bromoPhe4] Leu-enkephalin) folded conformation. Methionine
and [p-bromoPhe4] Met-entephalins unsolved but likely both are extended.
eEckle et al. 1984. [D-Nle2,L-NleS5] enkephalin; folded conformation.
Leucine Enkephalin
The first enkephalin X-ray diffraction structural information
came from a crystal structure determination of Leu-enkephalin
monohydrate in crystals grown from aqueous methanol (Smith and
Gri f f in  1978). The molecular conformation is characterized
a Gly2-Gly3 -bend stabilized by two intrmnolecular hydrogen
by
bonds, Tyr1(CO)-Phe4(NH) and Tyr1(NH)-Phe4(CO). The tyrosine
side chain is disordered and two positions of approximately
equal occupancies are found for the hydroxyphenyl atoms. The
Tyr and Phe side chains are located on the same side of the
molecular backbone "plane" and are roughly coplanar with it,
while the Leu side chain is on the opposite side and oriented
perpendicular to the backbone.
FIGURE 1
Molecular structure of leucine enkephalin in crystals grown from
aqueous methanol Smith and Griffin 1978. Copyright 1978,
American Association for the Advancement of Science
Subsequent to publication of this structure, Blundell et al.
(1979) discovered that the unit cell of the Leu-enkephalin
monohydrate crystals had been incorrectly characterized; the
true unit cell (see table 1) contains four independent peptide
molecules and the results of the structure analysis can be
interpreted as dercribing a conformation averaged over four
nearly identical molecules. The apparent disorder of the
tyrosine side chains I ikely ref lects two dist inct  tyrosine
orientations in the four independent enkephalins.
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[p-bromoPhe4] Leucine Enkephalin
A Ieucine enkephalin with bromine substituted at position four
of the phenylalanine phenyl ring was recently synthesized and
crystallized from an ethanol/water mixture for an X-ray
crystal lographic structure invest igat ion ( Ishida et  a l .  1984).
Reasons for bromine substitution were twofold: to add a
"heavy" atom which makes the structure solution easier, and to
see what effects slight modifications in chemical structure
would have on enkephalin solid-state conformation. Results of
the crystal structure determination show that even both the
substituted bromine and crystalization from ethanol/water
rather than methanol/cater, the conformation of [p-bromoPhe4]
Leu-enkephalin is almost identical to that of the previously
reported Leu-enkephal in.
FIGURE 2
Molecular conformation of [p-bromoPhe4]leucine enkephalin. Ishida
et al. 1984. Copyright 1984, The Biochemical Society, London.
The near identity of the the structures can be visualized by
comparison of figures 1 and 2. In this crystal from, the
[p-bromoPhe4] Leu-enkephalin molecule exhibits a -turn
between Gly2 and Gly3 that is stabilized by two Tyr1-Phe4
hydrogen bonds exactly as found in Leu-enkephalin.
Furthermore, just as initially described for Leu-enkephalin,
the tyrosine side chain is disordered between two equally
occupied positions. Torsion angles in the backbones and side
chains of the two structures match very closely; the largest
difference, 14°, is found in the leucine side chain and the
average difference over 21 angles is less than 4° Since the
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conformations of these two molecules are essentially
ident ical ,  including disordered tyrosine posi t ions, i t  is
natural to question whether the space group reported for
[p-bromoPhe4] Leu-enkephalin may also be misinterpreted with,
as found for the folded Leu-enkephalin, doubling of the b and
c axes necessary to characterize the correct unit cell. As of
this writing, lshida and coworkers have not reported observing
the weak diffraction intensities that could identify such a
circumstance.
Tyr-D-Nle-Gly-Phe-NIeS
X-ray crystallographic structure determination of a synthetic
analog of leucine enkephalin in which glycine 2 is replaced
by D-norleucine end leucine 5 by the sulfonic acid of
L-norleucine has been reported very recently (Eckle et al.
1984). The compound was crystalized from an ethanol/water
solution and the crystal asymmetric unit contains two
enkephalin analog molecules, one ethanol molecule and five
water  molecules.
Despite the amino acid substitutions at positions 2 and 5, the
conformations of both analog molecules are strikingly
similar to that of folded leucine enkephalin. Again, each
molecule exhibits a -bend between amino acids at the 2 and 3
positions with intramolecular hydrogen bonds between
Tyr1(CO)-Phe4(NH) and Tyr1(NH)-Phe4(CO).
FIGURE 3
Steroscopic projections of the two independent molecules of
Tyr-D-NLe-Gly-Phe-NLeS. Eckle et al. 1984. Copyright 1984.
International Union of Crystallography.
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The major differences between the two molecules in the
asymetric unit occur at the tyrosine, a situation analogous
to the two different tyrosine orientations found in the
previously discussed enkephalins. In contrast to those two
enkephalins, however, the side chains in this enkephalin
analog are oriented with the tyrosine and phenylalanine on
opposite sides of the peptide backbone.
I t  is  notewrthy,  in l ight  of  the fact  that  [D-Ala 2 ]
Leu-enkephalin is boiologically active, that insertion of a
D-amino acid at position 2 does not alter the basic enkephalin
folded backbone conformation.
EXTENDED CONFORMATIONS
Four enkephalin crystal forms have been reported in which the
molecules either display or are strongly suggested to display
extended -pleated sheet conformations. Three of the four
crystal structures have not yet been solved so that the
molecular structures cannot be described with absolute
certainty,  but extremely strong indicat ions in al l  three
instances point to extended conformations. One completed
crystal structure determination of leucine enkephal in with
four independent pentapeptides in the asymmetric unit has
found all four enkephalins to display extended backbone
conformations.
Unsolved Structures
The first indications that both leucine and methionine
enkephalins could have extended backbones in the solid state
came from X-ray investigations of crystals of the two
compounds obtained from ethanol/water solutions (BlundelI and
Woods 1982). Although these studies did not lead to
successful structure elucidations, the X-ray data did allow
determination of the pentapeptide backbone orientations. In
both the leucine and methlonine crystals, the backbones appear
to be extended and to form hydrogen-bonded -pleated sheets.
A simllar situation involving X-ray data sets for methlonine
enkephalin (the same crystal form as above) and [p-bromoPhe4]
Met-enkephalin was reported very recently (lshida et al.
1904). These investigators also were unable to solve the
crystal structures but were able to conclude that the
methionine and bromo-substituted methionine enkephalins have
extended conformations.
Leucine Enkephalin
A crystal form of leucine enkephal in grown from a water-DMF
mixture was found from measurment of unit cell volume and
density calculations to contain four independent enkephalin
molecules plus a large amount of solvent in the asymmetric
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unit. Elucidation of the crystal structure has shown that the
four  enkepha l in  pen tapep t ides  exh ib i t  s l i gh t l y  d i f fe r ing
molecular conformations but all have extended linear backbones
(Camerman et al. 1983; Karie et al. 1983).
The  ex tended  mo lecu les  fo rm a  s l i gh t l y  i r regu la r  an t ipa ra l le l
-pleated sheet with the amino
and below the backbone plane.
hydrogen bonds largely between
groups.
acid side chains oriented above
The sheet is held together by
peptide backbone NH and CO
Conformations of the four indepandent peptides in Lmaiuo
FIGURE 4
enkephalin crystals grown from water/DMF. Oxygen and nitrogen
atom are darkened. Camerman et al. 1983. Copyright 1983.
Macmill ian Journals Ltd.
Comparison of me molecular conformations of me four
independent enkephal ins reveals that  the greatest  d i f ferences
are the or ientat ions of  the tyrosine and leucine s ide chains;
the  pheny la lan ine  s ide  cha in  o r ien ta t ion ,  i n  con t ras t ,  d i f f e rs
only s l ight ly f rom molecule to molecule.
The peptide backbones of molacules A and D are similar and are
more puckered than those of B and C, which also resemble each
o ther .  I n  a l l  f ou r  mo lecu les ,  the  regu la r  a l te rna t ion  o f  r i de
chain positions causes the Tyr and Phe side chains to be
located on opposite sides of the backbone with the Leu side
chain on the same side as the Tyr.
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Conformational variations in the peptide backbones of leucine
enkephal ins are i l lustrated in table 2 which l is ts the
backbone torslon angles in the four independent extended
conformers and, for comparison, those in the folded molecule.
Analysis of the and angles for glycine residues 2 and 3
reveals that at these positions molecules A and D display
conformations characteristic of L-amino acids, while in B and
C the values are closer to those which would be favored by
D-amino acids. The only other angles which differ appreciably
between enkephalin molecules are those at leucine. These data
are compatible with, and may provide an explanation for, the
observations that substitution of D-alanine at position 2 and
D-leucine at posi t ion 5 yield biological ly act ive enkephal in
analogs, while substitution of D-phenylalanine at residue 4
dest roys  ac t iv i ty .
Extended Conformation and Biological Activity
Determining which enkephalin conformations are responsible for
binding to receptors and effecting the physiological actions
of these compounds would greatly aid our understanding of the
nature of opiate receptor binding and the molecular mechanisms
of analgesia. A sin i f icant step in th is direct ion has been
the synthesis of cyclic Leu-enkephalin analogs with enhanced
opiate µ receptor affinity (DiMaio and Schiller 1980; Schiller
and DiMaio 1982; DiMaio et al. 1982). Substitution of D
diaminobutyric acid for glycine in position 2 of the
enkephalin sequence and cyclization of the -amino group to
the leucine C-terminal carboxyl group has produced a compound
that is twice as potent as its uncyclized analogue and 20
times as potent as Leu-enkephalin in inhibiting electrically
evoked contractions of the guinea pig ileum.
A rat ionale for th is enhanced act iv i ty is that cycl izat ion
produces a relatively rigid, fixed conformation in contrast to
Leu-enkephelin which displays both extended and folded shapes
in solut ion and in the sol id state.  Addit ional ly,  th is f ixed
conformation is similar to the "active" conformation adopted
by enkephalins when binding to µ receptors.
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FIGURE 5
The four leucine  enkephalin extended backbone conformations
aligned in comparable orientations, Camerman et al. 1903.
Copyright 1983. Nacmilian Journals Ltd.
TABLE 2
Torsion Angles (deg) in the Enkephalin Backbonesa
Residue Angle A B
Tyr1 1 135 154
1 172 177
Gly2 2 -144 151
2 114 -155
2 -177 180
Gly3 3 -122 154
3 132 -151
3 -179 -170
Phe4 4 -122 -128
4 139 130
4 168 174
Leu5 5 -79 -72
5 176 167
C D F b
155 137 126
177 173 173
141 -131 59
-157 142 25
-178 179 179
174 -144 9 7
-170 131 -7
179 178 -174
-119 -147 -136
149 152 145
179 171 180
-141 -141 -105
137 151 -4
aEstimated standard deviations are 1.8-2.5°
bFolded leucine enkephalin.
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It has been demonstrated with molecular models that the
cyclized compound cannot retain the structural features of any
of the folded enkephalin conformations; thus, the µ receptor
active conformation almost certainly does not contain an
intramolecular bend (DiMaio and Schiller 1980). We have
investigated whether the crystal structure extended
conformations are compatible with the cyclized enkephal in
analog by constructing a model of the latter compound
derived from an extended Leu-enkephalin molecule with the
approp r la te  pos i t i on  2  subs t i t u t i  and  cyc l i a t i n  added .
The model is shown figure 6. Analysis of the model reveals
that ,  in order to form the cycl ic  analog,  the l inear pept ie
backbone has to be made somewhat more pleated, with the
largest changes in torsion angles occurring at Gly3.
FIGURE 6
Molecular model of Tyr-cycol-[- -DA2-bu-Gly-Phe-Leu-]
from leucine enkephalin extended conformation coordinated. A2bu:
diaminobutyric acid. Peptide linkage are shown in white:
-carbons and side chains are dark. (Camerma et al. 1983.
Copyright 1983, Macmillan Journals Ltd.
Comparison of figures 5 and 6 illustrates that although the
molecular fit is not exact, the main structural features of
the Leu-enkephalin extended conformation can be retained in
the cyclized analogue: the peptide backbone is linears
hydrogen bonding atoms are retained in similar positions and
orientations: Tyr and Leu side chains are located on the same
side of the backbone, while Phe is on the opposite side.
Quantitatively, the Tyr and Phe rings are, respectively, 8.2,
13.3, 13.9, and 8.9 Å apart in the extended molecules A, B, C,
and D and the same range of distances is permitted in the
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cyclized model. In terms of arrangement of hydrogen bond
acceptors and donors, the distance between Tyr1 and Gly3
carbonyl oxygen atoms ranges from 6.8 to 7.2 in the extended
molecules, while Gly2 and Phe4 nitrogen atoms are 6.6 to 7.1 Å
6.2 Å. I t  appears,  therefore,  that  i f  the enhanced act iv i ty
apart. These distances in the cyclized compound are 7.1 and
of the cyclized analog is due to forcing of the otherwise
flexible muIticonformationaI enkephalin molecule into a
conformation similar to that adopted when bound to µ
receptors, then conformations resembling the extended
molecules are suitable models for µ receptor active enkephalin
stereochemistry.
Apart from the extra atoms introduced by the substitution of
diaminobutyric acid for glycine, the biggest change to the
enkephal in structure on forming the cyclic analog is the
movement of Leu due to its Iinkage to the side chain at
pos i t i on  2 .  I t  i s  o f  i n te res t  tha t  fo r  a  se r ies  o f  cyc l i c
compounds differing in the identity of the linkage
substituent, inhibitory potencies in both the guinea pig ileum
bioassay and the rat brain 3H-naloxone binding assay increase
with increasing length of the linking side chain (DiMaio et
a l .  1982). As the length of this side chain is increased, we
would expect the change in position of the leucine from its
location in the extended enkephal in conformation to be
lessened in formation of the cyclic compounds. Thus, these
biological data are also compatible with and support the
concept of an extended enkephalin conformation as a primary
candidate for binding to opiate µ receptors.
CONCLUSIONS
X-ray crystallographic inveqtigations of enkephalins and
enkephalin analog have to date provided four complete
three-dimensional structure determinations and three other
data sets from which structural inferences can be draw.
These investigations have enabled us to view directly
enkephalinolecular stereochemistry in the solid state under
a variety of envirormental conditions and to formulate
conclusions about conformational preferences and stabilit ies
(1) The enkephalins are flexible molecules and when the whole
pentapeptide is considered (side chains as well as
backbone), several conformationaI arrangements are
equally probable.
(2) There appeer to be two favored backbone conformations,
the folded one characterized by a -bend between residues
2 and 3 stabilized by two Tyr1-Phe4 hydrogen bonds, and
the extended conformation stabilized by -pleated sheet
intermolecular hydrogen bonding.
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(3) D-amino acids can be substituted for glycine 2 without
changing either the folded or the extended backbone
conformat ions.  This correlates s igni f icant iy wi th the
fact that enkephalins with D-amino acids substituted at
pos i t ion  2  re ta in  b io log ica l  ac t i v i t y .
(4) As i t  is  possible for conformat ionaIIy restr icted
cyclized enkephal in analogs with greatly enhanced
receptor-mediated activity to maintain extended backbone
stereochemistry but not folded conformations, It is
Iikely that the enkephal in µ receptor active conformation
is one with an extended peptide backbone.
It is not known at present what factors are responsible for
the binding of enkephalins to each of the dlfferent classes of
opiate receptors.  One possibi l i ty ,  of  course,  is  that
dlfferent enkephalin conformations are required for
interact ion wi th the di f ferent  receptors. If this were the
case, then It would be reasonable to speculate from the
structural data that extended enkephalin molecules might bind
preferentially to the µ receptor and folded ones to the 8
receptor.  Further structure analyses,  part icular ly of
conformationaIIy restricted enkephalin analogs and other
peptides that bind selectively to one class of receptors, will
help to prove or disprove such speculations. They may also
help to eventually identify the factors that govern all types
of enkephal in-receptor interactions.
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The Search for Nonaddicting Strong
Analgesics: Hopes and Frustrations
Sydney Archer, Ph.D.
INTRODUCTION
The pleasures of the poppy have been known to man for many centuries and
have been glorified in literature by DeQuincy, among others. It was not until the
middle of the last century that the use and abuse of opium derivatives became a
serious cause for concern. Chemical examination of opium led to the isolation of
morphine by Serturner in 1803. Continued research on Papaver somniferum
resulted in the isolation and characterization of other alkaloids, and processes
were developed to make pure morphine readily available. The unrestricted
availability of this compound and the development of the hypodermic needle led
to widespread abuse of this alkaloid. The recognition of the addiction potential
of morphine stimulated attempts to find a substitute that would not be burdened
by this undesirable property. The first example was heroin, the diacetyl
derivative of morphine. This compound was indeed a satisfactory substitute in
the sense that it is an excellent analgesic and, on administration to morphine-
dependent subjects, prevented the appearance of the characteristic morphine
withdrawal syndrome. It was soon discovered that heroin was just as insidious as
its precursor. Two important lessons were learnt from this experience: first,
analogues of morphine may be clinically effective analgesics and, second, there is
the phenomenon of cross-dependence to be reckoned with.
There is very little relationship between the therapeutic dose of an opioid
analgesic and its potential for abuse. Some factors which are important in
determining overall abuse liability are: (1) the ability of a drug to induce
tolerance and physical dependence; (2) whether abrupt withdrawal of the drug
from a dependent individual will result in drug-seeking behavior; (3) whether
administration of the drug or a congener will relieve withdrawal symptoms
promptly; (4) whether the drug can be self-administered easily; and (5) whether
high doses of the drug will produce unpleasant side effects.
INITIAL STUDIES
A systematic search for a nonaddicting, strong analgesic was begun in 1929 when
the National Research Council and the National Academy of Sciences formed the
Committee on Drug Addiction whose charge was to develop a program involving
chemical synthesis, pharmacological evaluation, and clinical methodology to
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determine analgesic potency and to assess addiction liability. The chemical group
was headed by Dr. Lyndon Small, who at that time was a young assistant
professor at the University of Virginia. Small investigated derivatives of the
main phenathrene alkaloids in opium. He was joined by Dr. Erich Mosettig, a
student of Professor Spaeth, from the University of Vienna, who concentrated on
synthetic partial structures related to morphine. One of Mosettig’s students, Dr.
Everette L. May, joined the group in 1935, and continued this work which led to
many significant advances.
The pharmacology program was started in 1930 under the leadership of Dr.
Nathan B. Eddy, who later became Secretary of the Drug Addiction Committee.
In order for this fruitful collaboration to be even more effective, the two groups
were transferred to the National Institutes of Health (NIH) in 1938. About this
time, a primate facility was established at the University of Michigan under the
leadership of Professor Maurice Seevers, who developed techniques for measuring
dependence liability in monkeys.
During the first decade of this program, over 200 morphine analogues were
synthesized and evaluated. During the course of the next three decades, this NIH
facility tested over 9,000 compounds, most of which were submitted by
laboratories engaged in analgesic research with the same goals in mind. About
1,000 of these compounds were examined in Dr. Seevers’ laboratory, of which
approximately 10% were tested in the Addiction Research Center in Lexington,
Kentucky.
The Addiction Research Center was established in 1935 to develop methods to
quantitatively assay the addiction potential of new analgesics. The first Director
was Dr. Clifton K. Himmelsbach. One of the first methods perfected under
Himmelsbach’s direction was the direct substitution procedure. Prisoner addicts
were stabilized on a given dose of morphine for about 1 week. Then a putative
analgesic synthesized in either Dr. Small’s laboratory or elsewhere was substituted
for the morphine, using doses suggested by Dr. Eddy’s assessment of analgesic
potency in mice. When suitable doses were used, in every instance the addicts
were not aware that a drug had been substituted for morphine. It was judged
that drugs which could substitute successfully had a high addiction potential.
It was well known that when morphine is withdrawn from dependent individuals,
a syndrome develops which is characterized by a number of signs and symptoms.
Himmelsbach developed a method to quantitate the morphine abstinence
syndrome as shown in table 1. By plotting these Abstinence Syndrome Intensity
scores against time, the entire clinical process can be seen graphically as in
figure 1.
By the time World War II started, methodologies were available to determine the
potency of strong analgesics in rodents and their addiction potential in primates
and man. A major gap remained: methodology for the clinical evaluation of
analgesic potency. Henry Beecher was a pioneer who led the way to close this
gap. Two of his students, Louis Lasagna and Arthur Keats, as well as Raymond
Houde, made major contributions to solving the problem of determining analgesic
potency in man (Houde et al. 1965). A time-effect curve measuring the
analgesic potency of oral and intramuscular morphine is shown in figure 2.
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TABLE 1
Point System for Measuring Abstinence Syndrome Intensity by the Day (D) or
Hour (H)
Total abstinence syndrome intensity per day or per hour is the sum of  the points scored
in the (D) or (H) columns respectively, with due attention to the limits.
From Himmelabach, C.K., and Andrews, H.L. 1943. Copyright 1943 by The American Society for
Pharmacology and Experimantal Therapeutics.
FIGURE 1
Morphine Abstinence Syndrome
Perhaps the only clinically useful compound from the research efforts of Small
and his group during the 1929 to 1939 decade was metopon,l , prepared in several
steps from the enol acetate of dihydrocodone (Small et al. 1939).
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FIGURE 2
Time-Effect Curves For Oral (P.O.) And Intramuscular (I.M.) Morphine
From Houde, Wallenstein and Beaver 1965. Copyright 1965 by Academic Press.
This drug is about 3 times as potent as morphine and is reported to be more
effective orally than morphine. It readily substitutes for morphine in stabilized
addicts and is no longer available in the United States.
SYNTHETIC OPIOIDS
In the late 1930s. Schaumann discovered that meperidine (Demerol), 2, prepared
by Eisleb (Eisleb and Schaumann 1939). as an anticholinergic agent was in fact a
strong analgesic, a laboratory result that was confirmed in man. At first, it was
thought that meperidine produced less physical dependence than morphine, but
this was before it was appreciated that meperidine has a shorter duration of
action than morphine and tolerance develops more slowly. Continued
administration of high doses of the drug does produce physical dependence.
Abrupt withdrawal from dependent subjects results in a withdrawal syndrome
resembling that of morphine with somewhat less autonomic effects. Drug-
seeking behavior does occur. The finding that a totally synthetic agent could
mimic the effects of morphine led to the beginning of many research programs
devoted to the synthesis of analgesics.
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2, Meperidine (Demerol)
One of the more successful efforts was that of Bockmuhl and Ehrhart (1948),
who synthesized methadone. 3, and many of its congeners. Methadone is an
effective strong analgesic in man when administered either parenterally or orally.
3, Methadone
The drug substitutes for morphine in addicts and this property is the basis of the
methadone maintenance program. The abuse potential of methadone is
comparable to that of morphine.
d-Propoxyphene (Darvon), 4, an analogue of methadone, in which a methylene
group is inserted between the phenyl ring and the quaternary carbon, was
prepared in 1953 (Pohland and Sullivan 1953). In clinical trials, it was difficult
to show that the 32 mg oral dose was superior to a placebo. It was estimated that
90 to 120 mg of d-propoxyphene was equivalent to 60 mg of codeine (Beaver
1966). Combinations with aspirin give greater pain relief than either agent alone
(Lasagna 1964). Because d-propoxyphene does not substitute for morphine as
well as codeine, the drug was not classified as a narcotic, despite the fact that
when administered the subjects recognized it as an opioid.
4, d-Propoxyphene (Darvon)
However, the drug was so irritating when administered parenterally. that its
parenteral abuse was limited. Extensive experience with the drug led to the
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conclusion that at equianalgesic doses the abuse potential is the same as codeine.
Huge doses of d-propoxyphene resulted in deaths of some individuals. For these
reasons, the drug has been placed in Schedule IV of the Controlled Substances
Act.
5, Phenazocine
Phenazocine, 5, was synthesized in NIH laboratories by Everette May (May and
Eddy 1959). It is about 10 times as potent as morphine in rodent tests and does
not substitute well for morphine in dependent monkeys. This encouraging result
prompted extensive clinical studies which showed that the drug was about 3 to 4
times as potent as morphine in man. Human studies at the Addiction Research
Center showed that. in contrast to the findings in monkeys, 1 mg of phenazocine
substituted adequately for 8.5 mg of morphine, and direct addiction studies
showed that phenazocine produced a morphinelike physical dependence.
These are just a few examples which illustrate how the hopes of divesting strong
analgesia from addiction liability were dashed on the rocks of experience. All
the synthetic opioids which emerged from the laboratory as strong analgesics in
rodent tests are, in modern terminology, mu agonists and as such were found to
have morphinelike properties. The situation apppeared to be so bleak that
Schaumann was prompted to write:
It is therefore not correct to say that the depression of respiration
and the constipating effect of the analgesics are side effects.
They are inseparable from their analgesic action. This
unfortunately is also true for the liability to cause addiction. It
will, therefore, not be possible to find morphine-like analgesics
without this undesirable addiction and, in fact, all efforts in this
direction have been unsuccessful. (Schaumann 1956)
ANTAGONISTS AND AGONIST-ANTAGONISTS
A major development in opioid pharmacology was the finding by Unna (1943)
that N-allylnormorphine, nalorphine, 6, was a morphine antagonist. Nalorphine
precipitated a withdrawal syndrome in morphine-dependent subjects. Early
studies in postaddicts (Isbell 1956) led to the conclusion that the drug had no
dependence potential. In later investigations. it was found that after chronic
administration of high doses of nalorphine, abrupt withdrawal resulted in a
syndrome characterized by “electric shocks to the head,” and light headedness. as
well as some other signs found in the morphine withdrawal syndrome, but the
intensity of these effects were far less. There was no drug craving or drug-
seeking behavior.
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6, Nalorphine
Lasagna and Beecher (1954) reported that nalorphine was an analgesic in man.
This finding was confirmed by Keats (Keats and Telford 1956). who found that
6 was equal in milligram potency to morphine. Psychotomimetic effects occurred
in about 20% of the patients. The high incidence of unpleasant CNS side effects
precluded the use of nalorphine as a clinically acceptable analgesic. The Baylor
group (Telford et al. 1961) investigated a short series of narcotic antagonists as
analgesics. None of these showed agonist activity in the usual rodent tests, in
fact, they were antagonists. Some of the drugs proved to be potent analgesics in
man, but those that were also produced undesirable CNS side effects.
Some of us who were experiencing the frustrations in dealing with the problem
of separating analgesia from addiction were following these new developments
with keen interest. A critical analysis of all the pharmacology and addiction
studies carried out in my laboratory in 1959 led to the conclusion that the rodent
analgesic assays in use at that time were better predictors of addiction liability
than of analgesic potency. At the time we initiated our studies, there were no
laboratory tests which could evaluate the analgesic action of antagonists. A series
of benzomorphans of varying antagonist potency were prepared and several of
them were evaluated as analgesics in man by Keats (Keats and Telford 1964) and
Lasagna (Lasagna and deKornfeld 1963). The results are summarized in table 2.
Cyclazocine and pentazocine were chosen for further investigation because in
these early studies they produced less CNS side effects at analgesic doses than
any of the other antagonists. Further studies revealed that the morphine
equivalent dose of pentazocine was nearer to 30 mg than 20 mg, and that at doses
of 60 to 90 mg naloxone-reversible dysphoric effects occurred. Early studies at
the Addiction Research Center with pentazocine suggested that there was little, if
any, abuse potential for this drug, but more extensive investigations showed that
this was too optimistic a conclusion (Jasinski et al. 1970).
After chronic administration of 60 to 90 mg of pentazocine every 4 hours,
postaddicts develop a withdrawal syndrome possessing some features of both the
nalorphine and morphine withdrawal syndromes. The effects are milder in
intensity, but drug-seeking behavior is present.
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TABLE 2
Benzomorphan Antagonists In Man
Instances of abuse of the parenteral form were reported soon after the drug was
made available commercially, but for many years the drug was not seriously
abused by heroin addicts. About 1977, a combination of pentazocine (extracted
from crushed tablets) and the antihistamine tripelennamine taken intravenously
became a popular form of drug abuse in a few urban centers. In order to
counteract this abuse, the manufacturers introduced an oral formulation of
pentazocine and naloxone. Since the latter is a very poor antagonist when given
orally but a powerful one when administered parenterally, there would be no
interference with the oral efficacy of the drug but the parenteral actions would
be antagonized by the naloxone. As a result, there has been a substantial
reduction in the abuse of oral pentazocine.
Cyclazocine is a potent opioid antagonist which, as an analgesic, is about 40
times as potent as morphine and is highly effective when given orally. Abrupt
withdrawal after prolonged administration resulted in a nalorphinelike mild
withdrawal syndrome without drug-seeking behavior. Extensive clinical studies
showed that although the incidence of dysphoric effects at clinically useful doses
was not as high as with nalorphine, they occurred too frequently to allow the
introduction of cyclazocine into clinical medicine.
The realization that agonist-antagonist opioids can be clinically effective, strong
analgesics with reduced dependence liability and limited dysphoric effects,
prompted other investigators to enter the field. Naloxone, and naltrexone, the
cyclopropylmethyl analog, were developed in the Endo Laboratories (Lowenstein
1964; Lowenstein and Fishman 1967; Blumberg et al. 1967).
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7, Naloxone
Both naloxone and naltrexone are potent opioid antagonists essentially devoid of
agonist properties. Naloxone is used clinically and in the laboratory as a “pure”
opioid antagonist. Nalbuphine, an analog of naltrexone differing only in having
an N-cyclobutylmethyl group instead of the N-cyclopropylmethyl and an alcohol
rather than a keto function at C-6, is a mixed agonist-antagonist. It has about
the same milligram potency as morphine. At these clinical doses, dysphoric
effects are minimal or absent and it is only when doses of 70 mg are used that
unpleasant CNS symptoms appear. Chronic administration of nalbuphine
followed by naloxone precipitated a mild abstinence syndrome with drug-seeking
behavior. It is estimated that its abuse potential is similar to that of pentazocine
(Jasinski and Mansky 1972).
Butorphanol, 8, is a synthetic analog of nalbuphine (Monkovic et al. 1972, 1975)
and resembles the latter pharmacologically as well as clinically. As in the case of
nalbuphine, the presence of the 14-beta hydroxyl group lowered the incidence of
CNS side effects. Direct addiction studies at the Addiction Research Center
revealed that the drug produced a withdrawal syndrome of mild intensity similar
to other mixed agonist-antagonists.
8, Butorphanol
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Buprenorphine, 9 (Lewis et al. 1971) is a derivative of thebaine. It is an agonist-
antagonist whose parenteral analgesic potency is about 25 to 50 times thatof
morphine. Doses of 0.4 to 0.8 mg given sublingually produce satisfactory
analgesia in postoperative patients.
9, Buprenorphine
When naloxone was given to subjects who were receiving doses of 8 mg of the
drug daily, no withdrawal syndrome was precipitated as in the case of other
mixed agonist-antagonists. Nevertheless, abrupt withdrawal did elicit a syndrome
which included drug-seeking behavior (Jasinski et al. 1978).
The original hope that mixed agonist-antagonists could be clinically acceptable
strong analgesics with no abuse potential remains unfulfilled. What has been
accomplished is more modest. Drugs in the potency range equal to or greater
than morphine with few dysphoric effects and reduced abuse potential are now
available for clinical use. From a pharmacological standpoint, this class of drugs
was of immense value in leading to a far better understanding of how opioids
behave at a cellular and receptor level. Their diverse actions led to the
formulation of the concept of multiple opiate receptors (Martin 1967). He
postulated the presence of mu, kappa, and sigma receptors to which at least one
more, the delta receptor, has now been added (Kosterlitz et al. 1980). There are
no highly specific ligands for each of these receptors, but compounds of varying
degrees of selectivity are known. It is almost certain that a mu-specific ligand
would resemble morphine so closely that the chances are virtually nil for finding
a compound of this type with no addiction liability. The clinically available
agonist-antagonists are mixed mu-kappa agonists. It would be of great interest
to have specific kappa and delta agonists available for study.
FUTURE OUTLOOK
The seminal discovery of Hughes and Kosterlitz and their associates (Hughes et
al. 1975) that the brain produces its own opioids ushered in a new area of
research. Soon thereafter several new polypeptides from brain and pituitary were
isolated, and a host of synthetic peptides having opioid properties were prepared
in many laboratories throughout the world (Morley 1982). Much of the efforts,
particularly in industrial laboratories, were directed toward finding a drug with
no addiction liability, based on a tenuous hope that the human body would not
synthesize compounds which would be addictive. Unfortunately, this proved to
be another unfulfilled hope. Many of the opioid peptides are ineffective
373
analgesics when administered parenterally. In order to demonstrate opioid effects
in mammals, they must be administered intraventricularly. When this was done
in morphine-dependent rodents, the analgesic peptides prevented the appearance
of a withdrawal syndrome.
Addiction liability is not the only problem to be solved in the development of a
peptide analgesic. Intraventricular administration is not a clinically acceptable
method of giving drugs. The putative peptide drug must be effective when
given parenterally, preferably by the subcutaneous or intramuscular routes. If
the drug were not effective when given orally or sublingually, it would be
limited in value. Effectiveness is only one part of the story. Side effects, if
present, must be acceptable to the patient. Finally. there is a cost factor which
must be considered. In order to avoid diastereomeric mixtures, optically active
amino acids must be used. In order for the cost of manufacture to be acceptable,
the drug must be very potent so that the price of a dose would be economically
competitive. For all these reasons, it is difficult to be optimistic that the solution
to the opioid addiction problem will be found in an opioid peptide.
It is not generally appreciated that the structure and conformation of ligands are
extremely important for recognition by an opioid receptor, but postreceptor
activation events are independent of these factors. A great deal is known about
the pharmacological events following the activation of the mu receptor because,
at pharmacologically effective concentrations in vivo, morphine and some of its
congeners are essentially pure mu agonists. On the other hand, very little is
known about the pharmacological sequelae of activating the delta or kappa
receptors because of the lack of pure kappa or delta agonists. It is essential to
have such compounds because postreceptor events following activation of kappa
or delta receptors probably would be different from those following mu-receptor
activation. Although the optimism of my younger days has been eroded, it is for
the considerations just discussed that I do not share Schaumaoo’s extreme
pessimism that addiction liability and analgesic action are not separable.
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